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Abstract 
Despite several interventional measures, Clostridium difficile infection (CDI) 
continues to be a major problem for healthcare services worldwide. Clinical 
classification of patients at initial disease presentation is very challenging which 
makes it complex to accurately predict who will respond favourably to the 
treatment or have adverse outcomes such as recurrence. This thesis is based 
upon work undertaken on a prospective CDI cohort, which was the preferred 
study design, as it allowed for careful assessment of both clinical and biological 
factors. 
In order to identify clinical risk predictors for poor CDI outcomes, such as 
mortality and recurrence, clinical and laboratory variables were analysed, and 
predictive models derived.  Although some similarities were identified in the 
risk factors in our cohort when compared with previous published studies, 
overall, the potential for external replication was poor, indicating that many of 
the models had internal validity, but little external validity.  We also attempted 
to assess clinical prediction rules, and applied to our dataset.  Again, it was not 
possible to replicate the findings of the prediction rules. Most studies, including 
ours, are small with less than 500 evaluated patients, which may be the major 
factor in limiting their generalisability.  Future studies need to focus on much 
larger cohorts.   
The genetic polymorphism rs4073/-251T>A in the pro-inflammatory IL-8 gene 
has previously been reported to predispose to CDI. We were unable to replicate 
these findings using both a discovery cohort (286 CDI cases versus 135 AAD 
controls; p=0.84) and a replication cohort (100 CDI cases versus 170 healthy 
controls; p=0.87), and no association was found upon meta-analysis with the 
original study data (OR, 1.72; 95% CI, 0.63-4.71). We also failed to replicate 
previous findings of a significant association between faecal IL-8 concentration 
and IL-8 rs4073 genotype in a sub-set of our CDI patients (p=0.28). These 
findings suggest that this polymorphism is unlikely to constitute a major risk 
factor for CDI.  
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Faecal calprotectin and faecal lactoferrin have been used as biomarkers in 
inflammatory bowel disease.  We analysed these biomarkers in CDI cases 
compared with a group of diarrhoea control inpatients. There was a significant 
difference between cases and controls (p<0.0001; ROC>0.85), but there was no 
association with CDI clinical outcomes, including severity, recurrence, and 
length of stay, suggesting a limited applicability of both faecal biomarkers for 
disease stratification.  
An effective CDI vaccine would constitute an important breakthrough for 
tackling the disease, but progress in this area has been hampered in part due to 
the lack of reliable methods for quantitating toxin-specific immune-mediated 
responses. We have developed novel and enhanced assays to measure immune 
response to the major C. difficile toxin epitopes (tcdA, tcdB, cdtA and cdtB). 
Whilst lower anti-tcdA and anti-tcdB IgG titres correlated with severe disease at 
baseline (p<0.01 and p=0.04), lower anti-tcdB IgM titres were associated with 
recurrence (p=0.04) and decreased levels of anti-cdtB (the binding precursor of 
binary toxin) was linked with prolonged disease (p=0.01). Nonetheless, our 
overall findings did not confirm previous associations with disease recurrence, 
mortality or prolonged disease, which is probably related to the fact that we did 
not have access to longitudinal samples. 
The role of mannose binding lectin (MBL), a lectin protein whose deficiency has 
been linked with several acute infections, was investigated in CDI due to its 
immunomodulatory properties and association with inflammation and innate 
immunity. We demonstrated that MBL concentration, but not genotype, was a 
significant predictor of 90-day CDI recurrence at both <50 ng/ml (OR=3.18, 
P<0.001) and <100 ng/ml (OR=2.61, P<0.001). MBL seems to acts as an 
immunomodulator of CDI disease course, but not as a predisposing factor. 
In conclusion, the work in this thesis has focused on clinical and biological 
factors associated with differing clinical outcomes in patients with CDI.  Further 
work is needed to define host factors that modulate disease severity, and how 
they interact with the bacterium, in order to better understand the pathogenesis 
of disease, allow for stratification of treatment and improve clinical outcomes.   
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1.1 Overview 
The anaerobic, Gram-positive, spore-forming bacillus Clostridium difficile (C. 
diff) was first identified in 1935 as a component of the faecal microflora of 
healthy newborns. So named due to the difficulty involved in its isolation and 
culturing, it was not until the 1970s that a link was established between the 
microorganism, antibiotic-associated diarrhea (AAD) and pseudomembranous 
colitis (PMC) (Bartlett et al., 1978; Bartlett et al., 1977; Larson et al., 1977). 
Three decades later and Clostridium difficile infection (CDI) is now regarded as 
the major cause of PMC and accounts for 15-39% of all cases of AAD (Dubberke 
and Wertheimer, 2009; McFarland, 2009; Viswanathan et al., 2010). The 
dramatic increase in incidence and severity observed across both healthcare 
and community settings has largely been attributed to the emergence of 
hypervirulent strains of C. diff, and is associated with increased hospitalisation 
times, costs, morbidity, and mortality among patients (Dubberke et al., 2008; 
Kuijper et al., 2006). 
1.2 Clinical disease 
Asymptomatic colonisation by C. diff is not frequent amongst healthy adults, 
varying between 1.6-4% (Miyajima et al., 2011; Rea et al., 2012). However, 
disruption of gut flora by drugs or pathological processes may lead to a 
dysbiotic status, which in turn facilitates the establishment of C. diff. This 
significantly predisposes patients to progress to CDI, and it is widely recognised 
that the main at-risk group are the hospitalised elderly receiving antibiotic 
therapy (Bassetti et al., 2012). 
Symptomatic patients exhibit a broad range of clinical manifestations, from 
mild, watery diarrhoea to life-threatening fulminant PMC that can lead to severe 
complications, including toxic megacolon, septic shock and death (Rupnik et al., 
2009). Recently updated guidelines from Public Health England (Public Health 
England, 2013) categorised CDI individuals using the following definitions: - 
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 Mild CDI: Typically associated with <3 stools of type 5–7 on the Bristol 
Stool Chart (Lewis and Heaton, 1997) per day; not associated with a 
raised white cell count (WCC) 
 Moderate CDI: Typically associated with 3–5 stools per day and a raised 
WCC that is <15 x109/L 
 Severe CDI: Associated with a WCC >15 x109/L, or an acutely rising 
serum creatinine (i.e. >50% increase above baseline), or a temperature 
of >38.5°C, or evidence of severe colitis (abdominal or radiological 
signs). The number of stools may be a less reliable indicator of severity. 
 Life-threatening CDI: Includes hypotension, partial or complete ileus or 
toxic megacolon, or computed tomography (CT) evidence of severe 
disease 
One of the most challenging aspects of CDI concerns the recurrence of disease 
after apparent completion of successful initial therapy (Barbut et al., 2000; 
Johnson, 2009). Reported recurrence rates have been extremely variable 
ranging between 5-47% depending on the clinical definition and evaluation 
period employed (Aslam et al., 2005; Cocanour, 2011; Cohen et al., 2010; van 
Nispen tot Pannerden et al., 2011). It is generally defined as the presence of 
another CDI episode within a given period, typically 4-12 weeks following the 
onset of the previous episode (Bauer et al., 2011; D'Agostino et al., 2014; Kyne 
et al., 2001). It can be linked with either a relapse with the initial infecting strain 
or a re-infection with a new strain (Barbut et al., 2000; Johnson et al., 1989; 
O'Neill et al., 1991; Wilcox and Spencer, 1992), and both have the potential to 
affect clinical care and management.  
1.3 Pathogenesis 
Infection usually arises in susceptible individuals through the ingestion of 
environmental spores, shed by both infected and asymptomatic individuals 
(Lawley et al., 2009; McFarland et al., 1989; Shaughnessy et al., 2011). Hence 
the logical strategy is to target spore-mediated transmission, but the spores are 
highly resistant to desiccation, chemicals and extreme temperatures. Further to 
this, they can potentially persist for months or even years, as opposed to the 
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pathogen in its vegetative state, which perishes rapidly once subject to aerobic 
conditions. After resisting the acidity of the stomach, the spores pass through to 
the small intestine where favourable conditions including activators present in 
the bile and gastric juice lead to their germination into the vegetative form. 
Disruption of the normal intestinal microbiota or ‘gut flora’, typically by 
exposure to antimicrobial agents (see Figure 1.1), allows the vegetative cells to 
further invade the mucus layer, thus adhering to the surface of epithelial cells 
and establishing themselves in the gut (Karjalainen et al., 1994). 
 
 
Figure 1.1 – The effect of antibiotics on the normal gut flora and the risk of 
Clostridium difficile infection (CDI) (taken from (Rupnik et al., 2009) 
Patients are resistant to CDI if the diversity of the gut flora is not disrupted by antibiotics (a). Once 
antibiotic therapy starts, infection by C. diff strains resistant to the antibiotic is greatly maximised 
(b). When the antibiotic therapy ceases, the levels of the antibiotic in the gut diminish rapidly, but 
the microflora remains in a dysbiotic state for a variable period of time (indicated by the break in 
the graph), depending on the antibiotic given (c). During this time, patients can be infected with 
either resistant or susceptible C. diff strains. Finally, after the microflora recovers, colonisation 
resistance to C. diff is restored (d).  
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Vegetative cells subsequently produce and secrete a number of virulence 
factors, increasing as they enter the stationary phase of their growth and 
ultimately promoting intestinal damage and disease. It is generally accepted 
that CDI pathogenesis is multifactorial; it is dependent upon alterations in the 
gut flora, virulence factors produced by the infecting strain and host immune 
response and susceptibility factors (Barbut et al., 2000; McFarland et al., 1989). 
Figure 1.2 summarises the C. diff infection cycle. 
 
 
Figure 1.2 – The infection cycle of Clostridium difficile 
 
Both biochemical and molecular studies have shown that the major clinical 
signs and symptoms of CDI can be explained largely by the actions of two high 
molecular weight exotoxins, the enterotoxic toxin A (tcdA) and the cytotoxic 
toxin B (tcdB) (Jank et al., 2007; Rupnik et al., 2009; Thelestam and Chaves-
Olarte, 2000) (Figure 1.3a). Genetic inactivation of the tcdA and tcdB genes in a 
hamster model of infection has shown that they are essential for the occurrence 
of the disease (Kuehne et al., 2010). As well as tcdA and tcdB, specific strains of 
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C. diff also produce a third toxin: a C. difficile transferase, termed ‘binary toxin’ 
(CDT) [Figure 1.3b]. It is thought that this may act synergistically with tcdA and 
tcdB further increasing their glucosylating potency and therefore resulting in an 
increase in disease severity (Barbut et al., 2005). More recent research has 
identified that GTPase-independent toxin virulence mechanisms may also be 
important in CDI pathogenesis (Chumbler et al., 2012). 
 
 
 
Figure 1.3 - Toxins produced by Clostridium difficile (taken from (Rupnik 
et al., 2009)) 
a: Two large toxins, toxin A and toxin B (tcdA and tcdB), are encoded on the pathogenicity locus 
(PaLoc), which comprises five genes. In non-toxigenic strains, this region is replaced by a short 115 
bp sequence. Both toxins are single-chain proteins, and several functional domains and motifs have 
been identitifed. tcdB is shown in detail below the PaLoc 
b: A third toxin, the binary toxin or CDT, is encoded on a separate region of the chromosome 
(CdtLoc) and comprises three genes. The binary toxin is composed of two unlinked proteins, cdtB 
and cdtA. cdtB has a binding function and cdtA is the enzymatic/catalytic component. 
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1.3.1. Glucosylating toxins A & B 
Both tcdA and tcdB are large molecular-weight protein toxins of approximately 
308 and 270 kDa, respectively (Voth and Ballard, 2005). Differing in length, with 
tcdA about 350 amino acids longer than tcdB, both belong to a group of large 
clostridial toxins (LCTs) related to Clostridium sordellii, Clostridium novyi and 
Clostridium perfringens (Amimoto et al., 2007; von Eichel-Streiber et al., 1996). 
LCTs are single-chain proteins consisting of three main functional domains: an 
amino-terminal binding domain with characteristic tandem repeats, a carboxy-
terminal catalytic domain and a putative translocation domain (von Eichel-
Streiber et al., 1996), with structural studies having further elucidated the role 
of several other functional motifs (Jank et al., 2007) (Figure 1.3a). 
The binding domain interacts with putative cell-surface carbohydrate receptors 
allowing the toxins to bind to host cells. Seven potential carbohydrate binding 
sites have been proposed for tcdA (Greco et al., 2006; Ho et al., 2005). In 
animals the tcdA receptor carries the trisaccharide Gal1(α1–3)Gal(β1–4) GlcNac 
(Krivan et al., 1986) but this is probably not present in humans where the 
glycoprotein gp96 is thought to act as a co-receptor (Na et al., 2008). No 
receptor has yet been identified for tcdB, which has been shown to bind more 
effectively to the basolateral side of the host cell as opposed to the apical site 
favoured by tcdA (Thelestam and Chaves-Olarte, 2000).  
After cell binding and subsequent endocytosis, a decrease in endosomal pH 
induces a conformational change in the toxin enabling the amino-terminus to 
insert into the endosomal membrane via the formation of a pore (Jank and 
Aktories, 2008). The host cell is able to initiate autocatalytic cleavage of the 
amino-terminal region proximal to the cysteine protease site which in turn 
releases the carboxy–terminal catalytic domain into the cytoplasm leaving the 
remainder of the toxin polypeptide attached to the membrane (Reineke et al., 
2007). The catalytic domain is responsible for glycosylating small GTPases of 
the Rho and Ras families in host cells, resulting in their irreversible inactivation. 
This disrupts cell signaling pathways, cytoskeleton integrity and tight junctions 
(Reinert et al., 2005), resulting in decreased trans-epithelial resistance, fluid 
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accumulation and destruction of the intestinal epithelium (Riegler et al., 1995; 
Rupnik et al., 2009; Thelestam and Chaves-Olarte, 2000). In clinical terms, the 
complete mucosal damage is associated with severe colitis, pseudomembrane 
formation and the typical diarrhoea that characterises CDI (Fiorentini et al., 
1998; Kreimeyer et al., 2011; Poxton et al., 2001; Voth and Ballard, 2005). The 
toxins also elicit the release of inflammatory cytokines from the intestinal 
epithelial cells, mast cells and macrophages, promoting an influx of 
inflammatory cells and fluid secretion that results in recruitment and activation 
of neutrophils and propagates a vicious cycle of colonic inflammation 
(Pothoulakis, 2000; Sebaihia et al., 2006; Sun et al., 2010). 
The genes (tcdA and tcdB) encoding the respective toxins are contained within 
the pathogenicity locus (PaLoc), a critical region of the genome for toxin 
production and regulation (Lyerly et al., 1988; Rupnik et al., 2009). The PaLoc 
also contains the gene for a putative holin (tcdE) (Tan et al., 2001) thought to 
facilitate release of tcdA and tcdB, and two regulatory genes (tcdC & tcdR), 
which encode a negative regulator (Matamouros et al., 2007) and an alternative 
sigma factor involved in positive transcriptional regulation (Mani and Dupuy, 
2001), respectively. Present at the same chromosomal integration site in all 
toxigenic C. diff strain types that have been analysed to date, the PaLoc is non-
existent in non-toxigenic strains (tcdA−/tcdB−), being replaced by 115 base pair 
(bp) of non-coding sequence (Rupnik et al., 2009). Changes in the DNA sequence 
of the Paloc are observed across different C. diff strains and can be defined as 
different toxinotypes (Rupnik, 2008), with polymorphisms appearing more 
frequently in tcdA than in tcdB, especially deletions (Rupnik et al., 1998; van den 
Berg et al., 2004). Punctual and tandem repeat deletions in tcdC could lead to a 
lack of negative regulation and thus increased production of both tcdA and tcdB. 
Factors outside of the PaLoc, such as CodY (Dineen et al., 2007), may also be 
involved with the regulation of toxin synthesis. 
The relative importance of tcdA and tcdB to disease pathogenesis remains 
unclear, with both toxins extensively studied ever since C. diff was confirmed as 
a major etiological agent of PMC and AAD.  
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Early research suggested a key role for tcdA over tcdB. Initial experiments 
employing intragastric challenge of hamsters suggested that tcdA alone 
displayed enterotoxic effects that resulted in haemorrhagic fluid secretion, 
inflammation and necrosis of intestinal tissue, compared to tcdB alone, which 
had no effect unless applied with a sub-active concentration of tcdA (Lyerly et 
al., 1985). It was then postulated that clinically significant disease occurs only 
for toxigenic strains of C. diff that produce both tcdA and tcdB (Bartlett, 1992). 
The lethal effects of tcdB were shown to depend on the initial damage to the 
surface of the intestinal cells caused by tcdA (Depitre et al., 1993; Lyerly et al., 
1988), as opposed to the fact that tcdA did not appear to be dependent upon the 
action of any other virulence factors (Bartlett, 1994).  
However, more recent evidence further supports an essential role for tcdB over 
tcdA. Indeed, since the 1990’s experiments on human colonic tissue indicated 
that tcdB was significantly more potent than tcdA in causing mucosal necrosis 
and decreasing barrier function (Riegler et al., 1995). Furthermore, it has now 
been repeatedly reported that tcdA-/tcdB+ strains can consistently cause PMC 
and the full range of the CDI spectrum (Johnson et al., 2001; Kato et al., 1998; 
Limaye et al., 2000), with several outbreaks documented (Alfa et al., 2000; 
Drudy et al., 2007; Kuijper et al., 2001; Sato et al., 2004). These strains are 
distinguished by deletions in tcdA resulting in non-production of biologically 
active toxin (Sambol et al., 2000). Further investigation of the role of these 
toxins in disease pathogenesis has been facilitated by the more recent 
development of two systems for the genetic manipulation of C. diff (Heap et al., 
2007; Lyras et al., 2009a), with a comparison of mutants lacking one of the 
toxins, which revealed that tcdA−/tcdB+ mutants retain the ability to kill 
hamsters, whereas tcdA+/tcdB− mutants were not virulent (Lyras et al., 2009b). 
All naturally occurring pathogenic strains produce tcdB (but not necessarily 
tcdA) thus suggesting that tcdB has a more active role than was previously 
believed. This is further supported by evidence from clinical epidemiology 
studies (Loo et al., 2011), as well as porcine and humanised animal models 
(Savidge et al., 2003; Steele et al., 2013). The current impression is that both 
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toxins may cause severe C. diff colitis (Kuehne et al., 2010), with the relative 
importance of each toxin in disease pathogenesis still under intense debate. 
1.3.2 Binary toxin and non-toxin antigens 
In addition to tcdA and tcdB, further virulence factors have been implicated in 
CDI pathogenesis, including CDT binary protein and surface layer proteins 
(SLPs), both of which are involved in adherence to host epithelial cells and 
modulation of inflammatory and antibody responses (Madan and Jr, 2012; 
Vedantam et al., 2012), with evidence suggesting that C. diff strains that adhere 
better to human intestinal cell lines are more virulent in hamsters (Dingle et al., 
2011b). 
Present in 6-12% of C. diff clinical isolates including hypervirulent PCR ribotype 
027 strains (Sundriyal et al., 2010), CDT belongs to the family of ADP-
ribosylating toxins and is composed of two separate toxin proteins, binary toxin 
A (cdtA) and binary toxin B (cdtB) (Figure 1.3b). cdtB is the larger binding 
domain (~50kDa in its mature form), activated by serine proteases and docking 
to host cells via a lipolysis-stimulated lipoprotein membrane receptor 
(Papatheodorou et al., 2011), which allows translocation of the catalytic ADP-
ribosyltransferase, cdtA, into the cytosol, ultimately inducing depolymerisation 
of the actin cytoskeleton. Genes coding for CDT are located within the binary 
toxin locus (CdtLoc) and are distinct to the PaLoc (Popoff et al., 1988), and 
multiplex PCR-based diagnostic tests are now able to individually  detect the 
presence of both loci. 
Until recently, the extent to which CDT was contributing to C. diff pathogenicity 
was largely unclear. Although CDT is cytotoxic in tissue cultures and enterotoxic 
in a rabbit ileal loop assay, C. diff strains that are tcdA-/tcdB-/CDT+ are able to 
colonise in hamsters, but fail to produce disease (Bacci et al., 2011; Geric et al., 
2006; Perelle et al., 1997; Viscidi et al., 1981). However, a recent study by 
Schwan et al. found that CDT induces formation of microtubule-based 
protrusions that wrap and embed Clostridia, thereby acting in synergy through 
increased pathogen adherence (Schwan et al., 2009). Furthermore, 
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neutralisation of CDT in the gut of mice caused a significant decrease in 
colonisation of the caecal content, indicating that the increased adherence 
facilitates colonisation (Schwan et al., 2009). There are multiple epidemiological 
studies linking CDT with increased patient mortality (Bacci et al., 2011; Barbut 
et al., 2007; Goldenberg and French, 2011; Walker et al., 2013), but further 
studies are needed to confirm its significance as an important virulence factor. 
SLPs are a crucial group of proteins for the adherence of C. diff to the intestinal 
epithelium and subsequent gut colonisation (Calabi et al., 2002). C. diff is 
unusual in expressing two of these, which are of varying size in a number of 
strains and arise from post-translational cleavage of a single precursor, SlpA 
(Eidhin et al., 2006). These comprise the surface layer (S-layer) of C. diff 
vegetative cells, an exterior protein coat lying above the peptidoglycan layer of 
the Gram-positive cell wall common in many bacteria (Calabi et al., 2001). As 
well as mediating adhesion to enteric cells (Calabi et al., 2002), the S-layer has 
also been shown to infer protection from phagocytic attack or avoidance of the 
immune system (Sára and Sleytr, 2000). Considerable variation exists between 
SlpA across different strains, including the hypervirulent 027 strains (Eidhin et 
al., 2006; Fagan et al., 2009). Preliminary results indicate that the altered SlpA 
in hypervirulent strains is associated with increased adherence to human 
intestinal epithelial cells (Rupnik et al., 2009), and SlpA is now being considered 
as a potential vaccine candidate. Other possible virulence factors include 
bacteriophages, cell wall proteins and other non-toxin antigens, which are 
currently under scrutiny (Emerson et al., 2009; Govind et al., 2009; Lawley et al., 
2009; Stabler et al., 2009). 
1.3.3 Sporulation 
Before the C. diff toxins can exert their effects, ingestion and germination of 
spores in the intestinal tract is required (Kelly and LaMont, 1998). C. diff 
produces highly resistant, infectious spores that promote transmission within 
the healthcare setting, as well as across greater distance through subject 
carriers (Clements et al., 2010). Thus sporulation and germination are major 
regulators of virulence and propagation of the disease. 
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The spore is the dormant form of C. diff and as described above, in their 
metabolically inactive state they can potentially persist for months or even 
years, which is similar to other Gram-positive spore formers. Due to their 
anaerobic nature, vegetative cells are unable to survive outside of the host and 
therefore spores are the most important form of transmission and perpetuation 
of the organism. Both in vivo and in vitro studies demonstrate that germination 
can be induced in response to bile derivatives; a clear indicator that they are 
adapted for life in the gastrointestinal (GI) tract (Sorg and Sonenshein, 2008, 
2009). Epidemic strains of C. diff, such as PCR-ribotype 027/NAP1/BI, show 
increased sporulation levels in vitro, which may be associated with their 
increased propagation (Fawley et al., 2007; Merrigan et al., 2010). Furthermore, 
differences in sporulation capacity between strains have been associated with 
increased pathogenicity (Merrigan et al., 2010). A study focusing on a mouse 
model described a highly contagious “super-shedder state” of spores, mediated 
by antibiotics and characterised by a dramatically low microbiota diversity 
index, overgrowth of C. diff and excretion of an extremely high load of spores 
(Lawley et al., 2009). Furthermore, they found that spore-mediated 
transmission to antibiotic-treated immune-compromised mice resulted in 
severe, often fatal, intestinal disease, in contrast to a more moderate level of 
mucosal intestinal inflammation observed in immune-competent mice. 
More in-depth investigations of factors affecting both sporulation and 
germination have the potential to provide further insight into pathogenistic 
mechanisms and unveil novel treatment options. 
1.4 Epidemiology 
CDI remains the most common cause of hospital-acquired diarrhoea and in the 
past decade it has already surpassed methicillin-resistant Staphlococcus Aureus 
as the most common hospital-acquired healthcare facility-associated infection 
in the United States (US) (Miller et al., 2011). In the US, the number of CDI 
discharge diagnoses in hospitalised patients rose from 139,000 in 2000 to 
336,000 in 2009 (Centers for Disease Control and Prevention, 2012), with 
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similar trends having been observed across Canada (Pépin et al., 2004) and 
Europe (Freeman et al., 2010; Kuijper et al., 2008; Kuijper et al., 2006).  
1.4.1 Emergence of hypervirulent strains: 2002-2007 
In England, the prevalence of CDI gradually increased in the 1990s, with a 
pronounced increase in rates observed between 2001 and 2007 (Figure 1.4). In 
2007, over 55,000 cases of CDI were reported, with more than half of acute NHS 
trusts reporting 2 or more cases per 1,000 admissions in patients over 65 years 
(Health Protection Agency, 2009a).  
 
 
 
 
Figure 1.4: Voluntary laboratory reports of C. difficile positive faecal 
specimens: England, Wales and Northern Ireland* 1990-2007 (adapted 
from Public Health England, 2014) [*Northern Ireland reports included from 
2001] 
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This is consistent with the increases in CDI prevalence and severity observed in 
the last decade across many European countries (Barbut et al., 2011; Freeman 
et al., 2010; Kuijper et al., 2006). Amongst the most important developments in 
the field was the emergence of an epidemic, hypervirulent strain of C. diff which 
accounted for numerous outbreaks worldwide and triggered the introduction of 
profound changes in healthcare practice, such as the adoption of new testing 
algorithms, thorough risk assessment for the management of patients, deep 
cleaning measures, and reviews into antibiotic policy (Kuijper et al., 2006; 
Warny et al., 2005). 
First emerging in 2002/2003 (Clements et al., 2010), this epidemic strain, 
commonly referred to as 027/NAP1/B1 (dependent on the employed typing 
method; see section 1.6.7), was first recognised as the cause of the notable CDI 
outbreaks documented in Canada in 2003, and thereafter in the United Kingdom 
(UK), the Netherlands, Belgium and France (Kuijper et al., 2007; Pépin et al., 
2004). Through whole genome sequencing and phylogenetic analysis, a recent 
paper was able to define the global population structure of PCR ribotype 027, 
and track its subsequent spread through the global healthcare system (He et al., 
2013). Voluntary surveillance and strain typing has coincided with the increases 
in CDI prevalence observed from 2003 onwards, which may have resulted in the 
increases in severe disease, treatment failure, disease recurrence and mortality 
(Kuijper et al., 2006; Ricciardi et al., 2007; Warny et al., 2005). Strain 
characteristics postulated to contribute to the observed hypervirulence include: 
 Hyperproduction of both tcdA and tcdB 
 Ability to also produce  CDT 
 Complex genetic profile 
 Antibiotic resistance 
 Increased sporulation rates 
Compared to other strain types, this epidemic PCR-ribotype 027 strain has been 
shown to produce up to 16- and 23-fold more tcdA and tcdB, respectively 
(Warny et al., 2005), which may be the result of both accelerated kinetics and 
sustained production (Freeman et al., 2007). Normally, toxin synthesis in 
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common strains increases as bacteria enter the stationary phase, but with 
hypervirulent strains this is likely to occur in both the exponential and 
stationary growth phases (Freeman et al., 2007). As well as hyperproduction of 
both tcdA and tcdB, the synthesis and release of CDT (see section 1.3.2) may be 
a contributing factor for the hypervirulence of these strains. 
Interestingly, the PCR ribotype 027 strain and another so-called hypervirulent 
strain, here designated as PCR-ribotype 078, appear to be genetically divergent 
from other strains (Dingle et al., 2011a), and comparative molecular studies 
across multiple strains have identified that their observed hypervirulence may 
be a result of mutations in the tcdC gene, the negative regulator located in the 
PaLoc locus (Carter et al., 2011). However, historical isolates containing similar 
tcdC mutations were not responsible for outbreaks at that time (McDonald et al., 
2005b). It is therefore thought that the associated epidemic behaviour may be 
related to expression of multiple genetic elements, with five unique genetic 
regions identified in epidemic 027 strains (transcriptional regulators, a dual-
component regulatory system and a novel phage island) that are absent in non-
epidemic 027 strains (Stabler et al., 2009). 
Unlike historical 027 strains, hypervirulent 027 demonstrates high levels of 
antibiotic-resistance, most notably to fluoroquinolones and erythromycin 
(Drudy et al., 2006; Spigaglia et al., 2008). There are also concerns regarding 
this strain’s reduced susceptibility to metronidazole since a poor response rate 
to metronidazole treatment was observed in the publicised 027-associated 
Canadian outbreaks of  2004 (Pépin et al., 2004). A recent study of 398 
European C. diff isolates demonstrated that in general, 027 isolates had a two-
fold higher minimum inhibitory concentration (MIC) of metronidazole, capable 
of inhibiting 90% of bacterial isolates, than non-027 isolates (Debast et al., 
2013). However, another study failed to identify any significant differences in 
clinical outcome across metronidazole-treated CDI patients infected with 
reduced versus fully susceptible strains (Purdell et al., 2011). In addition, the 
027 strain has been associated with an increased in vitro sporulation rate in 
both the presence/absence of non-chloride cleaning agents (Akerlund et al., 
2008), with the subsequent production of more spores resulting in increased 
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environmental contamination, improved survival and the potential for further 
spread and sharing. 
1.4.2 Decreasing incidence: 2007-2014 
Due to the dramatic increases in incidence and severity of CDI, surveillance 
studies to monitor this and the associated spread of hypervirulent strains have 
been established since 2007 at both regional and national levels in Europe and 
North America (Wilcox et al., 2012). In England, a Clostridium difficile 
Ribotyping Network (CDRN) was created, stringent trajectory targets were 
established and all NHS hospitals were required to report all cases of CDI 
(mandatory notification status). 
Since 2006, the National Reference Laboratory of the Netherlands has observed 
a decrease in 027-associated CDI in hospitals, but an increase across other 
healthcare facilities such as nursing homes (Hensgens et al., 2009). Other 
European countries, such as Belgium, have remained relatively static (Viseur et 
al., 2011). However, the most substantial reduction in the overall incidence of 
CDI has occurred in England and Wales: voluntary reports peaked in 2007, but 
by 2010 had decreased by ~60% (Figure 1.5) (Public Health England, 2014). 
The most recent reports from 2013 demonstrated a 9.8% decrease from 2012 
(13,547 versus 15,011; Figure 1.5) (Public Health England, 2014). This 
reduction is coincident with control of the epidemic 027 strain and substantial 
decrease in 027-associated CDI cases: the 027 strain was responsible for 55% of 
all samples submitted to the CDRN in 2007-2008, subsequently decreasing to 
36% and 21% of samples submitted in 2008-2009 and 2009-2010, respectively 
(Wilcox et al., 2012). These findings coincided with a decrease in the number of 
CDI-attributed deaths in England, falling by 70% between 2007 and 2010 
(7,916 versus 2,335 death certificates) (Office of National Statistics, 2011). 
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Figure 1.5: Voluntary laboratory reports of C. difficile positive faecal 
specimens: England, Wales and Northern Ireland** 1990-2013* (taken 
from (Public Health England, 2014) 
 *Date from 2013 are provisional (date was extracted on 15th January 2014); **Northern Ireland 
reports included from 2001; 
 
Whilst the decrease in CDI-related complications is likely due to the observed 
reduction in cases accounted by hypervirulent, epidemic strains, the overall 
substantial decrease in CDI incidence is likely due to increased clinical vigilance 
(Wilcox et al., 2012): the introduction of enhanced infection control measures 
such as hand washing and more effective isolation of infected patients most 
likely limited the spread of spores within the hospital environment (Price et al., 
2010). Furthermore, strict antibiotic stewardship reduced the use of treatment 
linked with drugs such as fluoroquinolones, cephalosporins and clindamycin 
(Talpaert et al., 2011). 
Focusing on infection control measures will have been aided by the provision of 
timely information on the PCR ribotypes responsible for both individual cases, 
and clusters (Wilcox et al., 2012). Interestingly, it is also thought that the 
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observed emergence of less virulent PCR ribotypes, such as 012, 017, 019, 036, 
078 and 153 (Dawson et al., 2011; Knetsch et al., 2011), may also be involved in 
the reduction of severe cases across Europe (Goorhuis et al., 2008b). An 
increase in the prevalence of PCR ribotype 078, the predominant strain of C. diff 
in livestock such as calves and pigs, has been observed in both hospital and 
community settings (Goorhuis et al., 2008a) and a 2008 Pan-European 
surveillance study found that PCR ribotype 078 was the third most prevalent 
ribotype, accounting for 8% of all regional cases (Bauer et al., 2011). PCR 
ribotypes 014/020 (16%) and 001 (10%) were the two most frequently 
observed, with PCR ribotype 027 now accounting for just 5% (Figure 1.6). 
 
 
Figure 1.6: Geographical distribution of Clostridium difficile PCR ribotypes 
in European countries with more than five typable isolates, November, 
2008 (taken from (Bauer et al., 2011) 
Pie charts show proportion of most common PCR ribotypes per country. The number in the centre 
of pie charts is the number of typed isolates in the country. 
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1.4.3 Community-acquisition 
Although first described in the late 1980s/early 1990s, relatively few studies 
describe the epidemiology of CA-CDI. Despite being reported at a considerably 
lower rate than hospital-acquired CDI (HA-CDI), the incidence of CA-CDI has 
steadily increased with time: a recently published US population-based study 
showed a 5.3-fold increase in CA-CDI from 1991 to 2005, with CA-CDI 
accounting for a large proportion (41%) of the overall cases across this time 
period (Khanna et al., 2012b). Possible sources of CDI within the community 
include animals (e.g. pets), food (meat & vegetables) and the environment (soil 
& water) (al Saif and Brazier, 1996) but although similar PCR ribotypes were 
found, the basis for direct transmission has yet to be elucidated. 
Compared with HA-CDI patients, CA-CDI patients are younger (50 years versus 
72 years), more likely to be female (76% versus 60%) and suffer from less 
comorbidities (Jones et al., 2013; Khanna et al., 2012b). This is consistent with 
findings that CA-CDI affects groups previously considered ‘low-risk’ such as 
children or pregnant females (Centers for Disease Control and Prevention, 
2005), with paediatric studies showing a 12.5-fold increase in the incidence of 
CA-CDI over the last twenty years (Khanna et al., 2013a; Kim et al., 2008). 
Patients with CA-CDI are also less likely to have been exposed to antibiotics 
(78% versus 94%) (Jones et al., 2013), corresponding with US reports that 35% 
of their 7.7 cases per 100,000 persons per year received no antibiotics within at 
least 42 days of C. diff detection (Bassetti et al., 2012). With no CA-CDI 
outbreaks having been reported to date, it is thought that host factors resulting 
in increased susceptibility may be of greater importance than overall level of 
exposure to the organism (Jones et al., 2013). 
1.5 Risk factors 
With dramatic increases in the incidence of CDI observed globally, marked 
efforts have been made to identify risk factors for both susceptibility to C. diff 
acquisition and disease severity including complications, disease recurrence 
and mortality. Discussed below are some of the traditionally reported risk 
factors, including age at the time of diagnosis, medication exposure 
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(antibiotics/proton pump inhibitors (PPIs)) and hospitalisation history. 
Additional risk factors include, but are not limited to, underlying comorbidities 
such as malignancies, immunosuppression and inflammatory bowel disease 
(IBD), length of hospital stay, contact with active carriers, hypoalbuminaemia 
and enteral tube feeding (Khanna and Pardi, 2014). 
1.5.1 Age 
Increasing age is a consistently noted risk factor, likely due to the inability of 
older patients in mounting a sufficient immune response upon first exposure to 
the C. diff toxins, which unsurprisingly also results in a higher rate of disease 
recurrence in these patients (Dial et al., 2004; Kyne et al., 2001).  
Reports demonstrate between a 10- and 20-fold increased risk for patients aged 
60-90 years compared to the younger population (Bartlett and Gerding, 2008; 
Brown et al., 1990; Kelly and LaMont, 1998), with 90% of all CDI-related deaths 
occurring in persons aged 65 years and above (Brown et al., 1990). 
Furthermore, a two- to three-fold increase in mortality has been observed in 
elderly CDI patients infected with the PCR-ribotype 027 strains (Miller et al., 
2010b). 
1.5.2 Antibiotics 
As described in Section 1.3 and illustrated in Figure 1.1, disruption of the 
normal gut flora allows the vegetative cells to penetrate the mucus layer, adhere 
to the surface of epithelial cells and fully establish themselves in the gut 
(Karjalainen et al., 1994). Prior use of antibiotics has been well documented as a 
major cause of dysbiosis as it can particularly facilitate colonisation by strains 
resistant to the administered agent. Prior antibiotic exposure is therefore seen 
as a predominant risk factor for CDI, with CDI accounting for 15-20% of all 
cases of AAD (Bartlett and Gerding, 2008; Cohen et al., 2010). The majority of 
antibiotics have been reported to cause CDI, though some obviously carry 
higher risk than others. Ampicillin/amoxicillin, clindamycin and cephalosporins 
(in particular third-generation) have been consistently implicated, and more 
recently fluoroquinolones (Gaynes et al., 2004; Johnson et al., 1999; Loo et al., 
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2005; Muto et al., 2005; Pépin et al., 2005; Riley, 1996; Thomas et al., 2002). 
Epidemic strains of C. diff have differing antibiotic resistance profiles to their 
historical counterparts. Though once susceptible, emerging epidemic strains are 
able to evolve and acquire resistance, as with PCR-ribotype 027 and the various 
classes of fluoroquinolones, including gatifloxacin and moxifloxacin (Johnson et 
al., 1999; McDonald et al., 2005a). 
It has been estimated that the use of broad spectrum antibiotics increases CDI 
risk by 8-fold to 10-fold from the time of the initial exposure up to one month 
post-administration, and up to 3-fold for the following two months (Hensgens et 
al., 2012), though this is dependent on the antibiotic type administered 
(Merrigan et al., 2003a; Merrigan et al., 2003b). Increased risk has also been 
demonstrated for use of multiple antibiotics, as well as increased length of 
treatment (>10 days) (Brown et al., 1990; Gerding et al., 1986). Continued use 
of non-CDI antibiotics both during and post-CDI treatment is linked with poor 
disease prognosis: one study demonstrated a significant increase in disease 
recurrence within CDI patients receiving concomitant non-CDI antibiotics post-
therapy (Drekonja et al., 2011). Furthermore, two phase III trials comparing 
fidaxomicin to vancomycin demonstrated that patients receiving concomitant 
non-CDI antibiotics during therapy had a decreased cure rate and increased 
time to resolution of diarrhoea (Mullane et al., 2011). Patients receiving 
concomitant non-CDI antibiotics post-therapy in these two trials also showed a 
(non-significant) increase in disease recurrence (Mullane et al., 2011). 
Despite the high frequency of cases linked with their exposure, CDI can also 
occur without pre-exposure to antimicrobials: a 2005 study demonstrated that 
24% of CDI patients had no prior exposure, with a further 9% receiving 
antibiotics for only 3 days or less (Centers for Disease Control and Prevention, 
2005). Interestingly, of these patients with no exposure, 75% were either 
hospitalised or had had close contact with an individual suffering from a 
diarrhoea-related illness. 
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1.5.3 Gastric acid suppression 
As described in Section 1.3, the initial step in the CDI infection cycle is the 
ingestion of C. diff spores, which must subsist into their activated vegetative 
form before adherence/colonisation and subsequent infection can take place. 
After resisting the acidity of the stomach, the spores pass through to the small 
intestine where favourable conditions, including bile acids/salts facilitate this 
germination. It has therefore been hypothesised that a reduction in stomach 
acidity, through the use of suppressive medication including H2-receptor 
antagonists and PPIs, may enhance survival of the C. diff spores in the GI tract 
thus increasing their ability to convert to the vegetative form. 
Although a number of recent studies have demonstrated that a significant 
relationship between PPI use and CDI has been limited to univariate analysis 
and is not significant within multivariable models (Khanna et al., 2012a; Leekha 
et al., 2013; Leonard et al., 2012), there is evidence that acid-suppressive 
therapy may constitute a risk factor for CDI (Dial et al., 2005; Dial et al., 2006; 
Howell et al., 2010; Loo et al., 2011; Stevens et al., 2011), with some meta-
analyses having identified a significant relationship (Janarthanan et al., 2012; 
Kwok et al., 2012; Leonard et al., 2007). Howell et al observed a dose response 
effect, whereby the risk of CDI increased as with the degree of acid suppression, 
defined as (i) none, (ii) H2 receptor antagonists, (iii) once daily PPI and (iv) 
more frequent PPI (Howell et al., 2010). PPIs have also been identified as 
potential risk factors for CDI-related outcomes including complications, 
recurrence and mortality (Kim et al., 2010; Kim et al., 2012; Morrison et al., 
2011), but associations remain controversial and inconclusive. 
Despite a lack of conclusive evidence, in 2012 the US Food and Drug 
Administration (FDA) issued a warning regarding the prescription of PPIs in 
relation to CDI, and updated guidance on the management of CDI in the UK also 
reinforced the concept: “Given that acid suppression drugs, especially PPIs, may 
be over-prescribed and frequently not reviewed to determine if long-standing 
prescriptions are still justifiable, consideration should be given to 
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stopping/reviewing the need for PPIs in patients with or at high risk of CDI” 
(Public Health England, 2013). 
1.5.4 Hospitalisation & healthcare acquisition 
The combination of a spore-contaminated environment, sub-optimal hand 
hygiene of healthcare employees and a highly susceptible patient population, 
especially the elderly, make recent hospitalisation a further significant risk 
factor for acquisition of CDI (Bassetti et al., 2012). Recent hospitalisation also 
seems to modulate the risk in asymptomatic patients: Minnesota researchers 
identified toxigenic C. diff in 9.7% of 320 asymptomatic individuals, with 
multivariate analysis revealing recent hospitalisation (within 3 months), 
chronic dialysis and use of corticosteroids as the three main risk factors for 
colonisation by C. diff (Leekha et al., 2013). 
Although the majority of CDI infections are hospital-acquired, in 2010 the 
Centers for Disease Control and Prevention demonstrated that 94% of overall 
CDI cases were healthcare-associated, with the onset in 75% occurring outside 
of a hospital setting (Centers for Disease Control and Prevention, 2012). 
Another study demonstrated that as many as 25% of all CDI cases develop in 
nursing home patients (Centers for Disease Control and Prevention, 2012). 
Notably, the majority of cases occurring in a non-hospital healthcare setting 
involve recently hospitalised individuals (Guerrero et al., 2011; Kim et al., 
2011). Therefore, caution must be taken with residents of long-term care 
facilities involving concentrated elderly populations, polypharmacy and high 
antibiotic use, and frequent hospital visits and nosocomial exposure (Iv et al., 
2014).  
Available data on risk factors has largely been derived from studies on 
healthcare-associated CDI. However, with the increasing incidence of CA-CDI 
(Gerding et al., 1986) and a lack of understanding of preponderant risk factors 
within this population, it is believed that cases of CA-CDI may have different 
underlying causes. Recent studies have demonstrated that up to 94% of CA-CDI 
patients had had recent outpatient or emergency room visits, which suggests 
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that short-term healthcare without hospitalisation may also constitute a risk 
factor for CDI in this population (Centers for Disease Control and Prevention, 
2012; Chitnis et al., 2013; Khanna et al., 2013a; Lessa, 2013).  
1.6 Diagnosis 
Diagnosis of CDI is usually based on the combination of clinical history, the 
presence of diarrhoea and positive laboratory confirmation. Although CDI is a 
classic example of health-care-associated diarrhoea, reliably distinguishing C. 
diff from other causes is only possible through the use of laboratory tests. Many 
alternative laboratory screening methods are currently being employed, 
summarised in Table 1.1, such as direct culture and the glutamate 
dehydrogenase (GDH) antigen assay, which both target the organism itself; and 
the cell cytotoxicity neutralisation assay (CCNA) and enzyme-linked 
immunosorbent assay (ELISA), which instead detect the presence of the C. diff 
toxins in the specimens. A third group of tests detect the presence of the toxin 
genes via molecular methods, such as nucleic acid amplification tests (NAATs) 
(Kufelnicka and Kirn, 2011). Test performance varies widely and there is now 
increasing recognition of the advantages and disadvantages of each approach 
(Wilcox, 2011; Wilcox et al., 2010). CDI diagnosis remains a difficult issue for 
hospital diagnostic laboratories due to the lack of a single accepted gold 
standard (Curry, 2010). Indeed, a recent study evaluating multiple methods 
concluded that clinical outcomes differed according to the testing method 
employed, with multi-stage algorithms recommended over stand-alone 
approaches (Planche et al., 2013). 
In addition to high sensitivity, another crucial requirement for an ideal 
screening test is a rapid turnaround time (Fenner et al., 2008; Department of 
Health, 2012; Sharp et al., 2010; Swindells et al., 2010). Although some may 
argue that immediate results are not essential for CDI unless a patient has PMC 
or toxic megacolon (Wilkins and Lyerly, 2003), a rapid turnaround for CDI could 
reduce unnecessary antibiotic treatment that arises through the initiation of 
pre-emptive antibiotic therapy based on clinical evidence alone. Furthermore, a 
delay in results could potentiate transmission and hamper patient management. 
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Table 1.1 – Diagnosing Clostridium difficile infection (adapted from (Rupnik et al., 2009) 
 
C. diff: Clostridium difficile; CDI: Clostridium difficile infection; GDH: Glutamate dehydrogenase; PCR: Polymerase chain reaction; tcdB: Toxin B; *There are recent 
contradictory data regarding assay sensitivity; 
Question to be answered Detection method Advantages Disadvantages 
Is the organism present? 
Culture 
- Sensitive, but presence does not equate with 
infection as many C. diff strains are non-toxigenic 
- Useful for epidemiological investigation and 
surveillance 
- Slow turnaround times (days) 
- Suboptimal sensitivity in inexperienced hands 
- Requires anaerobic culturing capability 
Antigen (GDH) 
detection 
- High negative predictive value* 
- Rapid detection (hours) 
- Not specific for C. diff and therefore requires supplementary 
testing 
Is C. diff toxin present? 
Cytotoxin assay 
- Sensitive 
- High specificity for infection 
- Slow turnaround times (minimum 1–2 days) 
- Requires access to and/or experience of cell culture methods 
Enzyme 
immunoassays 
- Familiar methodology that can be used widely 
- Rapid (hours) 
- Variable sensitivity and specificity resulting in low positive 
predictive values, especially in populations with low prevalence of 
CDI 
- Requires laboratory facilities 
Membrane assays 
- Does not necessarily require laboratory facilities 
- Rapid (minutes to hours) 
- Variable sensitivity and specificity resulting in low positive 
predictive values, especially in populations with low prevalence of 
CDI 
Does the organism have the 
capacity to produce toxin? 
Cytotoxigenic 
culture 
- High sensitivity 
- Uncertain specificity for infection 
- Slow turnaround times (days) 
PCR detection of 
tcdB gene 
- High sensitivity 
- Rapid (hours) 
- Uncertain specificity for infection 
- Requires laboratory and molecular expertise 
- High cost 
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1.6.1 Cell cytotoxicity neutralisation assay & toxigenic culture 
CCNA was the accepted gold standard for many years. This comprises a two step 
approach where a cytotoxicity assay is firstly used to assess the ability of 
suspect faecal filtrates in causing apoptotic cell rounding, followed by an anti-
toxin neutralisation step that confirms whether or not this effect can be 
reversed through inoculation with a controlled amount of toxin-specific 
antibodies. The method has high specificity, can detect toxin (primarily tcdB) in 
the stool as low as 10 picograms (Iv et al., 2014) and a variety of cell lines can be 
used, including human foreskin cell monolayers and in-house cell lines such as 
Chinese hamster ovary K-1 cells (Bassetti et al., 2012). However, CCNA is the 
least-controlled test and combines high expense with a slow turnaround time 
(minimum of 2 days). Furthermore, there is a lack of standardisation across 
laboratories, with non-specific reactions commonplace in some, and the need 
for technical expertise and cell culture facilities means that application of this 
test is generally unavailable outside of a dedicated research facility or reference 
laboratory (Bassetti et al., 2012; Iv et al., 2014). 
More recently, toxigenic culture (TC) has been considered the method of choice 
due to the belief that it is more sensitive (Curry, 2010), though less specific, than 
CCNA when used in experienced laboratories. Stool is cultured for C. diff on 
specific, selective media such as Cycloserine–Cefoxitin–Fructose agar that 
allows recovery in the presence of enteric microbiota (George et al., 1979), and 
the organism’s ability to produce toxin is subsequently tested. Compared to 
CCNA, TC appears easier to apply on a routine basis and with the availability of 
internal control reference strains and the quality standards exerted by several 
brands on the production of effective selective media, TC also appears to be 
more reliable and reproducible. The 2010 guidelines provided by the Society for 
Healthcare Epidemiology of America/Infectious Diseases Society of America 
noted that “the sensitivity and specificity of stool culture followed by 
identification of a toxigenic isolate as performed by an experienced laboratory 
provides the standard against which other clinical tests should be compared” 
(Cohen et al., 2010). However, TC also comes with its limitations. The dual step 
approach of stool culture plus toxigenic culture means that turnaround time can 
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be anything up to a week, as opposed to the 24 and 48-hour values for positive 
and negative cytotoxicity assays, respectively. Most importantly, TC is only able 
to identify the potential of a strain to produce toxin but it does not measure 
actual toxin levels in the stool, which may lead to false conclusions. This is 
especially true when considering rates of asymptomatic colonisation, which 
may vary between 7% in hospitalised patients on admission (Kyne et al., 2000b) 
and 20% amongst elderly nursing home patients (Simor et al., 2002).  
Despite their high specificity and sensitivity, the turnaround times and technical 
demands posed by both CCNA and TC tests make them increasingly impractical 
for the routine diagnosis of CDI and management of patients.  
1.6.2 Enzyme immunoassay-detection of toxins A & B 
Toxin enzyme immunoassays (EIAs) are fast, convenient and inexpensive: 
unlike TC and CCNA they do not require specialist equipment/staff and they 
have a turnaround time of less than 24 hours. Advantages such as these resulted 
in their widespread uptake and they are now used by up to 90% of clinical 
diagnostic laboratories (Bartlett and Gerding, 2008). However, in terms of 
sensitivity and specificity, the assay performance of commercially-available C. 
diff toxin EIAs is considered sub-optimal when compared to gold-standard 
methods TC and CCNA. Although generally showing high specificity (~95%), 
sensitivity is low to moderate (60-90%) with some studies reporting sensitivity 
as low as 38% (Ticehurst et al., 2006): whereas CCNA has a reportedly lower 
limit of detection of around 10 picograms of toxin, the EIA usually requires 100-
1,000 picograms (Bartlett and Gerding, 2008). 
Positive predictive values (PPVs) and negative predictive values (NPVs) of all 
commercial EIAs may also vary depending upon the prevalence of the condition 
being detected. For instance, if positivity rates observed for C. diff in a given 
population decrease to 5-10%, assay PPV could be as low as 50% (American 
Society for Microbiology, 2010), thus potentially deeming them unacceptable 
for diagnostic purposes (Planche et al., 2008). Insufficient NPV results in false 
diagnosis of CDI, which can result in isolation of patients who are uninfected, 
leading to the misclassification of uninfected patients with those suffering from 
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active disease, unnecessary use of antibiotics and a delay in finding the true 
causes of the diarrhoea (Iv et al., 2014). 
Such lack of sensitivity has resulted in the current consensus that C. diff toxin 
EIAs should no longer be recommended as a standalone test (American Society 
for Microbiology, 2010). Confirmation of initial positive diagnoses, arising from 
one or more rapid sensitive screening methods and resulting in a two-step 
diagnostic algorithm, is strongly recommended and already in routine use 
across several laboratories. 
1.6.3 Detection of Glutamate Dehydrogenase antigen 
The lack of sensitivity and low NPV outlined above for toxin detection by EIA 
has led to a search for more accurate methods. GDH is a common, cell wall-
associated antigen expressed by all C. diff strains and as it is produced in 
significantly higher quantities than the toxins it results in a significantly more 
sensitive assay. Indeed, early studies reported sensitivity rates as high as 100% 
for C. diff detection (Peterson and Robicsek, 2009). Favoured due to their 
diagnostically-compatible turnaround time of 15-45 minutes, rapid GDH 
screening tests are increasingly popular, especially in tandem with the toxin 
EIA, to increase the sensitivity of current diagnostic algorithms. 
However, as with TC, GDH tests do not directly detect the presence of the toxin 
protein, nor can they distinguish between toxigenic (toxin-producing) and non-
toxigenic strains (Carman et al., 2012; Willis and Kraft, 1992). With 
approximately 20% of GDH positive-patients carrying a non-toxigenic strain 
(McFarland et al., 1989; Wilkins and Lyerly, 2003), the greatest utility of this 
assay appears to be as a primary screening step in a diagnostic algorithm. In 
such a scenario, GDH-negative specimens can be used to rule out negative cases, 
while GDH-positive specimens are then subject to a second test 
confirming/denying toxin production, thus giving increasing confidence for the  
diagnosis of the disease. 
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1.6.4 Nucleic acid amplification tests  
With the advent of diagnostic PCR-based commercial kits, PCR assays have now 
been applied for the detection of C. diff. Different regions have initially been 
targeted (Alonso et al., 1999; Arzese et al., 1995; Peterson et al., 2007) but since 
all pathogenic strains to date are able to synthesise tcdB, screening of the tcdB 
gene region (which is responsible for encoding the toxin) has become the 
mainstream standard. Although the cost can be significantly greater than for 
toxin EIA, the tcdB PCR-based assay is fast (turnaround time of 2 hours) and a 
meta-analysis comparing data from the four FDA-approved PCR assays against 
gold-standard TC returned a pooled sensitivity and specificity of 92 and 94%, 
respectively (O'Horo et al., 2012). Of these 4 approved assays, the Xpert C. diff 
assay (Cepheid, CA, USA) has been widely evaluated for routine diagnostics with 
its utility proven by various authors in comparative studies to both CCNA/TCA 
and EIA-based tests (Babady et al., 2010; Huang et al., 2009; Novak-Weekley et 
al., 2010; Tenover et al., 2010).  
Similarly to TCs, NAATs are able to identify toxigenic strains but do not measure 
the presence of the actual toxin in the stool and as a result concerns have been 
raised regarding over diagnosis due to the potential inclusion of asymptomatic 
carriers and issues related to the mandatory notification of CDI and inter-
hospital performance comparisons (Iv et al., 2014). Interestingly, the prevalence 
of positive samples has in fact increased since the introduction of PCR as a 
detection method, with some studies noting an increase from 6.5 to 15% (Fong 
et al., 2011). Secondly, findings that 56% of patients will be PCR-positive for 
months or years after completing therapy (Sethi et al., 2010) means that PCR 
cannot be used for suspected recurrence. Thirdly, the high expense involved 
with the necessary equipment limits its presence to a small handful of 
laboratories, though as these systems become increasingly validated and 
adopted, the likelihood is that their price will begin to drop. Finally, a recent 
meta-analysis of CDI diagnostic results obtained by PCR between 1995–2010 
found that the observed specificities and sensitivities were highly dependent 
upon the CDI prevalence rate, with decreasing prevalence resulting in 
decreased assay performance (Deshpande et al., 2011). Despite these 
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limitations, PCR may be diagnostically advantageous in epidemic conditions and 
multiples studies have demonstrated elevated sensitivity, specificity and test-
retest reliability, hinting that PCR is fast becoming an alternative gold standard 
to stool culture (Khanna et al., 2012c; Sloan et al., 2008). 
A variant method of the above involves detection of the toxin gene using loop-
mediated isothermal amplification (O'Horo et al., 2012). Targeting a conserved, 
204 bp region of the tcdA gene within the PaLoc, an FDA-licensed, commercial 
kit based on this method now exists (Illumigene, Meridian Bioscience, Europe). 
The Illumigene test is simple with a rapid turnaround time (one hour) and 
performance figures against the gold standards CCNA and TC have been 
promising (92% sensitivity, 98% specificity, 99% NPV and 84% PPV, 
respectfully; (Bamber et al., 2012)). However, since it is NAAT based, the main 
issue concerns its inability to specifically detect the C.diff toxins, which are the 
key causative agents of the disease. 
1.6.5 Non-laboratory testing: radiologic and endoscopic diagnosis 
Although the majority of CDI diagnosis takes place within a laboratory setting, 
the diagnosis of severe forms of the disease can sometimes be complemented by 
both radiology and endoscopy. Though not normally required for diagnosis of 
CDI, findings from abdominal CT scans such as the presence of pleural effusion 
and thickening of the colonic wall have both been associated with the 
development of severe disease. CT findings also correlate with other factors 
associated with severe disease including immunosuppression, leukocytosis and 
hypoalbuminemia (Valiquette et al., 2009). Lower GI endoscopy is able to 
highlight the presence of pseudomembranes or inflammation, as well as to 
collect tissue/stool samples for diagnostic purposes. It is recommended by The 
American College of Gastroenterology (ACG) guidelines when rapid diagnosis is 
necessary, for the exclusion of other coexisting etiologies including 
cytomegalovirus colitis, ischemic colitis or IBD, and when clinical suspicion is 
high but stool tests are inconclusive (Burkart et al., 2011; Fekety, 1997).  
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1.6.6 Algorithmic approaches 
With the incidence of CDI cases remaining relatively high in several developed 
countries, accurate and reliable laboratory diagnosis of CDI continues to be a 
priority. The limitations outlined above regarding the use of standalone tests 
based on toxin EIAs, GDH and PCR have led to the investigation of multiple 
algorithmic strategies for a confident CDI diagnosis. Such approaches are not 
novel and have become established for the diagnosis of other diseases, such as 
human immunodeficiency virus and syphilis. 
A recent study evaluated several diagnostic algorithms and concluded that 
diagnosis of CDI is improved by the use of two-stage algorithms (Davies et al., 
2012). Two of the more commonly recommended laboratory parameters are 
reliant on the initial detection of faecal GDH in stools, and NAAT, such as PCR, 
for the confirmation and detection of toxigenic C. diff strains (Crobach et al., 
2009; Surawicz et al., 2013). In England, updated guidance on the diagnosis and 
reporting of CDI (Department of Health, 2012) has been derived from a recent 
observational diagnostic NHS study of 12,441 specimens, resulting in the 
subsequent adoption of their recommended two-step algorithm (Figure 1.7) by 
affiliated NHS laboratories commencing in April 2012 (Department of Health, 
2012; Wilcox, 2012). Wilcox et al. evaluated the effectiveness of routine 
screening assays for GDH, the toxin gene and toxin itself, and found that an EIA 
for GDH detection or NAATs for toxin gene detection (including tcdB PCR) 
followed by confirmation of stool toxin (either by a relatively sensitive toxin EIA 
or CCNA) was the most effective testing algorithm in accurately distinguishing 
patients with and without CDI, resulting in enhanced specificity and PPV (90%) 
(Wilcox, 2012). This algorithm also identifies 'potential C. diff excretors', i.e. 
individuals with diarrhoeal samples that contain C. diff but without 
demonstrable toxin levels, who may be a relevant source of transmission of C. 
diff to susceptible patients. 
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Figure 1.7 - UK algorithm for CDI diagnosis taken from (Department of 
Health, 2012) 
35 
 
1.6.7 Complimentary Tests 
In practical terms, the simple detection of C. diff toxins combined with clinical 
evidence is all that is required for diagnostic purposes. However, 
characterisation of the strain through molecular typing, though generally not 
affecting therapeutic decision, can be useful for epidemiological surveys, 
outbreak monitoring and infection control (Janezic et al., 2012; Koene et al., 
2012; Mulvey et al., 2010).  
Several molecular typing methods have been introduced to study the 
epidemiology of C. diff (Table 1.2). Agarose gel-based PCR ribotyping is 
currently the most common method used across Europe to type C. diff, rising to 
prominence in 2003/4 with the emergence of the hypervirulent strain, PCR 
ribotype 027, whereas North America favour pulse field gel electrophoresis 
(PFGE). Usage of different typing methods results in different nomenclatures, 
which can complicate inter-laboratory data exchange. The epidemic strain 
responsible for the increase in CDI rates observed across North American 
hospitals, characterised as PCR ribotype 027 by PCR ribotyping, can also be 
characterised as B1 by restriction endonuclease analysis (REA) and Type 1 by 
PFGE (specifically North American pulse-field Type 1, or NAP1) (McDonald et 
al., 2005a). More recent developments include modified multiple-locus variable 
number tandem repeat analysis (mMLVA), capillary PCR-ribotyping and whole 
genome sequencing (WGS). 
WGS is increasingly being used for the study of C. diff transmission. Unlike 
multi-locus sequence typing (MLST) or PCR ribotyping, which are hampered by 
the large numbers of patients who share a genotype and hospital-based contact, 
WGS is able to show that substantial genetic diversity exists even within isolates 
of the same genotype (Didelot et al., 2012). Whilst most episodes of CDI are 
believed to result from recent acquisition within a health care setting, recent 
research using WGS has found that nosocomial transmission between 
symptomatic CDI cases contributes far less to current rates of infection than has 
been widely assumed (Didelot et al., 2012; Eyre et al., 2013). In particular, Eyre 
et al. found that 45% of all cases included in their study were genetically distinct 
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from all previous cases, clarifying the importance of future research into other 
transmission routes from genetically diverse sources other than symptomatic 
patients (Eyre et al., 2013). WGS can also be used with regards to disease 
recurrence, whereby it is able to distinguish between recurrences occurring due 
reinfection with a new strain or due to relapse with the same strain. This was 
recently used to demonstrate that was able to demonstrate that fidoxamicin is 
superior to vancomycin for preventing both reinfection and relapsing infection 
(Eyre et al., 2014). 
Reducing costs and high discriminatory power means it is likely that 
sequencing-based methods will be increasingly applied for C. diff 
epidemiological studies (Eyre et al., 2012a; Walker et al., 2012). Promising 
results from the initial WGS studies, described above, suggest that these 
approaches will become increasingly established in the next decade. 
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Table 1.2 – Summary of typing methods employed for characterisation of Clostridium difficile strains 
Technique Target Summary 
PCR 
ribotyping 
16S-23S ribosomal 
RNA spacer region 
Specific primers used for PCR-mediated amplification of the DNA encoding the target regions. Generates a few DNA bands as visualised by 
gel electrophoresis; the DNA band patterns are referred to as ribotypes 
PFGE SmaI restriction sites 
Enzyme cuts bacterial genome at target sites giving large DNA fragments. These are then slowly separated in a polyacrylamide gel, 
submitted to an electrical field in which the voltage repeatedly switches. The fragments migrate varying distances according to size and are 
visualised by DNA staining to reveal differences in banding patterns 
MLVA DNA repeat units 
Involves counting the numbers of repeat alleles in the genome for a series of predefined, conserved loci that are amplified by PCR. Requires 
expensive equipment but is highly discriminatory, and produces a consistent numerical result (code) for each strain that should be 
comparable between different laboratories 
REA 
HindIII restriction 
sites 
Relies on more frequent cutting of the bacterial genome than PFGE, resulting in large numbers of DNA fragments. These fragments are 
separated by electrophoresis in an agarose gel. This method is usually highly discriminatory, but produces complex DNA banding patterns 
that can be difficult to interpret and reproduce 
Toxinotyping 
B1 & A3 fragments of 
PaLoc 
RFLP-PCR based method where strains are assigned to 27 variant toxinotypes (I-XXVII), according to the lengths and restriction patterns of 
the two target fragments from the PaLoc when compared to the VPI 10463 reference strain 
MLST Housekeeping loci Similar in principle to MLVA 
AFLP 
PstI & MseI 
restriction sites 
Restriction enzymes cut genomic DNA, which is followed by ligation of adaptors to the ends of the restriction fragments. A subset of the 
restriction fragments are then amplified using primers that are complementary to the adaptor and part of the restriction site fragments, with 
the DNA visualised following gel electrophoresis 
AFLP: Amplified fragment length polymorphism; DNA: Deoxyribonucleic acid; MLST: Multi-locus sequence typing; MLVA: Multiple locus variable number tandem repeat 
analysis; PaLoc: Pathogenicity locus; PCR: Polymerase chain reaction; PFGE: Pulse field gel electrophoresis; REA: Restriction endonuclease analysis; RFLP: Restriction 
fragment length polymorphism; RNA: Ribonucleic acid;  
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1.7 Management 
Since this is an air borne transmissible disease, in order to prevent widespread 
transmission within hospitals, appropriate infection control measures should be 
implemented even before diagnosis of CDI has been confirmed. Updated 
measures for CDI prevention and control have been previously outlined in 
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 
guidelines (Vonberg et al., 2008), and termed a ‘bundle approach’. These 
generally include: - 
(a) Contact precautions such as the use of gowns and gloves, which 
has been shown to decrease CDI from 7.7 to 1.5 cases per 1,000 
discharges (Johnson et al., 1990) 
(b) Isolation and cohort nursing, thought to minimise horizontal 
transmission with patients in single rooms having a lower rate of 
transmission than those in double rooms (7% versus 17%) (McFarland 
et al., 1989) 
(c) Hand washing with soap and water, as alcohol rubs are ineffective 
against C. diff (Wullt et al., 2003), by all persons in contact with the 
patient including family and visitors 
(d) Environmental decontamination using chlorine-containing 
compounds or vaporised hydrogen peroxide (Gouliouris et al., 2011), 
with such standardised cleaning protocols having reduced infection rates 
on wards with high incidence of HA-CDI (Orenstein et al., 2011). 
With previous studies having suggested that the use of concomitant antibiotics 
is associated with a decreased cure rate as well as an increased risk of recurrent 
CDI (Garey et al., 2008; Mullane et al., 2011), it has been postulated that 
upstream antibiotic selection for non-clostridial infections may affect the risk 
for CDI infection (Malkan and Scholand, 2012). Therefore, it is imperative that 
such antibiotics should be discontinued whenever possible or, if absolutely 
necessary, conservative approaches should be in place, such as prescription for 
the shortest duration possible and/or the selection of targeted narrow 
spectrum antibiotics. This is known as antibiotic stewardship, supported by 
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evidence that restriction of high-risk antibiotics has been shown to reduce CDI 
risk (Aldeyab et al., 2012). There also remains the possibility for CDI-targeted 
antibiotic therapy to be started in elderly and severely ill patients who have 
pending stool test results but a high clinical suspicion of CDI due to risk factors 
and ongoing symptoms (Surawicz et al., 2013). Additional treatment measures 
may also include supplementary replacement of fluid and electrolytes, 
avoidance of anti-motility medications and a review of PPI use in high-risk 
patients (Bauer et al., 2009; Cohen et al., 2010; Janarthanan et al., 2012; 
Martinez et al., 2012; Surawicz et al., 2013). 
1.8 Treatment 
Metronidazole and vancomycin have been the mainstay treatment options for 
CDI for the last 30 years, which is rare for a common infectious disease in a 
developed country (Pepin, 2006) and is partially due to the lack of development 
of significant resistance (Iv et al., 2014). Indeed, from a number of recent 
studies there is no evidence for increased resistance to either metronidazole or 
vancomycin (Aspevall et al., 2006; Bourgault et al., 2006; Hecht et al., 2007). 
However, there are significant unmet medical and therapeutic needs including 
disease recurrence, meaning that a consensual drug of choice for treating CDI 
remains controversial. As such, the evolution of epidemic so-called 
hypervirulent strains have recently sparked doubts due to their increased 
resistance to a number of key antibiotics, such as quinolones and macrolides 
(Bourgault et al., 2006) This is consistent with results from complete genome 
sequencing of C. diff that revealed the presence of dynamic elements with the 
potential of developing antibiotic resistance (Sebaihia et al., 2006).  
More recently, a wide array of antibiotics and alternative therapies have been 
studied and as the epidemiology of CDI evolves, so should its treatment. Novel 
therapies or pre-existing strategies for CDI treatment have two main goals: 
eradicating the organism to ameliorate the infection, (despite continuation of 
concomitant therapy), and reducing the incidence of disease recurrence. This 
section summarises the current treatment options being pursued for the 
treatment and prevention of CDI. 
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1.8.1 Antibiotic therapy 
In addition to the two mainstays across all guidelines (vancomycin and 
metronidazole), a new FDA-approved drug has been brought to the market that 
is the only one shown to beat oral vancomycin in clinical trials: fidaxomicin.  A 
number of alternative therapies used in unusual circumstances have 
occasionally been tested for CDI, though with limited supporting evidence, such 
as nitazoxanide, rifaximin, teicoplanin and tigecycline (Bartlett, 2009; Johnson 
and Wilcox, 2012). 
1.8.1.1 Vancomycin and Metronidazole 
Although not FDA-approved for treating CDI, metronidazole is an inexpensive 
and generally effective treatment. Although under normal circumstances it is 
almost completely absorbed in the upper gastrointestinal tract, therapeutic 
levels are generally achieved in the faeces during diarrhoeal illnesses due to 
enhanced secretion across a more permeable gut mucosa (Bolton and Culshaw, 
1986). However, these levels can be modest and have been found to decrease to 
undetectable levels as mucosal inflammation improves and diarrhoea resolves 
(Bolton and Culshaw, 1986). Notably, metronidazole treatment has been shown 
to be less effective for CDI linked to specific strain variants, such as PCR-
ribotype 027 (Freeman et al., 2007). By contrast, due to negligible absorption by 
the intestinal tract, colonic levels of vancomycin are approximately 1,000-fold 
higher than the MIC of vancomycin for C. diff (Baird, 1989), meaning that 
suppression of C. diff to an undetectable level and resolution of diarrhoea occur 
more rapidly (Al-Nassir et al., 2008; Wilcox and Howe, 1995). A reliable but 
more costly treatment, vancomycin was the first, and until very recently, the 
only, FDA-approved drug for the management of CDI. Although concerns have 
previously been raised over links between vancomycin use and promotion of 
colonisation and transmission of vanomycin-resistant enterococci (VRE), results 
from a recent retrospective analysis indicate such concerns may be misplaced 
(Miller et al., 2010a). 
Despite having been the mainstays for treatment of CDI since 1978, until 2007 
only two prospective randomised trials compared vancomycin and 
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metronidazole, which incidentally demonstrated cure rates above 90% and no 
relevant differences between the two treatment options (Teasley et al., 1983; 
Wenisch et al., 1996). However, these studies were not blinded or placebo-
controlled and the treatments were not stratified by disease severity. Several 
studies have highlighted vancomycin’s superiority over metronidazole (Al-
Nassir et al., 2008; Lahue and Davidson, 2007; Wilcox and Howe, 1995; Zar et 
al., 2007), and results from a more recent clinical study further support this 
(Johnson et al., 2014). Metronidazole was inferior to vancomycin for achieving 
clinical success, with subgroup analyses demonstrating a similar trend in both 
moderate and severe patients, in CDI caused by PCR-ribotype 027, in patients 
over 65 years and for the treatment of first CDI recurrence (Johnson et al., 
2014). Furthermore, in a retrospective case record analysis, symptomatic 
response time was shown to be significantly shorter for patients treated with 
vancomycin as opposed to metronidazole (Wilcox and Howe, 1995). 
Progress has certainly been made, and current guidelines now reflect research 
arising from randomised, clinical trials that looked at stratification of 
treatments based on key outcomes, such as disease severity and recurrence. In 
mild-to-moderate CDI, oral metronidazole (e.g. 250–500 mg 3–4 times a day for 
10–14 days) is considered equivalent to vancomycin (Cohen et al., 2010; 
Surawicz et al., 2013; Zar et al., 2007), and is recommended for patients with 
first infection or first recurrence of mild/moderate CDI in the absence of 
contraindications (Cohen et al., 2010). Second or later recurrence of CDI should 
be treated with vancomycin, using a tapered and/or pulse regimen, as per 
recommendation by ESCMID. Oral vancomycin is also recommended for the 
treatment of severe CDI (125 mg 4 times a day for 10 days) due to its superior 
cure rates in these patients (97% versus 76%) (Cohen et al., 2010; Surawicz et 
al., 2013). In seriously ill patients with severe-complicated CDI, a higher dose 
(250–500 mg) in combination with intravenous metronidazole is recommended 
(Cohen et al., 2010). 
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1.8.1.2 Fidaxomicin 
Whilst generally effective in controlling C.diff levels, vancomycin and 
metronidazole are broad-spectrum antibiotics that significantly prolong colonic 
dysbiosis, a side effect that may predispose patients to disease recurrence. The 
macrocyclic antibiotic fidaxomicin, recently approved in Europe and North 
America for the treatment of CDI, has a narrow spectrum of activity against 
Gram-positive aerobic and anaerobic bacteria, including C. diff (Gerber and 
Ackermann, 2008), and is seemingly less disruptive to the commensal 
microbiota. Furthermore, it has a bactericidal mechanism of action (Venugopal 
and Johnson, 2012), a safety profile comparable to that of vancomycin (Weiss et 
al., 2012), and undetectable serum levels, whilst often achieving high faecal 
concentrations that average greater than 10,000 times the MIC for C. diff (Sears 
et al., 2012). Fidaxomicin delivered close to full protection in a hamster model 
of CDI (Johnson, 2007) and there are signs for its role in reducing toxin re-
expression and CDI recurrence (Louie et al., 2012). 
The majority of the attention surrounding fidaxomicin stems from the findings 
of two prospective, multi-centric, double-blind, randomised phase III trials, 
which demonstrated its non-inferiority to vancomycin for clinical cure rate, but 
superiority in reduction of recurrence and sustained clinical response (cure 
without recurrence during the 30 day follow-up) upon meta-analysis (Crook et 
al., 2012). Interestingly, when the meta-analysis was limited to the epidemic 
PCR-ribotype 027 strain, a 22% non-significant reduction in 
persistent/recurrent diarrhoea was observed (Crook et al., 2012). Although this 
lack of association may in fact be due to lack of power, the finding demonstrates 
that treatment of PCR-ribotype 027-associated cases remains more challenging. 
Most recently, fidaxomicin was shown to be successful in resolving CDI in an in 
vitro gut model, with observations of supra-MIC levels and prevention of spore 
recovery, therefore underscoring the in vivo observations that fidaxomicin is 
associated with a reduced risk of disease recurrence (Chilton et al., 2014).  
There are calls for prescription of fidaxomicin in the treatment of severe CDI 
patients at high risk of recurrence (Hu et al., 2009; Wilcox et al., 2012). 
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However, the current major stumbling block for its routine use concerns its 
extremely high costs. Its current average wholesale price is 135 US dollars 
(Lancaster and Matthews, 2012), compared to 0.72 for a 500 mg dose of 
metronidazole and 31.81 US dollars for a 125mg vancomycin capsule (Lancaster 
and Matthews, 2012). Therefore, the estimated costs for a 10-day course of 
fidaxomicin therapy (2 times daily) would be $2700, compared to the $22 and 
$1270 associated with metronidazole (3 times daily) and vancomycin 125 mg (4 
times daily), respectively (Lancaster and Matthews, 2012). The pharmaceutical 
company responsible for its retail is now developing several strategies to assist 
in cost reduction (Iv et al., 2014), with further studies needed on its cost-
effectiveness in CDI. 
1.8.1.3 Others 
A variety of other antibiotics have been explored for the treatment of CDI. These 
are summarised in Table 1.3. 
1.8.2 Non-antibiotic therapy 
1.8.2.1 Surgical management 
Surgical intervention is an aggressive alternative therapy and tends to be 
restricted to patients suffering from severe-complicated CDI, with colectomy 
having long been the procedure of choice. Indications include failure to respond 
to maximal medical management, caecal dilatation larger than 10 cm and 
presence of bowel perforation. A review of 165 CDI cases requiring admission to 
the intensive care unit (ICU) during the Quebec epidemic season between 2003-
2005 observed a significant decrease in mortality in individuals who had 
undergone a colectomy compared to those treated medically (Lamontagne et al., 
2007). However, that study was retrospective in nature and there are 
conflicting data regarding the preferred surgical procedure (Dallal et al., 2002; 
Koss et al., 2006; Neal et al., 2011). Most recently, a novel colon-sparing surgical 
procedure has been proposed as an interesting alternative to total colectomy 
(Neal et al., 2011). While further studies are needed to evaluate the beneficial 
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impact of this approach, colectomy remains the procedure of choice (Surawicz 
et al., 2013).  
Even after surgical intervention, mortality rates remain quite high (averaging 
over 50% in some series) (Dallal et al., 2002). With early surgery having been 
shown to be superior to delayed surgery in improving patients’ outcomes, early 
surgical consultation should be pursued for all severe-complicated CDI patients.  
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Table 1.3 – Overview of alternative antibiotics used for treatment of Clostridium difficile infection 
Antibiotic Details Pros Cons Considerations 
Nitazoxanide Anti-parasitic drug 
 
Highly active in vitro against C. diff 
 
Shown to prevent colitis in the hamster model 
 
Shown to be as effective as vancomycin & metronidazole 
for treatment of CDI 
 
 
Lack of safety and efficacy data 
 
Has not been directly compared 
against other drugs 
 
May currently only be considered as an alternative in 
patients unresponsive to standard therapy who may not 
be suitable candidates for FMT 
Rifaximin 
Broad spectrum 
antimicrobial 
 
Excellent in vitro activity against C. diff 
 
Not thought to significantly alter gut microbiota 
 
Studies demonstrate similarity to vancomycin 
for resolution of diarrhea and rates of recurrence 
 
Inferiority to vancomycin for 
achievement of clinical success 
 
Potential for resistance 
 
Not currently recommended as a monotherapy for 
CDI 
 
May be used at the end of primary treatment with 
vancomycin in an attempt to decrease recurrences 
(‘rifaximin chaser’) 
Teicoplanin 
Semi-synthetic 
glycopeptide antibiotic 
 
Spectrum of activity similar to that of vancomycin 
 
Equivalent, or in some cases superior, to vancomycin 
 
Licensed indication for treatment of CDI since 2013 
 
Lack of availability in the US 
 
High associated costs 
The cons associated with teicoplanin limit its use 
Tigecycline 
Broad-spectrum 
glycylcycline antibiotic 
 
Achieves fecal concentrations well above MIC for C. diff 
 
Doesn’t induce C. diff toxin production in vitro 
 
Several reports demonstrated success in severe CDI 
 
Not licensed for this indication 
 
No clinical trials conducted to date 
 
Recent report refuted its efficacy 
Despite initial promise, caution is urged for 
indiscriminate off-label use. Data from prospective 
clinical trials is needed. 
 
C. diff: Clostridium difficile; CDI: Clostridium difficile infection; FMT: Faecal microbiota therapy; MIC: Minimum inhibitory concentration; US: United States;  
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1.8.2.2 Reestablishment of colonic microflora 
As discussed previously, the human colonic microflora is one of the most 
important natural barriers against colonisation and infection by C. diff. 
Alterations in the balance of intestinal flora, such as those triggered by broad 
spectrum antimicrobials, have a critical role in disease pathogenesis (Na and 
Kelly, 2011). The host’s inability to restore gut microfloral balance is a 
commonly observed feature of disease recurrence (Lawley and Walker, 2013; 
Newton et al., 2013). Therefore, it is worth considering measures that promote 
restoration of gut microbiota diversity for future management of CDI patients. 
Such therapies have gained ground in recent years, and two approaches have 
been the subject of intense debate: the use of probiotics, and faecal microbiota 
transplantation (FMT).  
Probiotics 
Probiotics are living microorganisms that confer a health benefit to the host 
(World Health Organisation, 2001), with increasing evidence for their use in a 
variety of gastrointestinal conditions (Floch et al., 2011). A number of probiotic 
strains have been tested across CDI studies, most commonly Lactobacilli 
(especially Lactobacillus rhamnosus GG) and the yeast Saccharomyces boulardii 
(Parkes et al., 2009; Tasteyre et al., 2002). Activity against C.diff and other 
opportunistic pathogens, as well as modulation of host response, has been 
demonstrated experimentally using both in vitro studies and animal models 
(Castagliuolo et al., 1999; Chen et al., 2006; Qamar et al., 2001; Trejo et al., 
2006), and several recent meta-analyses have endorsed potential benefits for 
the use of probiotics (Martin et al., 2013). However, these meta-analyes are 
limited due to a lack of standardisation across studies and the administration 
method employed. 
Overall, there is a lack of large randomised controlled trials (RCTs) that include 
CDI treatment as a primary outcome, and results obtained from the existing 
RCTs are variable. Thus current evidence for the use of probiotics in treating 
CDI is limited and they cannot currently be recommended (Cohen et al., 2010; 
Public Health England, 2013). Further research involving large and well-
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controlled studies is clearly needed to fully determine the efficacy of this 
approach. One such study completed recruitment in 2012 but the results have 
yet to be published (Allen et al., 2012). 
Faecal Microbiota Transplantation 
In contrast, FMT appears highly effective for the treatment of CDI. First used 
over 50 years ago to successfully treat PMC that was later found to be due to CDI 
(Eiseman et al., 1958), this process is based on the concept that microorganisms 
in the stool of a healthy donor can re-establish microfloral diversity and 
suppress C. diff. In such an approach, the donor faeces is initially screened for 
transmissible infectious pathogens and then transferred into a CDI patient’s 
lower proximal, lower distal or upper GI tract via one of many employed 
methods including enema, nasogastric tube and colonoscopy. 
FMT has been proposed as an alternative treatment for patients suffering from 
both severe unresponsive and recurrent disease (Pacheco and Johnson, 2013; 
Russell et al., 2010), and existing data are very compelling. One study was able 
to show that the post-transplant bacterial composition of the recurrent CDI-
recipient’s stool becomes remarkably similar to that of the healthy donor 
(Khoruts et al., 2010). Recent meta-analyses of previous case series have 
reported clinical ‘cure’ rates of over 90% for refractory CDI (Guo et al., 2012; 
Kassam et al., 2013; Sofi et al., 2013). Notably, the first randomised controlled 
trial recently demonstrated that FMT following antibiotic treatment with an 
oral glycopeptide is highly effective in treating patients with multiple recurrent 
CDI (van Nood et al., 2013). 
Despite these promising results demonstrating FMT’s benefit to a large number 
of patients, the procedure is still regarded as a last resort treatment. However, 
recently published ECSMID guidelines strongly support FMT in combination 
with oral antibiotic therapy for multiple recurrent CDI cases, especially for 
those who have been unresponsive to repeated antibiotic therapy (Debast et al., 
2014). The recent introduction of a US FDA mandate requiring approval of FMT 
as a drug (Food and Drug Administration, 2013) may further restrict its use 
though it is hoped that similarly efficacious synthetic bacterial mixtures can be 
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developed for treating CDI in the future with investigative studies already 
underway. 
1.7.8.3 Binding agents 
Non-absorbable, anion exchange resins that remove cytotoxic activity through 
binding of C. diff toxins have also been used to treat CDI. Advantages of such a 
method include no disturbance of the normal intestinal flora (potentially 
decreasing the risk of recurrent disease), no underlying resistance issues, the 
availability of a non-antibiotic therapy for an antibiotic-induced disease, and 
relatively lower costs (Taylor and Bartlett, 1980). In the early stages 
cholestyramine and colestipol (Kreutzer and Milligan, 1978) were investigated 
but their observed activity was modest and thus other candidates were 
pursued, such as Tolevamer. Despite promising results in phase II (Louie et al., 
2006), Tolevamer’s performance was overshadowed in phase III studies by 
comparatively superior antimicrobial standard therapy with either 
metronidazole or vancomycin (Johnson et al., 2014). Designing non-antibody 
molecules that are able to sustainably bind with high affinity and avidity to C. 
diff toxins whilst at the same time avoiding other substrates circulating in the 
gut is extremely challenging and it is thought that monoclonal antibodies 
(MAbs) (see section 1.7.8.4) constitute a more realistic approach for toxin 
immobilisation or neutralisation (Lowy et al., 2010). 
1.7.8.4 Immunotherapy 
The prominent role of humoral immunity in neutralisation and clearance of 
C.diff toxins is widely accepted. As such, mounting a robust C. diff anti-toxin 
response has been shown to confer protection against the development of CDI 
following nosocomial colonisation with the organism (Kyne et al., 2000a, 2001), 
with mildly affected patients displaying high levels of anti-toxin 
immunoglobulin G (IgG) (Kyne et al., 2001; Viscidi et al., 1983; Warny et al., 
1994) and recurrent patients having comparatively lower anti-toxin Ig titres 
(Katchar et al., 2007; Kyne et al., 2001). Based upon this, early researchers 
hypothesised that anti-toxin neutralising antibodies could potentially become a 
primary line for treating CDI given their specificity for the toxins. Termed 
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immunotherapy, methods currently being used include the introduction of 
intravenous immunoglobulins or monoclonal antibodies (known as passive 
immunisation), and vaccination (known as active immunisation). 
Passive immunisation 
Intravenous immunoglobulin (IVIG) involves the administration of a blood 
product containing the pooled, polyvalent IgG antibodies isolated from multiple 
blood donors. This therapy has been used sporadically for the treatment of CDI 
since 1991 (Stanley et al., 2013), and its use for treating severe refractory and 
recurrent CDI has been met with mixed feelings by the scientific community due 
to variable rates of success. Although 15 small, mostly retrospective and non-
randomised reports have documented successful treatment of protracted, 
recurrent or severe CDI using IVIG, there are no randomised control trials 
endorsing its benefits (Abougergi et al., 2010). Furthermore, meta-analysis of 
these studies concluded that there is a lack of evidence to prescribe its use, 
though it is acknowledged that this is in part due to lack of consensus on 
indications, dosage, and/or data from trials tailored in design (Abougergi et al., 
2010). When combined with the fact that the cost of an individual IVIG 
approaches $10,000 per treatment course, clear cut proof of efficacy is 
important. A prospective study was undertaken evaluating the utility of IVIG in 
combatting severe CDI (Juang et al., 2007), but these results were inconclusive 
and could not demonstrate an obvious role for IVIG in ameliorating symptoms. 
In 2013, the ACG assessed its use for recurrent CDI, with subsequently 
published guidelines concluding that it does not have a significant role as a sole 
therapy agent in part due to a potential lack of specificity (Surawicz et al., 2013). 
Results from administration of mAbs directed against tcdA and tcdB seem 
slightly more promising. Having previously reduced hamster mortality 
following intra-peritoneal injection (Babcock et al., 2006a), the most successful 
study to date involves concurrent administration of two full MAbs (one against 
tcdA, the other against tcdB) in 200 symptomatic CDI patients concomitantly 
receiving either metronidazole or vancomycin (Lowy et al., 2010). This 
randomised, double-blind, placebo-controlled study found that overall 
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recurrence rate was remarkably lower in the MAb group compared to those 
receiving placebo (7 vs. 25%; p<0.001) (Lowy et al., 2010). Notably, it has also 
been shown that MAbs have a long serum half-life, typically 14-21 days for 
human IgG1 (Wang et al., 2008), which is a significant time frame given the 
typical duration of a primary episode and potential disease recurrence periods. 
Collectively, these results suggest that MAbs may represent a useful treatment 
option for CDI, with single infusions or sub-cutaneous injections offering 
sustained protection against primary and recurrent infections, respectively. 
Although this approach is not yet commercially available, it is now being 
pursued by large pharmaceutical companies with a phase III study underway to 
further establish its efficacy and safety (Khanna and Pardi, 2014). 
Active immunisation 
The current chief approach considered for the prevention of CDI is through the 
development of a vaccine, with substantial progress having been made in recent 
years. In 2005, Sougioultzis et al. reported successful prevention of further 
recurrence in 3 separate patients suffering from recurrent CDI who had been 
vaccinated with intramuscular administration of tcdA and tcdB (Sougioultzis et 
al., 2005). In 2010, Leav et al. showed that their toxoid vaccine was capable of 
inducing serum anti-tcdA and anti-tcdB IgG antibody levels that were typically 
associated with protection against recurrent CDI (Leav et al., 2010). More 
recently, development of a chimeric anti-toxin vaccine using an endotoxin-free 
expression system derived from Bacillus megaterium has begun, with initial 
data showing its capability for neutralising anti-toxin production and 
preventing spore-induced recurrence (Wang et al., 2012). 
Another pharmaceutical company, Sanofi Pasteur, has recently completed six 
Phase I trials across 200 individuals using bivalent formalin-inactivated 
vaccines against tcdA and tcdB, with the development of detectable specific 
antibodies (termed seroconversion) in 75% of participants by day 70 (Foglia et 
al., 2012). With their initial studies having verified safety and immunogenicity, a 
phase II trial of the vaccine assessing prevention of primary CDI is currently 
ongoing with 650 at risk US adults (Sanofi Pasteur). Other major vaccine 
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manufacturers are currently at a pre-clinical stage, utilising a similar parenteral 
approach. The major challenge for vaccine studies is related to their prospects 
for delivering immunity against all major nosocomial strains of C. diff as well as 
fully preventing CDI in a clinical setting for both primary and recurrent cases. 
1.8.3 Summary 
A recent Cochrane review of 15 studies concluded that a formal 
recommendation for a consensual antibiotic therapy of CDI could not be made 
(Nelson et al., 2011). Current comparison across studies is challenging due to a 
lack of standardisation. In particular, the use of varying definitions of disease 
severity result in the definition of phenotypically distinct populations, which in 
turn result in mixed conclusions, and this is especially true for small treatment 
groups (Wilcox, 2014). Therefore, the use of a standardised severity definition 
across all drug trials would certainly be beneficial but the lack of independently 
validated prediction tools that robustly define therapeutic clinical outcomes in 
CDI makes the task extremely difficult. 
Despite the observed limitations, there is an urgent need for clear cut and 
updated guidelines for the treatment of CDI. Guidelines are now stratifying 
treatment recommendations based on clinically defined sub-groups, including 
non-severe disease, severe disease, first recurrence and multiple recurrences. 
Recently updated ESCMID guidelines (Debast et al., 2014) are summarised in 
Figure 1.8. 
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Figure 1.8 – Schematic overview of therapeutic regimens for Clostridium difficile infection (taken from (Debast et al., 2014) 
1 Severe CDI or complicated course: surgical therapy not included in this overview; 2 It can be considered to increase the oral dosage of vancomycin to 500 mg four times 
daily for 10 days (B-III); 3 There is no evidence that supports the use of fidaxomicin in life-threatening CDI (D-III); Strength of recommendation (SOR) A = green (strongly 
suggests a recommendation for use); SoR B = blue (moderately supports a recommendation for use); SoR C = grey (marginally supports a recommendation for use); SoR 
D = red (recommendation against use). 
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1.9 Prognosis 
As outlined in section 1.8, guidelines for the stratification of treatment have 
become reliant upon disease outcomes. This is mainly due to the dramatic 
increases observed in disease severity, recurrence and mortality in the last 
decade. Although the majority of patients tend to initially respond well to either 
vancomycin or metronidazole, a significant amount of patients suffer from 
recurrence, with reported rates varying between 5 and 50% (Aslam et al., 
2005). Recurrent CDI remains a substantial challenge as it inevitably increases 
transmission periods and an initial recurrence constitutes a predisposing state 
that is often followed by further similar episodes. Pooled attributable mortality, 
within 90 days of diagnosis, has risen from 3.64% prior to the year 2000 to 
8.03% post-2000 (Karas et al., 2010). It has been shown that hospitalised 
patients with CDI are 2.74 times more likely to die during their hospitalisation 
stay than all other non-CDI patients (Wenisch et al., 2012), and absolute 
mortality within 30 days is increased by 10% in the presence of CDI (Loo et al., 
2005; Oake et al., 2010). 
At initial disease presentation most patients display similar symptoms and 
therefore predicting who may progress to experience unfavourable outcomes is 
difficult, though much needed. Identifying clinical parameters or host-related 
factors associated with adverse outcomes would improve the management of 
CDI in the early stages, and would enable the promotion of novel interventions 
for the prevention of recurrence (Johnson, 2009; Louie et al., 2011) or 
alternatively more aggressive treatment for patients at most risk of clinical 
complications (Bauer et al., 2009; Cohen et al., 2010). Progress within diagnosis 
of CDI (described in section 1.6) has resulted in molecular testing for tcdA and 
tcdB becoming more common in the US, whilst toxin detection remains the test 
of choice in Europe (Burnham and Carroll, 2013; Crobach et al., 2009). Use of 
these different tests has also generated an increasing need for treatment 
stratification based on defined clinical criteria/host biomarkers (Boone et al., 
2014). 
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A myriad of variables have been associated with increased CDI severity, 
recurrence and mortality, including increasing age, concomitant antibiotics 
and/or PPIs use, underlying comorbidities, fever, abdominal pain, increased 
WCC, elevated serum creatinine, decreased serum albumin, admission to ICU, 
PCR-ribotype and previous episodes of CDI (Belmares et al., 2007; Bishara et al., 
2008; Fujitani et al., 2011; Garey et al., 2008; Henrich et al., 2009; Hu et al., 
2009; Keddis et al., 2012; Khanna et al., 2013b; Miller et al., 2010b; Pant et al., 
2010; Pépin et al., 2004; Rodríguez-Pardo et al., 2013; Walker et al., 2013; Zar et 
al., 2007). A great deal of attention has been placed on information available at 
the time of diagnosis such as clinical/admission data and blood biomarkers 
routinely measured during a patient’s hospitalisation in order to facilitate 
development of simple scoring systems, or clinical prediction rules (CPRs) that 
could be used at the patient’s bedside for both prognostic care and treatment 
guidance, as well as evaluating response to therapy. Prevalent across varying 
areas of clinical medicine, multiple CPRs are in routine use across 
gastroenterology specialties (Forrest et al., 2005; Malinchoc et al., 2000; Rockall 
et al., 1996). Despite the existence of several CPRs for the prediction of CDI 
outcomes, none have gained widespread clinical acceptance, with a recent 
systematic review of 13 identified CPRs utilised for unfavourable CDI outcomes 
concluding that current implementation of existing CPRs is limited by several 
methodological issues, heterogeneity of phenotype definition and a lack of 
statistical power (Abou Chakra et al., 2012). 
Other biomarkers not routinely assessed in a clinical setting have been 
experimentally investigated, although only a small number of associations have 
been identified to date. Host anti-toxin immunoglobulin response has been 
shown to play a key role in influencing the duration of disease (Warny et al., 
1994), and determining the risk of recurrence (Kyne et al., 2001; Warny et al., 
1994) and mortality (Solomon et al., 2013). As well as the induction of an anti-
toxin response, some attention has been given to the release of pro-
inflammatory cytokines in vitro elicited by toxin exposure, thus constituting 
plausible candidates (Hippenstiel et al., 2000; Ishida et al., 2004). The single 
nucleotide polymorphism (SNP) rs4073/-251T>A within the gene encoding 
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pro-inflammatory cytokine interleukin-8 (IL-8) remains the only genetic 
association with CDI reported to date, with the AA genotype being shown to 
increase the odds of developing CDI, as well as experiencing recurrent disease, 
by at least 3-fold (Garey et al., 2010; Jiang et al., 2006; Jiang et al., 2007). The 
increase in secretion of pro-inflammatory cytokines results in augmented 
intestinal inflammation (Kelly and Kyne, 2011; Savidge et al., 2003), and 
consequently two faecal biomarkers widely used in IBD as indicators of 
intestinal inflammation, lactoferrin and calprotectin (D'Incà et al., 2008; García-
Sánchez et al., 2010; Jones et al., 2008; Langhorst et al., 2008; Schoepfer et al., 
2009; Schoepfer et al., 2010; Schoepfer et al., 2008; Sipponen et al., 2008a; 
Sipponen et al., 2008b; Sipponen et al., 2008c; van Langenberg et al., 2010), 
have been pursued for the study of CDI, with positive associations in a number 
of studies (Archbald-Pannone et al., 2010; Boone et al., 2013; El Feghaly et al., 
2013; LaSala et al., 2013; Shastri et al., 2008; Vaishnavi et al., 2000; Whitehead 
et al., 2014). Most recently, associations with poor CDI outcomes have been 
identified with interleukin-23 (IL-23) (Buonomo et al., 2013) and procalcitonin 
(PCT) (Rao et al., 2013). 
1.10 Aims of the thesis 
Despite the considerable progress made in relation to CDI diagnosis and 
treatment, the increasing burden of disease-related outcomes including 
recurrence and mortality means that a lack of robust prognostic markers 
remains a priority area for significant advances. Although numerous clinical 
investigations have been conducted for CDI, there remains no single parameter, 
or combination of parameters,  validated for the stratification of patient therapy, 
with the majority of studies suffering from suboptimal study design, 
inconsistent outcome definitions, small sample size, and a lack of 
standardisation (Abou Chakra et al., 2012). 
A similar situation can be seen with the associations identified for non-routinely 
measured biomarkers. Genetic associations with IL-8 have not been 
independently replicated, and studies assessing faecal biomarkers such as 
lactoferrin and calprotectin suffer from a wide array of limitations. Since the 
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majority of the significant associations regarding host anti-toxin response were 
identified, the CDI research landscape has undergone a significant reshuffle: the 
emergence of epidemic, CDT-producing strains has resulted in a need for re-
evaluation of existing concepts. Furthermore, the question remains as to 
whether more specific CDI biomarkers are yet to be discovered or whether the 
current methodologies simply lack the necessary credentials to achieve 
validation. This is of particular importance within vaccine development, 
whereby quantitation of antibody response is hampered by reliance on limited 
in-house ELISA methods and the absence of more innovative supporting 
approaches. 
Using a prospective cohort of carefully phenotyped individuals, this thesis aims 
to: - 
1. Determine independent risk predictors of CDI disease outcomes 
such as severe-complicated disease, recurrence and mortality, and to 
assess the consistency of existing clinical prediction rules for each 
individual outcome. 
 
2. Evaluate the IL-8 genetic variant implicated in predisposing to 
CDI and recurrent disease, relate it to faecal IL-8 levels and undertake a 
meta-analysis using available literature. 
 
3. Simultaneously evaluate both faecal lactoferrin and calprotectin 
in order to investigate whether these faecal biomarkers would add 
clinical value in the stratification of complicated CDI patients 
 
4. Develop a novel, sensitive assay for the quantification of host 
immune response to tcdA, tcdB, and CDT, the latter being a novel 
approach previously not reported in the literature.  
 
5. Evaluate the potential role of mannose-binding lectin (MBL), a key 
activator of the complement system and modulator of inflammation, as a 
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novel diagnostic/prognostic candidate for CDI and related outcome 
measures. 
 
6. Investigate the role of immunoglobulin G- and immunoglobulin 
M-driven responses to both tcdA and tcdB, as well as the previously 
uninvestigated CDT, as predictors of poor CDI outcomes. 
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Chapter 2 
PhD/Cohort study overview  
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2.1 Background 
My PhD formed part of an ongoing NIHR-funded research study that was set-up 
in 2008 as part of Liverpool’s Biomedical Research Centre status at the Royal 
Liverpool University Hospital: “Clostridium difficile-associated toxin disease: 
development of a tool to predict individual susceptibility based on 
environmental and genetic factors”. 
I was originally employed as a research technician to process the samples from 
this and other departmental studies in April 2008. In September 2009, my PhD 
began on a part-time basis alongside this role, funded through the Liverpool 
BRC. However, in late 2011 it was announced that Liverpool had not been 
renewed and as a BRC centre and from 1st April 2012 I would have no further 
funding. I was therefore encouraged to apply for an NIHR Biomedical Research 
Fellowship in order to obtain the necessary funding to continue my PhD. I was 
successful in my application (ref: BRF-2011-028) and received 18 months 
funding on a full-time basis, commencing 1st April 2012. 
2.2 Study overview 
2.2.1 Study design 
At study inception, we aimed to prospectively recruit 300 CDI cases and 300 
AAD controls, based upon the following power analysis taken from the initial 
study application: 
“We are unable to provide realistic power calculations in advance. However, we 
can calculate power for some simplistic analyses. In particular, for the power 
calculations below, we consider carrier / non-carrier analysis for a single SNP and 
a binary outcome (e.g. benefit/no benefit) or time to event outcome. Thus, the 
values given below are expected to substantially understate the true power of the 
studies, since combinations of SNPs will be analysed simultaneously via haplotype 
and regression-based analyses, and quantitative response variables will be 
available. A key variable is the frequency of variant carriers among patient. For 
rarer variants to be clinically important, their effect size (odds ratio (OR) or 
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hazard ratio (HR)) must be large. We therefore specify two benchmarks for the 
power analyses: we seek to have good power for (a) OR/HR=3 and a rare variant 
(p=5%); (b) OR/HR=2 for a common variant (p=20%). Note that these effect sizes 
are for a single causal variant, we expect to realise much larger overall effect sizes 
via combinations of causal variants. The assumed type 1 error is 5%.” 
2.2.2 Patient recruitment 
An overview of the recruitment process is provided in Figure 2.1. Ethical 
approval was obtained from the Liverpool Research Ethics Committee 
(reference number 08/H1005/32) and each patient provided written informed 
consent prior to recruitment. Blood and faecal specimens were collected from 
patients at study entry. 
2.2.2.1 Case and control definitions 
CDI cases: 
 Positive laboratory diagnosis of CDI (TOX A/B II, Techlab, Blacksburg) 
 Aged ≥18 years 
 Healthcare-associated diarrhoea 
o ≥3 liquid stools in 24 hours preceding assessment 
o Onset after being in hospital for >48 hours 
 Recent exposure (within 30 days) to antimicrobials and/or PPIs 
AAD controls: 
 Negative laboratory diagnosis of CDI (Toxin EIA A/B) 
 Aged ≥18 years 
 Healthcare-associated diarrhoea 
o ≥3 liquid stools in 24 hours preceding assessment 
o Onset after being in hospital for >48 hours 
 Recent exposure (within 30 days) to antimicrobials and/or PPIs 
 Strict exclusion criteria (see Figure 2.3) 
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Samples were then subject to microbiological culture. Any AAD control samples 
testing positive for culture were excluded from the study. 
 
 
Figure 2.1 – Overview of recruitment process for CDI cohort study 
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2.2.2.2 Amendments 
The adjustment of prior antimicrobial/PPI exposure to within 90 days outlined 
in the first substantial amendment (see flowchart) was necessary as throughout 
the study we noticed a significant number of new CDI cases in our Trust, where 
patients had no antibiotics in the previous 30 days while having a documented 
history of antibiotic usage in the 90 day period before the index date. The 3-
month guideline was also corroborated by the infection control team in our 
Trust and backed by reports from the recent literature (Dial et al., 2006; Dial et 
al., 2008). 
This substantial amendment also allowed us to recruit patients who lacked 
capacity through the involvement of a consultee. Until that date, approximately 
40% of patients approached had been ineligible to participate as they lacked 
capacity to consent. The reasons for lack of capacity varied and included acute 
confusion due to deranged liver/kidney function, dehydration, and long term 
cognitive impairment. It is extremely important to recruit from these vulnerable 
groups as they are more likely to suffer from serious symptoms and comprise 
an important group within the spectrum of the disease phenotype. By excluding 
those patients who cannot consent, we are in danger of getting selection bias 
which will lead to limited generaliseability.  Using the consultee process we 
managed to recruit 13 patients to our study. 
The adjustment of recruitment targets outlined in the second substantial 
amendment (Figure 2.1) was based on a revision of the existing cohort at that 
time, as well as on power calculations based on our current recruitment rates, 
timelines and overall numbers recruited to that date: 
- Inability to identify and recruit adequate numbers of AAD controls meeting 
our inclusion criteria meant that, given our timelines, we felt that we would 
have been unlikely to reach the target of 300. We therefore chose to recruit 
additional cases (360 as opposed to the original target of 300) as a 
compensatory measure in order to nullify any loss of power 
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- Power calculations estimated that the revised recruitment would have 90% 
power to detect an effect size of OR≥2.89 assuming an event frequency around 
5% (f~5%); and OR≥1.96 for a relatively common event (f~20%). We believed 
that the revised figures (360 CDI cases and 180 AAD controls) would be 
sufficiently powered for our investigation. Figure 2.2 shows the effect size able 
to detect with increasing power for both a relatively rare event (f=5%) and a 
common event (f=20%), with the increase in the number of cases compensating 
for the reduced number of controls. 
 
 
Figure 2.2 – Effect size able to detect with increasing power for both a 
relatively rare and a common event 
 
2.2.3 Final cohort 
As outlined in Figure 2.1, a total of 453 patients (308 CDI cases and 145 AAD 
controls) were prospectively recruited between July 2008 and March 2012, 
across two large hospital sites in Merseyside: the Royal Liverpool and 
Broadgreen University Hospitals Trust (RLBUHT) and Wirral University 
Teaching Hospital (WTH). The screening process involved in recruitment of this 
final cohort is summarised in Figure 2.3.  
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Figure 2.3 – Overview of recruitment screening (July 2008 – March 2012) 
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a: Adjusted to within 90 days (see flowchart); b: Includes cognitive impairment, confusion, dementia, lacking capacity, unresponsiveness, poorly, inability to 
communicate; c: Includes community patients and those admitted to sites to which we did not have recruitment access (e.g. Cardiothoracic centre); d: Includes 
annual leave/other work commitments of recruitment staff, decreased/low Hb; e: Patients provisionally recruited as AAD controls were also excluded if they 
developed CDI-positive diarrhoea during the study period; f: Also includes bowel, gastric and pancreatic problems, as well as colostomy, recent abdominal surgery, 
overflow diarrhoea, stoma and IBD; g: Diarrhoea that preceded antibiotics; h: Includes patients previously recruited to the study, those who have previously tested 
CDI positive, those on recent chemotherapy and other drug-related interactions, those who declined, those with nastrogastric and enteral feeding, those not 
admitted (e.g. outpatients or day cases), those with no evidence of diarrhoea (i.e. single stool), those with decreased/low Hb and those with known infections (e.g. 
Salmonella, Influenza, Rotovirus, Norovirus) 
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2.2.4 Data collection 
Relevant information on demographics, admission and clinical history was 
collected for each patient and recorded using a standardised research pro-
forma. Clinical progress was monitored for a period of 30 days. If the patient 
was discharged from hospital prior to final follow-up, we attempted in every 
case to obtain data from the hospital, general practitioner or the patient (the 
latter by a telephone call). 
2.2.5 Microbiological methods 
Faecal samples were tested for C. diff toxin using a TOX A/B II ELISA kit 
according to the manufacturer’s instructions (Techlab, Blacksburg, USA). Toxin 
positive samples were screened for faecal leukocytes (an indicator of intestinal 
inflammation) by microscopy of a wet preparation of faecal sample. Specimens 
were cultured for C. diff using Brazier’s cefoxitin-cycloserine egg yolk agar (Lab 
M Ltd, Bury, UK) and incubated for 48 hours at 37°C in an anaerobic chamber. 
Isolates were identified by characteristic smell, colonial morphology and 
fluorescence under long wave UV light. Identification was confirmed using a 
latex agglutination test for C. diff somatic antigen (Oxoid, Basingstoke, UK). 
Isolates were stored on PROTECT beads (Technical Services Consultants Ltd, 
Heywood, UK) at -70°C.  
The bacteria were recovered from storage at a later date for PCR-ribotyping. 
Isolates were sub-cultured onto fastidious anaerobe agar (Bioconnections, 
Wetherby, UK) and incubated for 48 h at 37°C in an anaerobic chamber. PCR 
ribotyping was performed using standard methods (Health Protection Agency, 
2009b) and compared to the ten commonest ribotypes circulating in the UK 
(Health Protection Agency, 2009b). 
 
 
 
68 
 
2.3 Cohort use across experimental chapters 
A breakdown of the total sample numbers used across each of the experimental 
chapters is provided in Figure 2.4. Experimental work was conducted as 
recruitment was ongoing, which is why specific chapters (in particular Chapters 
4 & 5) employ a smaller cohort. Figure 2.4 also contains information pertaining 
to the year during which the corresponding experimental work was carried out. 
 
 
Figure 2.4 – Overview of sample sizes employed across experimental 
chapters  
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2.4 Responsibility breakdown 
Study design was developed by the Principal Investigator (Professor Munir 
Pirmohamed), alongside the Study Lead (Dr Fabio Miyajima), Study 
Administrator (Ms Anita Hanson) a Microbiology Consultant (Dr Christopher 
Parry) and two leading Infectious Disease consultants (Dr Nicholas Beeching 
and Dr Mike Beadsworth). 
Patient recruitment was carried out by a senior research nurse (Mrs Margaret 
Little), with blood samples processed by myself whilst faecal samples were 
processed (including microbiological culture and ribotyping) by two members 
of the RLUH Microbiology team (Mr Paul Roberts and Miss Valerie Price). 
Appropriate data was collected by myself, Mrs Margaret Little, Dr Fabio 
Miyajima and Mr Paul Roberts.  
Experimental work contributing to this thesis was conducted by myself, with 
minor assistance from Dr Fabio Miyajima. The statistical analysis for the data 
generated through this work was conducted by myself, with advice provided by 
the statistician on my supervisory board (Dr Ruwanthi Kolamunnage-Dona), Dr 
Fabio Miyajima and a further member of my supervisory board (Dr Ana 
Alfirevic). However, the meta-analysis in Chapter 4 was conducted by Dr 
Ruwanthi Kolamunnage-Dona. 
This thesis was written by myself, and reviewed by all members of my 
supervisory board (Professor Munir Pirmohamed, Dr Fabio Miyajima, Dr Ana 
Alfirevic and Dr Ruwanthi Kolamunnage-Dona). 
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Chapter 3 
Predicting poor disease outcomes in a 
prospective cohort of CDI patients 
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3.1 Introduction 
As discussed in Chapter 1 (section 1.9), complications arising from CDI, such as 
recurrence and mortality, are common albeit very difficult to predict. This 
constitutes a stumbling block for the stratification of patients and provision of 
more personalised clinical care. Given the characteristic symptoms of the 
disease, a multitude of studies have attempted to ascertain key risk factors for 
selected outcome measures, such as recurrence, severe-complicated disease and 
mortality, which are summarised in Tables 3.1, 3.2 and 3.3, respectively. It can 
be noted that the most commonly associated variables across the multiple CDI 
outcomes are advanced age, elevated white cell blood count and serum levels of 
creatinine and hypoalbuminaemia. However, the studies are mainly 
retrospective in nature, and suffer from both a lack of standardised disease 
outcome measures and a high degree of heterogeneity for the variables selected. 
Furthermore, very few studies have statistically assessed the predictive 
capability of their own models. Most studies have simply reported associations 
with potential risk predictors, but an association does not necessarily imply 
clinical usefulness. 
Conversely several authors have proposed the development of a scoring system, 
or CPR, that could be used at the bedside for the prediction of unfavourable 
patient outcomes. Table 3.4 depicts a number of CPRs proposed for recurrence, 
severe-complicated CDI and mortality. The majority of these have not been 
validated, either internally or externally, and many are deemed 
overcomplicated due to the adoption of too many parameters. As a result, a 
single and reliable CPR is yet to gain widespread clinical acceptance. Using a 
prospective cohort of carefully phenotyped CDI patients, this study sought to:  
 Determine independent risk predictors of previously studied CDI disease 
outcomes (severe-complicated disease, recurrence and mortality), as 
well as prolonged duration of disease symptoms. 
 Assess the existing CPRs for each previously investigated disease 
outcome using our own patient cohort, for which we have the adequate 
information.
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Table 3.1 – Review of previous studies of Clostridium difficile infection investigating independent risk factors for disease 
recurrence 
Study Years Country 
Study 
design 
N 
Average 
age 
Definition, 
days 
No. of relapses 
(%) 
 
Significant multivariate variables 
 
Do et al. (1998)  1993-4 Canada R 59 77 45 (FD) 13a 
 
History of increased creatinine 
Increasing WCC (at diagnosis) 
Community-acquisition 
 
Kyne et al. (2001) 1998 US P 44 69 60 (FD1) 22 (50) 
 
Increasing age 
Severe/Extremely severe disease 
Concomitant antibiotics 
IgG and IgM against tcdA 
 
Pepin et al. (2005)  1991–2004 Canada R 845b - 60 (FD) 243 (29) 
 
Year of diagnosis 
Increasing age 
Prolonged hospitalisation 
 
Cadena et al. (2010)  2003-5 US R 129 67 90 (FD) 38 (29) 
 
Recent fluoroquinolone use 
 
Jung et al. (2010)  1998-2008 South Korea R 117b 64 90 (FT) 13 (13) 
 
Recent surgery prior to CDI 
 
Kim et al. (2010) 2006-7 Korea R 125 68 90 (FC) 27 (22) 
 
Increasing age 
Decreased serum albumin (at diagnosis) 
Concurrent PPI 
 
Bauer et al. (2011) 2008 34 European R 484 - 90 (FD) 86 (18) 
 
Recent use of ceftazidime 
Recent CDI episodes 
 
Choi et al. (2011)  2008-2010 Korea R 84 63 60 (FT1) 11 (13) 
 
Stool VRE colonisation 
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Table 3.1 (continued) - Review of previous studies of Clostridium difficile infection investigating independent risk factors for 
disease recurrence 
Study Years Country 
Study 
design 
N 
Average 
age 
Definition, 
days 
No. of relapses 
(%) 
 
Significant multivariate variables 
 
Eyre et al. (2012) 2006-10 UK P 1678 77 ≥14 (FD) 363 (22) 
 
Emergency admission 
Previous gastro ward admission(s) 
Diagnosis at admission 
Increasing age 
Previous total hours in hospital 
Recent inpatient before diagnosis 
 
Petrella et al. (2012)c  2006-9 Canada/Europe R 794 N/A 28 (FT) 150 (19) 
 
Strain type (REA group) 
Recent CDI episode 
Concomitant antibiotics 
Treatment choice 
 
Freedberg et al. (2013)  2009-12 US R 894 64 90 (FD) 167 (19) 
 
Black race 
Increasing age 
Increasing Charlson Comorbidity Index 
 
Lavergne et al. (2013)  2009-2010 Canada P 121 77 60 (FT) 40 (33) 
 
Increasing age 
Female gender 
Positive anti-toxin serology 
Lymphopenia at treatment completion 
 
Rodriguez-Pardo et al (2013)  2009 Spain P 348 72 56 (FD) 63 (18) 
 
Increasing age 
PPI use post-diagnosis 
Increasing WCC (at diagnosis) 
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CDI: Clostridium difficile infection; FC: From cure; FD: From diagnosis; FD1: From discharge; FT: From treatment completion; FT1: From treatment initiation; Gastro: 
Gastroenterology; IgG: Immunoglobulin G; IgM: Immunoglobulin M; N: Number; N/A: Not Available; P: Prospective; PPI: Proton pump inhibitor; R: Retrospective; REA: 
Restriction endonuclease analysis; UK: United Kingdom; US: United States; tcdA: Clostridium difficile toxin A; VRE: Vancomycin-resistant enterococci; WCC: White cell 
count; 
a This was a case-control study involving 13 recurrent cases and 46 randomly-selected non-recurrent cases; b Study was restricted to patients receiving metronidazole as 
CDI therapy; c Patients included in this study were enrolled in 2 phase III clinical trials, comparing the efficacy and safety of fidaxomicin versus vancomycin; 
Studies conducted exclusively in populations with specific pathologies or those undergoing specific procedures/surgery, such as organ transplants, CT-scans, 
endoscopies, colectomy etc, were excluded. Studies were also excluded that used only univariate comparisons between groups, or hypothesis-driven studies focusing upon 
the risk associated with one or two specific variables. 
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Table 3.2 - Review of previous studies of Clostridium difficile infection investigating risk factors for severe-complicated disease 
Study Years Country 
 
Study 
design 
 
N 
Average 
age 
Definition 
Nº (%) severe 
disease 
Significant multivariate variables 
Andrews et al. 
(2003) 
1995–9 Canada R 153 63 
 
Inpatient mortality (attributable) 
ICU admission 
Colectomy 
Hospital stay >14 days 
 
4 
(28.8) 
Increasing age 
Increasing comorbidity illness  
Recent CDI episode 
Pepin et al. 
(2004)  
1991-2003 Canada R 1675 - 
30-day mortality (attributable, FD) 
Toxic megacolon 
Perforation 
Colectomy 
Septic shock 
183 
(10.9) 
 
Increasing age 
Hospital acquisition 
Recent surgery 
Recent tube feeding 
Immunosuppression 
Increasing peak WCC 
Increasing peak creatinine 
Vancomycin as initial treatment 
 
Hardt et al. 
(2008)  
2003-6 Germany R 124 76 Heart rate bpm/systolic BP mmHg 
>1.5 (at diagnosis) 
27 
(22.0) 
 
Charlson Comorbidity Index 
Increasing CRP (at diagnosis) 
 
Cloud et al. 
(2009)  
2004-6 US R 272 67 
 
Inpatient mortality (attributable) 
ICU admission 
Toxic megacolon 
Colectomy 
 
60 
(22.1) 
Increasing WCC at diagnosis 
Increasing peak creatinine 
Gravel et al. 
(2009)  
2004-5 Canada P 1430 70 
30-day mortality (attributable, FO) 
ICU admission 
Colectomy 
82 
(5.7) 
 
Increasing age 
Admission from other hospital/LTCF 
Liver disease 
Vancomycin as initial treatment 
Change in CDI treatment 
 
Gujja & Friedenberg 
(2009) 
2003-8 US R 200 66 Mortality (attributable, FI) 
Colectomy 
32 
(16) 
 
Increasing WCC (at treatment initiation) 
Creatinine >50% increase over baseline 
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Table 3.2 (continued) - Review of previous studies of Clostridium difficile infection investigating risk factors for severe-
complicated disease 
Study Years Country 
 
Study 
design 
 
N 
Average 
age 
Definition 
Nº (%) severe 
disease 
Significant multivariate variables 
Henrich et al. 
(2009) 
2006-7 US R 336 64 
 
30-day mortality (attributable, FO) 
ICU admission 
Colectomy 
Perforation 
 
41 
(12.2) 
Increasing age 
Small bowel obstruction/ileus 
Abnormal abdominal CT scan 
Bauer et al. 
(2011)  
2008 34 European R 442 71 
 
90-day mortality (attributable, FD) 
ICU admission 
Colectomy 
 
44 
(10) 
Increasing age 
PCR ribotype (018/056) 
Fujitani et al. 
(2011)  
2006 US P 184 70 
30-day mortality (attributable, FD) 
ICU admission 
Toxic megacolon 
Perforation 
Refractory colitis 
19 
(10) 
 
Abdominal distention 
Increasing temperature 
Increasing WCC (at diagnosis) 
Decreasing albumin (at diagnosis) 
 
Manek et al. 
(2011)  
2007-8 Canada R 305 71 
 
Mortality (all cause, BT) 
ICU admission 
Severe hypokalemia 
Toxic megacolon 
Perforation 
Lower GI bleeding 
 
97 
(27) 
Previous CDI episodes 
Confusion 
Increasing systolic BP 
Increasing WCC (at diagnosis) 
Vancomycin as initial treatment 
Concomitant antibiotics 
Morrison et al. 
(2011)  
2004-8 US R 485 53 
 
Mortality (attributable) 
ICU admission 
Surgery 
Toxic megacolon 
 
47 
(10) 
Increasing age 
Recent acid suppression use 
Walk et al. 
(2012)  
2000-6 US R 310 57 
 
30-day mortality (attributable, FD) 
ICU Admission 
Surgery 
 
34 
(11) 
Altered WCC (at diagnosis) 
Altered albumin level (at diagnosis) 
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Table 3.2 (continued) - Review of previous studies of Clostridium difficile infection investigating risk factors for severe-
complicated disease 
Study Years Country 
Study 
design 
N 
Average 
age 
Definition 
Nº (%) severe 
disease 
Significant multivariate variables 
Wenisch et al. 
(2012)  
2009-10 Austria R 133 74 
30-day mortality (attributable, FO) 
ICU admission 
Surgical intervention 
24 
(18.1) 
 
Severe diarrhoea 
Chronic pulmonary& renal disease 
Diabetes mellitus 
 
Khanafer et al. 
(2013)  
2007-11 France R 40 63 
 
30-day mortality (attributable, FD) 
ICU admission 
Colectomy 
Toxic megacolon 
Colitis/Perforation 
Septic shock 
 
15 
(37.5) 
Male gender 
Increasing CRP 
Recent fluoroquinolone exposure 
Rodriguez-Pardo et al. 
(2013)  
2009 Spain P 348 72 
30-day mortality (FD) 
Colectomy 
53 
(15) 
 
Concomitant antibiotics 
Increasing Charlson Score 
Increasing age 
 
Shivashankar et al. 
(2013)  
2007-10 US R 1446 63 
30-day mortality (FD) 
ICU admission 
Colectomy 
487 
(33.7) 
 
Increasing peak WCC (within 7 days of diagnosis) 
Increasing peak creatinine (≥1.5 fold baseline) 
Increasing age 
Concomitant narcotics & acid suppression 
 
Hensgens et al. 
(2014)  
2006-9 Netherlands P 395 65 
30-day mortality (attributable, FD) 
ICU admission 
Colectomy 
47 
(12) 
 
Increasing age 
Admission due to diarrhoea 
Diagnosis at ICU 
Recent abdominal surgery 
Hypotension 
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BP: Blood pressure; BT: Before treatment completion; CDI: Clostridium difficile infection; CRP: C-reactive protein; CT: Computerised tomography; FD: From diagnosis; 
FI: From initiation of therapy; FO: From onset of diarrhoea; GI: Gastrointestinal; ICU: Intensive care unit; LTCF: Long term care facility; N: Number; P: Prospective; PCR: 
Polymerase chain reaction; R: Retrospective; UK: United Kingdom; US: United States; WCC: White cell count; 
Studies conducted exclusively in populations with specific pathologies or those undergoing specific procedures/surgery, such as organ transplants, CT-scans, 
endoscopies, colectomy etc, were excluded. Studies were also excluded that used only univariate comparisons between groups, or hypothesis-driven studies focusing upon 
the risk associated with one or two specific variables.  
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Table 3.3 - Review of previous studies of Clostridium difficile infection investigating risk factors for mortality 
Study Years Country 
 
Study 
Design 
 
N Average age Definition No. of deaths (%) Significant multivariate variables 
Kenneally et al. (2007)  2004-5 US R 278a 64 30-day (all cause, FD) 102 (36.7) 
 
Septic shock 
ICU transfer 
Increasing APACHE II score 
 
Lamontagne et al. (2007)  2003-5 Canada R 165a 75 30-day (all cause, FI) 87 (53) 
 
Leukocytosis using peak value 
Increasing peak lactate 
Increasing age 
Immunosuppression 
Septic shock  
Colectomy 
 
Marra et al. (2007)  2002-5 US R 58a 56 Inpatient (attributable) 16 (27.6) 
 
Increasing age 
Increasing SOFA score at onset 
 
Bishara et al. (2008)  1999-2000 Israel P 52 74 28-day (all cause, FH) 8 (15.4) 
 
Elevated serum urea 
Lack of occult blood in stool 
 
Labbe et al. (2008) 2000-4 Canada R 230 - 30-day (all cause, FD) 55 (23.9) 
 
PCR ribotype 027 
Increasing age 
Increased Charlson Index 
Increased recent hospitalisation 
 
Cloud et al. (2009)  2004-6 US P 272 67 Inpatient (all-cause) 33 (12.1) 
 
Increased WCC (at diagnosis) 
Male gender 
 
Cober et al. (2009)  2006 US R 70b 84 90-day (all cause, FD) 12 (17.1) 
 
Coronary artery disease 
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Table 3.3 (continued) - Review of previous studies of Clostridium difficile infection investigating risk factors for mortality 
Study Years Country 
 
Study 
Design 
 
N Average age Definition No. of deaths (%) Significant multivariate variables 
Sailhamer et al. (2009)  1996-2007 US R 199c 68 Inpatient (attributable) 69 (34.7) 
 
Increased age 
Altered peak WCC 
Increased peak neutrophil bands 
Vasopressors 
Intubation 
Vancomycin 
 
Zilberberg et al. (2009)  2004-5 US R 148d 76 30-day (all cause, FD) 67 (45.3) 
 
Increased age 
No history of CRD 
Lack of leucocytosis 
Septic shock 
 
Bhangu et al. (2010)  2006-7 UK R 158 82 30-day inpatient (all cause, FD) 60 (38) 
 
Increased CRP (at diagnosis) 
Decreased albumin (at diagnosis) 
Increased urea (at diagnosis) 
Increased WCC (at diagnosis) 
General surgery: Medicine 
 
Cadena et al. (2010)  2003-5 US R 129 67 90-day (all cause, FD) 38 (29) 
 
Severe disease 
 
Dudukgian et al. (2010)  1999-2006 US R 398 59 Inpatient (attributable) 41 (10.3) 
 
APACHE II score 
ASA class 
Pre-existing organ dysfunction 
Concomitant steroid use 
 
Pant et al. (2010) - US R 184 - 30-day inpatient (all cause, FD) 23 (13.6) 
 
Recent renal failure 
 
Wilson et al. (2010) 2007-8 UK P 128 83 30-day (all cause, FD) 46 (35.9) 
 
Ischemic heart disease 
Hypoalbuminemia (at diagnosis) 
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Table 3.3 (continued) - Review of previous studies of Clostridium difficile infection investigating risk factors for mortality 
Study Years Country 
 
Study 
Design 
 
N Average age Definition No. of deaths (%) Significant multivariate variables 
Morrison et al. (2011) 2004-8 US R 485 53 Attributable 23 (4.7) 
 
Increased age 
Prior acid suppression use 
 
Welfare et al. (2011)  2002-9 UK R 2761 82 30-day (all cause, FD) - 
 
Increased age 
Cancer 
Cognitive impairment 
Comorbidities 
 
Khan et al. (2012) 2006-9 Qatar R 123 51 30-day (all cause, FD) 38 (30.9) 
 
Occurrence among Qataris 
Prolonged hospitalisation 
Positive stool occult blood test 
Increased WCC 
Septic shock 
 
Venugopal et al. (2012)  2005-6 US P 118 68 30-day (all cause, FD) 29 (24.6) 
 
Recent ICU stay 
 
Bloomfield et al. (2013) 2010 UK P 131 74 30-day inpatient (all cause, FD) 13 (9.9) 
 
Increased WCC (at diagnosis) 
Decreased albumin (at diagnosis) 
 
Inns et al. (2013) 2009-11 UK R 1426 77 30-day (all cause, FD) 366 (25.7) 
 
PCR ribotype (015 & 027) 
Increased age 
Hospital-acquired 
 
Kim et al. (2013) 2005-10 South Korea R 536 64 30-day (all cause, FT) 48 (9) 
 
Malignant comorbidity 
Decreased albumin 
Increased WCC 
ICU admission 
Treatment response failure 
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Table 3.3 (continued) - Review of previous studies of Clostridium difficile infection investigating risk factors for mortality 
Study Years Country 
 
Study 
Design 
 
N Average age Definition No. of deaths (%) Significant multivariate variables 
Solomon et al. (2013) 2008-9 UK P 86 75 30-day (all cause, FD) 14 (16.3) 
 
Increased peak WCC 
Increased peak Creatinine 
Low peak day 12 IgG anti-tcdA titre 
 
Boone et al. (2014) 2010-11 US P 210 60 100-day (all cause, FD) 50 (24) 
 
Increased age 
ICU treatment 
Increased Charlson Index 
 
APACHE: Acute Physiology and Chronic Health Evaluation; ASA: American Society of Anesthesiologists; CRD: Chronic renal disease; CRP: C-reactive protein; FD: From 
diagnosis; FH: From hospitalisation; FI: From ICU admission; FT: From treatment completion; ICU: Intensive care unit; IgG: Immunoglobulin G; N: Number; P: 
Prospective; PCR: Polymerase chain reaction; R: Retrospective; SOFA: Sequential Organ Failure Assessment; tcdA: Clostridium difficile toxin A; UK: United Kingdom; US: 
United States; WCC: White cell count; 
a Only included patients in intensive care; b Restricted to patients aged ≥80 yrs; c Restricted to patients with fulminant disease defined by the need for colectomy and 
admission to the intensive care unit as a result of their infection; d A re-analysis of Kenneally et al (2009) but restricted to patients ≥65 yrs; 
Studies conducted exclusively in populations with specific pathologies or those undergoing specific procedures/surgery, such as organ transplants, CT-scans, 
endoscopies, colectomy etc, were excluded. Studies were also excluded that used only univariate comparisons between groups, or hypothesis-driven studies focusing upon 
the risk associated with one or two specific variables. 
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Table 3.4 – Existing clinical prediction rules for poor disease outcome in 
Clostridium difficile infection 
Study 
(Country) 
Variables Points Interpretation 
Recurrence  
Hu et al 
2009 (US)a 
Age >65 yrs 
Horn Index: Severe or Fulminant disease 
Additional antibiotics post-CDI therapy 
1 
1 
1 
Score ≥2: High risk 
D’Agostino et 
al 2014 (US)b 
Age ≥75 yrs 
Serum creatinine at baseline ≥106 umol/L 
Number of unformed bowel movements ≥10 
Prior episode of CDI 
1 
2 
1 
1 
Predicts recurrence risk when 
prescribing specific treatment 
Severe-complicated disease  
Rubin et al 
1995 (USA)c 
Age >90 yrs 
Albumin <30 g/L 
WCC >25 or <1.5 x109/L 
≥5% increase in Haematocrit 
Clindamycin use 
Immunosuppressive medication use 
Antiperistaltic/narcotic use 
Baseline/development of depressed mental status 
Renal insufficiency 
COPD 
Abdominal pain 
Abdominal distension 
Abdominal tenderness 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Score >4: Severe disease 
Drew et al 
2009 (IRE)d, e 
WCC ratio day 1: 2 days previous 
(0.5-1.5/>1.5-2 or <0.5/>2-4/>4) 
0/1/2/3 
Score ≥4: Risk of severe 
complications 
Urea day 1 (<10/10-20/>20 mmol/L) 0/1/2 
WCC day 1 
(4-10/>10-20 or <4/>20-30/>30 x109/L) 
0/1/2/3 
Albumin day 1 (>30/24-30/<24 g/L) 0/1/2 
Lungulescu et 
al 2011 (US)c 
History of malignancy 
WCC >20 x109/L (at admission) 
Albumin <30 g/l (at admission) 
Creatinine (at admission) >1.5 fold baseline 
1 
1 
1 
1 
Score ≥2: Risk of severe 
consequences 
Hensgens et al 
2014 (NET) 
Age (≤49 yrs/50-84 yrs/≥85 yrs) 
Department of diagnosis (other/Surgery/ICU) 
Recent abdominal surgery (90 days) 
Hypotension (at diagnosis) 
Diarrhoea is reason for admission 
0/1/3 
0/0/3 
-3 
2 
2 
Score ≥4: High risk 
Van Der 
Wilden et al 
2014 (US) 
Age >70 yrs 
WCC ≥20 or <2 x109/L (at diagnosis) 
Cardiorespiratory failure 
Diffuse abdominal tenderness on PE 
2 
1 
7 
6 
Score ≥6: High risk 
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Table 3.4 (continued) – Existing clinical prediction rules for poor disease 
outcome in Clostridium difficile infection 
Study (Country) Variables Points Interpretation 
Mortality  
Zilberberg et al 
2009 (US) 
Absence of history of respiratory disease 
Age ≥75 yrs 
Septic shock 
APACHE II score 20+ 
3 
3 
1 
1 
Score ≥6: 60% risk 
Score ≥8: 80% risk 
Bhangu et al 
2010 (UK)  
Age ≥80 yrs 
Severe disease (sepsis/peritonitis/≥10 stools in 24 h) 
WCC ≥20 x109/L or CRP ≥150 mg/L (72 h diagnosis) 
Urea ≥15 mmol/L (72 h diagnosis) 
Albumin ≤20 g/L (72 h diagnosis) 
1 
1 
1 
1 
1 
Score 0-1: 22% risk 
Score 2-3: 55% risk 
Score 4-5: 89% risk 
Welfare et al 
2011 (UK) 
Age 60-79 yrs 
Age ≥80 yrs 
Presence of renal disease 
Presence of cancer 
3 
4 
2 
2 
Score ≤3: <22% risk 
Score = 8: 66% risk 
Butt et al 
2013 (UK) 
Albumin ≤24.5 g/L (48 h diagnosis) 
CRP >228 mg/L (48 h diagnosis) 
WCC >12 x109/L (48 h diagnosis)f 
1 
1 
1 
Increasing score: 
Increasing risk 
APACHE: Acute Physiology & Chronic Health Evaluation; CDI: Clostridium difficile infection; COPD: 
Chronic obstructive pulmonary disease; CRP: C-reactive protein; h: hours; ICU: Intensive care unit; 
IRE: Ireland; NET: Netherlands; PE: Physical examination; UK: United Kingdom; US: United States; 
WCC: White cell count; yrs: Years; 
a This study produced two prediction rules - here we highlight their ‘Clinical prediction rule’, as 
opposed to their ‘Combined prediction rule’ that included an extra variable: ‘Anti-tcdA IgG <1.29 
ELISA units’; b This study utilised data from two clinical trials and their outcome was not to assess 
prediction of recurrence but to in fact produce a risk of recurrence for two separate treatment 
choices (fidaxomicin and vancomycin) dependent upon defined clinical variables; c Retrospectively 
derived; d Letter to the Editor; e Scoring system is to be used for assessment at days 1 & 3. We have 
presented day 1 only; f Initially included respiratory rate but excluded as not present for validation;  
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3.2 Methods 
3.2.1 Identification of independent risk factors associated with poor 
disease outcomes 
3.2.1.1 Study design 
Recruitment of patients was conducted using the criteria defined in Chapter 2. 
308 CDI cases and 145 AAD controls were recruited from July 2008 to March 
2012. 
3.2.1.2 Data collection 
Data for approximately 50 variables were analysed across the four primary 
outcomes, encompassing information on demographics, medication, clinical 
characteristics and underlying comorbidities, laboratory results, microbiology, 
current admission and CDI disease outcomes. 
Charlson Comorbidity Index (CCI) was derived on an individual basis without 
age adjustment, as per its original development (Charlson et al., 1987) as well as 
current research references (Boone et al., 2014; Caplin et al., 2011; Daskivich et 
al., 2014). Blood markers measurements were taken ±2 days of the positive C. 
diff test date. Analysis of concomitant immunosuppressive therapy included 
both anti-neoplastic therapy and glucocorticoids alongside standard 
immunosuppressive drugs. For data gathering prior to the patients’ current 
infection, a cut-off of 90 days was employed. An episode was considered 
nosocomial in acquisition if the diarrhoea arose ≥3 days from the day of hospital 
admission.  
3.2.1.3 Definition of outcomes 
Severe-complicated CDI was considered when patients met one of four 
eligibility criteria: - 
1. Death directly due to or contributed to by CDI, according to death 
certificates, within 30 days of CDI diagnosis (attributable mortality) 
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2. Admission to ICU or high dependency unit (HDU) prior to cure 
3. CT evidence of severe disease prior to cure, including colitis, perforation, 
ileus and toxic megacolon 
4. Need for colectomy prior to cure 
 
Recurrent CDI was defined as the development of subsequent CDI episodes up 
to a period of 90 days following diagnosis of the initial episode, with both 
relapses and re-infections included. In addition to monitoring attributable 
mortality, all-cause mortality within 30 days of CDI diagnosis was recorded as a 
primary outcome. Duration of symptoms, defined as the number of days from 
CDI diagnosis until diarrhoea resolution, was recorded and then dichotomised 
into episodes lasting more or less than 10 days.  
3.2.1.4 Statistical analysis 
The characteristics of the cohort were described by medians and interquartile 
ranges for continuous variables and proportions for categorical variables. 
Logistic regression models were used to identify the factors that predicted the 
development of primary outcome measures; this included a range of potential 
predictors (demographic, clinical and disease-specific), all initially examined by 
univariate models. Predictors significant at the 20% level (to account for 
correlations between predictors) were included in the initial multivariate 
models. A reduced multivariate analysis (again only retaining variables at 20% 
level) was conducted to minimise the number of variables and proportion of 
missing data in order to determine independent predictors (at the 5% 
significance level). Predictors were excluded from the multivariable models if 
there was a strong colinearity (>0.8) between them or on the grounds of 
biological plausibility. 
To assess the performance of these models, pseudo R2 values were produced for 
each multivariate model, Cragg & Uhler’s R2 (logistic). Hosmer-Lemeshow 
Goodness of Fit (GoF) test and the area under the ROC curve were used to assess 
the fit of the multivariate logistic regression model. Given that the exclusion of 
subjects with missing data can lead to biased estimates, as well as reducing 
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statistical efficiency particularly in multivariate models, we have imputed 
missing data using switching regression, an iterative multivariate regression 
technique that retains an element of random variation in the estimates. These 
imputed data were used in the final multivariate models to assess if the overall 
results were affected by data missingness. 
Next, a resampling approach was used to randomly split the dataset in two 
halves and test the calibration of our models by performing a fitness tests on 
both subgroup samples (training and testing sets). We have also carried out a K-
fold leave-one-out cross-validation of the multivariate models to estimate the 
expected level of fit of the model to an independent sample of patients, i.e. 
independent to the cohort used to derive the model. The cross-validation 
methods cited above were chosen as they were more appropriate for smaller 
datasets and provided estimated goodness-of-fit statistics (i.e. Hosmer-
Lemeshow Statistic and AUC). All analyses were undertaken using Stata, version 
9.2. 
3.2.2 Assessment of existing clinical prediction rules for poor 
disease outcomes 
A systematic review was performed using an electronic search of all studies 
published since January 1978 (the year that C. difficile was identified as the 
etiological agent of pseudomembranous colitis (Bartlett et al., 1979; Chang et al., 
1978) for the three primary outcome measures (recurrence, mortality and 
severe-complicated CDI). Pubmed was the electronic database used and the 
keywords employed were, “Clostridium difficile AND 
Recurrence/Mortality/Severe/Complicated AND predict/rule/risk index/risk 
score/risk model/risk scale”. The search was limited to studies published in 
English and conducted in humans, aged ≥18 years. In addition, the reference 
lists of identified CPRs were searched manually (crossreferencing). The final 
electronic search was performed on 31st May 2014. 
The following data was extracted into a standardised matrix: year of 
publication, location, definition of the outcome(s) of interest, sample size, 
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average age of cohort, frequency of the outcome(s) of interest, the variables 
included in the clinical prediction rule and the corresponding points/cut-offs 
used to produce the risk score. 
Only CPRs that incorporated variables available to us from our cohort could be 
assessed despite the extensive collection of data in place for this study. Risk 
scores for this cohort were calculated using the chosen CPRs and statistical 
analysis was conducted to identify the area under the curve (AUC), sensitivity, 
specificity, PPV and NPV. Where available, these were then compared against 
those of the original study. 
3.3 Results 
3.3.1 Patient characteristics 
Within our cohort, the median duration of diarrhoeal symptoms was 7 days 
with 109/274 (40%) experiencing prolonged disease (≥10 days), whilst 83/220 
(38%) suffered from disease recurrence within 90 days of diagnosis, and 
43/256 (17%) developed severe-complicated disease. All-cause 30-day 
mortality was 9% (26/305), with an attributable mortality rate of 2% (7/305). 
Table 3.5 shows a general description of the cohort.  
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Table 3.5 – Characteristics of all CDI patients (n=308) 
 N (%) or Median (IQR) 
Demographics 
 Age at baseline 74.7 (61.3-81.1) 
 Gender: Female 177/308 (57) 
 Smoking: Pack years 10.3 (0.0-35.0) 
 Body Mass Index 23.6 (20.3-27.7) 
Medication information 
 Number of co-medications at baseline 3.0 (0.0-4.0) 
 Taking fluoroquinolones prior to CDI 107/308 (35) 
 Taking PPIs prior to CDI 208/306 (68) 
 Concomitant antibiotics 152/308 (49) 
 Concomitant immunosuppressants 52/307 (17) 
 Clinical characteristics & underlying comorbidities 
 Number of stools at baseline 5.0 (3.0-6.0) 
 Fever (≥36.8°C) 18/293 (6) 
 Charlson Comorbidity Index score* 1.0 (0.0-2.0) 
 Diabetes 58/307 (19) 
 Hypotension 36/296 (12) 
 Current malignancy 8/308 (3) 
 Respiratory comorbidities at baseline 167/307 (54) 
 GI comorbidities at baseline 179/307 (58) 
 Recent abdominal surgery (90 days) 34/298 (11) 
Laboratory results at baseline 
 Hb (mmol/L) 10.8 (9.6-11.9) 
 WCC (109/L) 11.8 (8.3-17.7) 
 Neutrophils (109/L) 9.0 (6.0-14.8) 
 Platelets (109/L) 294.0 (211.0-392.0) 
 C-reactive protein (mg/L) 71.0 (31.0-140.0) 
 Creatinine (mmol/L) 81. 0 (59.0–133.0) 
 eGFR (ml/min/1.73m2) 67.8 (41.5-100.1) 
 Albumin (g/L) 30.0 (25.0-34.0) 
 Sodium (mmol/L) 135.0 (132.0-138.0) 
 Potassium (mmol/L) 3.8 (3.4-4.2) 
 Urea (mmol/L) 6.3 (4.1-10.7) 
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Table 3.5 (continued) – Characteristics of all CDI patients (n=306) 
 N (%) or Median (IQR) 
 Microbiological information 
 Presence of faecal leukocytes 162/313 (52) 
 Toxin OD 2.5 (0.7-3.0) 
 Presence of PCR ribotype 027 89/283 (31) 
 Current admission information 
 Length of hospitalisation prior to diagnosis, days 8.0 (1.0-20.0) 
 Admitted via an emergency ward 167/256 (65) 
 Admitted with diarrhoea 113/308 (37) 
 Suffered from previous CDI 46/284 (16) 
 Recent CDI infection (90 days) 28/292 (10) 
 Recent ICU/HDU admission (90 days) 46/250 (18) 
 Nosocomial admission 204/306 (67) 
 Duration of symptoms prior to diagnosis, days 2.0 (0.0-5.0) 
 CDI outcome information 
 ICU admission due to infection 8/246 (3) 
 Severe-complicated CDI 43/256 (17) 
 90-day recurrence 83/220 (38) 
 30-day all-cause mortality 26/305 (9) 
 Prolonged symptoms (≥10 days) 109/274 (40) 
 Duration of symptoms 7.0 (4.0-12.0) 
CDI: Clostridium difficile infection; CI: Confidence interval; eGFR: Estimated glomerular filtration 
rate; GI: Gastrointestinal; Hb: Haemoglobin; HDU: High dependency unit; ICU: Intensive care unit; 
IQR: Interquartile range; N: Number; OD: Optical density; OR: Odds ratio; PPI: Proton pump 
inhibitor; WCC: White cell count; 
*Charlson Comorbidity Index is calculated without age adjustment (see Methods) 
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3.3.2 Univariate risk factors for poor disease outcomes 
Table 3.6 illustrates univariate associations for clinical variables in patients 
suffering poor disease outcomes. A full breakdown for each individual disease 
outcome can be found in Appendices 1-4. 
Recurrent patients, in comparison to their non-recurrent counterparts, were 
significantly older (77.5 versus 69.6 years; p<0.01), more likely to have taken 
fluoroquinolones within 90 days of diagnosis (48 versus 31%; p=0.01) and less 
likely to have had abdominal surgery within the previous 90 days (4 versus 
17%; p=0.01). They also had increased baseline WCC (13.1 versus 10.6 109/L; 
p=0.05), neutrophils (10.1 versus 8.0 x 109/L; p=0.03), creatinine (95.5 versus 
71.5 mmol/L; p=0.04) and urea (7.6 versus 5.3 mmol/L; p<0.01), and decreased 
eGFR (58.5 versus 76.2 ml/min/1.73m2; p=0.02). 
Patients with severe-complicated disease, in comparison to their non-severe 
counterparts, were less likely to have taken PPIs within 90 days of diagnosis (50 
versus 71%; p=0.01), were taking less medications at diagnosis (2.0 versus 3.0; 
p<0.01) and were more likely to be suffering from hypotension (24 versus 10%; 
p=0.02) or a GI comorbidity (77 versus 58%; p=0.02). They also had increased 
baseline neutrophils (12.7 versus 8.7 109/L; p=0.01), C-reactive protein (CRP) 
(108.5 versus 66.0 mg/L; p=0.01) and urea (8.2 versus 6.0 mmol/L; p=0.02), 
and decreased haemoglobin (Hb) (9.9 versus 10.9 mmol/L; p=0.03) and 
albumin (27.0 versus 31.0 g/L; p<0.01). 
Patients who died within 30 days, compared to those who survived, were older 
(79.4 versus 74.4 years; p=0.02), had a decreased body mass index (BMI) (20.6 
versus 23.9; p=0.01), a higher median CCI score (2.0 versus 1.0; p=0.01) and 
were more likely to have a respiratory comorbidity (77 versus 53%; p=0.02). 
Patients suffering from ≥10 days of symptoms, in comparison to those having 
shorter episodes, had increased baseline neutrophils (10.3 versus 8.6 x 109/L; 
p=0.05), CRP (90.5 versus 61.0 mg/L; p=0.01), decreased Hb (10.3 versus 10.9 
mmol/L; p=0.03), and an increased duration of diarrhoea prior to testing 
positive for C. diff (2.0 versus 1.0 days; p=0.01). 
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Table 3.6 – Univariate analysis of clinical variables in CDI patients across poor disease outcomes 
 
OR (95% CIs) 
Recurrence Severe-complicated Mortality Prolonged disease 
Demographics    
 Age at baseline: per decade 1.44 (1.19-1.76) 0.91 (0.76-1.10) 1.49 (1.07-2.07) 1.16 (0.99-1.35) 
 Gender: Female 0.84 (0.49-1.46) 1.75 (0.87-3.55) 0.86 (0.38-1.92) 0.95 (0.58-1.55) 
 Smoking pack years: per year increase 1.00 (0.99-1.01) 1.00 (0.98-1.01) 1.01 (1.00-1.02) 1.00 (0.99-1.01) 
 Body Mass Index 0.99 (0.95-1.03) 0.99 (0.94-1.04) 0.88 (0.81-0.96) 0.99 (0.95-1.03) 
Medication information    
 Number of co-medications at baseline 1.04 (0.89-1.20) 0.76 (0.63-0.91) 0.90 (0.74-1.11) 0.95 (0.84-1.07) 
 Taking fluoroquinolones prior to CDI 2.10 (1.20-3.70) 0.74 (0.36-1.49) 1.42 (0.63-3.21) 1.15 (0.69-1.91) 
 Taking PPIs prior to CDI 1.17 (0.66-2.10) 0.41 (0.21-0.81) 1.07 (0.45-2.54) 0.82 (0.49-1.37) 
 Concomitant antibiotics 1.18 (0.68-2.03) 1.04 (0.54-2.00) 1.45 (0.65-3.28) 0.82 (0.50-1.33) 
 Concomitant immunosuppressants 1.53 (0.75-3.12) 1.57 (0.73-3.40) 0.38 (0.09-1.66) 1.25 (0.66-2.38) 
 Clinical characteristics & underlying comorbidities    
 Number of stools at baseline 0.99 (0.90-1.08) 1.05 (0.95-1.17) 0.95 (0.81-1.11) 1.05 (0.97-1.14) 
 Fever (≥36.8°C) 0.94 (0.30-2.92) 2.41 (0.79-7.36) 0.64 (0.08-5.00) 2.66 (0.94-7.54) 
 Charlson Comorbidity Index score 0.98 (0.81-1.19) 0.93 (0.75-1.15) 1.31 (1.07-1.61) 0.90 (0.77-1.06) 
 Diabetes 1.14 (0.57-2.30) 1.12 (0.48-2.61) 1.01 (0.36-2.80) 0.94 (0.51-1.76) 
 Hypotension 0.96 (0.40-2.28) 2.76 (1.15-6.62) 1.41 (0.46-4.37) 1.33 (0.63-2.84) 
 Current malignancy 1.10 (0.18-6.74) 3.12 (0.72-13.58) 3.79 (0.73-19.82) 2.06 (0.45-9.38) 
 Respiratory comorbidities at baseline 1.61 (0.92-2.82) 1.75 (0.87-3.49) 2.97 (1.16-7.62) 1.13 (0.70-1.84) 
 GI comorbidities at baseline 0.74 (0.42-1.28) 2.43 (1.14-5.20) 0.91 (0.40-2.07) 1.54 (0.93-2.53) 
 Recent abdominal surgery (90 days) 0.19 (0.06-0.67) 1.55 (0.62-3.87) 0.31 (0.04-2.37) 0.83 (0.38-1.80) 
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Table 3.6 (continued) – Univariate analysis of clinical variables in CDI patients across poor disease outcomes 
 
OR (95% CIs) 
Recurrence Severe-complicated Mortality Prolonged disease 
 Laboratory results at baseline 
 Hb: per unit (mmol/L) decrease 0.97 (0.83-1.13) 1.26 (1.02-1.55) 0.96 (0.76-1.22) 1.18 (1.02-1.36) 
 WCC: per 109/L increase 1.02 (1.00-1.05) 1.01 (0.99-1.03) 0.99 (0.94-1.03) 1.00 (0.99-1.02) 
 Neutrophils: per 109/L increase 1.03 (1.00-1.06) 1.04 (1.01-1.07) 0.99 (0.95-1.04) 1.03 (1.00-1.05) 
 Platelets: per 109/L increase 1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (0.99-1.00) 1.00 (1.00-1.00) 
 C-reactive protein: per ten unit (mg/L) increase 1.02 (0.99-1.05) 1.05 (1.01-1.08) 0.99 (0.94-1.04) 1.04 (1.01-1.07) 
 Creatinine:  per unit (mmol/L) increase 1.00 (1.00-1.01) 1.00 (1.00-1.00) 1.00 (0.99-1.00) 1.00 (1.00-1.00) 
 eGFR: per ten unit (ml/min/1.73m2) decrease 1.08 (1.01-1.16) 0.96 (0.90-1.03) 0.94 (0.88-1.02) 1.02 (0.97-1.07) 
 Albumin: per unit (g/L) decrease 1.03 (0.98-1.08) 1.11 (1.05-1.19) 1.01 (0.94-1.08) 1.04 (1.00-1.08) 
 Sodium: per unit (mmol/L) increase 0.99 (0.93-1.05) 1.01 (0.93-1.09) 1.01 (0.92-1.12) 0.98 (0.92-1.03) 
 Potassium: per unit (mmol/L) increase 0.90 (0.57-1.43) 1.50 (0.87-2.59) 0.92 (0.46-1.85) 0.95 (0.63-1.42) 
 Urea: per unit (mmol/L) increase 1.08 (1.03-1.14) 1.06 (1.01-1.11) 1.02 (0.97-1.08) 1.04 (1.00-1.08) 
 Microbiological information 
 Presence of faecal leukocytes 1.30 (0.75-2.27) 0.59 (0.30-1.15) 0.70 (0.31-1.61) 1.22 (0.75-1.99) 
 Toxin OD 0.86 (0.68-1.09) 1.16 (0.90-1.51) 1.07 (0.80-1.44) 0.95 (0.79-1.14) 
 Presence of PCR ribotype 027 1.52 (0.84-2.73) 0.57 (0.25-1.29) 1.08 (0.44-2.63) 1.45 (0.84-2.51) 
 Current admission information 
 Length of hospitalisation prior to diagnosis, days 1.01 (1.00-1.02) 1.00 (0.99-1.02) 0.99 (0.97-1.01) 1.01 (1.00-1.02) 
 Admitted via an emergency ward 1.57 (0.87-2.82) 1.09 (0.50-2.38) 2.41 (0.78-7.39) 1.03 (0.59-1.81) 
 Admitted with diarrhoea 1.22 (0.70-2.15) 1.04 (0.53-2.04) 0.74 (0.31-1.75) 1.01 (0.62-1.67) 
 Suffered from previous CDI 1.42 (0.66-3.04) 1.64 (0.71-3.78) 0.97 (0.32-2.97) 1.47 (0.75-2.89) 
 Recent CDI infection (90 days) 2.23 (0.88-5.65) 1.74 (0.65-4.65) 0.38 (0.05-2.95) 1.76 (0.74-4.15) 
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Table 3.6 (continued) – Univariate analysis of clinical variables in CDI patients across poor disease outcomes 
 
OR (95% CIs) 
Recurrence Severe-complicated Mortality Prolonged disease 
Current admission information (continued) 
Recent ICU/HDU admission (90 days) 1.01 (0.50-2.01) 1.57 (0.66-3.77) 0.22 (0.03-1.66) 1.04 (0.51-2.13) 
Nosocomial admission 0.92 (0.52-1.62) 1.17 (0.58-2.34) 1.77 (0.69-4.55) 1.02 (0.62-1.70) 
Duration of symptoms prior to diagnosis, days 1.03 (1.00-1.06) 1.00 (0.97-1.03) 1.00 (0.96-1.04) 1.04 (1.01-1.07) 
Red: p<0.05; Orange: 0.05≤p<0.10; Yellow: 0.10≤p<0.20; Grey: p≥0.2; 
CDI: Clostridium difficile infection; CI: Confidence interval; eGFR: Estimated glomerular filtration rate; GI: Gastrointestinal; Hb: Haemoglobin; HDU: High dependency 
unit; ICU: Intensive care unit; IQR: Interquartile range; N: Number; OD: Optical density; OR: Odds ratio; PPI: Proton pump inhibitor; WCC: White cell count;  
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3.3.3 Multivariate risk factors 
3.3.3.1 90-day recurrence 
Multivariate findings are summarised in Table 3.7. Consistent with previous 
literature, we identified independent associations with increased age (OR, 1.51; 
95% CI, 1.21-1.90) (Eyre et al., 2012b; Freedberg et al., 2013; Kim et al., 2010; 
Kyne et al., 2001; Lavergne et al., 2013; Pepin et al., 2005; Rodríguez-Pardo et 
al., 2013), recent fluoroquinolone exposure (OR, 2.11; 95% CI, 1.09-4.09) 
(Cadena et al., 2010) and an increased duration of hospitalisation prior to 
diagnosis (OR, 1.02; 95% CI, 1.00-1.03) (Eyre et al., 2012b). We also identified 
an inverse association with patients having recently had abdominal surgery 
(OR, 0.26; 95% CI, 0.07-0.99). Whilst this has not specifically been associated 
with disease recurrence, several studies report an association with complicated 
disease (Bhangu et al., 2010; Gravel et al., 2009; Hensgens et al., 2014; Pépin et 
al., 2004). It is speculated that these patients are often younger and fitter than 
their counterparts, which was indeed the case in our cohort where mean age 
(65.4 versus 70.5 years; p=0.09) and median CCI (0.0 versus 1.0; p=0.01) 
significantly differed between patients with and without previous surgery, 
respectively. 
Multiple studies have also identified associations with an increased WCC (Do et 
al., 1998; Rodríguez-Pardo et al., 2013), recent CDI infection (Bauer et al., 2011; 
Petrella et al., 2012), the presence of comorbidities (Freedberg et al., 2013; 
Kyne et al., 2001) and concomitant antibiotics (Kyne et al., 2001; Petrella et al., 
2012) (Table 3.1). An increase of both WCC and neutrophils was associated on 
univariate analysis, but only neutrophil count was included in the initial 
multivariate model given the better performance and high degree of collinearity 
between them; however this failed to reach significance in the final reduced 
model (p=0.19; Table 3.7). Recent CDI infection and the presence of an 
underlying respiratory comorbidity were both associated in our univariate 
analysis (Table 3.6; Appendix 1) and therefore included in the initial 
multivariate model. These again did not independently predict recurrence in the 
final reduced model (p=0.35 and p=0.37, respectively; Table 3.7). No difference 
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was found with concomitant antibiotics upon univariate analysis (p=0.56; Table 
3.6; Appendix 1). 
 
Table 3.7 - Multivariate analysis of possible risk factors for 90-day disease 
recurrence 
Variable P-value OR (95% CIs) 
Initial model (n=178) 
Age at baseline: per decade 0.01 1.39 (1.08-1.79) 
Taken fluoroquinolones prior to CDI 0.05 2.11 (1.01-4.42) 
Respiratory comorbidities at baseline 0.37 1.40 (0.67-2.95) 
Neutrophils: per 109/L increase 0.83 1.00 (0.95-1.04) 
eGFR:  per ten unit (ml/min/1.73m2) decrease 0.71 0.98 (0.87-1.10) 
Urea: per unit (mmol/L) increase 0.37 1.04 (0.96-1.12) 
Recent abdominal surgery (90 days) 0.20 0.41 (0.10-1.63) 
Presence of PCR ribotype 027 0.81 1.09 (0.53-2.25) 
Length of hospitalisation prior to diagnosis, days 0.11 1.01 (1.00-1.03) 
Admitted via an emergency ward 0.42 1.38 (0.64-3.00) 
Recent CDI infection (90 days) 0.35 1.74 (0.55-5.50) 
Duration of symptoms prior to diagnosis, days 0.07 1.04 (1.00-1.08) 
Reduced model (n=200) 
Age at baseline: per decade <0.01 1.51 (1.21-1.90) 
Taken fluoroquinolones prior to CDI 0.03 2.11 (1.09-4.09) 
Recent abdominal surgery (90 days) 0.05 0.26 (0.07-0.99) 
Neutrophils: per 109/L increase 0.19 1.02 (0.99-1.05) 
Length of hospitalisation prior to diagnosis, days 0.02 1.02 (1.00-1.03) 
Duration of symptoms prior to diagnosis, days 0.12 1.03 (0.99-1.07) 
CDI: Clostridium difficile infection; CI: Confidence interval; eGFR: Estimated glomerular filtration 
rate; OR: Odds ratio; PCR: Polymerase chain reaction;  
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3.3.3.2 Severe-complicated disease 
Multivariate findings are summarised in Table 3.8. Consistent with previous 
literature, an independent association was found with hypoalbuminaemia (OR, 
1.14; 95% CI, 1.04-1.25) (Fujitani et al., 2011; Walk et al., 2012). Other 
independent predictors identified were the presence of an underlying GI 
comorbidity (OR, 3.00; 95% CI, 1.00-8.99) and current malignancy (OR, 10.11; 
95% CI, 1.28-78.92), which is in line with reports linking underlying 
comorbidities with CDI clinical complications (Gravel et al., 2009; Wenisch et al., 
2012). Recent PPI exposure (OR, 0.27; 95% CI, 0.10-0.75) was found to have a 
protective effect, which is in contrast with claims suggesting that it is a risk 
factor (Morrison et al., 2011) but is consistent with previous literature 
suggesting a role for PPIs in shielding the gut mucosa (Tsuji et al., 2002). 
Multiple studies have also identified associations with increased age (Andrews 
et al., 2003; Bauer et al., 2011; Gravel et al., 2009; Henrich et al., 2009; Hensgens 
et al., 2014; Morrison et al., 2011; Pépin et al., 2004; Rodríguez-Pardo et al., 
2013; Shivashankar et al., 2013) and elevated WCC at diagnosis (Cloud et al., 
2009; Fujitani et al., 2011; Gujja and Friedenberg, 2009; Manek et al., 2011) 
(Table 3.2). Similarly to disease recurrence, an increase of both WCC and 
neutrophils was associated on univariate analysis, but only neutrophil count 
was included in the initial multivariate model given the better performance and 
high degree of collinearity between them; however this failed to reach 
significance in the initial multivariate model (p=0.65; Table 3.8). No significant 
difference was found with increased age upon univariate analysis (p=0.33; 
Table 3.6; Appendix 2). 
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Table 3.8 - Multivariate analysis of possible risk factors for severe-
complicated disease 
Variable P-value OR (95% CIs) 
Initial model (n=155) 
GI comorbidities at baseline 0.02 5.86 (1.40-24.49) 
Hb: per unit (mmol/L) decrease 0.14 1.31 (0.91-1.88) 
Neutrophils: per 109/L increase 0.65 0.98 (0.91-1.06) 
Albumin: per unit (g/L) decrease 0.04 1.13 (1.01-1.26) 
C-reactive protein: per ten unit (mg/L) increase 0.18 1.05 (0.98-1.14) 
Urea: per unit (mmol/L) increase 0.02 1.13 (1.02-1.26) 
Potassium: per unit (mmol/L) increase 0.20 2.02 (0.69-5.95) 
Number of co-medications at baseline 0.05 0.71 (0.50-1.00) 
Taking PPIs prior to CDI 0.03 0.20 (0.05-0.86) 
Respiratory comorbidities at baseline 0.50 1.57 (0.42-5.82) 
Gender: Female 0.02 5.56 (1.28-24.18) 
Presence of faecal leukocytes 0.15 0.40 (0.11-1.39) 
Presence of PCR ribotype 027 0.73 0.79 (0.20-3.05) 
Fever (≥38.6°C) 0.07 6.30 (0.84-47.41) 
Current malignancy 0.11 11.10 (0.61-203.23) 
Hypotension 0.65 1.45 (0.29-7.28) 
Reduced model (n=183) 
GI comorbidities at baseline 0.05 3.00 (1.00-8.99) 
Hb: per unit (mmol/L) decrease 0.07 1.34 (0.98-1.84) 
Albumin: per unit (g/L) decrease 0.01 1.14 (1.04-1.25) 
Urea: per unit (mmol/L) increase 0.11 1.06 (0.99-1.14) 
Potassium: per unit (mmol/L) increase 0.14 1.84 (0.83-4.10) 
Taking PPIs prior to CDI 0.01 0.27 (0.10-0.75) 
Gender: Female 0.06 2.84 (0.97-8.26) 
Fever (≥38.6°C) 0.07 4.16 (0.90-19.18) 
Current malignancy 0.03 10.11 (1.28-79.82) 
Hypotension 0.15 2.61 (0.71-9.59) 
CDI: Clostridium difficile infection; CI: Confidence interval; GI: Gastrointestinal; Hb: Haemoglobin; 
OR: Odds ratio; PCR: Polymerase chain reaction; PPI: Proton pump inhibitor; 
 
3.3.3.3 30-day mortality 
Multivariate findings are summarised in Table 3.9. Not surprisingly, we 
identified independent associations with increased age (OR, 1.46; 95% CI, 1.02-
2.08), which corroborates with several other reports (Boone et al., 2014; Inns et 
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al., 2013; Labbé et al., 2008; Lamontagne et al., 2007; Marra et al., 2007; 
Morrison et al., 2011; Sailhamer et al., 2009; Welfare et al., 2011; Zilberberg et 
al., 2009), as well as with increased CCI score (OR, 1.31; 95% CI, 1.03-1.67) 
(Boone et al., 2014; Labbé et al., 2008). We also identified an independent 
association with low BMI (OR, 0.87; 95% CI, 0.78-0.96). 
Multiple studies have also identified associations with PCR-ribotype 027 (Inns 
et al., 2013; Labbé et al., 2008), elevated WCC at diagnosis (Bloomfield et al., 
2013; Cloud et al., 2009; Solomon et al., 2013), hypoalbuminaemia at diagnosis 
(Bloomfield et al., 2013; Kim et al., 2013; Wilson et al., 2010) and the presence 
of septic shock (Kenneally et al., 2007; Khan et al., 2012; Lamontagne et al., 
2007; Sailhamer et al., 2009; Zilberberg et al., 2009) (Table 3.3). However, we 
did not confirm association with the former three upon univariate analysis 
(p=0.87, p=0.53 and p=0.79, respectively; Table 3.6; Appendix 3), whilst for 
septic shock a comparison was not possible to be conducted as this information 
was not available from our cohort. 
 
Table 3.9 - Multivariate analysis of possible risk factors for 30-day 
mortality 
Variable P-value OR (95% CIs) 
Initial model (n=141) 
Age at baseline: per decade 0.85 1.05 (0.66-1.66) 
Body Mass Index 0.03 0.87 (0.77-0.98) 
Charlson Comorbidity Index score 0.04 1.41 (1.02-1.94) 
Smoking pack years: per year increase 0.10 1.02 (1.00-1.04) 
Platelets: per 109/L increase 0.24 0.97 (0.93-1.02) 
Respiratory comorbidities at baseline 0.43 1.81 (0.41-7.99) 
Admitted via an emergency ward 0.30 2.26 (0.49-10.55) 
Reduced model (n=286) 
Age at baseline: per decade 0.04 1.46 (1.02-2.08) 
Body Mass Index 0.01 0.87 (0.78-0.96) 
Platelets: per 109/L increase 0.08 0.97 (0.93-1.00) 
Charlson Comorbidity Index score 0.03 1.31 (1.03-1.67) 
CI: Confidence interval; OR: Odds ratio; 
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3.3.3.4 Prolonged disease 
Multivariate findings are summarised in Table 3.10. To the best of our 
knowledge, no previous studies have focus upon the identification of 
independent risk predictors for this outcome. As expected, length of diarrhoeal 
symptoms prior to CDI diagnosis was directly associated with prolonged disease 
and was considered a significant independent predictor (OR, 1.04; 95% CI, 1.01-
1.08). Likewise, neutrophilia (OR, 1.03; 95% CI, 1.00-1.06) and decreased Hb 
(OR, 1.21; 95% CI, 1.02-1.43) also produced independent associations. 
 
Table 3.10 - Multivariate analysis of possible risk factors for prolonged 
disease 
Variable P-value OR (95% CIs) 
Initial model (n=170) 
Age at baseline: per decade 0.28 1.14 (0.90-1.45) 
GI comorbidities at baseline 0.08 1.91 (0.92-3.93) 
Duration of symptoms prior to diagnosis, days 0.03 1.04 (1.00-1.08) 
Neutrophils: per 109/L increase 0.02 1.06 (1.01-1.11) 
Albumin: per unit (g/L) decrease 0.86 1.01 (0.94-1.07) 
Length of hospitalisation prior to diagnosis, days 0.42 1.01 (0.99-1.02) 
Hb: per unit (mmol/L) decrease 0.12 1.18 (0.96-1.46) 
Urea: per unit (mmol/L) increase 0.21 1.04 (0.98-1.09) 
Presence of PCR ribotype 027 0.99 1.01 (0.47-2.15) 
C-reactive protein: per ten unit (mg/L) increase 0.31 1.02 (0.98-1.07) 
Fever (≥38.6°C) 0.18 2.43 (0.66-9.01) 
Recent CDI infection (90 days) 0.73 1.23 (0.37-4.05) 
Number of stools at baseline 0.69 1.02 (0.91-1.15) 
Reduced model (n=237) 
Age at baseline: per decade 0.19 1.14 (0.94-1.37) 
Duration of symptoms prior to diagnosis, days 0.01 1.04 (1.01-1.08) 
Presence of PCR-ribotype 027 0.19 1.51 (0.82-2.77) 
Neutrophils: per 109/L increase 0.04 1.03 (1.00-1.06) 
Urea: per unit (mmol/L) increase 0.07 1.04 (1.00-1.09) 
Length of hospitalisation prior to diagnosis, days 0.07 1.01 (1.00-1.03) 
Hb: per unit (mmol/L) decrease 0.03 1.21 (1.02-1.43) 
CDI: Clostridium difficile infection; CI: Confidence interval; GI: Gastrointestinal; Hb: Haemoglobin; 
OR: Odds ratio; PCR: Polymerase chain reaction; 
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3.3.3.5 Statistical assessment and validation of multivariate models 
A statistical assessment of the performance of the derived multivariate models 
was conducted, which showed that patient drop-outs due to missing data was 9, 
29, 6 and 14% of the total cohort for 90-day recurrence, severe-complicated 
disease, 30-day mortality and prolonged disease, respectively (Table 3.11). 
Multiple imputation of missing values, whilst narrowing CIs and minimising the 
impact of missing data, demonstrated that the non-imputed and imputed 
datasets were comparable with the vast majority of independent predictors 
identified remaining unchanged (see Appendices 9-12).  
ROC AUC values were obtained for each of the primary outcome measures and 
while model performance for 90-day recurrence, 30-day mortality and 
prolonged disease was considered acceptable (0.75, 0.78 and 0.70, 
respectively), the severe-complicated model provided the most fitting results 
(0.86). Furthermore, the Hosmer-Lemeshow test showed that the models 
generated for all four outcomes could not be rejected after splitting the data into 
ten subgroups (p=0.62, p=0.30, p=0.90 and p=0.52, respectively). 
Prognostic models are prone to over-fitting as they tend to deliver over-
optimistic performance in the dataset from which they are initially developed 
(Steyerberg, 2009). We therefore assessed two cross-validation approaches for 
our models by: a) random sampling; and b) K-fold leave-one-out (LOO) cross-
validation. Resampling approach was used to randomly split the data in two and 
test the calibration of our models by performing a GoF test on both subgroup 
samples. Although model performance outlined in Table 3.11 were comparable 
in datasets 1 (calibration sample) and 2 (testing sample) from the subgroups, 
there was evidence for over-fitting with several inconsistencies in the 
prediction of independent variables between them and CIs considerably 
widened (see  Appendices 5-8), as well as the observation of a lack of fitness in 
the validation sample for 90-day recurrence and prolonged disease (Table 3.11). 
LOO cross validation tests indicated that there wasn’t sufficient evidence to 
reject the prospect of these cross-validated models being generalisable to 
independent datasets (i.e. with GoF p-values being non-significant). However, 
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despite original AUC values already demonstrating room for improvement, 
noticeable dips in our overall performance of the models were observed, with 
AUC absolute values decreasing by 3, 7, 5 and 5% for 90-day recurrence, severe-
complicated disease, 30-day mortality and prolonged disease, respectively 
(Table 3.12). 
 
3.3.4 Assessment of existing clinical prediction rules 
An overview of the systematic review process can be seen in Appendix 13. 
3.3.4.1 90-day recurrence 
Of the two selected CPRs focusing on disease recurrence and described in Table 
3.4, we only had data available to assess one: D’Agostino et al. (D'Agostino et al., 
2014) (Table 3.13). It is important to note that this CPR has not been validated 
in an independent cohort and evaluation using our cohort data was limited by 
the use of differing outcome definitions, with D’Agostino et al. defining 
recurrence cut-off time as 30 days post-completion of CDI therapy (D'Agostino 
et al., 2014) as opposed to our definition that used 90-day post-CDI diagnosis. 
We did, however, attempt to assess their CPR using both 30- and 90-day cut-off 
points following CDI diagnosis. 
Although we achieved a similar overall AUC to D’Agostino et al., using both 30- 
and 90-day recurrence (0.64 versus 0.62, and 0.61, respectively; Table 3.13), the 
overall performance was not satisfactory. We observed that the optimum cut-off 
value in our analysis was a score of 4 points and above, however, whilst this 
delivered high specificity (>97%), sensitivity, PPV and NPV were all very poor. A 
direct comparison to D’Agostino et al. model was not possible since this 
information was not provided by their work. 
A full breakdown of the scores within our cohort can be seen in Appendix 14. 
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Table 3.11 – Random sampling model validation across all disease outcomes 
Outcome Dataset 1 (Training) Dataset 2 (Testing) 
 N AUC 
Correctly 
classified 
Cragg & Uhler’s 
R2 
Hosmer-Lemeshow 
P-value 
N AUC 
Correctly 
classified 
Cragg & Uhler’s 
R2 
Hosmer-Lemeshow 
P-value 
90-day recurrence 99 0.72 66% 0.19 0.42 91 0.78 71% 0.36 0.04 
Severe-complicated disease 83 0.86 83% 0.42 0.66 100 0.86 90% 0.42 0.34 
30-day mortality 141 0.82 94% 0.21 0.94 145 0.79 90% 0.17 0.15 
Prolonged disease 122 0.72 72% 0.20 0.65 115 0.74 72% 0.23 0.05 
AUC: Area under the curve; N: Number; 
 
Table 3.12 –Model statistics across all disease outcomes 
Outcome Original model: Overall data Leave-one-out cross-validation 
 N (%) AUC 
Correctly 
classified 
Cragg & Uhler’s 
R2 
Hosmer-Lemeshow 
P-value 
AUC 
Hosmer-Lemeshow 
P-value 
90-day recurrence 200/220 (91) 0.75 71% 0.24 0.62 0.72 0.16 
Severe-complicated disease 183/256 (71) 0.86 86% 0.39 0.30 0.79 0.07 
30-day mortality 286/305 (94) 0.78 92% 0.18 0.90 0.73 0.65 
Prolonged disease 237/274 (86) 0.70 71% 0.17 0.52 0.65 0.53 
AUC: Area under the curve; N: Number; 
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Table 3.13 – Assessment of existing clinical prediction rules for CDI recurrence  
CPR Data 
Outcome 
definition 
N 
Prevalence of 
outcome (%)  
Cut-off score AUCa Sensitivity Specificity PPV NPV 
D’Agostino et al, 2014b 
Original 30-day (FT) 962 194 (20) NP 0.64 - - - - 
Current study 
30-day (FD) 
239 
72 (30) 
≥4c 
0.62 0.10 0.97 0.58 0.71 
90-day (FD) 109 (46) 0.61 0.08 0.98 0.75 0.56 
AUC: Area under the curve; CPR: Clinical prediction rule; FD: From diagnosis; FT: From treatment completion; N: Number; NP: Data not provided; NPV: Negative 
predictive value; PPV: Positive predictive value; 
a All AUCs in this table are overall values, and are not assessed using the cut-offs; b This study utilised data from two clinical trials and their outcome was not to assess 
prediction of recurrence but to in fact produce a risk of recurrence for two separate treatment choices (fidaxomicin and vancomycin) dependent upon defined clinical 
variables; c Cut-off suggested based on our data as no cut-off provided in the literature; 
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3.3.4.2 Severe-complicated disease 
Of the five existing CPRs for prediction of severe-complicated disease, described 
in Table 3.4, we had data available to assess three of them (Table 3.14). 
Firstly, we assessed the CPR of Drew et al. (Drew and Boyle, 2009) using their 
suggested cut off value of ≥4 points. Notably, our patient cohort was 
significantly larger (192 versus 58) and while our AUC was 0.60, their work did 
not provide that data, although they reported information on sensitivity, 
specificity, PPV and NPV (Table 3.14). Despite our larger sample size, our 
sensitivity was markedly lower (0.41 versus 0.80) even though specificity, PPV 
and NPV values were comparable.  
Next the CPR by Lungulescu et al. (Lungulescu et al., 2011) was investigated 
using their suggested cut-off value of ≥2 points. Although we observed a slightly 
higher specificity than theirs (0.74 versus 0.65), all other statistics we generated 
were markedly inferior (Table 3.14), including AUC (0.56 versus 0.78). 
Thirdly, we assessed the CPR of Hensgens et al. (Hensgens et al., 2014) using 
their suggested cut-off of ≥4. This CPR was the only one for the prediction of 
severe-complicated disease to have been validated in a separate cohort of 
patients. All statistics assessed for our cohort were markedly lower than those 
of the original derivation cohort and the subsequent validation cohort (Table 
3.14), including AUC (0.51 versus 0.78 and 0.73, respectively). 
A full breakdown of the scores within our cohort for each CPR can be seen in 
Appendices 15-17. Although definitions of severe-complicated disease differed 
slightly across all studies including our own, these normally included some form 
of attributable mortality, ICU admission and the need to undergo a related 
surgical procedure, such as colectomy. In general, the prevalence of severe-
complicated disease was similar across all studies (Table 3.14).  
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Table 3.14 – Assessment of existing clinical prediction rules for severe-complicated Clostridium difficile infection 
CPR Data 
Outcome 
definition 
N 
Prevalence of 
outcome (%) 
Cut-off 
score 
AUCa Sensitivity Specificity PPV NPV 
Drew et al, 
2009b 
Original 
28-day mortality (attributable, FD) 
ICU admission 
Colectomy 
Pancolitis 
58 8 (14) ≥4 NP  0.80  0.77  0.25  0.98  
Current study 
30-day mortality (attributable, FD) 
ICU/HDU admission 
Colectomy 
CT evidence of severe disease 
192 34 (18) ≥4 0.60 0.41 0.79 0.30 0.86 
Lungulescu et al, 
2011c 
Original 
Inpatient mortality (attributable) 
Critical care monitoring and/or 
colectomy 
Attributable hospital stay >10 days 
255 47 (18) ≥2 0.78 0.82 0.65 0.38 0.93 
Current study See above 188 32 (17) ≥2 0.56 0.38 0.74 0.23 0.85 
Hensgens et al, 
2014 
Original 
30-day mortality (attributable, FD) 
ICU admission 
Colectomy 
D: 395 
V: 139 
D: 47 (12) 
V: 7 (5) 
≥4 
D: 0.78 
V: 0.73 
D: 0.43 
V: 0.43 
D: 0.90 
V: 0.92 
D: 0.39 
V: 0.21 
D: 0.92 
V: 0.97 
Current study See above 234 29 (12) ≥4 0.51 0.14 0.78 0.15 0.77 
AUC: Area under the curve; CT: Computed tomography; D: Derivation cohort; FD: From diagnosis; HDU: High dependency unit; ICU: Intensive care unit; N: Number; NP: 
Not provided; NPV: Negative predictive value; PPV: Positive predictive value; V: Validation cohort; 
a All AUC values here are based upon the cut-off threshold suggested by the publication in question; b Letter to the Editor; c Retrospectively derived; 
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3.3.4.3 30-day mortality 
Of the four CPRs regarding mortality, described in Table 3.4, own data was 
available to assess three of them (Table 3.15), with only one of them being 
validated in a separate cohort of patients (Butt et al., 2013). 
Within our cohort, we were able to calculate overall AUCs for the CPRs of 
Bhangu et al. and Welfare et al. (0.52 and 0.59, respectively; Table 3.15). 
However, these studies did not provide a reference value for comparison. Our 
AUC value for the CPR of Butt et al. was markedly lower than that of both the 
derivation and validation cohorts employed by them (0.51 versus 0.70 and 0.65, 
respectively; Table 3.15). 
Both Welfare et al. and Butt et al. failed to inform cut-off values meaning that 
data regarding sensitivity, specificity, PPV and NPV was unavailable for 
comparison (Butt et al., 2013; Welfare et al., 2011). However, using suggested 
cut-offs of ≥6 and ≥2 points, respectively, derived from our own data we were 
able to simulate these (Table 3.15). Despite acceptable specificity and NPV, 
sensitivity and PPV were appreciably poor. Although Bhangu et al. did suggest a 
cut-off value (≥4 points) (Bhangu et al., 2010), we failed to identify any patients 
within our cohort above this threshold, thus limiting any assessment in our 
samples. 
A full breakdown of the scores within our cohort for each CPR can be seen in 
Appendices 18-20. Although definitions of mortality were similar across all 
studies including our own (generally all cause within 30 days), it is important to 
note that the all-cause mortality rate in our cohort was markedly lower 
compared to the aforementioned studies (Table 3.15). 
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Table 3.15 – Assessment of existing clinical prediction rules for mortality in Clostridium difficile infection 
CPR Data 
Outcome 
definition 
N 
Prevalence of 
outcome (%) 
Cut-off 
score 
AUCa Sensitivity Specificity PPV NPV 
Bhangu et al, 
2010 
Original 
30-day inpatient 
(all cause, FD) 
158 60 (38) ≥4 NP 0.14 0.99 0.89 0.65 
Current study 
30-day 
(all-cause, FD) 
224 17 (8) ≥4 0.52 NA NA NA NA 
Welfare et al, 
2011 
Original 
30-day 
(all cause, FD) 
2761 835 (30) NP NP - - - - 
Current study See above 306 26 (8) ≥6b 0.59 0.27 0.84 0.13 0.93 
Butt et al, 
2013 
Original 
Inpatient (all cause) 
or 30-day (all cause, FD1) 
D: 213c 
V: 158 
D: 51 (24) 
V: 60 (38) 
NP 
D: 0.70 
V: 0.65 
- - - - 
Current study See above 239 19 (8) ≥2b 0.51 0.11 0.83 0.05 0.91 
AUC: Area under the curve; D: Derivation cohort; FD: From diagnosis; FD1: From discharge; NA: Not able to be assessed as limited/no patients within the category the 
original study used; NP: Data not provided; NPV: Negative predictive value; PPV: Positive predictive value; V: Validation cohort; 
a All AUCs in this table are overall values as cut-offs were either not provided or we had no patients above the suggested cut-off and therefore could not assess our cohort 
based on this; b Cut-off suggested based on our data as no cut-off provided in the literature; c Limited to a specialised C. diff cohort ward;  
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3.4 Discussion 
Using a prospective cohort of well-phenotyped patients we have been able to 
identify a number of independent risk predictors for unfavourable CDI disease 
outcomes that are generally consistent with previous literature (Tables 3.7-
3.10). However, subsequent statistical assessment and validation of our models 
identified that despite adequate overall performance, they were unstable and 
unlikely to be generalised and validated in external cohorts (Tables 3.11 and 
3.12). Random sampling resulted in widening of confidence intervals and a 
number of inconsistencies were found between calibration and testing datasets, 
whereas LOO cross validation suggested a noticeable drop in performance of the 
cross validated models in relation to the original training counterparts (see 
Appendices 5-8). Our cohort was also used to assess existing CPRs for CDI 
disease outcomes. For all the CPRs that we were able to evaluate, performance 
was considered inadequate for the prediction of the selected primary outcome 
measures (Tables 3.13-3.15). 
A number of statistical procedures have been undertaken in order to assess core 
characteristics and performance of our derived multivariable models, but whilst 
this constitutes an important exercise towards the standardisation and 
validation of results, similar measures have only been taken by a minority of 
studies (Bloomfield et al., 2013; Boone et al., 2014; Sailhamer et al., 2009) out a 
myriad of publications investigating risk factors for the prediction of CDI 
outcomes (Tables 3.1-3.3). Whilst the majority of studies simply reported 
univariate associations between potential risk predictors and the outcomes, this 
does not necessarily result in a clinically useful predictive risk capability. 
Perhaps unsurprisingly, only a handful of studies chose to progress towards 
CPR development (Table 3.4). Whilst the majority of these studies undertook 
more extensive statistical assessment, only 3 out of 11 studies reviewed have 
validated their CPR in an external cohort (Butt et al., 2013; Hensgens et al., 
2014; Hu et al., 2009), with a further three incorporating some form of 
internal/cross validation (D'Agostino et al., 2014; Welfare et al., 2011; 
Zilberberg et al., 2009). In addition to the lack of literature, we were only able to 
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assess a limited number of CPRs mainly due to existence of overly complicated 
parameters, which are often not routine and are very difficult to derive. This is 
contradictory to a CPR premise which achieves optimum performance and 
widespread acceptance when it employs generalisable easy-to-obtain 
parameters and algorithms that are simple to implement without sacrificing 
accuracy (Gagliardi et al., 2011; Kastner et al., 2011). Furthermore, of the tools 
that could be assessed, the majority did not provide sufficient information to 
warrant a full comparison nor did such studies presented adequate statistical 
assessment. 
The poor external validity demonstrated through CPR assessment is likely to be 
the result of a very large degree of heterogeneity observed across previous 
studies, especially in relation to the definition of primary outcomes, CDI 
diagnostic algorithms, clinical parameters collected, patient recruitment 
sources, small sample sizes, nature of study design and temporal distribution. 
Outcome definition is probably one of the most significant as this varies 
significantly across studies (Table 3.16). For recurrence, for example, the most 
common cut-off adopted has been both 60- and 90-days, but these were each 
present in only 38% of the studies reviewed, respectively. For mortality, 30-day 
all-cause death was the most commonly employed definition; again this time 
point was only adopted by 52% of studies. The severe-complicated disease 
definition is usually a composite of multiple variables, of which the major 
component was mortality (incorporated in 94% of studies) with 30-day 
attributable death being the most commonly parameter definition (43% of 
studies reviewed). Another point of intense debate is the lack of consensus 
regarding the baseline/starting point of events, with the majority defining it 
‘from CDI diagnosis’. This was present in 54, 57 and 65% of studies focusing 
upon recurrence, severe-complicated disease and mortality, respectively (Table 
3.16). Of the 48 studies reviewed by this work, only nine studies used a two-step 
approach for ascertaining diagnosis and selecting their CDI cases, with another 
three studies using PCR as a stand-alone test. The majority of the remaining 
studies used toxin EIA alone (Table 3.16), which has been criticised due to its 
poor sensitivity performance and low NPV (type II error). As such, their cohorts 
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may have been skewed towards overly symptomatic cases, thus reducing 
representativeness of their results. 
It is likely that the majority of CDI studies to date suffered from a lack of 
statistical power. Historically, previously derived CPRs for conditions such as 
heart disease and pneumonia have incorporated cohorts >30,000 patients 
(Auble et al., 2007; Fine et al., 1997), which is in stark contrast to the CDI-
related CPRs outlined in Table 3.4: with ~50% of the cohorts totalling less than 
200 patients and ~75% totalling less than 400 patients. Whilst meta-analysis 
across studies would be of potential benefit, this has seriously been limited by 
the heterogeneity of the literature. In this respect, unsurprisingly only one 
investigation has been conducted to date and that focused upon disease 
recurrence (Garey et al., 2008). Furthermore, the majority of previous studies 
included patients who have been retrospectively recruited. This type of study 
design is significantly more affected by missing data, making it less suitable for 
direct comparisons, such as in causal analysis for the estimation of the effect of 
risk factors in the original publications. 
Our CDI cohort was recruited through a two-step process (toxin EIA followed by 
toxigenic culture) and our outcome definitions were consistent with those most 
commonly used in the literature. As described previously, our study also 
benefits from a prospective design and the assessment of variables was readily 
available at baseline. Furthermore, it is the first study to our knowledge to focus 
upon risk factors for prolonged disease and is one of the few to concurrently 
investigate multiple outcomes. Despite these advantages, this work is not 
without its limitations. Firstly, despite a sample size larger than or comparable 
to over 75% of the previous investigations across all outcomes, the study is 
likely to lack adequate power in order to draw further conclusions. Secondly, we 
did not search conference abstract databases and therefore may be missing out 
a small number of experimental CPRs that, despite not being published, may 
have fared well in our assessment. Thirdly, the use of a prospective recruitment 
strategy has meant that we were unable to recruit the most severe of CDI 
patients, particular those in life threatening conditions, and as such our cohort 
may not be fully representative of the entire disease spectrum, which may have 
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further biased our data analysis. For instance, this can be observed through our 
markedly lower all-cause 30-day mortality rate (8%) in comparison to some 
previous studies (Inns et al., 2013; Kenneally et al., 2007; Khan et al., 2012; 
Labbé et al., 2008; Solomon et al., 2013; Wilson et al., 2010; Zilberberg et al., 
2009), despite using an identical definition. However, these figures may also 
have been confounded by the source of their patient recruitment (i.e. specialty 
ward), in which some studies displayed similar figures than ours. Altogether the 
above may have influenced on our ability to adequately assess mortality-
focused CPRs. 
The results presented here clearly demonstrate that whilst associations 
between readily available variables and CDI outcomes are possible to be 
identified, statistical assessment of their utility reveals that these may not 
always be clinically applicable and translated to the bedside. This is further 
highlighted by the poor utility of existing CPRs for the prediction of primary 
outcomes in our cohort. Before advancements can be made, there is a need for 
standardisation across multiple areas (see Table 3.16) in future studies and 
collaborative efforts for the recruitment of large, and well-defined prospective 
cohorts.
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Table 3.16 – Overview of the three main criteria requiring standardisation across future studies for the identification of risk 
factors associated with poor disease outcomes in CDI 
 Recurrence (n=13) Severe-complicated (n=17) Mortality (n=23) 
Different options Most popular (%) Different options Most popular (%) Different options Most popular (%) 
Diagnostic testing method 
Culture 
Toxin EIA (46%) 
Culture 
Toxin EIA (47%) 
Cytotoxin assay 
Toxin EIA (48%) 
Cytotoxin assay Cytotoxin assay Toxin EIA 
Toxin EIA Toxin EIA PCR 
PCR PCR Toxin EIA + cytotoxin 
GDH + Cytotoxin assay Toxin EIA + culture Toxin EIA + culture 
Initiation of outcome 
From diagnosis 
From diagnosis (54%) 
From diarrhoea onset 
From diagnosis (57%) 
From hospitalisation 
From diagnosis (65%) 
From treatment initiation From diagnosis From diagnosis 
From treatment completion From treatment initiation From ICU admission 
From cure Not applicable (e.g. inpatient) From treatment completion 
From discharge Not specified Not applicable (e.g. inpatient) 
Outcome threshold 
≥14 days 
60 days (38%) 
90 days (38%) 
Inpatient 
30 days (59%) 
Inpatient 
30 days (65%) 
30 days 30 days 30 days 
45 days 90 days 90 days 
60 days Prior to treatment completion 100 days 
90 days None specified None specified 
EIA: Enzyme immunoassay; ICU: Intensive care unit; PCR: Polymerase chain reaction; 
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Is the interleukin-8 promoter polymorphism 
rs4073/-251T>A associated with Clostridium 
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4.1 Introduction 
As described in Chapter 1 Section 1.3, the pathogenesis of CDI has been 
attributed to the two potent clostridial toxins, tcdA and tcdB (Babcock et al., 
2006b; Lyras et al., 2009b), both of which are reported to damage the epithelial 
mucosa (Hatheway, 1990) and elicit a strong immunological response 
(Hippenstiel et al., 2000; Ishida et al., 2004). Our current understanding of 
factors that determine variability in patient response to CDI is limited (Kelly et 
al., 1994; McDonald et al., 2005b; Poxton et al., 2001). 
It has been previously shown for various infectious diseases that variations in 
genes that encode molecules that mediate attachment, pathogen recognition, 
inflammatory cytokine response, and innate and acquired immunity can affect 
disease severity as well as determine susceptibility to specific pathogens and 
infectious diarrhea, including STAT3 (Amre et al., 2010; Cenit et al., 2010; 
Ferguson et al., 2010), JAK2 (Ferguson et al., 2010), IL1RN (Queiroz et al., 2009), 
TNFA (Queiroz et al., 2009), IL10 (Flores et al., 2008), NOD2 (Queiroz et al., 
2009) and IL8 (Jiang et al., 2003). As well as being associated with susceptibility 
to enteroaggregative Escherichia coli diarrhoea, a common polymorphism in the 
promoter region of IL8 (rs4073, -251 T>A) has been investigated in CDI (Garey 
et al., 2010; Jiang et al., 2006; Jiang et al., 2007). 
The pro-inflammatory cytokine IL-8 is one of the major mediators of the 
inflammatory response. Disruption of the actin cytoskeleton by C. diff toxins has 
been shown to coincide with p38 mitogen-activated protein kinase (p38 
MAPK)-dependent and MAPK-activated protein kinase 2 (MK2)-dependent IL-8 
release into the intestinal lumen during CDI (Bobo et al., 2013; Garey et al., 
2010; Steiner et al., 1997). Higher levels of faecal IL-8 are commonly found in 
CDI subjects and the risk AA-genotype of an IL-8 gene promoter polymorphism 
(-251 T>A, rs4073) has been shown to increase the odds of both developing CDI 
and recurrent disease by at least 3-fold, as well as increasing IL-8 release in the 
intestine lumen (Garey et al., 2010; Jiang et al., 2006; Jiang et al., 2007). As a 
result IL-8 has been proposed as a potential biomarker by other groups (Garey 
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et al., 2010), though the genetic associations have not been independently 
replicated and its clinical validity has not been clearly demonstrated. 
Using a prospectively recruited cohort of carefully phenotyped patients, this 
study aimed to evaluate the IL-8 variant with regards to the risk of CDI and 
recurrent disease, relate the variant to faecal IL-8 levels and undertake a meta-
analysis using the available literature. 
4.2 Methods 
4.2.1 Study design 
Using the criteria defined in Chapter 2, a discovery cohort (n=423) comprising 
288 CDI cases and 135 controls with AAD, was recruited from July 2008 to 
November 2011 across two large hospital sites in Merseyside; RLBUHT and 
WTH (Figure 4.1). Blood and faecal samples were collected from all patients. 
A retrospective replication cohort comprising 270 individuals (170 CDI cases & 
100 healthy volunteers as controls) was used to confirm our genetic 
observations (Figure 4.1). Cases were recruited from RLBUHT between October 
2000 and September 2001, whilst controls were healthy volunteers (staff and 
students) from the University of Liverpool. 
Relevant information on demographics, admission and clinical history of CDI 
was collected for each patient and recorded in an anonymised case report 
proforma. Ethical approval for the study was obtained from the Liverpool 
Research and Ethical Committee under reference numbers 08/H1005/32 and 
08/H1017/19, and each patient provided written informed consent prior to 
recruitment. All individuals were white Caucasians.  
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Figure 4.1 – Overview of study design 
AAD: Antibiotic-associated diarrhea; CDI: Clostridium difficile infection; n: number;  
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4.2.2 Definition of outcomes 
Cases and controls were defined as per Chapter 2. Disease outcomes studied by 
Garey et al. included recurrent CDI, refractory CDI and all-cause mortality rate, 
all assessed at 90 days (Garey et al., 2010). Recurrent disease was defined as the 
development of subsequent CDI episodes following treatment of the initial 
episode and refractory disease was considered if patients did not respond to the 
initial standard treatment and diarrhoea was not immediately resolved. 
4.2.3 DNA isolation & genotyping 
DNA was extracted from human blood samples using either Chemagen 
paramagnetic bead chemistry (Chemagen Biopolymer-Technologie AG; 
Baesweiler, Germany) or EZ 96 Total DNA Isolation Kit (Omega Biotek, 
Norcross, USA) following manufacturers’ protocols.  
IL-8 rs4073 (-251 T>A) was genotyped using an off-the-shelf TaqMan allelic 
discrimination genotyping assay (Life Technologies Ltd., Paisley, UK). Total 
reaction volume was 5 µl and consisted of: - 
 2 µl of 1x Taqman genotyping master mix 
 0.13 µl of 1x Taqman genotyping assay 
 2.87 µl of distilled water (dH2O) 
 20 ng of dried genomic DNA 
 
Reactions were run on the Applied Biosystems HT 7900 Fast Real-Time PCR 
system (Applied Biosystems, USA) using the following cycling conditions: - 
 Stage 1: 50°C for 2 min 
 Stage 2: 95°C for 10 min 
 Stage 3: 50 cycles 
o 95°C for 15 s 
o 60° for 60 s 
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Genotype calls were made in accordance to the reference alleles and sequence 
orientation of dbSNP (NCBI build 37).  Quality control measures included 
Hardy-Weinberg equilibrium (HWE, p>0.01), as well as the incorporation of 
repeat samples and blanks. Results were analysed using the provided SDS 
software (version 2.2).  
4.2.4 Biomarker measurement in stools 
In order to replicate previous findings of a direct link between IL-8 genotype 
and faecal IL-8 levels, a subset of patients was selected from the discovery 
cohort (76 CDI cases & 33 AAD controls), which was of an equivalent size of the 
original report (Jiang et al., 2006). 
For stool testing, as per previous studies (Greenberg et al., 2002; Steiner et al., 
1997), aliquots of neat stools were diluted 1:5 in phosphate buffer solution 
(PBS) supplemented with 2.5 μg/mL leupeptin, 11 μg/mL aprotinin, and 5 mM 
of 4-(2-aminoethyl) benzenesulfonyl fluoride (Sigma, Haverhill, UK) and stored 
at −70°C until further use. A commercial ELISA kit was used to test the subset of 
patients for IL-8 (Quantikine, R&D systems, Abingdon, UK), with the minimum 
detectable dose (MDD) equal to 3.5 pg/ml. All procedures were carried out 
according to manufacturer’s instructions, and a standard 4-parameter logistic 
nonlinear regression method was used to calculate protein concentrations.  
4.2.5 Statistical analysis 
Chi-squared test assuming a recessive mode of effect and test for allelic 
distribution assuming an additive effect (binary regression assuming one 
degree of freedom) were performed to ascertain differences in genotypic 
distribution between cases and control groups, as well as within cases for 
differences in genotypic distribution for detectable/undetectable levels of faecal 
IL-8 (defined as <3.5 pg/ml as per manufacturer’s instructions) and the 
presence/absence of recurrent CDI, refractory CDI and mortality within 90 
days. Our discovery and replication cohorts were analysed separately, with the 
replication cohort only used for genotypic distribution between cases and 
controls. All analyses were performed using Stata statistical package v.9.2 
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(StataCorp, College Station, USA) and StatsDirect v.2.7.9 (StatsDirect Ltd, 
Altrincham, UK).  
Due to the relatively small sample sizes of both our own and the previous 
studies, meta-analyses were conducted as a way of increasing the statistical 
power to detect significant associations. Prior to meta-analysing, the data was 
analysed by two different statistical methods (assuming additive or recessive 
modes of effect) to account for the differing statistical methods of choice for 
both our own and the previous studies. For this purpose, cases from our 
discovery and replication cohorts were combined and, as with the previous 
studies, analysed against both AAD and healthy controls, respectively. 
Adjustment for potential confounders was lacking in the previous literature, 
meaning this could not be incorporated into the analysis here. Meta-analysis 
ORs and 95% CIs were generated based on a random effects model using the 
‘Metafor’ package of ‘R’ v.2.15.2. Power calculations were simulated using 
nQuery Advisor and nTerim (Statistical Solutions Ltd., Cork, Ireland). 
4.3 Results 
4.3.1 Demographics 
Outlined in Table 4.1, the discovery cohort comprised a total of 288 CDI cases 
and 135 controls. No significant differences were observed between CDI cases 
and AAD controls for gender (57% female versus 56% female, respectively; 
p=1.00) or median CCI score (1.0 versus 1.0; p=0.52). However, significant 
differences (p<0.01) were identified for mean age (70.6 versus 65.6 yrs), mean 
BMI (24.4 versus 26.9) and median time delay between testing positive and 
subsequent recruitment (3.0 versus 2.0 days). Furthermore, all-cause mortality 
within 90 days was significantly greater amongst CDI cases (21.1% versus 
4.5%; p<0.01). 46% (89/192) of CDI cases assessed during recruitment 
experienced recurrence within 90 days. The prevalence of refractory CDI was 
51% (108/211). 
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Table 4.1 – Demographics of discovery cohort 
 
CDI Cases 
(n=288) 
AAD Controls 
(n=135) 
P-value* 
Patient’s characteristics  
Gender = Female - n (%) 163/288 (57) 75/133 (56) 1.00 
Age – Mean in years (SD) 70.6 (16.0) 65.6 (17.5) <0.01 
BMI – Mean (SD) 24.4 (6.2) 26.9 (7.0) <0.01 
CCI score** – Median (IQR) 1.0 (0.0-2.0) 1.0 (0.0-2.0) 0.52 
Time delay (testing/recruitment) – Median (IQR) 3.0 (2.0-4.0) 2.0 (2.0-3.0) <0.01 
Clinical Parameters  
All cause death within 90 days– n (%) 54/256a (21.1) 6/132a (4.5) <0.01 
Refractoriness within 90 days – n (%) 108/211b (51.2) -  
Recurrence within 90 days – n (%) 89/192b (46.4) -  
Presence of ribotype 027 – n (%) 86/266c (32.3) -  
AAD: Antibiotic-associated diarrhoea; BMI: Body mass index; CCI: Charlson Comorbidity Index; 
CDI: Clostridium difficile infection; IQR: Interquartile range; n: number; 
* Means for normally distributed, continuous variables were compared using Independent samples 
T-test for continuous, for non-normal distribution median values were compared using Mann 
Whitney U test. Categorical data was assessed using a Chi-squared test; **CCI score is calculated 
without accounting for age 
a Data regarding death within 90 days was unavailable for 32 of our cases and 3 of our controls; b 
Data regarding refractoriness and recurrence of disease within 90 days was unavailable for 47 and 
66 of our cases, respectively. A further 30 cases died within the follow-up period prior to 
experiencing recurrent/refractory CDI and therefore could not be included in the final analysis; c 
Isolates were successfully recovered from 266/288 (92%) of our cases and thus ribotyping could 
not be done in 22 cases; 
 
For the two sub-cohorts used in the measurement of faecal IL-8, no significant 
differences were observed between CDI cases (n=73) and AAD controls (n=39) 
for gender (55% female versus 72% female, respectively; p=0.10), median 
Charlson Comorbidity Index score (1.0 versus 1.0; p=0.90) or time delay (2.0 
versus 1.0 days; p=0.18). However, significant differences were identified for 
median age (75.9 versus 64.9 yrs; p=0.01) and BMI (23.0 versus 28.3; p<0.01) 
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Furthermore, all-cause mortality within 90 days was significantly greater 
amongst CDI cases (23.3 versus 7.7%; p=0.04). 
Our replication cohort consisted of 100 CDI cases, of which 52 (52%) were male 
and 48 (48%) female, with a combined median age of 71.3 yrs. The healthy 
control arm consisted of 70 males (41%) and 100 females (59%) with a 
combined median age of 29 yrs. This cohort was used solely for replication of 
our genetic analysis, and data on ribotyping or measurement of faecal IL-8 was 
not available for these patients. 
4.3.2 Genotypic analysis 
4.3.2.1 CDI cases versus AAD controls 
Genotype call rate was >98% and all replicates showed concordant results. 
Genotypic distribution across all groups was in HWE and the observed minor 
allele frequency (MAF) was consistent with previous literature. Case-Control 
analysis in both cohorts showed no significant differences in rs4073 genotype 
distribution (p=0.84 and p=0.87; Table 4.2). We also failed to observe 
significant differences after combining all cases and comparing them against the 
AAD and healthy control groups using both recessive (p=0.63 and p=0.42; Table 
4.3) and additive (p=0.89 and p=0.35; Table 4.4) models. 
 
Table 4.2 - Genetic analysis of CDI cases versus controls across individual 
discovery and replication cohorts 
rs number Minor Allele Genotype Counts (MAF) Cases vs. Controls 
Discovery Cohort CDI Cases (n=286) AAD Controls (n=135) P-value OR (95% CI) 
rs4073 A 93/141/48 (0.42) 39/72/20 (0.43) 0.84 0.97 (0.71-1.31) 
Replication cohort CDI Cases (n=100) Healthy Controls (n=170) P-value OR (95% CI) 
rs4073 A 30/47/21 (0.45) 49/84/36 (0.46) 0.87 0.97 (0.68-1.38) 
CI: Confidence Intervals; IL-8: Interleukin-8; MAF: Minor Allele Frequency; OR: Odds Ratio;  
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Table 4.3 - Genetic analysis of combined CDI cases versus individual 
control groups assuming a recessive mode of effect 
 
Genotype 
n P-value 
OR 
(95% CI) AA AT or TT 
 
CDI cases (combined) 
 
 
AAD controls 
 
71 
 
315 
 519 
(386 vs. 133) 
0.63 
1.14 
(0.67-1.92) 
22 
 
111 
 
CDI cases (combined) 
 
 
Healthy controls 
71 
 
315 
 555 
(386 vs. 169) 
0.42 
0.83 
(0.53-1.31)  
36 
 
 
133 
 
AAD: Antibiotic-associated diarrhoea; CI: Confidence Intervals; HWE: Hardy-Weinburg 
Equilibrium; n: number; OR: Odds Ratio; 
 
Table 4.4 - Genetic analysis of combined CDI cases versus individual 
control groups assuming an additive mode of effect 
 
Genotype 
HWE n P-value 
OR 
(95% CI) AA AT TT 
CDI cases (combined) 
 
 
AAD controls 
 
71 
 
 
191 
 
 
124 
 
0.87 
519 
(386 vs. 133) 
0.89 
0.98 
(0.74-1.30)  
22 
 
 
72 
 
 
39 
 
0.24 
CDI cases (combined) 
 
 
Healthy controls 
 
71 
 
 
191 
 
 
124 
 
0.87 
555 
(386 vs. 169) 
0.35 
0.88 
(0.68-1.14)  
36 
 
 
84 
 
 
49 
 
1.00 
AAD: Antibiotic-associated diarrhoea; CI: Confidence Intervals; HWE: Hardy-Weinburg 
Equilibrium; n: number; OR: Odds Ratio; 
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4.3.2.2 Association with faecal IL-8 level 
Faecal IL-8 concentrations across genotypes within both CDI cases and AAD 
controls are summarised in Table 4.5. We failed to replicate previous findings of 
a significant association between faecal IL-8 concentration and IL-8 rs4073 
genotype in our CDI patients (p=0.28), despite a similar sample size to that of 
the original study (Jiang et al., 2006). We also failed to replicate these findings 
when analysing based on a cut-off of 3.5 pg/ml for detectable levels (as per the 
manufacturers information), using both recessive (p=0.73; Table 4.6) and 
additive (p=0.96; Table 4.7) modes of effect. 
 
Table 4.5 - Faecal IL-8 production split per genotype group of the IL-8 -251 
SNP (rs4073) in a subset of CDI cases and AAD subjects  
Group N Median (pg/ml) IQR  
CDI Cases (n=73; MAF=44.5%)    
T/T 21 172.5 87.6 - 601 
T/A 39 29.3 5.4 - 569 
A/A 13 257.1 <3.0 - 1,473.4 
AAD Controls (n=39; MAF=44.9%)    
T/T 12 <3.0 <3.0 -<3.0 
T/A 19 <3.0 <3.0 – 4.0 
A/A 8 7.9 <3.0 - 22.7 
IQR: Inter-quartile range; MAF: Minor Allele Frequency; N: Numbers; SE: Standard Error;  
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Table 4.6 – Analysis of detectable faecal IL-8 level versus IL-8 rs4073 
genotype within CDI cases only, assuming a recessive mode of effect 
 
Genotype 
n P-value OR (95% CI) 
AA AT or TT 
Cases detectable for IL-8 
 
 
Cases undetectable* for IL-8 
 
9 
 
 
53 
 74 
(62 vs. 12) 
0.73 0.84 (0.31-2.24) 
 
4 
 
8 
CI: Confidence interval; IL-8: Interleukin-8; n: Number; OR: Odds ratio; *Defined as <3.5 pg/ml 
 
Table 4.7 - Analysis of detectable faecal IL-8 level versus IL-8 rs4073 
genotype within CDI cases only, assuming an additive mode of effect 
 
Genotype 
n P-value OR (95% CI) 
AA AT TT 
Cases detectable for IL-8 
Cases undetectable* for IL-8 
9 33 20 
74 (62 vs. 12) 0.96 0.99 (0.56-1.74) 
4 7 1 
CI: Confidence interval; IL-8: Interleukin-8; n: Number; OR: Odds ratio; * Defined as <3.5 pg/ml 
 
4.3.2.3 CDI disease outcomes 
A comparison between patients with 90-day recurrent CDI and those with a 
single episode in our discovery cohort did not reveal any differences in 
genotypic distribution under either recessive or additive inheritance modes 
(p=0.79 and p=0.75, respectively; Tables 4.8 & 4.9). Similarly, no genotypic 
distribution differences were observed when comparing patients suffering from 
90-day refractory CDI against those having undergone successful treatment 
(p=0.70 and p=0.79, respectively; Tables 4.8 & 4.9) and when comparing 
patients suffering from 90-day mortality against those who had survived 
(p=0.61 and p=0.40, respectively; Tables 4.8 & 4.9). There was also no 
relationship with carriage of the 027 strain when analysed using either 
recessive (p=0.78) or additive (p=0.83) modes of effect. 
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Table 4.8 – IL-8 rs4073 versus CDI disease outcomes assessed at 90 days, 
using the discovery cohort only and assuming a recessive mode of effect 
Disease outcome 
Genotype 
n P-value OR (95% CI) 
AA AT or TT 
Recurrence 
 
 
Non-recurrence 
 
16 
 
73 
192 
(89 vs. 103) 
0.79 1.11 (0.52-2.35) 
 
17 
 
86 
Refractory 
 
 
Non-refractory 
 
20 
 
88 
211 
(108 vs. 103) 
0.70 1.15 (0.56-2.34) 
 
17 
 
86 
Mortality 
 
 
Non-mortality 
 
11 
 
43 
256 
(54 vs. 202) 
0.61 1.22 (0.57-2.60) 
 
35 
 
167 
CI: Confidence Intervals; n: number; OR: Odds Ratio;  
 
Table 4.9 – IL-8 rs4073 versus CDI disease outcomes assessed at 90 days, 
using the discovery cohort only and assuming an additive mode of effect 
Disease outcome 
Genotype 
n P-value OR (95% CI) 
AA AT TT 
Recurrence 
 
 
Non-recurrence 
 
16 
 
46 27 
192 
(89 vs. 103) 
0.75 1.07 (0.71-1.62) 
 
17 
 
53 33 
Refractory 
 
 
Non-refractory 
 
20 
 
54 34 
211 
(108 vs. 103) 
0.79 1.06 (0.71-1.56) 
 
17 
 
53 33 
Mortality 
 
 
Non-mortality 
 
11 
 
29 14 
256 
(54 vs. 202) 
0.40 1.21 (0.78-1.87) 
 
35 
 
103 64 
CI: Confidence Intervals; n: number; OR: Odds Ratio; 
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4.3.4 Meta-analysis & power calculations 
Meta-analyses combining our data with those published in the literature using 
several phenotypes were also undertaken – the results are shown in Tables 4.10 
& 4.11. Significant associations (OR (95% CIs)) identified by the previous 
literature for IL-8 rs4073 genotype in relation to CDI cases versus AAD controls 
(3.26 (1.09-9.71)), CDI cases versus healthy controls (3.37 (1.13-10.02)), faecal 
IL-8 levels (6.75 (1.43-31.90)) and 90-day recurrence (2.74 (1.01-7.40)) were 
no longer significant after meta-analysis (1.72 (0.63-4.71), 1.53 (0.39-5.94). 
2,17 (0.28-16.64), & 1.64 (0.68-3.95), respectively). Non-significant associations 
identified by the previous literature remained so after meta-analysis. 
Power calculations across the multiple outcome measures were based on odds 
ratio and effect sizes reported by Jiang et al. (2006) and Garey et al. (2010) and 
revealed that their power to detect true associations was limited and estimated 
to be 59% for case-control comparison, 72% for predicting faecal IL-8 levels, 
52% for 90-day recurrence, 7% for 90-day refractory disease and 26% for 90-
day mortality. A direct comparison with our cohorts produced estimates of 
around 99%, 97%, 68%, 9% and 45%, respectively. 
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Table 4.10 – Meta-analysis of IL-8 rs4073 relating to CDI susceptibility using data generated by this study and available 
literature (Garey et al., 2010; Jiang et al., 2006) [CI: Confidence interval; IL-8: Interleukin-8; OR: Odds ratio] 
Outcome Source 
Chi2 test assuming a recessive 
effect mode  
Genotype OR 
(95% CIs) 
P-value 
Meta-analysis plot  for each study and combined data under a 
recessive mode of effect  (OR, 95% CIs) AA 
AT  
TT 
CASE-CONTROL 
COMPARISON  
VS. 
 IL-8 RS4073 
GENOTYPES 
 
Jiang et 
al. 2006 
CDI Cases (38) 
vs. 
Diarrhoea controls (36) 
15 23 3.26 
(1.09-9.71) 
0.03 
 
6 30 
This 
study 
CDI cases (386)  
vs. 
Diarrhoea controls (133) 
71 315 1.14 
(0.67-1.92) 
0.63 22 111 
Jiang et 
al. 2006 
Cases (38) 
vs. 
Healthy controls (37) 
15 23 3.37 
(1.13-10.02) 
0.025 
 
6 31 
This 
study 
Combined cases (386)  
vs. 
Healthy controls (169) 
71 315 0.83 
(0.53-1.31) 
0.42 36 133 
FAECAL IL-8 
LEVELS 
VS. 
IL-8 RS4073 
GENOTYPES 
(CASES ONLY) 
Jiang et 
al. 2006 
Cases detectable (13) 
vs. 
Cases undetectable (20) 
9 4 6.75 
(1.43-31.90) 
0.01 
 
5 15 
This 
study 
Cases detectable (62) 
vs. 
Cases undetectable (12) 
9 53 0.84 
(0.31-2.24) 
0.73 4 8 
 
Jiang et al, (2006) 
Jiang et al, (2006) 
Jiang et al, (2006) 
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Table 4.11 – Meta-analysis of IL-8 rs4073 relating to CDI disease outcomes using data generated by this study and available 
literature (Garey et al., 2010; Jiang et al., 2006) [CI: Confidence interval; IL-8: Interleukin-8; OR: Odds ratio] 
Outcome Source 
Chi2 test assuming a recessive 
effect mode  
Genotype OR 
(95% CIs) 
P-value 
Meta-analysis plot  for each study and combined data under a 
recessive mode of effect  (OR, 95% CIs) AA 
AT  
TT 
90-DAY 
RECURRENCE  
VS. 
IL-8 RS4073 
GENOTYPES 
(CASES ONLY) 
 
Garey et 
al. 2010 
Recurrence (23) 
vs. 
Non-recurrence (73) 
10 13 2.74 
(1.01-7.40) 
0.04 
 
16 57 
This 
study 
Recurrence (89) 
vs. 
Non-recurrence (103) 
16 73 1.11 
(0.52-2.35) 
0.79 17 86 
90-DAY 
REFRACTORY 
DISEASE 
VS. 
IL-8 RS4073 
GENOTYPES 
(CASES ONLY) 
 
Garey et 
al. 2010 
Refractory (30) 
vs. 
Non-refractory (66) 
7 23 0.75 
(0.28-2.05) 
0.58 
 
19 47 
This 
study 
Refractory (108) 
vs. 
Non-refractory (103) 
20 88 1.15 
(0.56-2.34) 
0.70 17 86 
90-DAY 
MORTALITY 
VS. 
IL-8 RS4073 
GENOTYPES 
(CASES ONLY) 
 
Garey et 
al. 2010 
Mortality (21) 
vs. 
Non-mortality (75) 
8 13 1.95 
(0.70-5.45) 
0.20 
 
18 57 
This 
study 
Mortality (54) 
vs. 
Non-mortality (202) 
11 43 1.22 
(0.57-2.60) 
0.61 35 167 
Garey et al, (2010) 
Garey et al, (2010) 
Garey et al, (2010) 
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4.4 Discussion 
Acute CDI disease occurs as a result of an uncontrolled toxin-driven 
inflammatory response culminating in generalised colitis and colonic necrosis 
(Bobo et al., 2013), a process that is compounded by inter-individual variability 
in both CDI susceptibility and recurrence. IL-8 has previously been suggested as 
a potential biomarker for inter-individual variation in susceptibility (Garey et 
al., 2010; Greenberg et al., 2002; Jiang et al., 2006; Steiner et al., 1997). 
Using a prospective cohort of well-characterised patients, we failed to replicate 
previous findings of an association between IL-8 rs4073 and an increased risk 
of developing CDI (Jiang et al., 2006) and experiencing recurrent disease (Garey 
et al., 2010), confirmed in a meta-analysis with the previously published data 
(Tables 4.10 & 4.11, respectively). This could well be due to unforeseen 
population stratification. Our patients were all Caucasian with observed MAF 
(43.5%) very similar to that reported in Caucasians by both the Hapmap and 
1000 genomes projects (~40%). However, the previous studies in question did 
not undertake ethnically matched analyses and the prior knowledge that rs4073 
allele frequency varies greatly across ethnic groups may explain why the 
genotypic distribution for their AAD controls differed significantly from HWE 
(p<0.007). Our power calculations suggest that previous studies have been 
significantly underpowered to detect true associations. 
Although this polymorphism is located in a putative transcriptionally active 
domain, it remains uncertain whether it actually influences the secretion and 
overall release of IL-8 in the colon during CDI: we were unable to replicate a 
previous association between IL-8 levels and rs4073 genotype using a slightly 
larger cohort size, also confirmed in a meta-analysis with previously published 
data (Table 4.10). We also explored the possibility that the risk AA genotype 
would be more likely affected by NAP1/BI1/027 strains than other circulating 
strains, but our results showed no association (Chi-squared p=0.78). 
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While the findings of our study were generally negative, we have adopted 
stringent criteria in our approaches, employing a significantly larger sample size 
than previous studies as well as an ethnically matched group of Caucasian 
patients. Furthermore, we employed an independent set of individuals for the 
purpose of replication of our case-control findings. 
There are a number of potential limitations in our study. Firstly, our study, as 
well as those conducted previously, did not carry out longitudinal sampling of 
stools to monitor the trajectory of faecal IL-8 over time. Secondly, we only used 
a single laboratory test (ELISA for CDT) for the primary identification of CDI 
cases. Although this is still a common procedure, modern algorithms currently 
make use of a more sensitive first step screening - based on either GDH, or a 
nucleic acid amplification test NAAT - to minimise the odds of reporting false 
negative results. Therefore it is possible that our cohort may have lacked a fully 
representative range of cases. 
Thirdly, we have focused on only one SNP and therefore cannot exclude the 
possibility of other SNPs within the IL-8 gene having an effect on CDI 
susceptibility. However, there is a general lack of understanding of the genetic 
basis of inter-individual variability underlying both CDI susceptibility and 
recurrence. Although we evaluated two cohorts of patients, and our sample size, 
was larger than in the studies published previously, we cannot exclude a lower 
effect size of this SNP.  For such a complex disease it is highly likely that various 
genes across various pathways will be involved, and the effects that variation in 
single genes have on disease susceptibility or severity will be modest at most 
(Flores and Okhuysen, 2009).  
Biomarkers which can act as indicators of disease, disease relapse and disease 
stratification, are needed to direct CDI therapies more effectively. Further 
studies are certainly warranted to identify the genetic predisposition to CDI, 
and the adoption of systematic hypothesis-free methods using genome-wide 
coverage coupled with larger cohort sizes and a well-defined array of 
phenotypes will be pivotal for unveiling and validating true genetic 
susceptibility markers.  
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Chapter 5 
Investigation of faecal lactoferrin and 
calprotectin in a prospective CDI cohort 
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5.1 Introduction 
As outlined in Chapter 1 Section 1.3, pathogenesis of CDI is attributed to the two 
potent clostridial toxins, tcdA and tcdB (Babcock et al., 2006b; Lyras et al., 
2009b). Their synergistic effects cause fluid accumulation and damage to the 
epithelial mucosa (Hatheway, 1990), further eliciting pro-inflammatory 
cytokine release (Hippenstiel et al., 2000; Ishida et al., 2004). Concurrent 
activation and recruitment of neutrophils results in an inflammatory response 
in the gastrointestinal tract of CDI patients, but this is variable, ranging from 
self-contained mild inflammation to severe pseudomembranous colitis (Kelly 
and Kyne, 2011; Savidge et al., 2003). 
Toxins are the essential virulence factors accounting for CDI pathogenicity. 
Current diagnostic tools rely on their detection by either cytotoxin 
neutralisation or enzyme immunoassays. Multi-step algorithms have also been 
adopted in an attempt to improve sensitivity by combining toxin detection with 
sensitive screening of the presence of the organism by selective culture, GDH 
detection and/or NAAT of the PaLoc (Planche et al., 2013). These tests do not 
allow for stratification of disease severity and prognosis in patients with CDI. 
Validated non-invasive enteric markers for CDI that allow for better patient 
assessment and enable a more personalised approach to treatment would be 
valuable (Planche et al., 2013). 
Faecal material represents a very complex and heterogeneous biological matrix. 
Candidate faecal biomarkers must possess properties that ensure reliability and 
reproducibility of results and they must be unaffected by extra-digestive 
processes. FL and FC, derived predominantly from activated neutrophils and 
unaffected by extra-digestive processes, have been extensively evaluated in IBD 
and infectious diarrhea (D'Inca et al., 2007; García-Sánchez et al., 2010; Jones et 
al., 2008; Langhorst et al., 2008; Schoepfer et al., 2009; Schoepfer et al., 2010; 
Schoepfer et al., 2008; Sipponen et al., 2008a; Sipponen et al., 2008b; Sipponen 
et al., 2008c; van Langenberg et al., 2010). 
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A small number of studies have investigated FL and FC in the context of CDI 
(Table 5.1). Some have shown an association of FC in several acute diarrhoeal 
diseases caused by bacteria, with the highest mean levels observed in patients 
with CDI (192 mg/l) (Shastri et al., 2008). Others have shown a significant 
association when comparing FC levels in toxin positive and GDH positive plus 
tcdA/tcdB PCR confirmed patients to diarrhoea controls (Whitehead et al., 
2014). Similarly, FL has been shown to be elevated in patients with CDI 
(Archbald-Pannone et al., 2010; LaSala et al., 2013; Vaishnavi et al., 2000; van 
Langenberg et al., 2010) with more recent studies suggesting a positive 
correlation with disease severity (Boone et al., 2013; El Feghaly et al., 2013; 
Steiner et al., 1997) and fluoroquinolone resistance (Pawlowski et al., 2009). 
There are however limitations with the published studies: these include their 
retrospective nature, limited phenotype data, lack of matched controls, use of 
non-quantitative tests, and variations in the assessment of CDI outcome 
measures.  Sample sizes have varied from 2 to 120, and none of the studies have 
compared FC and FL in the same patient groups. 
In this study, we use a prospective design, a carefully phenotyped cohort and 
simultaneous evaluation of both faecal markers, to investigate whether FL and 
FC would have clinical value in patients suffering from CDI. 
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Table 5.1 – Overview of previous studies evaluating the role of lactoferrin and calprotectin in faeces in patients with 
Clostridium difficile infection 
Study Country 
Healthcare 
setting 
Paticipants Measure used Results 
Associated outcomes 
(p-value) 
Faecal Lactoferrin 
Steiner 
et al. (1997) 
USA Hospital 
Mild CDI (n=6) 
Severe CDI (n=12) 
Qualitative 
(positive/negative) 
1/6 = positive 
9/12 = positive 
Disease severity* 
(P=0.021) 
Vaishnavi 
et al. (2000) 
India Hospital 
CDI cases (n=41) 
Diarrhoea controls (n=190) 
Qualitative 
(positive/negative) 
33/41 = positive 
123/190 = negative 
C. diff toxin positivity & negativity 
(P<0.001 for both) 
Pawlowski 
et al. (2009) 
USA Hospital CDI cases (n=34) 
Cut-off 
(72.5 µg/g) 
10 resistant = >72.5 µg/g 
16 resistant = <72.5 µg/g 
8 susceptible = <72.5 µg/g 
Moxifloxacin resistance (P=0.041) 
Archbald-
Pannone 
et al. (2010) 
USA LTCF 
CDI cases (n=2) 
Diarrhoea controls (n=22) 
Continuous 
134.1 µg/ml 
28.8 µg/ml 
C. diff colonisation 
(P=0.008) 
Van Langenberg 
et al. (2010) 
Australia Hospital 
CDI cases (n=8) 
Diarrhoea controls (n=334) 
Continuous 
33.3 µg/ml 
22.6 µg/ml 
C. diff positivity 
(P=0.017) 
El Feghaly 
et al. (2013) 
USA Hospital CDI cases (n=120) 
Cut-off 
(7.25 µg/ml) 
72/120 (60%) = >7.25 µg/ml 
(Outcome data not provided) 
Severe HINES VA Score** 
(P=0.002) 
Boone 
et al. (2013) 
USA 
Hospital & 
outpatients 
Mild CDI (n=7) 
Moderate CDI (n=57) 
Severe CDI (n=21) 
Continuous 
73 µg/g 
292 µg/g 
961 µg/g 
(Ribotype data not provided) 
Disease severity*** and Ribotype 027 
(P = 0.0003 & P=0.012) 
LaSala 
et al. (2013) 
USA Hospital 
GDH neg (n=43) 
GDH positive/Tox neg/PCR neg (n=14) 
GDH positive/Tox positive (n=25) 
GDH positive/Tox neg/PCR positive (n=30) 
Continuous 
13 µg/ml 
18 µg/ml 
80 µg/ml 
24 µg/ml 
Toxin positivity 
(vs. GDH negative; p=0.006) 
(vs. GDH positive/CDT negative/PCR negative; p=0.002) 
(vs. GHD positive/CDT negative/PCR positive; p=0.015) 
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Table 5.1 (continued) - Overview of previous studies evaluating the role of lactoferrin and calprotectin in faeces in patients 
with Clostridium difficile infection 
Study Country 
Healthcare 
setting 
Paticipants Measure used Results 
Associated outcomes 
(p-value) 
Faecal Calprotectin 
Shastri 
et al. (2008) 
Germany Hospital 
CDI cases (n=87) 
Healthy controls (n=200) 
Continuous 
192 mg/l 
171/196 = <15 mg/l 
- 
Whitehead 
et al. (2014) 
UK Hospital 
Tox positive (n=45) 
GDH positive/PCR positive (n=75) 
Diarrhoea controls (n=99) 
Continuous 
336 µg g-1 
249 µg g-1 
106 µg g-1 
C. diff positivity 
(P<0.05) 
*Disease was considered severe if any of the following was present: diarrhoea severe enough to produce clinical signs of volume depletion and to require hospitalisation, 
WBC count of >10,000/ml, or temperature of >38.3°C 
**Scoring system accounting for fever (>38°C), ileus (clinical or radiographic), systolic blood pressure (<100 mmHg), WBC (15000<WBC<30000 cells/µl) and CT scan 
findings (colonic wall thickening, colonic dilatation, ascites) 
***Automatically classified as severe if age ≥65 years, WBC >15 × 109/L, stool ≥10 per day, not able to tolerate oral intake, usually abdominal complaints, radiographic 
or peritoneal signs, multiple comorbidities including but not limited to renal failure and immunosuppression  
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5.2 Methods 
5.2.1 Study design 
164 CDI cases and 52 AAD controls were recruited from RLBUHT between July 
2008 and May 2010. Blood and faecal samples were collected from all patients. 
Recruitment criteria were defined as per Chapter 2. As well as case versus 
control analysis, we also investigated four primary CDI disease outcomes: 90-
day recurrence, 30-day mortality and prolonged disease (defined as per Chapter 
3 Section 3.2.1) and disease severity at baseline. The severity of CDI symptoms 
at baseline were assessed using the guidelines proposed by Public Health 
England (Public Health England, 2013), except for incorporation of a more 
stringent cut-off for WCC (>20 x109/L) and replacement of acute rising 
creatinine with an estimated Glomerular Filtration Rate (eGFR) of <30 
ml/min/1.73m2. 
5.2.2 Biomarker measurement in stools 
Aliquots of neat stools were prepared as per Chapter 2. Both FC and FL levels 
were measured using commercially available in vitro diagnostic (IVD) ELISA kits 
(Calpro, Lysaker, Norway; IBD Scan Techlab, Blacksburg, USA, respectively).  All 
procedures were carried out according to manufacturer’s instructions, with the 
exception of the FL sample preparation step, whereby an inoculation loop was 
used as an agitator during a 30 minute shaking step in order to ensure optimal 
recovery of proteins. Where necessary, further dilutions and extra points on the 
standard curve were included. A standard 4-parameter logistic nonlinear 
regression method was used to calculate faecal biomarker concentrations. 
5.2.3 Statistical analysis 
Levels of FL and FC were subject to 4-tier percentile categorisation (i.e. Low 
<25%, Medium-Low 25-50%, Medium-High 50-75% and High >75%). 
Univariate binary logistic regression was conducted for both case-control 
comparison and sub-group analysis of cases for the outcomes proposed above. 
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Covariates including age, gender, BMI, CCI score, presence of ribotype 027 and 
time delay between testing positive and subsequent recruitment were assessed. 
CCI was originally developed without adjustment for age (Charlson et al., 1987) 
and therefore as age was already included as an individual covariate, we 
calculated our CCI unadjusted for age, consistent with previous studies (Boone 
et al., 2014; Caplin et al., 2011; Daskivich et al., 2014), in order to avoid 
introducing an undesirable level of collinearity into our analysis. Although an 
outcome measure itself, severity of disease was also assessed as a covariate for 
all other CDI outcomes. Statistically significant covariates were added to the 
final regression model to produce adjusted p-values and ORs. A p-value of <0.05 
was considered significant. 
Retrospective power calculations were simulated using nQuery Advisor + 
nTerim 2.0 (Statistical Solutions Ltd., Cork, Ireland). The literature lacks reliable 
data for conducting a priori power calculation. 
Receiver operating characteristic (ROC) curve analysis was conducted to 
identify optimal cut-off values for our CDI cohort and to compare these against 
the recommended kit values established for active intestinal inflammation. The 
Pearson correlation coefficient was employed to assess the relationship 
between the faecal markers. 
5.3 Results 
5.3.1 Demographics 
Demographics of the patient cohort are summarised in Table 5.2. No significant 
differences were observed between CDI cases and AAD controls for mean age 
(70.2 versus 66.4 yrs; p=0.13), gender (58% female versus 67% female, 
respectively; p=0.26) or median CCI score (1.0 versus 1.0; p=0.22). However, 
significant differences were identified for mean BMI (24.6 versus 28.2; p<0.01) 
and the median time delay between testing positive and subsequent 
recruitment (3.0 days versus 2.0 days; p<0.01). C. diff isolates were successfully 
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recovered from 149 (91%) of the CDI cases, of which all were toxigenic and 72 
(48%) had the ribotype 027.  
The proportion of patients suffering from symptoms of 10 or more days was 
higher amongst CDI cases compared with controls (34.8 versus 18.2%, 
respectively; p=0.04). This difference was also significant when considering 
durations of symptoms as measured from initial onset of symptoms (57.2% 
versus 26.1%; p<0.01). Of the CDI cases, 37.2% (61/164) were assessed as 
having severe disease, while 36% (49/137) of cases experienced recurrent 
episodes during the 90-day follow-up period. 
5.3.2 Comparative analysis 
ROC case-control analysis of FL resulted in a cut-off value of 8.1 ng/µl with an 
AUC of 0.86 (95% CI 0.80-0.92), producing a sensitivity of 81.7% (75.8-87.6%), 
specificity of 76.9% (65.4-88.4%), PPV of 91.8% (87.3-96.3%) and NPV of 
57.1% (45.5-68.7%) (Figure 5.1). This result is similar to the recommended kit 
cut-off point (7.25 ng/µl). For FC our optimal cut-off value differed from that 
proposed by the manufacturer (148 versus 50 mg/kg, respectively), suggesting 
that FC levels are elevated in the AAD group. ROC analysis resulted in an AUC of 
0.86 (0.81-0.92), producing sensitivity of 81.8% (75.8-87.8%), specificity of 
76.5% (64.9-88.1%), whilst PPV and NPV were 91.5% (86.9-96.1%) and 57.4% 
(45.6-69.2%), respectively (Figure 5.1). There was a high degree of correlation 
between FC and FL (r2=0.74), consistent across all patient groups (Figure 5.2). 
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Table 5.2 –Demographics of discovery cohort 
 
CDI Cases 
(n=164) 
AAD Controls 
(n=52) 
P-value* 
Patient’s characteristics   
Gender – Female n (%)  95 (58)  35 (67)  0.26 
Age – Mean in years (SD)  70.2 (15.9)  66.4 (15.8)  0.13 
BMI – Mean (SD)  24.6 (6.4)  28.2 (6.9)  <0.01 
CCI score** – Median (IQR) 1.0 (0.0-2.0) 1.0 (0.0-2.0) 0.22 
Time delay (testing/recruitment) – Median (IQR) 3.0 (2.0-4.8) 2.0 (2.0-3.0) <0.01 
Clinical Parameters   
Duration of symptoms – 10 days and over – n (%) 48/138 (34.8)  8/44 (18.2) 0.04 
All cause death within 30 days – n (%) 14/164 (8.5)  1/52 (1.9)  0.13 
Disease severity at baseline – n (%) 61/164 (37.2) - - 
Recurrence within 90 days – n (%)  49/137b (35.8)  - - 
Frequency of ribotype 027 – n (%) 72/149c (48.3) - - 
AAD: Antibiotic-associated diarrhoea; BMI: Body mass index; CCI: Charlson Comorbidity Index; 
CDI: Clostridium difficile infection; IQR: Interquartile range; n: number; SD: Standard deviation; 
*Means for normally distributed, continuous variables were compared using Independent samples 
T-test for continuous, for non-normal distribution median values were compared using Mann 
Whitney U test. Categorical data was assessed using a Chi-squared test for all counts >5, and 
Fisher’s Exact test for those <5; 
**CCI score is calculated without accounting for age (see section 3.2.3); 
a Data regarding duration of symptoms was unavailable for 26 of our cases and 8 of our controls; b 
Data regarding recurrence of disease within 90 days was unavailable for 11 of our cases. A further 
16 cases died within the follow-up period prior to experiencing any recurrent symptoms and 
therefore could not be included in the final analysis; c Isolates were successfully recovered from 
149/164 cases and thus ribotyping could not be done in 15 of our cases; 
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Figure 5.1 – ROC curve analyses of Faecal Lactoferrin and Faecal 
Calprotectin concentrations in Clostridium difficile infection cases (n=164) 
versus Antibiotic-associated diarrhoea controls (n=52) 
 
 
 
Figure 5.2 – Correlation plot of Faecal Lactoferrin and Faecal Calprotectin 
concentrations in all patients (cases and controls combined; n=210) 
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5.3.3 Faecal concentrations in relation to CDI 
Median levels of both markers were significantly higher in CDI cases compared 
to AAD controls (57.9 versus 2.7 ng/µl and 684.8 vs. 66.5 mg/kg, respectively; 
Table 5.3), which was confirmed by percentile case-control analysis (p<1 x 10-5 
for both; Table 5.4). 
No significant associations were identified through sub-group percentile 
analysis for CDI disease outcomes (Tables 5.5-5.8). Although a marked increase 
was observed for both faecal markers in patients suffering from severe disease 
compared to their non-severe counterparts (FL: 104.6 versus 40.1 ng/μl; FC 
969.3 versus 512.7 mg/kg; Table 5.3), these narrowly missed statistical 
significance (p=0.06 and p=0.26, respectively; Table 5.8). The lack of association 
identified with prolonged symptoms remaining when this outcome was 
alternatively measured from symptom onset. 
Carriers of the ribotype 027 generally displayed higher median levels of FC and 
FL (1011 versus 658 mg/kg and 83.2 versus 51.0 ng/µl, respectively), but this 
was not statistically significant (p=0.09 and p=0.57, respectively). Median levels 
of both FC and FL were higher in culture positive compared with culture 
negative samples, but again this failed to reach statistical significance (712.2 
versus 345.8 mg/kg, p=0.46 for FC; 63.5 versus 31.7 ng/µl, p=0.22 for FL). 
However, median levels of both FC and FL were significantly higher in culture 
negative patients compared to AAD controls (345.8 versus 66.5 mg/kg, p<0.01 
for FC; 31.7 versus 2.7 ng/µl, p<0.001 for FL). 
4.3.4 Power calculations 
For both biomarkers, power to detect a significant difference was calculated as 
≥99% for the majority of analyses (Table 5.9). However, we had inadequate 
power for analysis of 30-day mortality for both FL and FC.  
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Table 5.3 - Descriptive levels of faecal lactoferrin & calprotectin in relation to Clostridium difficile infection disease outcomes 
Outcome 
Lactoferrin Calprotectin 
N Median, ng/µl (IQR) Min. – Max. N Median, mg/kg (IQR) Min. – Max. 
Case versus Control 
CDI case 164 57.9 (11.4-177.5) 0.5-1,839.0 159 684.8 (203.7-1,581.0) 9.7-21,450.2 
AAD control 52 2.7 (0.7-7.8) 0.1–203.5 51 66.5 (23.1-145.7) 3.1-1,810.9 
Death within 30 days 
Death 14 62.4 (19.6-223.2) 0.9-1,250.0 14 543.8 (139.7-2,678.9) 38.1-4,418.0 
Non-death 150 57.9 (11.0-174.5) 0.5-1,839.0 145 702.6 (203.9-1,549.1) 9.7-21,450.2 
Duration ≥10 days 
Yes 48 59.0 (25.6-157.7) 0.5-1,839.0 46 737.2 (289.9-1,608.1) 9.7-21,450.2 
No 90 48.3 (7.8-178.2) 0.6-1,510.0 88 581.5 (175.1-1,458.4) 20.9-6,415.4 
Recurrence within 90 days 
Recurrence 49 83.6 (9.8-189.4) 0.6-1,839.0 46 744.1 (318.7-1,755.8) 22.9-5,660.6 
Non-recurrence 88 55.7 (12.1 – 158.4) 0.5-1,510.0 87 627.9 (173.3-1,423.6) 9.7-21,450.2 
Severity at baseline 
Severe 61 95.1 (16.3-187.6) 0.6-799.9 60 889.6 (275.2-1,876.2) 38.8-21,450.2 
Non-severe 103 40.1 (10.2-176.9) 0.5-1,839.0 99 535.0 (173.3-1,541.0) 9.7-6,047.0 
AAD: Antibiotic-associated diarrhoea; CDI: Clostridium difficile infection; IQR: interquartile range; Min: minimum; Max: maximum; n: number;   
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Table 5.4 – Faecal lactoferrin and calprotectin levels: CDI cases versus AAD 
controls 
Faecal lactoferrin 
CDI Cases 
(n=164) 
AAD Controls 
(n=52) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
Low (Comparator group) 20 33 - - 
Medium-Low 41 14 <0.0001 5.03 (2.05-12.34) 
Medium-High 51 3 <0.0001 31.67 (8.14-123.26) 
High 52 2 <0.0001 41.57 (8.55-202.10) 
Global p-value <1 x 10-5 
Faecal calprotectin 
CDI Cases 
(n=159) 
AAD Controls 
(n=51) 
Adjusted 
P-valueb 
Adjusted OR 
(95% CI) 
Low (Comparator group) 21 31 - - 
Medium-Low 38 15 0.02 3.03 (1.21-7.53) 
Medium-High 49 4 <0.0001 21.82 (6.13-77.71) 
High 51 1 <0.0001 85.87 (10.21-721.90) 
Global p-value <1 x 10-5 
AAD: Antibiotic-associated diarrhoea; CDI: Clostridium difficile infection; CI: Confidence interval; 
IQR: Interquartile range; n: number; OR: Odds ratios; 
P-value was calculated using binary logistic regression with data grouped into percentiles. 
Analysis was adjusted for significant covariates: a BMI and time delay between testing positive and 
subsequent recruitment; b BMI, score on Charlson Comorbidity Index and time delay between 
testing positive & subsequent recruitment 
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Table 5.5 – Faecal lactoferrin and calprotectin levels: 30-day mortality 
Faecal lactoferrin 
Death 
(n=14) 
Survival 
(n=150) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
Low (Comparator group) 2 39 - - 
Medium-Low 5 36 0.22 3.00 (0.51-17.56) 
Medium-High 3 38 0.28 2.90 (0.41-20.41) 
High 4 37 0.25 2.91 (0.47-18.17) 
Global p-value = 0.63 
Faecal calprotectin 
Death 
(n=14) 
Survival 
(n=145) 
Adjusted 
P-valueb 
Adjusted OR 
(95% CI) 
Low (Comparator group) 4 35 - - 
Medium-Low 4 36 0.89 0.90 (0.20-3.97) 
Medium-High 1 39 0.25 0.27 (0.03-2.56) 
High 5 35 0.61 1.46 (0.35-6.11) 
Global p-value = 0.51 
AAD: Antibiotic-associated diarrhoea; CDI: Clostridium difficile infection; CI: Confidence interval; 
IQR: Interquartile range; n: number; OR: Odds ratios; 
P-value was calculated using binary logistic regression with data grouped into percentiles. 
Analysis was adjusted for significant covariates: a Score on Charlson Comorbidity Index and disease 
severity at baseline; b Disease severity at baseline; 
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Table 5.6 – Faecal lactoferrin and calprotectin levels: Prolonged symptoms 
Faecal lactoferrin 
≥10 days 
(n=48) 
<10 days 
(n=90) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
Low (Comparator group) 7 29 - - 
Medium-Low 17 19 0.02 3.71 (1.29-10.63) 
Medium-High 14 19 0.04 3.05 (1.04-8.95) 
High 10 23 0.30 1.80 (0.59-5.47) 
Global p-value = 0.07 
Faecal calprotectin 
≥10 days 
(n=46) 
<10 days 
(n=88) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
Low (Comparator group) 10 25 - - 
Medium-Low 12 21 0.49 1.43 (0.52-3.96) 
Medium-High 12 23 0.61 1.30 (0.47-3.59) 
High 12 19 0.39 1.58 (0.56-4.42) 
Global p-value = 0.84 
AAD: Antibiotic-associated diarrhoea; CDI: Clostridium difficile infection; CI: Confidence interval; 
IQR: Interquartile range; n: number; OR: Odds ratios; 
P-value was calculated using binary logistic regression with data grouped into percentiles. 
Analysis was adjusted for significant covariates: a No adjustment occurred as no covariates were 
found to be significant; 
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Table 5.7 – Faecal lactoferrin and calprotectin levels: 90-day recurrence 
Faecal lactoferrin 
Recurrence 
(n=49) 
Non-recurrence 
(n=88) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
Low (Comparator group) 14 20 - - 
Medium-Low 9 25 0.33 0.55 (0.17-1.83) 
Medium-High 13 22 0.61 0.75 (0.26-2.21) 
High 13 21 0.91 1.07 (0.36-3.16) 
Global p-value = 0.69 
Faecal calprotectin 
Recurrence 
(n=46) 
Non-recurrence 
(n=87) 
Adjusted 
P-valueb 
Adjusted OR 
(95% CI) 
Low (Comparator group) 7 24 - - 
Medium-Low 14 22 0.29 1.84 (0.60-5.60) 
Medium-High 11 24 0.43 1.59 (0.51-4.98) 
High 14 17 0.08 2.85 (0.90-9.05) 
Global p-value = 0.35 
AAD: Antibiotic-associated diarrhoea; CDI: Clostridium difficile infection; CI: Confidence interval; 
IQR: Interquartile range; n: number; OR: Odds ratios; 
P-value was calculated using binary logistic regression with data grouped into percentiles. 
Analysis was adjusted for significant covariates: aAge and presence of ribotype 027; b Age; 
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Table 5.8 – Faecal lactoferrin and calprotectin levels: Disease severity 
Faecal lactoferrin 
Severe 
(n=61) 
Non-severe 
(n=103) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
Low (Comparator group) 12 29 N/A N/A 
Medium-Low 11 30 0.81 0.89 (0.34-2.32) 
Medium-High 22 19 0.03 2.80 (1.13-6.96) 
High 16 25 0.35 1.55 (0.62-3.88) 
Global p-value = 0.06 
Faecal calprotectin 
Severe 
(n=60) 
Non-severe 
(n=99) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
Low (Comparator group) 13 26 N/A N/A 
Medium-Low 11 29 0.57 0.76 (0.29-1.99) 
Medium-High 19 21 0.20 1.81 (0.73-4.50) 
High 17 23 0.40 1.48 (0.59-3.69) 
Global p-value = 0.26 
AAD: Antibiotic-associated diarrhoea; CDI: Clostridium difficile infection; CI: Confidence interval; 
IQR: Interquartile range; n: number; OR: Odds ratios; 
P-value was calculated using binary logistic regression with data grouped into percentiles. 
Analysis was adjusted for significant covariates: a No adjustment occurred as no covariates were 
found to be significant; 
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Table 5.9 – Assessment of power across Clostridium difficile infection 
outcome analyses 
Disease outcome N 
Power (%) 
Faecal lactoferrin Faecal calprotectin 
Case vs. control 164 vs. 52 99 99 
30-day mortality 14 vs. 150 6a 19b 
Prolonged symptoms (test) 48 vs. 90 86 99 
90-day recurrence 49 vs. 88 99 91 
Disease severity (egfr) 61 vs. 103 99 99 
a: To achieve 80% power we would require 1370 patients in both sample groups 
b: To achieve 80% power we would require 167 patients in both sample groups  
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5.4 Discussion 
FC and FL are derived from neutrophils in faecal material, and have been shown 
to correlate with the degree of inflammation in diseases such as IBD.  Since CDI 
is also characterised histologically by intense neutrophilic infiltration (Price and 
Davies, 1977), FC and FL may represent potential biomarkers of disease activity.  
Using a prospective cohort of inpatient CDI cases and AAD controls, we 
confirmed previous findings that both FC and FL increase during CDI 
(p<0.0001) (Archbald-Pannone et al., 2010; Shastri et al., 2008; Vaishnavi et al., 
2000; van Langenberg et al., 2010; Whitehead et al., 2014). There was a high 
degree of correlation between the two biomarkers, not surprising given their 
cellular origin.  No previous CDI studies have evaluated both faecal biomarkers 
in the same patient group. These findings are consistent with those seen in IBD 
(D'Inca et al., 2007; Jones et al., 2008; Langhorst et al., 2008; Schoepfer et al., 
2008; Sipponen et al., 2008a; Sipponen et al., 2008b; Sipponen et al., 2008c).  
There are more studies on FL than FC for CDI (Table 5.1) but only a few have 
provided quantitative data. For FL, the reported mean/median values for CDI 
cases have differed markedly across studies (33-961 µg/ml; Table 5.1) 
(Archbald-Pannone et al., 2010; Boone et al., 2013; LaSala et al., 2013; van 
Langenberg et al., 2010). Our median value is at the lower end of this range 
(57.9 ng/µl). By contrast, our observed median level for FC was markedly 
higher than that in the two previous CDI studies (648.8 mg/kg versus 192 and 
249-336 mg/kg) (Shastri et al., 2008; Whitehead et al., 2014). The median levels 
in our AAD controls were lower for both FL and FC (2.7 ng/µl versus 22.6-22.8 
µg/ml and 66.5 mg/kg versus 106 µg/g, respectively; Table 5.1) than reported 
previously in the two FL studies and one FC study that included diarrhoea 
controls in their analysis (Archbald-Pannone et al., 2010; van Langenberg et al., 
2010; Whitehead et al., 2014).  Another study showed that 171 of 196 healthy 
controls (87%) had an FC level less than 15 mg/l (Shastri et al., 2008), a similar 
observation to that seen in our AAD controls (41/51; 80%). Considerable 
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variability was observed in different patients with CDI, which is consistent with 
data from IBD studies for both FL (4.34-179 µg/ml) (Langhorst et al., 2008; 
Langhorst et al., 2005; Schoepfer et al., 2008; Sipponen et al., 2008a; Sipponen 
et al., 2008b; Sipponen et al., 2008c) and FC (164-2171 mg/kg) (Costa et al., 
2003; García-Sánchez et al., 2010; Langhorst et al., 2005; Schoepfer et al., 2009; 
Schoepfer et al., 2010; Sipponen et al., 2008a; Sipponen et al., 2008b; Sipponen 
et al., 2008c; Summerton et al., 2002; Tibble et al., 2000).    
While our data show that FC and FL can differentiate between CDI and AAD, the 
use of these biomarkers for diagnosis per se would not add much value to the 
diagnostic paradigms currently in place.  However, identification of patients 
with complicated CDI disease (for example disease leading to more prolonged 
symptoms and recurrent disease) would be useful.  Despite marked increases in 
both faecal biomarkers in relation to disease severity, these failed to reach 
statistical significance and we observed no association with the other outcome 
measures evaluated. It is important to note that we had adequate statistical 
power to detect all of these outcomes except for 30-day mortality (Table 5.9). 
Direct comparisons between this and other studies are limited by variability in 
methodologies adopted, the lack of quantitative data, and differences in the 
severity grading criteria (Boone et al., 2013; El Feghaly et al., 2013; Steiner et 
al., 1997).  Another problem may result from the potential short-lived 
characteristics of the biomarkers, which may hamper the predictive power of 
these markers unless they are captured within specific timeframes. A 
longitudinal study of FL (Boone et al., 2012) suggested that FL could be used to 
monitor disease activity and response since FL tends to return to baseline very 
rapidly following remission (Boone et al., 2013; Boone et al., 2012).  
Our study has limitations. Firstly, we only used a single laboratory test (ELISA 
for CDT) for the primary identification of CDI cases. Although this is still a 
common procedure, modern algorithms currently make use of a more sensitive 
first step screening - based on either GDH, or NAAT - to minimise the odds of 
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reporting false negative results. Therefore it is possible that our cohort may 
have lacked a fully representative range of cases. Furthermore, our AAD 
controls were not a homogenous group of patients and it is difficult to assess 
their fitness for this sort of analysis given that antimicrobials and/or PPIs may 
not be the sole underlying cause of their gastrointestinal tract dysbiosis.  
Nevertheless, our data highlight the difficulties in using FL and FC as 
biomarkers for CDI.  The variability observed would reduce predictive accuracy, 
part of which may be due to differences in laboratory methodology. The volume 
of diluent for specimen suspension, and laboratory handling can each influence 
results, and caution should be exercised in the interpretation of single results 
(Kopylov et al., 2014).  Although serial testing may have some value, it would 
add to the cost, and may be challenging in diseases such as CDI, thus further 
reducing its utility.  Furthermore, these biomarkers can be elevated due to other 
diseases (Kopylov et al., 2014), and this is particularly important for CDI where 
infected patients are usually elderly with multiple co-morbidities.   
There are no guidelines concerning the use of faecal biomarkers for the 
classification of CDI cases. In IBD research, where faecal biomarkers constitute a 
potential non-invasive alternative to colonoscopy, the most recent diagnostics 
guidance by UK National Institute for Health and Care Excellence (NICE) 
(National Institute for Health and Care Excellence, October 2013) still 
recommends that further research is needed on the use and clinical utility of 
faecal marker testing.  Biomarkers which can act as indicators of disease, 
disease relapse and disease stratification, are also needed to direct CDI 
therapies more effectively. Our results suggest that FC and FL have limited 
applicability in this role.  
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Chapter 6 
Development of ECL assays to measure host 
immune response from serum during CDI 
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6.1 Biomarkers 
In 1998, the Biomarker Definitions Working Group of the National Institutes of 
Health (NIH) defined a biomarker as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (Group., 2001; Strimbu and Tavel, 2010).  The term biomarker is 
comprehensive and encompasses substances: - 
A) That are introduced into an organism as a means to examine organ 
function or other aspects of health (e.g. rubidium chloride as a 
radioactive isotope to evaluate perfusion of heart muscle) 
B) Whose detection indicates a particular disease state (e.g. the presence of 
a specific antibody may indicate an infection) 
 
Biomarkers currently play a major role in medicinal biology but the term is 
thought to have first been coined as early as 1980 during the investigation of 
the role of serum UDP-galactosyl transferase in breast carcinoma (Paone et al., 
1980). Biomarkers have been used across several scientific fields and are 
pivotal in clinical diagnosis and pre-clinical research as reliable indicators of 
biological state/status changes that indeed correlate with disease 
risk/susceptibility, progression or response to a treatment. The importance of 
biomarkers is emphasised by the significant budgets allocated by the NIH to 
support biomarker research: in 2008-2009, over $2.5 billion of the USA budget 
was awarded through research grants. 
Clinical biomarkers aid healthcare professionals in several areas including drug 
target identification, drug response, early diagnosis, disease prevention and 
stratification of treatment. Drug-related biomarkers are traditionally inherent 
to early drug development studies and clinical trials, and employed as a means 
to investigate drug processing, metabolism, and effectiveness with the aim to 
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establish optimal doses and dosing regimen for future studies. This is often 
supplemented by the study of safety biomarkers, such as the ones used to 
monitor liver and cardiac function. Conversely disease-related biomarkers are 
used to assess a pre-existing disease-condition, the probable treatment 
response of the patient, and the individual disease progression with or without 
treatment (Sapsford et al., 2010). Biomarkers are commonly divided into three 
main classes, all of them being relevant to infectious disease research: 
a) Risk indicators/predictive biomarkers 
b) Diagnostic biomarkers 
c) Prognostic biomarkers 
 
The biomarker development process is briefly summarised in Figure 6.1. 
 
Fig 6.1 Overview of biomarker development process 
 
The use of laboratory-measured biomarkers in both pre-clinical and clinical 
research is still relatively modern, and therefore development and refinement 
of best practice is a continuous process (Strimbu and Tavel, 2010). This is 
important when considering the increased appeal offered by the use of 
molecular biomarkers as substitutes for rather subjective clinical parameters, 
which is still a widespread practice and largely employed for the management 
of various diseases (Biomarkers Definitions Working Group, 2001). Several 
molecular biomarker tests have become established in clinical care and are 
routinely used for the ascertainment of a patient’s general health and 
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homeostasis. Attempts to develop clinical risk indices involving multiple 
mainstream markers are being pursued for the identification of patients at most 
risk of experiencing acute and fatal conditions, with exemplary approaches 
utilised for the assessment of cardiovascular diseases (Cross et al., 2012; 
Folsom, 2013; Macdonald et al., 2013), lymphoma (Katsuya et al., 2012; Perry et 
al., 2012), human immunodeficiency virus (HIV) infection (Tate et al., 2013), 
chronic obstructive pulmonary disease (COPD) (Motegi et al., 2013) and 
inflammation-related diseases such as Crohn’s and CDI (Benitez et al., 2013; 
Bloomfield et al., 2013). However, validation of disease-specific markers is 
challenging and requires a deep knowledge of the pathogenesis and biological 
processes. 
6.1.1 Biomarkers in CDI 
Biomarker evidence for CDI has been limited, in part due to the lack of 
comprehensive studies and mechanistic understanding of the disease. 
Predictive biomarkers have not been validated for CDI yet and there is an 
imperative need for new biomarkers to stratify CDI patients. There is the 
question as to whether CDI biomarkers simply have yet to be discovered, or 
whether the current methodologies in place to measure existing parameters 
lack the necessary credentials to pursue validation, such as sensitivity, 
specificity, or reliability issues.  
As outlined in Chapter 1 Section 1.3, both biochemical and molecular studies 
have shown that the major clinical signs and symptoms of CDI can be explained 
largely by the actions of two large, glucosylating toxins, namely tcdA and tcdB 
(Babcock et al., 2006a; Kim et al., 1987; Lyerly et al., 1985; Lyras et al., 2009b). 
Clinical manifestations range from asymptomatic carriage and mild diarrhoea to 
fulminant pseudomembranous colitis (Kelly et al., 1994; Kyne et al., 1999; 
McFarland et al., 1989; Rubin et al., 1995). It appears that host, rather than 
bacterial, factors determine these differences in clinical presentation (Cheng et 
al., 1997; McFarland et al., 1991). 
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Antibody responses to tcdA and tcdB are evident in approximately 60% of 
healthy individuals (Kelly et al., 1992; Viscidi et al., 1983), suggesting 
widespread exposure to C. diff in the environment. Furthermore, there is 
evidence that the toxin-specific immune response is important for both CDI 
pathogenesis and course of disease (Aronsson et al., 1985; Bauer et al., 2014; 
Drudy et al., 2004; Islam et al., 2014; Johnson et al., 1992; Katchar et al., 2007; 
Kyne et al., 2000a, 2001; Mulligan et al., 1993; Sanchez-Hurtado et al., 2008; 
Solomon et al., 2013; Warny et al., 1994). Studies having investigated immune 
response to C. diff are summarised in Appendix 21. 
The recent emergence of hypervirulent epidemic C. diff resistant strains has 
warranted the development of novel, non-antibiotic based treatment regimes. 
These strains have been linked with increased morbidity, mortality and 
recurrence rates worldwide (McDonald et al., 2005b; Warny et al., 2005), 
largely because of their increased virulence and hyperproduction of tcdA and 
tcdB (Kuehne et al., 2010; Thelestam and Chaves-Olarte, 2000). However, only a 
fraction of individuals exposed develop infection and therefore it is important to 
understand inter-patient variability and the immune response patterns 
associated with CDI. It has been shown that antibody-mediated neutralisation of 
these toxins affords protection against CDI (Giannasca and Warny, 2004; 
Giannasca et al., 1999). This includes both anti-tcdA and anti-tcdB passive 
immunisation studies (Babcock et al., 2006a; Kink and Williams, 1998; Lowy et 
al., 2010; Lyerly et al., 1991; Roberts et al., 2012; van Dissel et al., 2005) and 
vaccines designed to evoke an effective neutralising immune anti-toxin 
response (Greenberg et al., 2012). As detailed in Chapter 1 Section 1.8, the 
current focus for vaccine development has been placed on the antibody 
response to C. diff toxins due to its closer relationship to CDI. Part of these 
efforts has been hampered by the lack of reliable methods to quantitate this 
immune response and to date no commercial assays have been validated. 
Previous research has been limited to in-house methods based on traditional 
ELISA and qualitative measurement of response against toxins A and B only.  
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Phylogenetic analysis has shown that the unprecedented wave of outbreaks 
witnessed in the last decade was a result of global spread of emerging strains 
originating from North America, most likely driven by increased resistance to 
several classes of antibiotics such as fluoroquinolones (He et al., 2013). Since 
then, the research landscape has focused on gaining a better understanding of 
the spread, evolution and establishment of the disease. For example, the 
demonstration that tcdB but not tcdA is necessary for full virulence of C. diff in 
experimental infection models (Lyras et al., 2009b) has called into question the 
importance of tcdA in disease pathogenesis since a number of pathogenic 
strains do not possess the encoding gene. Strains such as PCR-ribotype 
027/NAP1/BI1, have also been found to express a third unrelated virulence 
factor in the form of a binary toxin complex (Barbut et al., 2005; Cartman et al., 
2010; McDonald et al., 2005b), which is characterised by an enzymatically 
active “A” domain (cdtA) and a cell binding and translocation “B” component 
(cdtB) (Xie et al., 2014). Although the exact role of the binary toxin in the 
pathogenesis and development of CDI is still debatable, recent data on its 
mechanism of action and significant correlations of binary-producing strains 
with CDI progression suggest that further research is needed in this area. 
Given all the uncertainties, there is a need to re-evaluate the role of the immune 
response to C. diff toxins. This study aimed to develop improved assays for 
quantification of immune response to tcdA and tcdB, as well as novel assays for 
quantification of CDT, something that has never been described in the literature. 
6.2 Measurement of biomarkers 
Various approaches currently exist for the measurement of proteomic, 
metabonomic, secretomic, genomic and transcriptomic biomarker targets. 
However, examination of any molecular biomarker is highly dependent upon its 
physico-chemical and biological properties as well as on the complexity of the 
biological matrix that is being examined.  
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Moreover, the protein content of the human serum/plasma proteome is made 
up of proteins across wide quantitative dynamic ranges; at the high-end, 
albumin (normal concentration range 35-50 mg/ml) and at the low-end, 
interleukin-6 (normal range 0-5 pg/ml) (Anderson and Anderson, 2002). Hence, 
discovery and validation per se of specific protein biomarkers is already 
confined to low abundance targets amongst a multitude of high abundance 
molecules such as albumin and as such, screening methodologies are required 
by default to deliver extremely high levels of sensitivity and specificity in order 
to be able to accurately measure them (Anderson and Anderson, 2002). Since 
one of the predominant features of CDI research involves a systemic, often 
acute, host-mediated response, the present work sought to develop a robust 
framework for the evaluation of disease-related protein biomarkers readily 
available from sera of CDI patients. Whilst microarray technology offers great 
potential for biomarker discovery, the primary focus of this work was to 
improve current methods for quantification of immune response markers and 
therefore focus was given to portable methods showing high translational 
potential, described below. 
6.2.1 ELISA 
ELISA is a popular protein analysis method to quantify levels of response 
markers, such as inflammatory cytokines and antibodies released as result of a 
disease or condition. The ELISA was first developed in the 1970s when PhD 
graduate student Eva Engvall, using the premise that specific enzymes in the 
presence of an appropriate substrate will react to induce a detectable colour 
change (Avrameas, 1969; Engvall et al., 1971; Nakane and Pierce, 1966, 1967). 
Based on this principle, the traditional ELISA is an absorbancy-based test that 
uses antibodies in which colour change is an indication of a positive reaction 
with a target protein. The ELISA became the preferred choice of immunoassays 
after the use of radio-immunoassays (RIAs), the then established method, was 
diminished due to the potential hazard posed by the handling of radioactive 
165 
 
 
 
products, which were employed for signaling the reaction of labeled 
antigens/antibodies with designated targets (Yalow and Berson, 1960) .  
Various variants of ELISA are now in widespread use, such as the indirect ELISA, 
sandwich ELISA, competitive ELISA, and multiple and portable ELISA, with the 
most typical being the sandwich ‘double-antibody’ immunoassay. In such a 
scenario, primary antibody is coated onto well-bottoms of designed plates, 
typically in a 96-well format. A series of steps involving washing of wells and 
addition of sample results in the target analyte being bound to the primary 
capture antibody. A secondary enzyme-linked (typically horseradish 
peroxidase, HRP) antibody then binds to a separate region of the antigen. The 
appropriate substrate is then added, and the resultant colour change is detected 
using spectrophotometry. 
ELISA is renowned for its simplicity and reproducibility. It has been employed 
in a broad range of applications within and outside human medicine, becoming 
a standard diagnostic tool for autoimmune diseases and other conditions such 
as HIV (Iweala, 2004; Le Pottier et al., 2009). In CDI, ELISAs were originally 
employed as a method of choice for the initial examination of antibody immune 
response to tcdA and tcdB (Aronsson et al., 1983; Jiang et al., 2007; Katchar et 
al., 2007; Kyne et al., 2000a, 2001; Leung et al., 1991; Sanchez-Hurtado et al., 
2008). Such an extensive range of applications resulted in commercialisation of 
ELISA kits and related instruments, such as automated pipetting, multichannel, 
washing station and reader devices (Lequin, 2005). Furthermore, the increase 
in the commercial production of plate-based assays has led to the emergence of 
multiplex formats (Kingsmore, 2006; Lash et al., 2006; Mendoza et al., 1999). 
One of them, Pierce SearchLight (ThermoFisher, USA), relies on accurate pre-
spotting of multiple capture antibodies and is essentially an enhanced ELISA 
array. 
Despite their widespread uptake, ELISAs are not without their flaws. Seen as 
labour- and time-intensive, their performance is largely dependent on antibody 
166 
 
 
 
quality, the incubation periods and the selection of appropriate blocking and 
dilution buffers (Malekzadeh et al., 2012). 
Furthermore, they are prone to both cross-reactivity and matrix interference 
(Malekzadeh et al., 2012), and have limited sensitivity and linear detection 
range for several applications. This is critical particularly for protein targets 
present at very low concentrations and for reliable analysis of different body 
fluids (Lequin, 2005). Ultrasensitive ELISA kits have been brought to the market 
in attempt to counteract this but are considerably more expensive and simply 
result in shifting and further narrowing the already restricted dynamic range 
(Malekzadeh et al., 2012). 
Over the last decade there has been an increase in the popularity of enhanced 
platforms based on fluorescent and electrochemiluminescent (ECL) 
technologies. These newer ELISA-like multiplex-capable platforms propose 
replacement of the chromogenic technology, which the traditional ELISA relies 
upon. Their technologies allow the creation of quantifiable signals that benefit 
from higher sensitivities and a wider dynamic range, which alongside quicker 
turn-around times and reduction in sample and reagent consumptions make a 
compelling case for their adoption (Leng et al., 2008; Toedter et al., 2008). As 
they are linked to non-enzymatic reporters, they are not strictly ELISAs per se 
but are grouped with these due to similarities in general principles and 
laboratory practice. 
6.2.2 Fluorescence versus Electrochemiluminescence (ECL) 
Fluorescent immunoassays are typically bead-based, with notable platforms 
including Luminex (Luminex Corporation, Texas) and GyroLab (Gyros AB, 
Sweden). The fluidic-based Luminex platform is the most widely used 
incorporating fluorescent technology. Following the principles of a traditional 
sandwich immunoassay, a primary antibody is linked to a polystyrene bead, 
each of which is internally dyed with a red fluorophore. Antigen binding then 
167 
 
 
 
occurs by one of two methods; by a biotin-labelled secondary antibody or by 
directly labeled phycoerythrin (PE). The amount of protein bound is identified 
by the PE-emitted fluorescence. Luminex xMAP technology allows for 
recognition of up to 100 different beads identified by the fluorescence ratio of 
the internal red dye, and therefore up to 100 different target analytes can be 
screened concomitantly. The ability to perform multiplex analysis of several 
analytes in a single sample is xMAP’s major selling point (Marchese et al., 2009). 
One major disadvantage of this platform is the potential structural damage 
sustained as a result of the conjugation chemistry required to covalently bind 
antibodies to the beads (Anderson et al., 2011; Marchese et al., 2009). GyroLab 
employs microfluidic technology involving a compact disc (CD) containing 
microchannels and a reaction chamber coated with streptavidin but is grouped 
with other bead-based platforms due to a lack of notable 
differences/technological advantages. 
ECL-based techniques also provide a viable alternative to the colorimetric 
methods of the traditional ELISAs (Blackburn et al., 1991; Deaver, 1995; 
Guglielmo-Viret and Thullier, 2007), with a reported eight-fold increase in 
sensitivity (Guglielmo-Viret and Thullier, 2007). ECL-based platforms, such as 
that provided by Roche Diagnostics (Roche Diagnostics Ltd, UK) and Meso Scale 
Discovery (MSD, USA), provide high sensitivity levels and good reproducibility, 
combined with generally low levels of interference from epitopes in serum, 
plasma and other complex matrices (Blackburn et al., 1991; Guglielmo-Viret and 
Thullier, 2007; Swanson et al., 1999). ECL also reduces the potential need for 
retesting of high concentration samples due to a broader dynamic range 
(Marchese et al., 2009) and has further benefits such as speed of analysis and 
the absence of integrated fluids, which eliminate the clogging issues common to 
the bead-based systems discussed above (Marchese et al., 2009). ECL was 
initially adopted by Roche, whose assay involves separate cartridges and 
reading cells. MSD provides an advance by developing current generation 
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integrated to the analytical plates, which in turn maximises assay performance 
and throughput. 
Owing the technical limitations of the traditional ELISA, it is apparent that there 
is marked room for improvement. The advantages of the emerging ECL 
platforms combined with the need for robust methods to quantitate host-
mediated antibody responses to both tcdA and tcdB provide sufficient basis for 
both the improvement of existing methods and the development of novel 
strategies, including the development of novel assays for the detection of 
response to cdtA and cdtB. 
Unlike ECL, bead-based methods do not offer enough flexibility for the 
customisation of these assays and the option for the ECL system (MSD) was 
made after conducting a thorough review of the available literature and 
following careful consideration of existing platforms in the market. 
Furthermore, steady transition of existing ELISAs onto the ECL format is 
possible given the existence of transferrable information and in such a 
circumstance, provided a valuable basis for the development and typing of one 
of the candidate markers of this study (i.e. the immunity-linked protein MBL - 
see Chapter 7). 
6.2.3 Meso Scale Discovery (MSD) 
Meso Scale Discovery (MSD) technology revolves around microtitre plates with 
integrated carbon electrodes at the bottom of each well, to which biological 
reagents can be passively adsorbed whilst retaining a high level of biological 
activity. Detection antibodies are conjugated with electrochemiluminescent 
labels (MSD SULFO-TAG), which emit light when electrochemically stimulated. 
The detection process is initiated at the carbon electrodes whereby the 
necessary electrical stimulus causes the ruthenium label (Ru(bpy)3 2+) in the 
detection tags to emit light at 620 nm. This redox reaction (illustrated in Figure 
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6.2) is enhanced by co-reactants, such as tripropylamine (TPA), present in the 
MSD read buffer, and multiple excitation cycles of each label amplify the signal 
to enhance light levels and improve sensitivity. 
 
 
 
Figure 6.2 – Overview of redox reaction required for  
electrochemiluminescence 
 
The necessary voltage is applied by the MSD imager that is also responsible for 
measuring the intensity of the emitted light, providing a quantitative measure of 
analyte in the sample. Background signals are minimal because the stimulation 
mechanism (electricity) is decoupled from the signal (light). In addition to the 
separation-based (“wash”) method employed by conventional ELISAs, MSD ECL 
assays have the potential to be used in a separation-free format (“no-wash”), 
where ready buffer is applied directly to the sample and well. The no-wash 
method may offer the advantage of removing a potential source of variation and 
reducing operating times at the cost of decreasing sensitivity (Thompson et al., 
2009). This is possible with MSD-ECL given the proximity-based nature of its 
signal generation where only labels near the electrode are excited and detected 
(Thompson et al., 2009). Other technologies (fluorescent polarisation (FP)) and 
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platforms (AlphaLISA, PerkinElmer, USA; Quansys, Quansys Biosciences, USA; 
Pierce SearchLight, ThermoFisher, USA) based upon enhanced 
chemiluminescence, including some with bead-based formats, are comparable 
to MSD-ECL in terms of assay parameters but lack the potential for both 
multiplexing and development process of custom assays. 
A recent study comparing four different ligand-binding assay technology 
platforms (ELISA, MSD, GyroLab and AlphaLISA) for measurement of a human 
IgG1 MAb drug analyte in rat serum evaluated MSD and GyroLab as future 
default platforms for total MAb biotherapeutic assay development, based mainly 
on superior assay performance and parameters (Table 6.1 & Table 6.2) (Leary 
et al., 2013). 
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Table 6.1 – Summary of assay platforms and parameters for the human IgG generic (Fc-specific) assay (adapted from Leary et 
al. 2013) 
Various assay parameters for the platform comparison are summarised in Table 5.1. The dynamic range and assay sensitivity for each platform are listed in 100% 
matrix; total assay time includes both estimated sample preparation time and incubation times 
 
Platform LBA format Readout 
Dynamic range 
(ng/ml) 
Sensitivity 
(ng/ml) 
Sample 
MRD 
Required sample 
volume (µl) 
Total assay 
time (h) 
ELISA Plate Colorimetric 8.0-666 88.0 20 12 5 
MSD Plate ECL 15.6-4000 15.6 4 25 2 
Gyrolab Bead Fluorescence 10.5-6400 10.5 2 4 1.5 
AlphaLISA Bead Luminescence 181-1097 181 N/A 2.5 2.5 
LBA: Ligand-binding assay; MRD: Minimum required dilution 
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Table 6.2 – Additional platform selection considerations (adapted from Leary et al. 2013) 
In addition to assay performance and parameters listed in Table 5.1, other factors considered for ligand-binding assay platform selection are summarised in Table 
5.2. These factors include costs, special equipment needs and reagent requirements 
 
Platform Cost Requires special buffers Special equipment required Reagent modifications required 
Single vendor for 
technology 
ELISA + No 
Spectrophotometric plate 
reader 
Labeled detector reagent (e.g. biotin, 
enzyme etc) 
No 
MSD ++ Read buffer (proprietary) MSD plate reader Biotin capture & Ru detector reagent Yes 
Gyrolab ++++ 
Sample & detection buffers 
(proprietary) 
Gyrolab Instrument Biotin capture and Alexa detector reagent Yes 
AlphaLISA +++ No Envision plate reader Bead conjugation, biotinylation of capture Yes 
+: least expensive; ++++: most expensive; Ru: Ruthenium 
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The platform of choice for this study is justified on the grounds of three 
significant requisites, whereby MSD-ECL was superior: costs, degree of 
customisation and transferability. Costs were inclusive of the reading 
instrument itself as well as per-run cost for consumables, both of which were 
lower for the MSD-ECL platform (Leary et al., 2013). Crucially, the MSD-ECL 
platform offers flexibility for the customisation of both existing and novel 
biomarker immunoassays. Analogies in the fundamental basis of workflows 
with ELISA affords ECL a rapid and convenient transition from chemistries 
utilised in existing ELISAs to the MSD platform, thereby benefitting from several 
of its technical advantages over ELISA. In terms of transferability, this is a 
common issue due to each technology being only available from a single vendor. 
Hence, discontinuation of a platform would require transfer of assays to an 
alternate methodology, where compatible. Due to the plate-based nature of MSD 
assays, a hypothetical MSD-to-ELISA transfer would be relatively simple, as 
opposed to the moderate optimisation required for other formats such as the 
microfluidic Gyrolab platform (Leary et al., 2013).  
The combination of ultra-low detection limits, wide dynamic ranges, minimal 
sample usage and decreased matrix effects have led the MSD plate-based format 
to become a widely adopted platform by research departments of the 
pharmaceutical sector (Myler et al., 2011). Given the reasons above, the MSD-
ECL constitutes in the platform-of-choice for the assay development of 
candidate protein biomarkers of this thesis. 
6.3 Assay development 
6.3.1 Overview 
Different sandwich immunoassays formats can be developed using MSD plates; 
typical immunoassays involve those using antibodies as capture tags (Figure 
6.3A). Non-antibody molecules (such as proteins/antigens, carbohydrates, 
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virus-like particles, membranes and cells) can also be used as capture reagents 
(Figure 6.3B). For this work toxin proteins (tcdA, tcdB and cdtA/B) have 
especially been utilised as epitopes for the detection of specific antibodies 
(circled). 
 
 
 
Figure 6.3 – Overview of the different sandwich immunoassay formats that 
may be developed using MSD plates (Meso Scale Discovery, 2013): (A) 
Typical immunoassays using capture antibodies; (B) Immunoassays using 
non-antibody capture reagents 
Typical immunoassays: The graphic provides examples of different assay formats that are 
possible using antibodies as capture reagents on MSD plates. (1) MSD SULFO-TAG is directly 
conjugated to the detection antibody. (2) Biotinylated detection antibody binds to SULFO-TAG 
Streptavidin. (3) Detection antibody binds to SULFO-TAG-conjugated anti-species antibody. 
Immunoassays using non-antibody capture reagents: Capture materials, such as peptides 
antigens, carbohydrates, lysates, cells, membranes, and virus-like particles, can be directly 
immobilised on MSD plates. 
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ECL assay development needs to follow several optimisation procedures and 
ultimately comply with a number of performance requisites. MSD provides 
plates with two different surface types: High Bind (HB) plates have a 
hydrophilic surface and can facilitate the quantification of analytes at higher 
concentrations, Standard Bind (SB) plates have a hydrophobic surface and tend 
to offer higher sensitivity whilst frequently exhibiting lower non-specific 
binding, especially with complex sample matrices. Both plate types are the 
primary initial choices recommended by the manufacturer for the assay 
development process. Other variables associated with the optimisation are 
coating concentration of epitopes, type of coating buffer and blocking buffer, 
dilution factor of samples and concentration of detection antibodies, amongst 
others. The objectives of successful assay development are: -  
 High signal-to-background ratio (SBR) 
 Sensitivity 
 Specificity 
 Reproducibility 
 Wide linear dynamic range 
 
Signals were determined using a proprietary SECTOR Imager and should be 
directly proportional to the amount of analyte present in the samples. This 
section provides a detailed description of all optimisation steps leading to assay 
completion, summarised in Figure 6.4. 
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Figure 6.4 – Overview of steps involved in assay development pathway: 
assay optimisation and qualification 
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6.3.2 Biological Materials 
6.3.2.1 Capture 
Purified aliquots of native tcdA and tcdB, derived from reference strain 
vpi10463, were obtained through collaboration with Dr. Clifford Shone from 
Public Health England in Porton (formerly Health Protection Agency). 
cdtA and cdtB (both precursor (cdtB-pre) and active (cdtB-act) forms), from 
strain 196, were produced recombinantly through the expression in Bacillus 
megaterium and were obtained from the research group of Professor Klaus 
Aktories (University of Freiburg, Germany). 
6.3.2.2 Detection 
Monoclonal IgG and IgM antibodies were ordered from Hybridoma Reagent 
Laboratory (HRL) (Stratech Ltd, UK). 
Polyclonal IgG and IgM antibodies were ordered from Jackson ImmunoResearch 
Laboratories Inc. (Pennsylvania, USA). These were sulfo-tagged on site. 
6.3.2.3 Samples 
Patient recruitment and sampling is described in detail in Chapter 2. Human 
sera were used across all assays, isolated from whole blood via centrifugation 
(2600g for 20 min), aliquoted and stored at -80°C prior to use. 
 
6.4 Toxin A & B assays 
The first four assays developed involved measurement of both IgG and IgM 
response to major C. diff toxins tcdA and tcdB, based upon the sandwich assay 
ELISA format using directly labeled antibodies.  
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6.4.1 Determination of initial working conditions 
6.4.1.1 Selection of the type of ECL bind plate and initial run 
Using manufacturer’s guidelines, the following fixed conditions were included 
for the selection of either plate types (SB versus HB): 1x PBS as coating buffer, 
1x PBS + 0.05% Tween20 (PBST) as washing buffer, PBST + 5% Foetal Bovine 
Serum (FBS) as blocking buffer and detection antibody concentration at 1 μg/ml 
(diluted in blocking buffer). Varying conditions were assessed and optimised as 
follow: toxin coating concentration (0-5 μg/ml) and sample dilution factor (neat 
to 1:625). 
A generalised MSD assay protocol is as follows: - 
1. Dilute capture in coating buffer. Add 25 μl to each well. Tap plate to ensure 
even coverage. Seal and incubate overnight at 4°C 
2. Wash 3 x 150 μl with washing buffer 
3. Add 150 μl blocking buffer and seal. Incubate for 1 h at room temperature 
with shaking 
4. Wash 3 x 150 μl with washing buffer 
5. Add 25 μl sample, diluted to appropriate factor in blocking buffer, and seal. 
Incubate for 2 h at room temperature with shaking 
6. Wash 3 x 150 μl with washing buffer 
7. Add 25 μl of detection (anti-isotype antibody plus streptavidin Sulfo-Tag 
diluted to appropriate concentration in blocking buffer) and seal. Incubate 
for 1 h at room temperature with shaking 
8. Wash 3 x 150 μl with washing buffer 
9. Add 150 μl of MSD Read Buffer (diluted to 2x working mixture with 
distilled water) 
10. Read plate within 15 min 
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The initial optimisation runs suggested a flat response with the use of HB plates 
with no meaningful differences in relation to baseline signal (zero coating and 
buffer only conditions), irrespective of the analyte (toxins), antibody isotypes or 
test samples employed (see Table 6.2 for IgG response to tcdA). Conversely, 
data generated using SB plates demonstrated a continuous trend in signal 
intensity (highlighted in red) as toxin coating concentrations increased and this 
was particularly marked for IgG response to both tcdA and tcdB (Table 6.2 for 
IgG response to tcdA). Hence, only SB plates were taken forward for full 
optimisation and development. Further tables can be viewed in Appendices 22-
24. 
 
Table 6.2 – Comparison of standard- and high-bind plates for IgG response 
to tcdA 
Sample 
code 
Plate 
type 
Coating conc. 
(µg/ml) 
Fold Dilution 
Buffer 625 125 25 5 Neat 
A3X 
HB 
0.0 136 123 156 211 162 227 
2.5 125 115 137 177 141 214 
5.0 126 128 155 181 155 223 
10.0 129 121 169 165 117 208 
SB 
0.0 121 105 117 171 165 125 
2.5 95 104 157 167 158 148 
5.0 87 373 132 209 215 209 
10.0 414 201 333 346 387 361 
PHR 
HB 
0.0 110 118 157 217 194 948 
2.5 107 116 146 189 158 940 
5.0 107 122 149 241 168 920 
10.0 111 116 153 192 149 924 
SB 
0.0 95 102 150 272 353 248 
2.5 116 117 161 306 358 305 
5.0 101 121 172 391 441 386 
10.0 223 279 265 635 541 490 
HB: High bind; SB: Standard bind; 
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6.4.1.2 Determination of coating concentration and selection of blocking 
buffer 
For practical reasons, tcdA was employed for the initial determination of 
coating concentrations. Given the high homology between the two proteins, the 
optimum settings could then be successfully transferred to the tcdB assays. 
Further fixed conditions included in this step were plate type (SB) and detection 
antibody concentration (1 μg/ml). Varying conditions were blocking buffer 
(PBST + 5% FBS versus PBST + 1% Bovine serum albumin (BSA) + 1% milk 
powder), coating buffer (PBS, PBS + 0.1% sodium dodecyl sulfate (SDS) versus 
PBS + 0.1% Tween20 (PBST-coat)), toxin coating concentration (0-50 μg/ml) 
and sample dilution factor (neat to 1:25). 
A high SBR combined with a steady signal increase at a particular dilution range 
would deliver optimum results. By focusing on SBR, it was possible to 
determine an optimal coating concentration (25 μg/ml). For IgM, the SBR 
tended to fall at high coating concentrations (i.e. 50 μg/ml), suggesting that 
concentrations above 25 μg/ml are not recommended (Table 6.4). Compared to 
PBST + 5% FBS, PBST + 1% BSA + 1% milk powder blocking buffer (Blocker 1) 
delivered superior performance and required a lower concentration of toxin 
coating in order to achieve an acceptable SBR (Tables 6.3 & 6.4 illustrate this 
with the PBS coating).  PBST + 5% FBS also showed a higher background for IgG 
response (Table 6.3). Further tables can be viewed in Appendices 25-28. 
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Table 6.3 - Comparison of blocking buffers for IgG response to tcdA across 
varying PBS coat concentrations 
Coat Block 
Coating conc. 
(µg/ml) 
Sample dilution 
Buffer SBR 
Neat 1:5 1:25 
PBS 
Blocker 1 
0 101 92 108 111 0.9 
5 197 92 107 91 2.2 
25 243 110 109 93 2.6 
50 185 109 107 100 1.9 
PBST + 
5% FBS 
0 76 79 89 95 0.8 
5 133 106 123 106 1.3 
25 191 120 158 128 1.5 
50 233 170 174 119 2.0 
FBS: Foetal bovine serum; PBS: Phosphate buffer solution; PBST: 1x phosphate buffer solution + 
0.05% Tween20; SBR: Signal-to-background ratio; 
 
Table 6.4 - Comparison of blocking buffers for IgM response to tcdA across 
varying PBS coat concentrations 
Coat Block 
Coating conc. 
(µg/ml) 
Sample dilution 
Buffer SBR 
Neat 1:5 1:25 
PBS 
Blocker 1 
0 125 119 113 114 1.1 
5 502 1513 346 132 3.8 
25 463 387 211 94 4.9 
50 187 189 145 95 2.0 
PBST + 
5% FBS 
0 89 82 89 96 0.9 
5 166 105 91 85 2.0 
25 401 247 189 110 3.6 
50 338 168 108 82 4.1 
FBS: Foetal bovine serum; PBS: Phosphate buffer solution; PBST: 1x phosphate buffer solution + 
0.05% Tween20; SBR: Signal-to-background ratio; 
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6.4.1.3 Determination of coating buffer and efficacy of toxin sonication 
As described above, three coating buffers were tested with various 
concentrations of capture epitopes. PBS and PBS + 0.1% SDS provided a 
significantly better SBR in comparison to PBST-coat as a coating solution 
(Tables 6.3 & 6.4; Appendices 24-28), and thus the latter was not included for 
further testing. Again for practical reasons, the initial assessment of both IgG 
and IgM response was conducted with tcdA and optimum conditions were then 
replicated with tcdB. In addition, coating images during this process suggested a 
certain degree of toxin aggregation (Figure 6.5A). In order to assess the impact 
of this on assay performance, a 5-minute sonication step was included prior to 
the coating steps with either PBS alone, or PBS + 0.1% SDS. Sonication led to a 
decrease in observed toxin aggregation (Figure 6.5B) with either coating 
buffers. As previous, the use of PBS alone delivered higher overall signals and a 
significantly better SBR than those observed when using PBS + 0.1% SDS (Table 
6.5).  PBS alone was therefore selected as the primary choice of coating vehicle 
for the downstream steps with both tcdA and tcdB. Further tables can be viewed 
in Appendices 29 & 30. 
 
 
Figure 6.5 –Toxin coating diluted in PBS 
A: Aggregation observed using unsonicated toxin coating; B: Aggregation combatted by sonication 
of toxin prior to coating  
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Table 6.5 – Electrochemiluminescence signal comparison for IgG response 
to tcdA across varying blocking buffers 
Antibody Analyte Sample Dilution 
Mean signal 
PBS (SBR) PBS + 0.1% SDS (SBR) 
IgG tcdA 
A3X 
Buffer 81 74 
Neat 1,173 (14.5) 924 (12.5) 
5 703 (8.7) 343 (4.6) 
25 449 (5.5) 337 (4.6) 
PHR 
Buffer 72 71 
Neat 4,427 (61.5) 4,126 (58.1) 
5 1,397 (19.4) 1,255 (17.7) 
25 613 (8.5) 559 (7.9) 
IgG: Immunoglobulin G; PBS: Phosphate buffer solution; SBR: Signal-to-background ratio; SDS: 
Sodium dodecyl sulfate; tcdA: Clostridium difficile toxin A; 
 
6.4.1.4 Determination of polyclonal IgG and IgM detection antibodies and 
optimal IgM sample dilution 
Despite the acceptable development progress, signal spectra observed were 
modest, and did not significantly improve during the initial optimisation 
process, and were irrespective of sample dilution factor adopted. Hence, further 
optimisation was pursued and polyclonal IgG and IgM antibodies were tested as 
equivalent replacements to their respective monoclonal IgG and IgM versions. 
In order to ensure steady progress of the assay development, this optimisation 
made use of the optimal conditions previously identified and an additional 8 
clinical samples (CDA 1004, CDA 1022, CDN 0529, CDN 0538, CDN 0574, CDP 
0022, CDP 0054 and CDP 0057) were tested to compare results between 
monoclonal versus polyclonal antibodies. Since the objective here was rapid 
assessment of the potential benefits of the polyclonal antibodies, samples were 
run at a single dilution factor (1:5 for measuring IgG response and 1:2 for IgM)  
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Both polyclonal IgG and IgM antibodies significantly improved the signal and 
differentiation of samples over their monoclonal counterparts. Using correlation 
analysis, it was possible to determine that sample rank order was also 
preserved: R2 = 0.946 and R2 = 0.999, respectively (Figure 6.6 for IgM; for IgG 
see Appendix 31). Sample dilution at 1:2 for IgM was satisfactory for all 
samples. There was no evidence for assay saturation and no further 
optimisation was necessary. In contrast, IgG assays produced an extremely wide 
signal range and signal saturation was observed in a number of cases. Therefore 
dilution linearity was performed for all IgG assays (tcdA and tcdB) in order to 
identify the optimal conditions. 
 
 
Figure 6.6 – Signal correlation across two different anti-IgM antibodies 
*Correlation value is inclusive of sample outlier, which is not shown in the figure. 
 
y = 0.0138x + 96.021 
R² = 0.999* 
0
50
100
150
200
250
0 2,000 4,000 6,000 8,000 10,000 12,000
A
n
ti
-I
g
M
 m
o
n
o
cl
o
n
a
l 
si
g
n
a
l 
Anti-IgM polyclonal signal 
Series1
Linear (Series1)
185 
 
 
 
6.4.1.5 Determination of optimal sample dilution with IgG polyclonal 
antibodies 
Two coded clinical samples previously tested (CDA 1004 and CDN 0538) were 
subject to varying sample dilutions ranging from 1:5 to 1:160. These had 
previously given high and low signals for IgG response with monoclonal 
antibodies, respectively. 
For the high signal intensity sample (CDA 1004), linearity was only reached 
after 1:40 dilution (Table 6.6, Figure 6.7), with a variation of 0.7% between the 
1:40 and 1:80 dilutions. For the low intensity sample (CDN 0538), linearity was 
observed between the 1:20 and 1:40 dilutions (Appendices 32 & 33), but as 
dilution further increased this tended to be less consistent. This is explained by 
the fact that as samples were diluted further, their signal intensity levels fast 
approached background levels, and therefore background noise accounted for a 
larger proportion of the overall signal. Based on the above, a dilution factor of 
1:40 was proposed for both IgG assays (tcdA and tcdB) as opposed to the 1:2 
dilution factor employed for the IgM assays. With IgG known to account for a 
large percentage of total antibodies in the serum, it was anticipated that signal 
intensity for the IgG assays would be considerably higher than IgM assays. 
 
Table 6.6 – Dilution linearity for IgG response to tcdB in a high response 
sample (CDA 1004) 
Sample Sample dilution 
Absolute signal 
(ECL units) 
Signal factored for 
dilution 
CDA 1004 
1:5 1,383,713 6,918,565 
1:10 1,357,893 13,578,930 
1:20 1,098,406 21,968,120 
1:40 701,970 28,078,800 
1:80 348,661 27,892,880 
1:160 189,475 30,316,000 
ECL: Electrochemiluminescence; 
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Figure 6.7 – Dilution linearity for IgG assay with tcdB in a high response 
sample (CDA 1004) 
 
6.4.2 Assay qualification 
In order to ensure reproducibility, specificity and sensitivity of the assays, a 
number of quality control measures were undertaken. 
6.4.2.1 Addition of competitive unconjugated goat anti-rabbit antibodies 
to assess potential interference caused by non-specific binding of the 
detection antibodies 
High background could be the result of non-specific binding of the Fc 
(Fragment, crystallisable) region of the detection labelled antibodies to the 
biological matrix, analyte or plate. Fc regions are important for modulating 
immune cell activity and therefore are able to interact with serological proteins 
as well as with specific Fc receptors (FcR) present in leukocytes. To address this 
0
5,000,000
10,000,000
15,000,000
20,000,000
25,000,000
30,000,000
35,000,000
5 10 20 40 80 160
S
ig
n
a
l 
X
 D
il
u
ti
o
n
 F
a
ct
o
r 
Sample dilution 
CDA 1004
 
187 
 
 
 
possibility, an extra step involving the addition of a competitive unconjugated 
goat anti-rabbit antibody - similar in characteristics in the Fc region to the 
detection antibody - was added between the addition of samples and incubation 
with detection antibody. If the Fc fragment was indeed a key factor for causing 
background noise, then a decrease in the signal would be expected following the 
addition of the extra antibody step. Clearly, no variation in signal was found 
(Table 6.7), indicating that the background noise observed in the runs was not 
due to non-specific binding of the goat Fc fragment of the sulfo-tagged detection 
antibody. 
 
Table 6.7 – Addition of extra antibody 
Antibody Analyte Sample 
Signal 
CV 
Extra antibody No extra antibody 
IgG 
tcdA 
C1 43,015 43,170 0.3 
C2 58,197 57,028 1.4 
C3 48,621 47,470 1.7 
C4 42,067 40,762 2.2 
CDN 0529 147,396 144,621 0.4 
CDN 0538 10,062 10,296 1.6 
CDP 0057 39,708 41,399 2.9 
tcdB 
C1 20,097 19,988 0.4 
C2 24,144 24,153 0.0 
C3 20,548 20,468 0.3 
C4 42,664 42,375 0.5 
CDN 0529 232,613 219,165 4.2 
CDN 0538 1,988 1,978 0.4 
CDP 0057 8,294 8,525 1.9 
CV: Coefficient of variation; IgG: Immunoglobulin G; tcdA: Clostridium difficile toxin A; tcdB: 
Clostridium difficile B; 
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6.4.2.2 Sample spiking and re-equilibration 
Sample Spiking 
Serial spiking of samples with free toxin was employed as a means of quality 
control, in which signal inhibition would be indicative of the specificity of the 
assay. Rather than binding to the toxin coated onto the plate, specific response 
antibodies present in sera, can instead bind to the circulating free toxin. This 
will then prevent the immunoglobulins to form a complex attached to the plate 
and generate a signal. Therefore, by adding controlled amounts of epitope 
(toxins) to the sample, a proportional decrease in the signal level would then be 
expected until a point of signal inhibition close to the background noise was 
reached (point of saturation). If the signal originally observed was a result of 
non-specific binding, then toxin spiking would be unlikely to affect this process. 
a) IgM assay: 
Three samples (CDA 1026, CDN 0511 and CDN 0516) with high intensity 
response to the toxins (ECL units) were pooled together to be spiked with toxin. 
In the same way, two samples (CDA 1022 and CDP 0022) with low intensity 
responses were combined for this purpose.  Strong inhibition was achieved 
across both the high and low intensity pooled samples at the optimal 1:2 sample 
dilution. Optimal inhibition would result in a decreased signal approaching 
background levels; here, SBR for un-spiked samples versus the samples spiked 
with the highest toxin concentration (12,800 pg/ml) resulted in a dramatic 
decrease (Table 6.8; 330.6 versus 23.7 and 21.0 versus 4.8, respectively).  
b) IgG assay: 
Since the baseline IgG responses were considerably higher than the 
corresponding IgM counterparts, it was necessary to assess inhibition in 
samples displaying higher intensity responses: PHR and CDA 1004 (medium 
and high intensity responses, respectively). Although not as effective as the IgM 
assays, significant inhibition was observed using a top spike of 3,200 pg/ml at 
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the optimal 1:40 sample dilution (Appendices 34 & 35). The experiment 
suggested that a much larger amount of toxin was needed in order to 
demonstrate complete inhibition, which would become impractical for the 
purpose of this investigation given the restricted availability of these toxins, 
especially in a native presentation. 
 
Table 6.8 – Spiking results for IgM response to tcdB using pooled samples 
Toxin  
(pg/ml) 
Signal (1:2 dilution) 
Pooled high response (SBR) Pooled low response (SBR) 
Buffer 75 77 
Unspiked 24,800 (330.6) 1,618 (21.0) 
200 23,762 (316.8) 827 (10.7) 
800 18,725 (249.7) 754 (9.8) 
1,600 15,267 (203.6) 675 (8.8) 
3,200 12,519 (166.9) 611 (7.9) 
6,400 8,335 (111.1) 492 (6.4) 
12,800 1,781 (23.7) 366 (4.8) 
SBR: Signal-to-background ratio; 
 
Re-equilibration of antibodies 
IgGs are smaller molecules than IgMs and incomplete inhibition is potentially 
due to the re-equilibration of response antibodies from the spiked free toxin 
and subsequent binding to the analyte on the plate. Re-equilibration implies 
that the longer the spikes samples are incubated, the greater the chances of 
dissociation of the antibodies, thus allowing them to generate a signal. As spiked 
samples were originally incubated for 30 minutes, incubation times were 
stratified with a range of incubation periods between 5-30 minutes and 
examined for the IgG assay using the same two samples (PHR and CDA 1004). 
Interestingly, the highest degree of signal inhibition was observed for the 5 min 
incubation period, with inhibition decreasing as time increased (Table 6.9). This 
190 
 
 
 
indicates that re-equilibration is present and occurs rapidly, suggesting that the 
inability to attain complete inhibition through antigen spiking is at least in part 
due to re-equilibration of the antigen-antibody complex. Other technical issues 
such as the large quantities of the analytes may also have prevented 
demonstration of complete signal inhibition. As such, the combined spiking data 
indicates that both IgG and IgM assays have a satisfactory level of specificity. As 
a further precaution, fixed controls were included for all downstream steps in 
order to account for background effects and inter-plate variability. 
 
Table 6.9 – Re-equilibration results for IgG response to tcdB 
Analyte Sample 
Spike conc. 
(pg/ml) 
Incubation time (min) Mean signal 
tcdB 
CDA 1004 
3,200 
5 20,436 
10 36,560 
20 65,550 
30 57,950 
Unspiked 30 357,380 
PHR 
3,200 
5 9,851 
10 11,303 
20 17,947 
30 21,909 
Unspiked 30 57,595 
tcdB: Clostridium difficile toxin B; 
 
6.4.2.3 No-coating analyte and buffer controls 
Including uncoated wells (zero coating) allows the investigation of non-specific 
events, such as binding of serum proteins and/or labelled antibodies directly to 
the surface of the ECL plate. Signals levels in the absence of analyte varied 
across samples but were generally low. Conversely, the presence of toxin 
coating accounted for a substantial rise in SBR for all samples tested, which 
indicated that the assay had good sensitivity (Table 6.10). The inclusion of 
buffer controls (analyte coating + blank/PBS (no sample) + detection antibody) 
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allowed observation of the level of non-specific binding of the detection 
antibody directly to the analyte and/or to the surface of the plate in the absence 
of sample. Buffer signals were extremely low throughout the entire assay 
optimisation process and no interference was noticed. 
 
Table 6.10 – Overview of results for no coating control 
Antibody Analyte Sample  Coat No coat 
IgG 
tcdA 
C2 17,802 2,396 
 WP 0018 263,574 8,345 
WP 0019 43,016 9,403 
WP 0020 77,240 8,663 
tcdB 
C2 13,891 2,460 
WP 0018 48,778 9,490 
WP 0019 34,657 8,378 
WP 0020 25,029 8,949 
IgM 
tcdA 
C2 
17,067 391 
tcdB 7,838 699 
IgG: Immunoglobulin G; IgM: Immunoglobulin M; tcdA: Clostridium difficile toxin A; tcdB: 
Clostridium difficile toxin B; 
 
6.4.2.4 Plate controls 
Once initial conditions were optimised, 3 sample controls (CDA 1004, PHR and 
C1) were used throughout the development process to account for inter-plate 
variability. For each control sample, a correction factor was derived from the 
overall plate runs and then applied across individual plates. Furthermore, of the 
88 clinical samples tested on each plate, 8 samples were tested in duplicate in 
order to monitor intra-plate variability. 
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6.5 Binary toxin assays 
Optimal settings obtained from the development of the tcdA and tcdB assays 
were applied for the initial development of the C. diff binary toxin assays based 
on IgG and IgM responses to: a) cdtA alone (cdtA); b) cdtB-activated alone 
(cdtB-act); c) cdtB-precursor alone (cdtB-pre); d) combined cdtA + cdtB-
activated (cdtA+cdtB-act). 
The binary toxin epitopes have differing molecular weights (50, 100 and 75 kDa 
for cdtA, cdtB-pre and cdtB-act, respectively), confirmed by in-house data 
(Figure 6.8). Figure 6.9 shows that cdtB-act forms oligomers that are stable in 
favorable conditions (e.g. PBS and SDS) but get dissociated with heat and other 
denaturing buffers, further indicating that these epitopes are reliable, match the 
proposed molecular weight and have the expected properties. Therefore it was 
proposed to test them in isolation, and also combined; cdtB-act, but not cdtB-
pre, form hepatmers and it is thought that approximately 2-3 cdtAs will enter a 
cell with one cdtB-act heptamer (data unpublished).  As such, this study 
incubated 1 cdtA molecule with 2 cdtB-act molecules to form the activated 
complex. 
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Figure 6.8 – Confirmation of binary toxin analytes via gel electrophoresis 
 
 
Figure 6.9 – Assessing the stability of binary toxin analytes via gel 
electrophoresis 
Both lanes show equal amounts of cdtB from the same prep. Gel is Coomassie stained. Lane 1: cdtB 
after activation in Lammli-Buffer (SDS) – NOT boiled. Lane 2: cdtB after activation in Lammli-
Buffer (SDS) – Boiled 
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6.5.1 Identification of initial working conditions 
6.5.1.1 Determination of coating & detection antibody concentrations for 
IgG response to cdtB-act, cdtB-pre and cdtA+cdtB-act 
This step focused primarily on the optimisation of IgG assays for all four binary 
toxin analytes. As with the original toxin assays, non-variable conditions were 
PBS coating buffer, SB plate type, Blocker 1 as blocking buffer and 1 μg/ml 
detection as the selected antibody concentration. Varying conditions comprised 
coating concentration (4 & 16 μg/ml) and sample dilution factor (1:5 & 1:10). 
Three samples were used: two from patients who had CDI caused by a binary 
toxin-producing strain (ribotypes 027 & 078), which also provided overall high 
signals for the tcdA and tcdB assays (CDA 1130 & CDN 0552), and PHR, a 
control individual who had continuous exposure to C. diff strains. 
Initial testing conditions delivered particularly high signals meaning that 
samples required further dilution (Table 6.11). Despite this, the majority of 
samples showed an adequate coefficient of variation (CV <20) between analyte 
coating concentrations of 4 and 16 μg/ml (Table 6.11; highlighted in orange). 
The lower threshold of 4 μg/ml of either toxin was thus selected as the 
concentration of choice for the development process.  
6.5.1.2 Adjustment of sample dilution for IgG response to cdtA, cdtB-act, 
cdtB-pre and cdtA+cdtB-act 
Given the saturation observed with the initial optimisation run, serial dilution 
between 1:50 and 1:500 was attempted for all combinations using a strategy 
similar to step 1, except that a fixed analyte coating concentration of 4 μg/ml 
was adopted throughout.   
Good linearity was observed for three analytes (cdtB-act, cdtB-pre and cdtA+B-
act) (Figure 6.10). The 1:200 dilution was selected as optimal as it afforded a 
large signal window of detection, whilst maintaining linearity and sensitivity. In 
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contrast, linearity was not achieved for the IgG assay with cdtA (Figure 6.11) 
and therefore required further work. Further figures can be viewed in 
Appendices 36 & 37. 
 
Table 6.11 – Overly high signals observed during initial binary toxin 
optimisation 
Analyte Sample Blocker 
Sample 
dilution 
Signal 
CV 
4 µg/ml coat 16 µg/ml coat 
cdtA 
A1130 
Blocker 1 
1:5 254,340 348,505 22.1 
1:10 145,804 231,356 32.1 
N552 
1:5 245,056 299,822 14.2 
1:10 193,859 236,424 14.0 
PHR 
1:5 344,903 399,004 10.3 
1:10 238,062 268,967 8.6 
cdtB-act 
A1130 
1:5 1,361,890 1,325,172 1.9 
1:10 1,263,441 1,073,002 11.5 
N552 
1:5 1,420,483 1,402,840 0.9 
1:10 1,400,590 1,367,432 1.7 
PHR 
1:5 552,921 459,209 13.1 
1:10 331,897 296,178 8.0 
cdtB-pre 
A1130 
1:5 1,361,138 1,352,364 0.5 
1:10 1,315,927 1,288,236 1.5 
N552 
1:5 1,415,749 1,412,210 0.2 
1:10 1,379,213 1,359,311 1.0 
PHR 
1:5 639,693 578,503 7.1 
1:10 395,303 340,103 10.6 
cdtA+cdtB-act 
A1130 
1:5 1,367,318 1,350,041 0.9 
1:10 1,228,036 1,290,665 3.5 
N552 
1:5 1,398,775 1,385,480 0.7 
1:10 1,378,744 1,355,331 1.2 
PHR 
1:5 698,381 634,508 6.8 
1:10 421,545 426,227 0.8 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-
pre: Clostridium difficile binary toxin B component – precursor; cdtA+cdtB-act: Clostridium 
difficile binary toxin A plus active Clostridium difficile binary toxin B; CV: Coefficient of variation; 
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Figure 6.10 – Dilution linearity plot for the IgG assay with the combined 
analyte cdtA+cdtB-act using Blocker 1 
 
  
Figure 6.11 – Dilution linearity plot for IgG assay with cdtA using Blocker 1 
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6.5.1.3 Further adjustment of analyte coating concentration and detection 
antibody concentration for the IgG assay with cdtA 
In addition to further sample dilution, it is possible that the lack of linearity 
observed with the IgG assay with cdtA was the result of suboptimal settings for 
the analyte coating and the detection antibody concentrations. It was therefore 
hypothesised that if the signal intensity can be decreased by adjusting these 
conditions, then improved linearity may be observed for the cdtA assay. 
Concentrations for the analyte coating were further reduced from 4 and 16 
μg/ml to 3.2 and 1.6 µg/ml, whilst for the detection antibodies this was brought 
down from 1.0 µg/ml to 0.8 and 0.4 µg/ml. Other conditions were as previously 
described. 
The combination of 1.6 µg/ml analyte coating with both 0.4 and 0.8 µg/ml 
detection antibody concentrations delivered the highest SBRs at all dilutions 
(dilutions 1:50 and 1:500 illustrated in Tables 6.12 & 6.13). The slight 
improvement in overall performance observed with the 0.8 µg/ml detection 
antibody resulted in the 1.6 µg/ml analyte coating with 0.8 µg/ml detection 
antibody being taken forward. However, dilution linearity was still 
unsatisfactory with differences in the corrected signals becoming more 
apparent as samples were further diluted to 1:500 (Figure 6.12). Further figures 
relating to other concentrations can be viewed in Appendices 38-40.  
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Table 6.12 – ECL signal values for the IgG assay with cdtA using varying 
combinations of coating and detection concentrations 
Sample 3.2C/0.8D 3.2C/0.4D 1.6C/0.8D 1.6C/0.4D 
Buffer 455 431 181 157 
Signal at 1:50 dilution 
CDA 1130 47,060 40,542 45,073 39,020 
CDN 0552 67,853 53,977 66,563 54,616 
PHR 53,534 44,479 60,206 51,613 
Signal at 1:500 dilution 
CDA 1130 9,968 8,585 8,678 7,480 
CDN 0552 13,337 12,179 14,183 13,040 
PHR 6,823 6,245 7,348 6,379 
C: Coating, in µg/ml; D: Detection, in µg/ml; 
 
Table 6.13 – SBR for the IgG assay with cdtA using varying combinations of 
coating and detection concentrations 
Sample 3.2C/0.8D 3.2C/0.4D 1.6C/0.8D 1.6C/0.4D 
SBR at 1:50 dilution 
CDA 1130 103.4 94.1 249.0 248.5 
CDN 0552 149.1 125.2 367.8 347.9 
PHR 117.7 103.2 332.6 328.7 
SBR at 1:500 dilution 
CDA 1130 21.9 19.9 47.9 47.6 
CDN 0552 29.3 28.3 78.4 83.1 
PHR 15.0 14.5 40.6 40.6 
C: Coating, in µg/ml; D: Detection, in µg/ml; 
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Figure 6.12 – Dilution linearity for IgG response to cdtA using a 
combination of 1.6 µg/ml coating and 0.8 µg/ml detection 
 
The lack of dilution linearity was particularly evident for one of the test samples 
(CDN 0552), suggesting the presence of a significant level of matrix interference. 
Since the observed blank (zero sample) signal was very modest, this allowed 
assessment of a further increase in sample dilution (ranging from 1:500 to 
1:4,000) in order to address the issue. Two additional randomly selected 
samples (CDN 0545 and CDN 0555) were also included for this purpose.  
These changes delivered more consistent results with improved linearity being 
observed across all samples (Figure 6.13). For the 1:1,000 dilution, linearity had 
only just begun to be achieved and therefore the 1:2,000 sample dilution factor 
was taken forward as it maintained both suitable linearity combined with a 
reasonable SBR (Table 6.14; highlighted in orange). 
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Table 6.14 - Signal to background ratio for IgG response to cdtA at 1:2,000 
dilution using a combination of 1.6 µg/ml coating and 0.8 µg/ml detection 
Sample Dilution Coat signal SBR 
No coat buffer control - No coat signal = 77 - 
CDA 1130 
500 8,827 114.6 
1000 4,828 62.7 
2000 3,030 39.4 
4000 1,390 18.1 
CDN 0545 
500 12,687 164.8 
1000 6,848 88.9 
2000 3,453 44.8 
4000 1,767 22.9 
CDN 0552 
500 14,239 184.9 
1000 10,418 135.3 
2000 5,262 68.3 
4000 2,924 38.0 
CDN 0555 
500 5,157 67.0 
1000 3,060 39.7 
2000 1,513 19.6 
4000 850 11.0 
PHR 
500 9,096 118.1 
1000 4,336 56.3 
2000 2,602 33.8 
4000 1,529 19.9 
SBR: Signal-to-background ratio; 
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Figure 6.13 – Dilution linearity plot for IgG response to cdtA using a 
combination of 1.6 µg/ml coating and 0.8 µg/ml detection antibody with 
sample dilutions ranging from 1:500 to 1:4,000 
 
6.5.1.4 Determination of optimal assay conditions for IgM assay with all 
binary toxin epitopes 
Compared to the IgG assays with either tcdA or tcdB analytes, it was previously 
identified that the detection range for the IgM assays were narrower and a 
much lower dilution factor was required. Hence, this information served as the 
basis for the initial development of the IgM assays with the binary toxin 
analytes. Four samples, which overlapped with the ones employed in the 
previous steps, were utilised (CDA 1130, CDN 0545, CDN 0552 and PHR) and 
sample dilutions ranged between 1:5 and 1:100. All other settings were 
transferred from the optimal conditions obtained with the development of the 
IgG assays using the binary toxin analytes (Blocker 1; 1.6 µg/ml coating and 0.8 
µg/ml detection for cdtA; 4 µg/ml coating and 1.0 µg/ml detection for all other 
binary epitopes). 
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From the initial run, it was possible to infer that linearity was suboptimal for all 
analytes tested (Figure 6.14; Appendices 41-43). As observed in Table 6.15, SBR 
steadily moved closer to background levels and as such, diluting the samples 
beyond 1:100 would have hampered the sensitivity of the assay by compressing 
the detection window. A trade-off between linearity and signal detection range 
was therefore necessary and a dilution factor of 1:50 was selected for further 
development. 
 
Table 6.15 – Overview of SBR at increasing dilution for all binary toxin 
analytes 
Analyte Sample 
SBR across dilutions 
1:5 1:10 1:50 1:100 
cdtA 
CDA 1130 163.8 105.8 25.7 16.3 
CDN 0545 536.5 348.3 96.5 55.4 
CDN 0552 111.4 79.9 29.7 19.4 
PHR 78.1 61.2 26.3 16.3 
cdtB-act 
CDA 1130 162.3 66.1 14.8 9.5 
CDN 0545 115.8 77.3 24.2 15.3 
CDN 0552 280.3 80.0 17.2 12.3 
PHR 238.0 141.7 36.4 21.2 
cdtB-pre 
CDA 1130 120.1 69.7 22.0 16.2 
CDN 0545 462.3 268.8 74.8 42.7 
CDN 0552 352.4 104.6 34.7 24.6 
PHR 60.0 48.3 22.1 13.6 
cdtA+cdtB-act 
CDA 1130 261.7 131.5 28.4 19.1 
CDN 0545 533.0 303.1 76.2 42.5 
CDN 0552 237.3 138.6 29.9 20.5 
PHR 246.5 171.1 47.2 30.8 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-
pre: Clostridium difficile binary toxin B component – precursor; cdtA+cdtB-act: Clostridium 
difficile binary toxin A plus active Clostridium difficile binary toxin B; SBR: Signal-to-background 
ratio; 
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Figure 6.14 – Dilution linearity plot for IgM response to cdtB-pre 
 
6.5.1.5 Use of no-coat sample controls for the determination of sample 
background noise 
Following the examination of the initial conditions set for the measurement of 
both IgG and IgM responses to the binary toxin analytes, a no-coating 
optimisation was conducted in order to evaluate biological matrix interference 
present in an individual sample (CDN 0527).  
Compared to the no-coat buffer sample control, the results indicated that a 
significant proportion of the background noise was due to biological matrix 
interference. This was observed with both IgG and IgM assays across all binary 
toxin analytes (Table 6.16). To address this problem, a further optimisation 
with an additional blocking buffer was undertaken.  
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Table 6.16 – No coat controls for the IgG and IgM assay with the binary 
toxin analytes using Blocker 1 and sample CDN 0527 
Antibody Binary toxin component Detection conc. (µg/ml) Dilution Signal 
IgG 
No coat 
0.8 1:2,000 
1,330 
cdtA 2,919 
No coat 
1.0 1:200 
19,684 
cdtB-act 25,048 
cdtB-pre 33,936 
cdtA+cdtB-act 26,073 
IgM 
No coat 
0.8 
1:50 
1,434 
cdtA 2,581 
No coat 
1.0 
1,589 
cdtB-act 2,494 
cdtB-pre 2,763 
cdtA+cdtB-act 2,522 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-
pre: Clostridium difficile binary toxin B component – precursor; cdtA+cdtB-act: Clostridium 
difficile binary toxin A plus active Clostridium difficile binary toxin B; IgG: Immunoglobulin G; IgM: 
Immunoglobulin M; 
 
6.5.1.6 Selection of 1x Tris Buffered Saline with 1% Casein as blocking 
buffer for comparison against Blocker 1 
Given the high degree of background observed in the previous optimisation 
condition with Blocker 1, the use of 1x Tris Buffered Saline with 1% Casein 
(Casein Blocker) was considered as an alternative blocking agent. Comparison 
with Blocker 1 blocking buffer was therefore conducted with two samples, 
including CDN 0527 that was used in the previous no-coating control step. 
Again, data was analysed based upon the percentage of total signal represented 
by the background of the no-coat control samples. Results indicated that the 
proportion of signal accounted by the no-coat control was significantly lower 
with the Casein Blocker compared to Blocker 1. This was true for both the IgG 
(Figure 6.15) and IgM assays (Appendix 44). Furthermore, the rank order of 
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samples for coating signal before and after subtraction of the no coat 
background signal was better conserved in the presence of Casein Blocker 
compared to Blocker 1, particularly for IgM (Table 6.17; mismatching ranks 
highlighted in orange) 
 
 
Figure 6.15 – Percentage of overall signal accounted by background noise 
(no coat sample data) for the IgG assay using all binary toxin analytes with 
Blocker 1 (A) and Casein Blocker (B) 
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Table 6.17 – No coat data for IgG & IgM assays using all binary toxin analytes with Blocker 1 or Casein blocker 
Epitope Blocker Antibody Dilution Sample 
Signal Rank order 
Coat No coat Coat minus no coat Coat Coat minus no coat 
cdtA 
Blocker 1 
IgG 
1:2,000 
C1 1,611 399 1,212 8 7 
CDN 0527 3,233 2,156 1,077 7 8 
cdtB-act 
1:200 
C1 5,964 3,986 1,978 6 6 
CDN 0527 27,599 22,994 4,605 3 5 
cdtB-pre 
C1 14,380 3,956 10,424 4 3 
CDN 0527 46,063 24,292 21,771 1 1 
cdtA+cdtB-act 
C1 10,967 4,189 6,778 5 4 
CDN 0527 35,185 24,705 10,480 2 2 
cdtA 
IgM 1:50 
C1 2,754 1,423 1,331 3 1 
CDN 0527 2,983 1,686 1,297 1 2 
cdtB-act 
C1 2,393 1,164 1,229 6 4 
CDN 0527 2,204 1,595 609 7 8 
cdtB-pre 
C1 2,042 1,272 770 8 7 
CDN 0527 2,797 1,628 1,169 2 5 
cdtA+cdtB-act 
C1 2,547 1,292 1,255 5 3 
CDN 0527 2,668 1,623 1,045 4 6 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-pre: Clostridium difficile binary toxin B component – precursor; 
cdtA+cdtB-act: Clostridium difficile binary toxin A plus active Clostridium difficile binary toxin B; IgG: Immunoglobulin G; IgM: Immunoglobulin M; 
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Table 6.17 (continued) – No coat data for IgG & IgM assays using all binary toxin analytes with Blocker 1 or Casein blocker 
Epitope Blocker Antibody Dilution Sample 
Signal Rank order 
Coat No coat Coat minus no coat Coat Coat minus no coat 
cdtA 
Casein Blocker 
IgG 
1:2,000 
C1 2,089 200 1,889 7 5 
CDN 0527 848 385 463 8 8 
cdtB-act 
1:200 
C1 2,702 1,379 1,323 6 7 
CDN 0527 5,125 2,882 2,243 3 4 
cdtB-pre 
C1 2,979 1,338 1,641 5 6 
CDN 0527 10,984 5,814 5,170 1 1 
cdtA+cdtB-act 
C1 3,965 1,437 2,528 4 3 
CDN 0527 6,129 3,063 3,066 2 2 
cdtA 
IgM 1:50 
C1 953 259 694 2 2 
CDN 0527 1,007 251 756 1 1 
cdtB-act 
C1 437 258 179 8 7 
CDN 0527 520 347 173 7 8 
cdtB-pre 
C1 776 266 510 4 4 
CDN 0527 947 323 624 3 3 
cdtA+cdtB-act 
C1 662 295 367 6 6 
CDN 0527 679 290 389 5 5 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-pre: Clostridium difficile binary toxin B component – precursor; 
cdtA+cdtB-act: Clostridium difficile binary toxin A plus active Clostridium difficile binary toxin B; IgG: Immunoglobulin G; IgM: Immunoglobulin M; 
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6.5.1.7 Adoption of a no-wash blocking step using Casein Blocker and 
dilution linearity for both IgG and IgM assays 
No-wash blocking 
Although the use of Casein Blocker resulted in a significant improvement over 
the previously adopted procedure, matrix interference was still present, 
particularly for IgG. The current procedure adopted had involved an incubation 
of 150 μl of blocking buffer for 1 h followed by washing of the wells and 
addition of samples. To bolster blockade of non-specific binding, the incubation 
step was modified such that a reduced volume of 25 μl of Casein Blocker was 
added to the wells and no wash was performed prior to the addition of samples. 
This resulted in greater suppression of the no-coat signal for all binary toxin 
analytes across the samples tested. For IgG, the highest signal values obtained 
were now ≤1,000, which was considered to be reasonable, with a decrease 
observed in the overall percentage of signal accounted for by the background no 
coat signal (Table 6.18; decreases highlighted in orange). Furthermore, the rank 
order of coated signals, as well as overall signals for no coat signals subtracted 
from coated signals, remained unaltered (Table 6.19; mismatching ranks 
highlighted in orange). This was not the case when using the previous 150 μl 
blocking/wash step (Table 6.17). For IgM, initial matrix interference and the 
rank order of samples were already satisfactory, and these observations 
remained consistent after introduction of the no-wash blocking step. 
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Table 6.18 – No coat data for IgG assay using all binary toxin analytes, Casein Blocker & two blocking protocols 
Epitope Antibody Dilution Sample 
Percentage of signal attributed to background 
Difference 
150 μl/Wash 25 μl/No wash 
cdtA 
IgG 
1:2,000 
C1 9.6 31.4 21.8 
CDN 0527 45.4 40.8 -4.6 
cdtB-act 
1:200 
C1 51.0 46.4 -4.6 
CDN 0527 56.2 62.9 6.6 
cdtB-pre 
C1 44.9 14.8 -30.1 
CDN 0527 52.9 25.3 -27.6 
cdtA+cdtB-act 
C1 36.2 25.0 -11.2 
CDN 0527 50.0 39.6 -10.4 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-pre: Clostridium difficile binary toxin B component – precursor; 
cdtA+cdtB-act: Clostridium difficile binary toxin A plus active Clostridium difficile binary toxin B; IgG: Immunoglobulin G; 
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Table 6.19 – No coat data for IgG assay using all binary toxin analytes and Casein Blocker 
Epitope Antibody Dilution Sample 
Signal Rank order 
Coat No coat Coat minus no coat Coat Coat minus no coat 
cdtA 
IgG 
1:2,000 
C1 239 75 164 8 8 
CDN 0527 306 125 181 7 7 
cdtB-act 
1:200 
C1 857 398 459 6 6 
CDN 0527 1,723 1,083 640 4 5 
cdtB-pre 
C1 2,715 402 2,313 2 2 
CDN 0527 4,279 1,082 3,197 1 1 
cdtA+cdtB-act 
C1 1,524 381 1,143 5 4 
CDN 0527 2,451 971 1,480 3 3 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-pre: Clostridium difficile binary toxin B component – precursor; 
cdtA+cdtB-act: Clostridium difficile binary toxin A plus active Clostridium difficile binary toxin B; IgG: Immunoglobulin G; 
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Dilution linearity 
As optimal sample dilution had previously been defined using Blocker 1, it was 
important to ascertain this in the presence of the new blocking protocol (25 μl 
of Casein Blocker, no wash step). Sample CDN 0529 was also included to ensure 
sample CDN 0527 was representative. All other settings were consistent with 
those previously employed with Blocker 1. 
For the IgM assay, dilution linearity was assessed from 1:5-1:100.  Results were 
comparable to the ones found with Blocker 1 and dilution linearity was again 
suboptimal. However, at the 1:50 and 1:100 dilutions, no difference was 
observed between the no coat signals for both samples compared to the large 
differences observed at the 1:5 and 1:10 dilutions (Table 6.20). When combined 
with overall SBR achieved (Table 6.21), a sample dilution factor of 1:50 was 
confirmed as the preferred choice for the IgM assay using Casein Blocker. For 
the IgG assay, dilution linearity was assessed between 1:500-1:4,000. Previous 
IgG dilution linearity in the presence of blocker 1 was satisfactory; however, in 
the presence of Casein Blocker, as with IgM, dilution linearity was suboptimal. 
Furthermore, large differences were observed between the no coat signals for 
both samples across all dilutions (Table 6.20), and as a result, required further 
attention. 
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Table 6.20 – Differences in no coat signal between samples CDN 0527 and CDN 0529 across varying dilutions for the IgG and 
IgM assays using Casein Blocker 
Binary condition Block buffer Antibody Detection conc. (ug/ml) Dilution 
No coat signal 
CDN 0527 CDN 0529 
CDN 0527/ 
CDN 0529 
No coat Casein Blocker 
IgG 
0.8 
500 542 127 4.3 
1000 294 99 3.0 
2000 188 90 2.1 
4000 118 66 1.8 
1 
100 3194 627 5.1 
200 1532 291 5.3 
500 571 164 3.5 
1000 335 83 4.0 
IgM 
0.8 
5 2962 977 3.0 
10 849 614 1.4 
50 234 207 1.1 
100 128 146 0.9 
1 
5 3060 1139 2.7 
10 879 686 1.3 
50 234 214 1.1 
100 138 131 1.1 
IgG: Immunoglobulin G; IgM: Immunoglobulin M; 
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Table 6.21 – Dilution linearity SBR values in two samples for the IgM assay with binary toxin analytes using Casein Blocker 
Binary condition Block buffer Dilution 
CDN 0527 CDN 0529 
Signal 
SBR 
Signal 
SBR 
No coat Coat No coat Coat 
cdtA 
Casein Blocker 
5 2,962 5,428 1.8 977 13,965 14.3 
10 849 2,311 2.7 614 7,393 12.0 
50 234 958 4.1 207 1,545 7.5 
100 128 422 3.3 146 836 5.7 
cdtB-act 
5 3,060 3,266 1.1 1,139 4,772 4.2 
10 879 980 1.1 686 3,461 5.0 
50 234 255 1.1 214 1,300 6.1 
100 138 233 1.7 131 755 5.8 
cdtB-pre 
5 3,060 5,375 1.8 1,139 3,851 3.4 
10 879 2,470 2.8 686 2,107 3.1 
50 234 749 3.2 214 615 2.9 
100 138 443 3.2 131 336 2.6 
cdtA+cdtB-act 
5 3,060 4,677 1.5 1,139 14,956 13.1 
10 879 1,781 2.0 686 7,707 11.2 
50 234 498 2.1 214 1,692 7.9 
100 138 282 2.0 131 870 6.6 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-pre: Clostridium difficile binary toxin B component – precursor; 
cdtA+cdtB-act: Clostridium difficile binary toxin A plus active Clostridium difficile binary toxin B; IgG: Immunoglobulin G; IgM: Immunoglobulin M; SBR: Signal-to-
background ratio; 
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6.5.1.8 Detection antibody concentrations for IgG assay: all binary toxin 
analytes 
Due to the lack of linearity observed in the IgG assay in the previous 
optimisation, detection antibody concentration was decreased from 1.0 to 0.4 
and 0.1 μg/ml. An optimum detection antibody concentration of 0.1 μg/ml using 
a sample dilution factor of 1:500 delivered the highest SBR (Table 6.22; 
highlighted in orange). No apparent benefits were found with the use of the 
intermediate 0.4 μg/ml concentration, with varying dilutions delivering the 
highest SBR (Table 6.22; highlighted in purple).  
6.5.2 Assay qualification 
In order to ensure that observations using samples CDN 0527 and CDN 0529 
would be representative of the study cohort, and to ensure that the set 
conditions were sufficiently robust and reproducible for the downstream steps, 
an additional run with 20 clinical samples was conducted using the optimum 
conditions achieved for both IgG and IgM assays with the binary toxin analytes.  
All samples provided minimum no-coat signals across both IgG and IgM assays 
(Table 6.23).  For the calculation of general no-coat background levels the mean 
signal was taken for each assay (125 ECL units for IgG with all binary toxin 
analytes, 120 ECL units for IgM with cdtA and 119 ECL units for IgM with all 
other binary toxin analytes, respectively), to which was added 3 standard 
deviation units (SD = 114, 63 and 69, respectively), giving hypothetical cut-off 
points of 467, 308 and 325 ECL units, respectively. Therefore, any samples 
whose raw signals were below these hypothetical cut-off points would not be 
treated as meaningful for the analysis (Table 6.23; highlighted in orange), 
whereas signal intensities higher than that would be assumed to be 
representative of a positive response to the analyte.  Our rate was ~8%, which 
is consistent with that expected when assuming a Gaussian distribution (5%). 
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Table 6.22 – Overview of SBR values for IgG assay with all binary toxin 
analytes using detection antibody concentrations of 0.4 and 0.1 μg/ml 
Binary epitope Coating conc. (ug/ml) Detection conc. (ug/ml) Dilution 
Signal 
SBR 
No coat Coat 
cdtA 0.04 
0.1 
500 455 1,348 3.0 
1,000 239 573 2.4 
2,000 153 336 2.2 
4,000 107 197 1.8 
0.4 
500 466 1,174 2.5 
1,000 236 548 2.3 
2,000 167 339 2.0 
4,000 111 191 1.7 
cdtB-act 
0.1 
0.1 
100 1,790 2,502 1.4 
200 933 1,267 1.4 
500 388 569 1.5 
1,000 232 301 1.3 
0.4 
100 2,763 3,406 1.2 
200 1,030 1,547 1.5 
500 466 660 1.4 
1,000 236 344 1.5 
cdtB-pre 
0.1 
100 1,790 5,691 3.2 
200 933 2,954 3.2 
500 388 1,474 3.8 
1,000 232 655 2.8 
0.4 
100 2,763 8,866 3.2 
200 1,030 3,852 3.7 
500 466 1,790 3.8 
1,000 236 807 3.4 
cdtA+cdtB-act 
0.1 
100 1,790 2,991 1.7 
200 933 1,444 1.5 
500 388 665 1.7 
1,000 232 376 1.6 
0.4 
100 2,763 4,624 1.7 
200 1,030 2,146 2.1 
500 466 867 1.9 
1,000 236 458 1.9 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-
pre: Clostridium difficile binary toxin B component–precursor; cdtA+cdtB-act: Clostridium difficile 
binary toxin A plus active Clostridium difficile binary toxin B; SBR: Signal-to-background ratio; 
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Table 6.23 – Overview of samples in relation to hypothetical cut-off points across all binary toxin analyte assays 
Sample 
IgG IgM 
No coat cdtA cdtB-act cdtB-pre cdtA+cdtB-act 
No coat 
(cdtA) 
No coat 
(other) 
cdtA cdtB-act cdtB-pre cdtA+cdtB-act 
CDN 0589 78 637 388 2,371 900 53 56 217 130 353 222 
CDN 0594 109 472 226 665 294 153 61 331 133 382 235 
CDP 0001 239 5,404 267 1334 529 124 143 1,117 309 907 552 
CDP 0022 164 563 16,101 11,920 15,197 66 63 305 977 1,095 1,333 
CDP 0006 128 641 250 1,472 5,421 115 126 212 166 296 202 
CDP 0069 168 553 327 903 420 299 315 733 397 767 521 
CDA 1128 65 617 189 1,028 491 66 73 561 150 487 394 
CDA 1129 69 218 242 545 235 89 104 282 156 318 219 
CDA 1131 63 675 454 931 802 59 59 575 166 372 479 
CDA 1132 112 1,360 1,475 4,543 791 140 140 472 342 705 293 
CDA 1133 91 797 185 772 304 102 115 425 181 355 295 
CDA 1134 65 480 399 796 496 131 68 722 258 995 439 
CDP 0065 570 976 1,119 2,309 1,229 123 119 435 261 574 423 
CDP 0014 89 2,788 419 3,994 1,892 100 108 1,461 675 1,558 1,287 
CDP 0016 76 1,148 740 2,191 1,078 92 94 1,003 299 1,055 536 
CDP 0017 67 1,006 480 1,829 724 78 82 657 186 720 389 
CDP 0019 77 480 239 986 434 131 133 606 219 669 508 
CDP 0023 99 652 4,396 5,613 3,663 232 252 574 703 960 774 
CDP 0024 67 318 282 898 289 58 62 322 128 387 204 
CDP 0030 108 2,225 706 2,946 1,409 197 208 3,217 501 3,717 2,755 
cdtA: Clostridium difficile binary toxin A; cdtB-act: Active Clostridium difficile binary toxin B; cdtB-pre: Clostridium difficile binary toxin B component – precursor; 
cdtA+cdtB-act: Clostridium difficile binary toxin A plus active Clostridium difficile binary toxin B; IgG: Immunoglobulin G; IgM: Immunoglobulin M; 
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6.5.3 Typing of samples from the entire patient cohort 
Although four combinations of candidate epitopes were tested, only two were 
selected for typing of the cohort: cdtA and precursor cdtB. C. diff binary toxins 
require the coupling of the catalytic cdtA component with its mature and larger 
cdtB counterpart in order to become functional. cdtB is the crucial binding 
domain and is activated by enzymes present in the gut environment shortly 
before its connection to cdtA and to the host target receptor (lipolysis-
stimulated lipoprotein receptor; LSR) (Papatheodorou et al., 2011). However, 
freely available activated cdtB is thought to be short-lived and therefore less 
immunogenic than precursor cdtB. Furthermore, the manipulation of C. diff 
binary toxin complex is still an evolving field and a difficult procedure to control 
in vitro as the optimum proportion of cdtA binding in relation to cdtB is not well 
defined.  
Consistent with the information described above, our optimisation results 
illustrated in Table 6.23 demonstrate that higher percentage of samples in the 
cdtA and cdtB-pre assays are able to be distinguished from the hypothetical 
calculated cut-off. Hence, the selection of cdtA and precursor cdtB as preferred 
analytes, as opposed to activated cdtB or the combination of activated cdtB + 
cdtA, was justified for the typing of the cohort. 
Final assay protocols can be seen in Appendix 45. As with the tcdA and tcdB 
assay, 3 sample controls (CDA 1004, PHR and C1) were used throughout the 
development process to account for inter-plate variability. For each control 
sample, a correction factor was derived from the overall plate runs and then 
applied across the individual plates. Furthermore, of the 88 clinical samples 
tested on each plate, 8 samples were tested in duplicate in order to monitor 
intra-plate variability. 
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6.6 Conclusions 
There is a substantial need for novel and better assays that are able to quantify 
host response against C. diff toxins. Using the advanced technologies of the MSD 
ECL platform combined with a systematic development protocol and the use of 
fully characterised epitopes, some of them uniquely sourced, enabled the 
successful development of enhanced quantitative assays for the candidate 
epitopes tested. Notably, it was also possible to deliver novel assays to measure 
total IgG and IgM responses to C. diff binary toxins, something that has never 
been attempted.  
Only one commercially available assay exists on the market (tgcBIOMICS GmbH, 
Bingen, Germany), but a major methodological limitation of this and in-house 
developed formats, including those from this study, has been the lack of 
validated humanised standards, both positive and negative, for the development 
of standard curves, ascertainment of antibody concentrations and accurate 
control of non-specific binding events. Hence, this restricts transferability of the 
assay and it is possible that the results of this work may also have been biased 
by the presence of some samples with a high degree of biological matrix 
interference, leading to relative ECL analysis being conducted on the basis of 
percentile categorisation. 
The use of in-house standards by previous studies that allowed the absolute 
quantification of specific antibody responses were limited due to their reliance 
upon ELISA technology as opposed to the increased sensitivity associated with 
MSD’s ECL technology employed here. The toxin spiking strategy was 
introduced with the aim of assessing assay specificity. While this was a 
worthwhile exercise, results were not fully conclusive due to the fact that 
spiking did not bring signals down to background levels (especially for the IgG 
assay with tcdA and tcdB). Accurate determination of matrix background levels 
of an assay can only be undertaken through the use of true negative controls 
free from anti-toxin antibodies. In this sense it is understood that most 
individuals at some point in their lives would have been exposed to C. diff and 
its toxins and therefore some degree of response would be expected. Therefore, 
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selective immunodepletion of a human serum pool using the toxin epitopes 
would constitute a potential strategy to address this problem but not without its 
drawbacks, such as the need for unattainable quantities of material (both 
samples and toxin epitopes) and the development of a lengthy methodological 
protocol. Through collaborative efforts, we are currently obtaining 
complimentary data regarding neutralisation of tcdA and tcdB. Samples with 
high anti-toxin titres would be expected to neutralise the toxins, whilst samples 
with low titres may not achieve neutralisation. Whilst research is still ongoing, 
initial results are promising. 
There is a great application potential of these assays for a more accurate 
investigation of the host immune response to C. diff toxins during both 
symptomatic and asymptomatic phases. As long as the general limitations of the 
methodology and clinical background are understood, this work provides a 
robust platform for generating further research opportunities, directly 
benefiting both observational and interventional studies, including monitoring 
of CDI patients during vaccine trials.   
Details on typing of the patient cohort using the developed assays described 
above can be found in Chapter 8.  
220 
 
 
 
Chapter 7 
Investigating the role of mannose-binding lectin 
in Clostridium difficile infection  
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7.1 Introduction 
The initiation and propagation of inflammatory cascades is an essential 
housekeeping property of the innate immune response during infections. The 
success of the immune response depends upon a network of cellular and 
humoral factors including effector mechanisms that range from innate immune 
cells (e.g. epithelial cells and phagocytes) to innate immune soluble factors (e.g. 
cytokines, coagulation factors and soluble pattern recognition molecules). MBL, 
a key pattern recognition molecule, activates the lectin-complement pathway of 
innate immunity through binding to repetitive sugar arrays on microbial 
surfaces (Turner, 2003). MBL is also a potent regulator of inflammatory 
pathways: it can modulate phagocyte interaction with mucosal organisms at the 
site of infection (Super et al., 1989), and interacts with other components of the 
innate immune system such as toll-like receptors (Wang et al., 2011).  
Low MBL concentrations have been associated with increased susceptibility to 
infections in both animal models and humans (Møller-Kristensen et al., 2006; 
Shi et al., 2004), as well as with poor disease prognosis (Turner, 2003). The 
modulation of disease severity is partly thought to be through a complex, dose-
dependent influence on cytokine production (Jack et al., 2001a). Serum MBL 
concentrations range from negligible to as high as 10,000 ng/ml (Madsen et al., 
1998; Osthoff and Trendelenburg, 2013; Steffensen et al., 2000); this varies with 
ethnicity and with the screening method adopted (Harrison et al., 2012). Within 
healthy Whites the median concentration has been shown to be 800-1,000 
ng/ml (Hansen et al., 2003; Steffensen et al., 2000). 
Despite the existence of two sets of MBL genes in the mammalian genome 
(MBL1 and MBL2), only MBL2 remains functional in humans and the 
implications of this evolutionary loss are unclear (Sastry et al., 1989). MBL 
secretion in humans is dependent on the MBL2 genetic architecture (Guo et al., 
1998; Sastry et al., 1995). To date, 57 genetic variants have been identified 
within the entire MBL2 gene (SNP database, Build 140), with only six of them 
known to affect secretion and/or function of the encoded protein (Figure 7.1) 
(Madsen et al., 1995; Madsen et al., 1998).  
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Figure 7.1 – Schematic representation of the major MBL2 isoform and genetic polymorphisms. 
Polymorphisms responsible for the haplotypes that ultimately determine MBL expression levels are indicated by the red arrows . [*In this study, rs10556764 (6 bp 
deletion) was used as a proxy SNP for rs7095891] 
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The mutated alleles B, C or D are collectively termed O and their correspondent 
wild-type alleles are jointly referred to as variant A, with the presence of any 
given O variant (in either the heterozygous or homozygous state) resulting in 
MBL deficiency (Madsen et al., 1995; Madsen et al., 1998). The existence of 
strong linkage disequilibrium (LD) between the promoter and structural gene 
variants means that only seven common haplotypes (out of a possible 64) have 
been described: HYPA, LYQA, LYPA, LXPA, HYPD, LYPB and LYQC (Bernig et al., 
2004; Garred et al., 2006).  HYPD, LYPB and LYQC lead to the production of 
unstable ligands with shorter half-lives that are easily degraded to lower 
oligomeric forms.  Studies that have evaluated both genetic mutations and 
serum concentrations in White adults are summarised in Table 7.1. 
Clostridium difficile is an opportunistic spore-forming bacterium that can 
effectively colonise the intestinal tract following antibiotic-driven dysbiosis. 
Clostridium difficile infection (CDI) is the result of intense colonic inflammation 
caused by the release of potent enterotoxins. Though research into both 
diagnostic/prognostic biomarkers for CDI is limited, investigations have largely 
focused on mediators of inflammation in the gut such as faecal interleukin-8 (El 
Feghaly et al., 2013), lactoferrin (El Feghaly et al., 2013) and calprotectin 
(Shastri et al., 2008), and linked them with disease severity (El Feghaly et al., 
2013; Rao et al., 2014).  More recently, both serum interleukin-23 and 
procalcitonin have also been proposed as potential biomarkers for CDI severity 
(Buonomo et al., 2013; Rao et al., 2013). However, the role of these biomarkers 
in the stratification of problematic CDI patients remains unclear, and thus 
remains an important area of research.  
To date, there have been no studies on the role of either MBL levels or MBL2 
genetic variants with CDI, possibly because MBL is not thought to bind to the 
surface of C. difficile (Townsend et al., 2001). However, there is growing 
evidence for an association between MBL and major modulators of 
inflammation, such as toll-like receptors and CRP, both of which have been 
associated with CDI (Eyre et al., 2012b; Ryan et al., 2011). Therefore, we sought 
to investigate the role of MBL in a prospective cohort of CDI cases and inpatient 
controls.
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Table 7.1 – Disease-related studies investigating both MBL2 genotypic data and protein concentrations of MBL in White adults 
Study Country Disease n* Association with outcome 
Infection-related conditions 
Garred et al. 1997  Denmark HIV 96 Yes (G) 
Garred et al. 1999 Denmark Infection in SLE patients 91 Yes (G) 
Soborg et al. 2003 Denmark Tuberculosis 59 Yes (G) 
Yang et al. 2003 Australia Chronic obstructive pulmonary disease 82 Yes (G) 
Bouwman et al. 2005 Netherlands Severe infection post-liver transplant 49 Yes (G) 
Druszczyńska et al. 2006 Poland Tuberculosis 108 Yes (P) 
Eisen et al. 2006  Australia Sepsis 170 Yes (G+P) 
Gordon et al. 2006 United Kingdom Sepsis 80 Yes (G+P) 
Perez-Castellano et al. 2006  Spain Community-acquired pneumonia 97 No 
Louropoulou et al. 2008 Netherlands Periodontitis 92 No 
Van Till et al. 2008  Netherlands AYI in secondary peritonitis patients 88 Yes (G+P) 
Ampel et al. 2009  USA Coccidioidomyosis 38 Yes (P) 
Harrison et al. 2012  United Kingdom Aspergillosis 108 Yes (G+P) 
Navratilova et al. 2012  Czech Republic Prosthetic Joint Infection 92 Yes (G) 
Wong et al. 2012 Sweden Infection in neutropaenic chemotherapy patients 108 No 
Chalmers et al. 2013 United Kingdom Infection in bronchiecstasis patients 470 Yes (G+P) 
Osthoff et al. 2013  Australia Staphylococcus Aureus infection 70 Yes (G+P) 
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Table 7.1 (continued) – Disease-related studies investigating both MBL2 genotypic data and protein concentrations of MBL in 
White adults 
Study Country Disease n* Association with outcome 
Other conditions 
Garred et al. 2000 Denmark Rheumatoid arthritis 189 Yes (G) 
Megia et al. 2004  Spain Gestational diabetes mellitus 105 Yes (G+P) 
Seibold et al. 2004  Switzerland Inflammatory bowel disease 76 Yes (G+P) 
Kamesh et al. 2007 United Kingdom ANCA-associated vessel vasculitis 137 No 
Nielsen et al. 2007 Denmark Crohn’s disease 171 No 
Swierzko et al. 2007  Poland Reproductive tumours 183 No 
Christiansen et al. 2009  Denmark Recurrent late pregnancy loss 75 Yes (G) 
Kaunisto et al. 2009 Finland Diabetes 1064 No 
Hoffmann et al. 2010 Germany Inflammatory bowel disease 181 No 
Troelsen et al. 2010a Denmark SLE 41 Yes (G+P) 
Troelsen et al. 2010b Denmark Rheumatoid arthritis 114 Yes (P) 
Troelsen et al. 2010c Denmark Rheumatoid arthritis 229 Yes (G+P) 
Kiseljaković et al. 2014  Bosnia-Herzegovina Postmenopausal osteoporosis 37 No 
n: number; HIV: Human Immunodeficiency virus; SLE: Systemic lupus erythematosus; AYI: Abdominal yeast infection; ANCA: Anti-neutrophil cytoplasmic antibody; G: Genetic; 
P: protein 
*This refers to total number of White patients differs with both serum concentration & genotypic data and therefore may differ from total study number
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7.2 Methods 
7.2.1 Study design 
Recruitment of patients was conducted using the criteria defined in Chapter 2. 
308 CDI cases and 145 AAD controls were recruited from July 2008 to March 
2012, of whom 98% were Whites. As well as case versus control analysis, four 
primary CDI disease outcomes were also investigated: 90-day recurrence, 30-
day mortality and prolonged disease (defined as per Chapter 3 Section 3.2.1) 
and disease severity at baseline (defined as per Chapter 4 Section 4.2.1). 
7.2.2 Determination of MBL serum concentrations 
Serum was isolated from whole blood via centrifugation at 2,600 g for 20 
minutes and then stored at -80°C until further use. 
A commercially-available IVD ELISA kit (Sanquin Blood Supply; Amsterdam, 
Netherlands) was transferred onto the MSD ECL-based platform, undergoing 
appropriate optimisation prior to use (see Appendix 46), which adhered to the 
standards outlined in Chapter 6. The MBL kit control was used across all plates 
to determine inter-plate variability and subsequent correction factor used for 
each plate. Final minimum detection level (lower limit of detection; LLOD) and 
minimum quantification level (lower limit of quantification; LLOQ) were 
calculated by taking the mean values across all plates. The mean LLOD and 
LLOQ across all plates were 11.3 and 11.0 ng/μl, respectively. 
Signal values ranged from only 50-500 ECL units, which denote a compressed 
signal range inherent with the assay. To counteract this effect, an attempt was 
made to increase the upper range of the standard curve and subsequently adopt 
a lower sample dilution. However, this proved unfeasible due to the 
unavailability of higher standards and technical impracticalities of using 
standalone recombinant MBL protein. Since this may have potentially limited 
discrimination of the quantitative values, data were subject to binary 
categorisation based on three previously used deficiency cut-offs: 50, 100 and 
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500 ng/ml (Eisen et al., 2008; Gröndahl-Yli-Hannuksela et al., 2013; Seibold et 
al., 2004). 
7.2.3 Determination of MBL2 variants 
DNA was extracted from human blood samples using Chemagen paramagnetic 
bead chemistry (Chemagen Biopolymer-Technologie AG; Baesweiler, Germany) 
according to manufacturers’ protocol. A total of nine variants lying in the 
promoter and exon 1 were typed (Figure 7.1) by either pyrosequencing 
(PyroMark Q96 custom assays, Qiagen; rs36014597, rs7084554, rs1800451, 
rs1800450, rs5030737 and rs10556764) or Taqman SNP genotyping (Applied 
Biosystems; rs7096206, rs11003125 and rs11003123).  The variants 
rs1800451 (C), rs1800450 (B), rs5030737 (D), rs7096206 (X/Y) and 
rs11003125 (H/L) were used for haplotype determination, whilst rs10556764, 
a 6bp Ins/Del in complete linkage disequilibrium with rs7095891 (P/Q), was 
used as a proxy.  Another recognised tagging marker for P/Q (rs11003123) was 
independently typed to evaluate the accuracy of the pyrosequencing assays.  
7.2.3.1 Pyrosequencing 
PyroMark Assay Design software v.2.0 was used to design our pyrosequencing 
assays. Assay 1 targeted rs1800451, rs1800450 and rs5030737 (exonic 
mutations). Assay 2 targeted the deletion, rs10556764, as well as rs36014597 
and rs7084554. Primers and probes are summarised in Table 7.2.  
PCR optimisation was conducted using 20 ng genomic DNA and temperature 
gradients following standard guidelines, with PCR products assessed using an 
Agilent Bioanalyser 2100 (Agilent Technologies; Berkshire, UK). Optimised PCR 
reactions for both Assays 1 and 2 comprised 15 µl as follows: - 
 2x PCR mastermix – 7.5 µl 
 10 x Primer set – 1.5 µl 
 Distilled water – 5 µl 
 DNA - 1µl (at 20 ng/µl) 
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Final cycling conditions were as follows: - 
 95°C for 3 mins 
 40 cycles 
o 95°C for 20 s 
o Assay 1: 58°C for 30 s/Assay 2: 61°C for 30 s 
o 72°C for 30 s 
 72°C for 5 mins 
Optimised products were then run on a PyroMark Q96 ID following the 
recommended assay protocol. Repeat samples and blanks were included for 
quality control (QC) purposes and results were analysed using PyroMark Q96 
v.2.5.8 software. 
7.2.3.2 Taqman genotyping 
rs7096206 and rs11003123 were genotyped using off-the-shelf SNP genotyping 
assays, whilst rs11003125 was genotyped using a custom SNP genotyping assay 
(Applied Biosystems, USA) as per Michaud et al. (Michaud et al., 2013). The 
primers and probes are summarised in Table 7.2. Final reactions for all three 
SNPs comprised 6 µl as follows: - 
 2 µl of 1x Taqman genotyping master mix 
 0.13 µl of 1x Taqman genotyping assay 
 2.87 µl of distilled water (dH2O) 
 20 ng of dried genomic DNA 
Reactions were run on the Applied Biosystems HT 7900 Fast Real-Time PCR 
system (Applied Biosystems, USA) using the following cycling conditions: - 
 Stage 1: 50°C for 2 min 
 Stage 2: 95°C for 10 min 
 Stage 3: 45 cycles 
o 95°C for 15 s 
o 60° for 60 s 
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Repeat samples and blanks were incorporated for QC purposes, and results 
were analysed using SDS software (version 2.2; Applied Biosystems, USA). 
 
Table 7.2 –Primers and probes used for determination of MBL2 variants 
Pyrosequencing 
Assay 1 Forward: 5’-ATGGTGGCAGCGTCTTACTC-3’ 
Reverse: 5’-Biotin- ACAGAACAGCCCAACACGTA – 3’ 
Sequencing primer: 5’-TTCCCAGGCAAAGAT-3’ 
Assay 2 Forward: 5′-Biotin- TCAGCTGCCCAGATACAAAGATG-3’ 
Reverse: 5′-AATGAGTGGAAACCCAGGTGTCT-3’ 
Sequencing primer: 5’- CCCAGGTGTCTGTAGG -3’ 
Taqman SNP genotyping 
rs11003125 Forward: GGAGTTTGCTTCCCCTTGGT 
Reverse: GGGCCAACGTAGTAAGAAATTTCCA 
Reporter 1 (VIC): CAAGCCTGTGTAAAAC 
Reporter 2 (FAM): CAAGCCTGTCTAAAAC 
 
7.2.4 Statistical analysis 
Median MBL serum concentrations were compared for individual SNPs and 
haplotypes by the Mann-Whitney U-test, and then subjected to stratification 
based upon previously used two-marker grouping profiles termed high- (YA/YA 
& XA/YA), intermediate- (XA/XA & YA/YO) and low-expressing (XA/YO & YO/YO) 
genotypes (Chalmers et al., 2013; Eisen et al., 2008). 
The effect of both MBL2 genetics (based on stratified expression genotypes) and 
serum MBL concentrations (based upon deficiency cut-offs) were individually 
taken forward for case-control comparison and sub-group analysis of cases. For 
the latter, this included logistic regression for the following outcome measures: 
A) severity of disease, B) duration of symptoms longer than 10 days, C) 90-day 
recurrence, and D) 30-day mortality. Covariates including demographic 
variables, the presence of PCR ribotype 027/NAP/BI1 and potential 
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confounders (immunosuppressive therapy, renal disease and diabetes, CCI 
score and time delay between sample testing positive and recruitment) were 
individually assessed. CCI was originally developed without adjustment for age 
(Charlson et al, 1987), therefore as age was already included as an individual 
covariate in our analysis, we calculated our CCI unadjusted for age in order to 
avoid introducing an undesirable level of collinearity into our analysis. This is 
consistent with previous studies (Boone et al., 2014; Caplin et al., 2011; 
Daskivich et al., 2014). Although an outcome measure itself, severity of disease 
was also assessed as a covariate for all other CDI outcomes. Statistically 
significant covariates were added to the final regression model to produce 
adjusted P-values, odds ratios and 95% confidence intervals. All analyses were 
carried out using SPSS v.20. Retrospective power calculations were simulated 
using nQuery Advisor + nTerim 2.0 (Statistical Solutions Ltd., Cork, Ireland).  
7.3 Results 
7.3.1 Patient demographics 
Demographics of the patient cohort are summarised in Table 7.3. No significant 
differences were observed between CDI cases and AAD controls for gender 
(57% female for both; p=1.00), presence of immunosuppression (17 versus 
24%; p=0.07), renal comorbidity (51 versus 57%; p=0.27) or diabetes (19 
versus 27%; p=0.06), and mean CCI score (1.0 versus 1.0; p=0.44). However, 
significant differences were identified for mean age (70.1 versus 65.0 years; 
p<0.01), mean BMI (24.6 versus 26.9; p<0.01) and median time delay between 
testing positive and recruitment (3.0 versus 2.0 days; p<0.01). C. diff isolates 
were successfully recovered from 283 (92%) of the CDI cases, of which all were 
toxigenic and 89 (31%) had the ribotype 027. 
The proportion of patients suffering from symptoms of 10 or more days was 
higher amongst CDI cases compared with controls (39 versus 12%; p<0.01). 
This difference was also significant when considering durations of symptoms as 
measured from initial onset of symptoms (60 versus 24%; p<0.01). Of the CDI 
cases, 41% (127/308) were assessed as having severe disease, while 38% 
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(83/220) of cases experienced recurrent episodes during the 90-day follow-up 
period. 
 
Table 7.3 – Demographics of patients with Clostridium difficile infection 
(CDI) and antibiotic-associated diarrhea (AAD)  
Patient’s characteristics  
CDI Cases 
(n=308) 
AAD Controls 
(n=145) 
P-value* 
Gender – Female, n (%)  177/308 (57) 81/142 (57) 1.00 
Age – Mean in years (SD)  70.1 (16.4) 65.0 (17.6) <0.01 
BMI – Mean (SD)  24.6 (6.8) 26.9 (6.9) <0.01 
Presence of immunosuppression – n (%) 52/307 (17) 35/144 (24) 0.07 
Presence of renal comorbidity – n (%) 157/307 (51) 82/144 (57) 0.27 
Presence of diabetes – n (%) 58/307 (19) 39/144 (27) 0.06 
CCI score – Median (IQR)  1.0 (0.0-2.0) 1.0 (0.0-2.0) 0.44 
Time delay (testing/recruitment) – Median (IQR) 3.0 (2.0-4.0) 2.0 (2.0-3.0) <0.01 
Clinical Parameters     
Duration of symptoms ≥10 days – n (%)a 107/271 (39) 15/125 (12) <0.01 
All-cause mortality within 30 days – n (%)  26/305 (9)  5/142 (4)  0.07 
Disease severity at baseline – n (%) 127/308 (41) - - 
Recurrence within 90 days – n (%)b 83/220 (38) - - 
Frequency of ribotype 027 – n (%)c 89/283 (31) - - 
%: percentage; AAD: Antibiotic-associated diarrhea; BMI: body mass index; CCI: Charlson 
Comorbidity Index; CDI: Clostridium difficile infection; IQR: Interquartile range; n: number; SD: 
Standard deviation; 
*Means for normally distributed, continuous variables were compared using Independent samples 
T-test for continuous, for non-normal distribution median values were compared using Mann 
Whitney U test. Categorical data was assessed using a Chi-squared test for all counts >5, and 
Fisher’s Exact test for those <5; 
a Data regarding duration of symptoms was unavailable for 37 of our cases and 20 of our controls; 
b Data regarding recurrence of disease within 90 days was unavailable for 60 of our cases. A 
further 28 cases died within the follow-up period prior to experiencing any recurrent symptoms 
and therefore could not be included in the final analysis; c Isolates were successfully recovered from 
283/308 cases and thus ribotyping could not be done in 25 of our cases;  
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7.3.2 Power calculations 
Power to detect a significant difference was calculated as ≥99% for Case versus 
control and 90-day recurrence analyses. However, for analysis of 30-day 
mortality, prolonged symptoms and disease severity at baseline we had 
inadequate power (67, 78 & 75%, respectively; Table 7.4). 
 
Table 7.4 - Assessment of power across clinical outcome associated with 
Clostridium difficile infection  
Disease outcome Number Percentage power achieved 
Case versus control 305 vs. 142 99 
30-day mortality 26 vs. 276 67a 
Prolonged symptoms 107 vs. 161 78b 
90-day recurrence 81 vs. 136 99 
Disease severity 125 vs. 180 75c 
Achieving 80% power would require the following number of patients in each group: a 66; b 134; c 
166; 
 
7.3.3 Relationship of genotype with serum MBL concentrations 
Where appropriate, genotype frequency data were compared against those of a 
recent genome-wide association study (GWAS) involving a subset of these 
patients to identify any potential discrepancies. All duplicates were found to be 
concordant within and across genotyping platforms. A selection of 
pyrosequencing outputs can be seen across Appendices 47-51. 
Of the 9 variants typed in the CDI cases and AAD controls, 3 were excluded: 1 
SNP (rs7084554) deviated from Hardy-Weinberg Equilibrium (HWE <0.001); 
rs11003123 was deemed redundant due to complete LD with the INS/DEL 
polymorphism (rs10556764); and rs36014597 was also in complete LD with 
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both rs10556764 and rs11003123.  As mentioned previously, rs11003123 was 
employed as a QC proxy for the pyrosequencing of the deletion polymorphism 
and therefore complete LD was expected. Conversely, rs36014597 had not been 
confirmed to be in LD with rs10556764, nor P/Q. Of the 6 polymorphisms 
analysed, genotyping success rate was ≥95%. Their minor allele frequencies 
were in line with those reported in the literature (Table 7.5). 
For both groups, seven common haplotypes were derived from the 6 
polymorphisms (Figure 7.2), which is consistent with other previous studies in 
Whites (Table 7.6) (Adamek et al., 2013; Steffensen et al., 2000). Presence of the 
mutant allele for all individual MBL2 variants had a significant influence on 
serum MBL concentration across all patients, except for the X allele encoded by 
rs7096206 (p=0.30; Table 7.5). All the assembled MBL2 haplotypes also 
significantly impacted on serum concentrations, except for haplotype LXPA 
where there was no difference compared with the overall median value 
(p=0.34; Table 7.6). Genotypic and haplotypic analyses demonstrated that the 
presence of a variant allele for any of the three exonic variants (rs1800451, 
rs1800450 and rs5030737) were the major contributing factors for lower MBL 
concentration (Tables 7.5 & 7.6). 
 
 
Figure 7.2 – Linkage disequilibrium plots, detailing D’ (A) and R2 (B), for 
the 6 MBL2 polymorphisms known to affect protein expression levels. 
Here, P/Q refers to the 6 bp deletion (rs10556764) used as a proxy SNP in this study .
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Table 7.5 – Overview of the six MBL2 variants employed for the haplotype construction and association with MBL 
concentrations 
 
rs11003125 rs10556764 rs7096206 rs5030737 rs1800450 rs1800451 
Nucleotide change 
-550 
G>C 
-327 to -332 
CTCTTT/- 
-221 
G>C 
+219 
G>A 
+227 
C>T 
+235 
C>T 
Haplotype component H/L 
Ins/Del 
(P/Q proxy) 
X/Y Codon 52 (D) Codon 54 (B) Codon 57 (C) 
Minor allele H Del Y D B C 
MAF 0.36 0.20 0.23 0.07 0.14 0.01 
Median for presence 
of minor variant:  ng/ml (n) 
537.5 (262) 503.2 (158) 396.1 (185) 158.3 (58) 73.8 (113) 51.0 (12) 
Median for absence 
of minor variant: ng/ml (n) 
223.1 (180) 330.6 (265) 376.8 (256) 483.8 (373) 578.5 (315) 419.7 (419) 
P-value* <0.001 <0.001 0.30 <0.001 <0.001 <0.001 
MAF = Minor Allele Frequency; n: Number; *P-value was calculated using a Mann-Whitney U test comparing median concentrations for presence versus absence of the 
minor variant of each individual SNP, across all patients (cases and controls combined); 
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Table 7.6 – MBL serum concentrations across MBL2 haplotypes in patients with Clostridium difficile infection and antibiotic-
associated diarrhea  
 
HYPA LYPA LYQA LXPA HYPD LYPB LYQC 
Presence of haplotype        
n (% frequency) 213 (29)  44 (6)  143 (19)  170 (23)  55 (7)  108 (15)  11 (1)  
Median, ng/ml 
(Range)  
612 
(17 - 3,981) 
587 
(0 - 2,500) 
529  
(0 - 3,981) 
428  
(0 - 2,968) 
157  
(0 - 815) 
73  
(0 - 637) 
48  
(0 - 492) 
Absence of haplotype        
n (% frequency) 198 (9) 367 (17) 268 (13) 241 (11) 356 (17) 303 (14) 400 (19) 
Median: Absence, ng/ml 
(Range) 
171 
(0 – 2,374) 
388 
(0 - 3,981) 
324 
(0 - 2,968) 
377 
(0 - 3,981) 
484 
(0 - 3,981) 
568 
(0 - 3,981) 
420 
(0 - 3,981) 
P-value* <0.001 0.04 <0.001 0.34 <0.001 <0.001 0.001 
n: number; % freq.: Percentage frequency; *P-values were calculated using a Mann-Whitney test comparing MBL serum concentrations against the presence/absence of 
each individual haplotype; 
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Patients with high-expressing genotypes had a median serum MBL 
concentration of 714 ng/ml, compared with 190 ng/ml with intermediate-
expressing genotypes, and 32 ng/ml with low-expressing genotypes (p<0.001; 
Table 7.7; Figure 7.3A). The contribution of the X allele, seemingly insignificant 
when evaluated on an individual basis (Table 7.5), became apparent with a 
gradual decrease when compared with the equivalent genotypes containing the 
Y allele in the rank order: XA/YA < YA/YA; XA/XA < XA/YA, and XA/YO < YA/YO 
(Table 7.7; Figure 7.3B). 
 
Table 7.7 – Median serum MBL concentrations across previously defined 
expression genotype groups* 
MBL expression 
group 
Genotype n 
Median 
(ng/ml) 
Combined median 
(ng/ml) 
High 
YA/YA 124 854 
714 
XA/YA 113 561 
Intermediate 
XA/XA 16 270 
190 
YA/YO 91 175 
Low 
XA/YO 41 32 
32 
YO/YO 26 31 
*Expression groups defined according to Eisen et al. 2008 (Eisen et al., 2008) 
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Figure 7.3 – Median serum MBL concentrations in relation to: (A) 3-tier grouping based on proposed expression profiles; and 
(B) individual genotypic groups within proposed expression profiles 
 
A B 
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7.3.4 MBL deficiency cut-off points in relation to haplotype groups 
In total 59 (13%), 93 (21%) and 258 (58%) patients had serum MBL 
concentrations below 50, 100 and 500 ng/ml, respectively.  When these data 
were compared with the “expressing” genotype groups, 78% (42/54) and 68% 
(59/87) of those with concentrations below 50 and 100 ng/ml, respectively, 
were low expressors, compared to 28% (66/236) of those with a concentration 
less than 500 ng/ml (Table 7.8). The corresponding figures for high expressors 
were 4% (2/54), 6% (5/87) and 30% (70/236), respectively.  Similarly, 96% 
(52/54) and 93% (81/87) of those with concentrations below 50 and 100 
ng/ml, respectively, carried the deficient (O) haplotypes, compared to 65% 
(153/236) of those with a concentration less than 500 ng/ml (Table 7.8). Based 
on the results above, only the 50 and 100 ng/ml cut-offs were taken forward for 
further analysis, which is consistent with previous literature (Gröndahl-Yli-
Hannuksela et al., 2013; Seibold et al., 2004). 
7.3.5 Comparison of MBL levels versus CDI disease outcomes 
Serum MBL concentrations are shown in Table 7.9. Analysis using both <50 and 
<100 ng/ml as cut-off points to signify deficiency identified no significant 
differences between CDI cases and AAD controls (p=0.79 and p=0.09, 
respectively) (Table 7.10). Evaluation of the clinical outcomes in CDI cases 
showed a significant association with CDI recurrence (p<0.01 for both; Table 
7.10) with odds ratios of 3.18 and 2.61 at the <50 and <100 ng/ml cut-off 
points, respectively. No association was identified with any of the other 
outcomes including prolonged symptoms, 30-day mortality and disease severity 
at baseline (Table 7.10). 
In order to ensure our association for recurrence holds true for early versus late 
recurrence, we assessed median MBL levels across three different recurrent 
groups using 2-way comparisons as follows: (1) 0-30 days versus 31-90 days 
(2) 0-60 days versus 61-90 days. Median MBL levels did not differ significantly 
across comparisons (p=1.00 & p=0.37, respectively), which suggests that the 
association of MBL with recurrence has not been biased, by either early or late 
240 
 
time-points, and holds true for overall recurrence. Furthermore, although the 
majority of our recurrent patients were recruited as an initial infection (81%), a 
small number (19%) had experienced at least one episode of CDI prior to the 
current episode for which they were recruited; median MBL levels did not differ 
significantly between these two groups of recurrent patients (p=0.64). 
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Table 7.8 – Distribution of expression genotypes and deficiency haplotypes across three different serum MBL deficiency cut-
offs* 
Cut-off 
(ng/ml) 
n (%) 
High expressors Intermediate expressors Low expressors 
50 (n=54) 2 (4) 10 (18) 42 (78) 
100 (n=87) 5 (6) 23 (26) 59 (68) 
500 (n=236) 70 (30) 100 (42) 66 (28) 
 
Homozygous non-deficient 
haplotypes 
Heterozygous deficient 
haplotypes 
Homozygous deficient 
haplotypes 
Dominant 
modela 
50 (n=54) 2 (4) 34 (63) 18 (33) 52 (96) 
100 (n=87) 6 (7) 57 (65) 24 (28) 81 (93) 
500 (n=236) 83 (35) 128 (54) 25 (11) 153 (65) 
n: number; a Dominant model refers to the presence of ≥1 deficiency haplotype across both the maternal and paternal haplotypes of each patient 
*The number of patients deemed high (YA/YA & XA/YA), intermediate (XA/XA & YA/YO) and low (XA/YO & YO/YO) expressors, plus the number of patients carrying 
either deficient (O) or non-deficient (A) haplotypes, was assessed across three individual serum MBL deficiency cut-offs. 
  
242 
 
Table 7.9 - Descriptive MBL serum concentrations in relation to 
Clostridium difficile infection disease outcomes 
 Median, ng/ml (IQR) 
Case versus Control 
Case (n=308) 361.8 (128.3-747.7) 
Control (n=145) 491.9 (160.0-856.0) 
Death within 30 days 
Death (n=26) 330.3 (115.9-673.0) 
Non-death (n=279) 372.9 (128.4-754.2) 
Duration ≥10 days 
Yes (n=107) 372.1 (83.7-728.9) 
No (n=161) 392.9 (148.7-819.7) 
Recurrence within 90 days 
Recurrence (n=83) 196.7 (60.9-570.4) 
Non-recurrence (n=137) 452.1 (169.6-844.5) 
Severity at baseline 
Severe (n=127) 372.1 (128.3-728.2) 
Non-severe (n=181) 354.6 (128.0-787.1) 
n: number; IQR: interquartile range; Min: minimum; Max: maximum; 
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Table 7.10 – Analysis of Clostridium difficile infection disease outcomes 
versus serum MBL concentration based on deficiency cut-offs of 50 and 
100 ng/ml 
 Case (n=308) Control (n=145) P-value OR (95% CI) 
<50 ng/ml 41 (13%) 18 (12%) 0.79a 1.09 (0.58-2.06) 
<100 ng/ml 70 (23%) 23 (16%) 0.09b 1.61 (0.93-2.79) 
 Death (n=26) Survival (n=276) P-value OR (95% CI) 
<50 ng/ml 3 (12%) 37 (13%) 0.78c 1.22 (0.31-4.82) 
<100 ng/ml 5 (19%) 64 (23%) 0.84c 0.88 (0.27-2.89) 
 ≥10 days (n=107) <10 days (n=161) P-value OR (95% CI) 
<50 ng/ml 16 (15%) 19 (12%) 0.45d 1.31 (0.64-2.69) 
<100 ng/ml 29 (27%) 32 (20%) 0.17d 1.50 (0.84-2.67) 
 Recurrence (n=81) Non-recurrence (n=136) P-value OR (95% CI) 
<50 ng/ml 18 (22%) 13 (10%) <0.01e 3.18 (1.40-7.24) 
<100 ng/ml 29 (36%) 24 (18%) <0.01e 2.61 (1.35-5.04) 
 Severe (n=125) Non-severe (n=180) P-value OR (95% CI) 
<50 ng/ml 16 (13%) 25 (14%) 0.78d 0.91 (0.46-1.79) 
<100 ng/ml 29 (23%) 41 (23%) 0.93d 1.02 (0.60-1.76) 
n: number; OR: odds ratio; CI: confidence interval; 
P-values & ORs were calculated using univariate logistic regression and adjusted for the presence 
of significant covariates: a Age, BMI, time delay between testing positive and recruitment & the 
presence of diabetes; b Age, BMI, time delay between testing positive and recruitment & the 
presence of diabetes and immunosuppressive therapy; c Age, BMI, score on Charlson Comorbidity 
Index and disease severity at baseline; d No covariates were found to be significant & therefore P-
value remains unadjusted; e Age;  
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Despite the strong correlation observed between genotypes/haplotypes and 
serum MBL concentrations in this cohort, no significant associations were 
identified between high-, intermediate- and low-expressing genotypes and CDI 
disease outcomes (Table 7.11). There was an inverse correlation between MBL 
and CRP serum concentrations (Pearson’s Correlation Coefficient R2=-0.16, 
p=0.001; Figure 7.4). No significant correlation was identified with white cell 
count (R2=-0.04, p=0.44). 
 
Table 7.11 – Analysis of Clostridium difficile infection disease outcomes 
versus high, intermediate and low expressing MBL2 genotypes 
 Case (n=308) Control (n=145) P-valuea OR (95% CI) 
High expressing group (comparator) 165 73 0.86 - 
Intermediate expressing group 75 34 0.75 0.92 (0.55-1.55) 
Low expressing group 44 24 0.61 0.85 (0.47-1.56) 
 Death (n=26) Survival (n=276) P-valueb OR (95% CI) 
High expressing group (comparator) 14 150 0.77 - 
Intermediate expressing group 8 67 0.47 1.49 (0.50-4.43) 
Low expressing group 3 40 0.75 1.26 (0.31-5.03) 
 ≥10 days (n=102) <10 days (n=149) P-valuec OR (95% CI) 
High expressing group (comparator) 60 84 0.89 - 
Intermediate expressing group 27 40 0.85 0.95 (0.52-1.71) 
Low expressing group 15 25 0.64 0.84 (0.41-1.73) 
 Recurrence (n=78) Non-recurrence (n=133) P-valued OR (95% CI) 
High expressing group (comparator) 42 83 0.46 - 
Intermediate expressing group 22 31 0.32 1.43 (0.71-2.86) 
Low expressing group 14 19 0.33 1.50 (0.66-3.39) 
 Severe (n=120) Non-severe (n=185) P-valuec OR (95% CI) 
High expressing group (comparator) 64 101 0.33  
Intermediate expressing group 36 39 0.18 1.46 (0.84-2.53) 
Low expressing group 16 28 0.77 0.90 (0.45-1.80) 
n: number; OR: odds ratio; CI: confidence interval; 
P-values & ORs were calculated using univariate logistic regression and adjusted for the presence 
of significant covariates: a Age, BMI, time delay between testing positive and recruitment & the 
presence of diabetes; b Age, BMI, score on Charlson Comorbidity Index and disease severity at 
baseline; c No covariates were found to be significant & therefore P-value remains unadjusted; d 
Age; 
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Figure 7.4 – Correlation plots comparing MBL concentrations against routine blood markers (A) CRP and (B) White blood cells 
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7.4 Discussion 
Studies evaluating the role of MBL in infectious and immune diseases have 
focused on either genotype, phenotype, or occasionally on both parameters.  
The latter approach is preferred as it can show discordance between genotype 
and phenotype.  This study is one of the larger disease-related studies 
concurrently investigating both genotypic/haplotypic variants and serum 
concentrations in Whites (Table 7.1) and is the first to demonstrate an 
association between serum MBL concentrations, but not genotype, and 
recurrence of CDI within 90 days using two distinct cut-off values for MBL 
deficiency. It was further established that this association has not been biased, 
by either early or late outcome onset, and holds true for overall recurrence. 
The mechanistic basis of the association is unclear.  With other bacterial and 
viral infections, MBL is thought to be capable of binding to the cell surfaces of 
invasive pathogens thereby stimulating a downstream immune response. 
However, this does not seem to be the case with C. difficile where binding of 
MBL has been shown to be low (Townsend et al., 2001).  This suggests that MBL 
deficiency does not per se predispose to CDI and is consistent with the observed 
lack of difference in circulating concentrations of MBL between CDI cases and 
AAD controls.  MBL has other functions including modulation of inflammation 
and clearance of apoptotic cells (Dommett et al., 2006).  The former may be 
relevant to CDI, where MBL may be acting as a modulator of the disease. 
Consistent with this, clinical manifestations of MBL deficiency appear to be of 
more relevance either in infants when the immune system is still maturing or in 
susceptible groups when there is an associated immunodeficiency (Koch et al., 
2001), such as in hospitalised elderly patients or following major clinical 
interventions. However, these are hypotheses that need further investigation. 
Although MBL concentrations remain relatively constant in individuals due to 
genetic determinants, MBL is known to be a relatively modest acute phase 
reactant (Dean et al., 2005). This is in sharp contrast to other acute phase 
proteins such as CRP whose concentrations can increase sharply by 10 to 1,000-
fold during acute inflammation (Ip et al., 2009). Elevated CRP concentrations 
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have previously been shown to be associated with various CDI outcomes 
including disease severity and recurrence (Eyre et al., 2012b; Khanafer et al., 
2013). Consistent with this, low MBL concentrations have been associated with 
an increase in the level of CRP (Garred et al., 2002), and with our findings of the 
association with CDI recurrence and inverse correlation with CRP.  In keeping 
with the immunomodulatory effect of MBL, it is known that low concentrations 
lead to increased secretion of the pro-inflammatory cytokines interleukin-6, 
interleukin 1-beta and TNF alpha (Garred et al., 2002; Jack et al., 2001b), all of 
which have also been shown to be elevated in response to CDI (Hirota et al., 
2012; Vohra and Poxton, 2012). 
The genetic architecture of the MBL2 gene is complex (Figure 7.1) with the 
existence of numerous common functional polymorphisms and haplotypes 
(Figure 7.1, Tables 7.5-7.7). MBL2 haplotype frequencies and the corresponding 
impact on serum MBL concentrations were in line with those previously 
reported (Madsen et al., 1995; Steffensen et al., 2000) (Table 7.6). This was also 
evident after stratification of MBL haplotypes based on previously defined 
expression genotypes (Chalmers et al., 2013; Eisen et al., 2008) with carriers of 
low-expressing genotypes showing much lower serum MBL concentrations than 
both intermediate- and high-expressing genotypes (32 ng/ml versus 190 and 
714 ng/ml, respectively; Table 7.7). Despite the strong association observed 
between MBL2 genotypes and serum MBL concentrations, and the association 
between MBL concentrations and CDI recurrence, there was no association 
between MBL genotype and CDI outcomes. Other studies have also identified 
associations with protein levels, but not with genotype (Table 7.1), highlighting 
the need to evaluate both MBL genotype and phenotype in infection and other 
immune conditions.  The lack of association between MBL genotype and disease 
outcome may be due to the incomplete genetic penetrance of MBL genetic 
variation on phenotype.  In this study, only 78% and 68% of the low-expressing 
genotypes accounted for deficient serum levels using the cut-off values of <50 
and <100 ng/ml, respectively (Table 7.8). Genetic heterogeneity due to 
functionally related genes such as L-ficolin, MASP2, and surfactant proteins may 
also play a role, but this needs further investigation.  
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Our study sought to adhere to a stringent methodology through the use of a 
relatively large cohort size and extensive QC, but it is not without its limitations. 
Although there is less chance of MBL concentrations being confounded by 
infection-related events when compared to other response markers, one of the 
clear drawbacks of this work is the lack of longitudinal measurements, which is 
now being addressed in a new prospective study.  The effect of proteins 
functionally related to MBL, and other markers of inflammation, and the relative 
roles they play in disease modulation needs further investigation.  Previous 
studies have used various definitions for MBL deficiency, with commonly used 
cut-offs ranging from 50 (Gröndahl-Yli-Hannuksela et al., 2013) to 500 ng/ml 
(Eisen et al., 2008). It is thus difficult to compare results across different study 
groups given the heterogeneity of platforms, profile of cohorts and standards 
adopted for the measurement of MBL. Discrepancies between studies could be 
due to low sample sizes, poor assay performance and differences in techniques 
adopted by laboratories. We have tried to overcome some of these limitations 
by evaluating a number of cut-off levels but there is a need for international 
consensus and harmonisation in this area. 
In conclusion, our data suggest that low serum MBL concentrations may act as a 
predictor of CDI recurrence.  Further work is needed to validate these findings 
in an independent cohort of patients and to evaluate the mechanistic basis of 
this association.   This area of research would also be advanced through 
consensus on definitions of deficiency, standardisation of methods employed for 
measurement of serum concentrations, and further evaluation of the genotype-
phenotype relationships. 
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Chapter 8 
Analysis of host immune response in relation to 
CDI primary outcomes  
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8.1 Introduction 
The hypothesis behind the work detailed here is described in Chapter 6 Section 
6.1.1. This study aimed to investigate the role of IgG and IgM responses to both 
tcdA and tcdB, as well as the previously uninvestigated CDT, as predictors of 
poor CDI outcomes using newly developed assays. 
8.2 Methods 
8.2.1 Study design 
Recruitment of patients was conducted using the criteria defined in Chapter 2. 
As well as case versus control analysis, four primary CDI disease outcomes were 
also investigated: 90-day recurrence, 30-day mortality and prolonged disease 
(defined as per Chapter 3 Section 3.2.1) and disease severity at baseline 
(defined as per Chapter 4 Section 4.2.1). 
8.2.2 Assay development & serum typing 
The majority of previous studies that have quantified the serum immune 
response to C. diff toxins utilised an ELISA-based method from 1992 (Kelly et al., 
1992). Due to the limitations surrounding ELISA-based methods, assays with 
increased sensitivity were developed for quantification in our patient cohort, 
using MSD’s ECL technology (described in detail in Chapter 6). Finalised assays 
targeted IgG and IgM responses to tcdA and tcdB, as well as cdtA and cdtB-pre. 
Serum was isolated from whole blood via centrifugation at 2600 g for 20 mins 
and stored at -80°C until further use. Controls were included across plates to 
determine inter-plate variability and subsequent correction factor for each 
plate. Of the 88 clinical samples tested on each plate, 8 control samples were 
tested in duplicate to monitor intra-plate variability. 
8.2.3 Statistical analysis 
Toxin-specific antibody response levels were subject to 4-tier percentile 
categorisation (Low <25%, Medium-Low 25-50%, Medium-High 50-75% and 
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High >75%). Sub-group analysis was carried out based on a number of 
outcomes: severity of disease, 90-day recurrence, duration of symptoms and 30-
day mortality, using univariate binary logistic regression. Covariates including 
gender, age, BMI and the presence of PCR-ribotype 027 were individually 
assessed via univariate binary logistic regression, as well as potential 
confounders of the host immune response such as immunosuppressive and 
antineoplastic therapy (immunosuppressants, corticosteroids and 
chemotherapy drugs), presence of renal disease or diabetes, time delay between 
sample testing positive and recruitment, and CCI score. CCI was originally 
developed without adjustment for age (Charlson et al., 1987) and therefore as 
age was already included as an individual covariate, CCI was calculated without 
adjustment for age to avoid the introduction of an undesirable level of 
collinearity into the analysis. This is consistent with previous studies (Boone et 
al., 2014; Caplin et al., 2011; Daskivich et al., 2011; Daskivich et al., 2014). 
Although an outcome measure itself, severity of disease was also assessed as a 
covariate for all other CDI outcomes. 
Statistically significant covariates were added to the final regression model to 
produce adjusted P-values, ORs and 95% CIs. All analyses were carried out 
using SPSS v.20. Retrospective power calculations were simulated using nQuery 
Advisor + nTerim 2.0 (Statistical Solutions Ltd., Cork, Ireland). The literature 
lacks reliable data for conducting a priori power calculation. 
8.3 Results 
8.3.1 Patient demographics 
Patient demographics are described in Chapter 7: Section 7.3.1 and Table 7.1.  
8.3.2 Antibody response to C. diff toxins versus disease outcomes 
Median anti-toxin IgG and IgM serum concentrations across all disease 
outcomes are summarised in Tables 8.2 & 8.3. 
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Table 8.2 – Descriptive antibody response levels to toxins A and B versus multiple CDI outcomes 
 
IgG/tcdA1 IgG/tcdB1 IgM/tcdA2 IgM/tcdB2 
N Median, ng/ml (IQR) N Median, ng/ml (IQR) N Median, ng/ml (IQR) N Median, ng/ml (IQR) 
Case versus Control 
Case 306 43,207 (24,758-75,371) 306 18,942 (10,924-57,843) 300 21,508 (12,341-37,505) 300 5,260 (2,910-12,165) 
Control 142 39,084 (23,215-66,748) 142 19,032 (11,314-38,081) 136 24,085 (15,002-42,391) 137 5,229 (2,560-8,865) 
30-day mortality 
Death 26 40,834 (25,499-79,546) 26 21,456 (14,033-85,624) 26 18,785 (10,243-23,699) 26 4,580 (2,671-9,956) 
Non-death 277 43,747 (24,948-72,445) 277 18,839 (10,668-52,453) 271 21,732 (13,027-38,597) 271 5,347 (3,006-12,793) 
Duration of symptoms 
≥10 days 106 34,089 (23,043-57,595) 106 16,875 (9,725-40,435) 104 19,966 (11,658-32,574) 103 4,633 (2,684-12,954) 
≤9 days 163 46,215 (26,825-78,806) 163 19,200 (11,518-57,751) 159 22,092 (12,188-38,339) 160 5,375 (3,141-10,711) 
90-day recurrence 
Recurrence 82 39,468 (24,996-67,139) 82 19,070 (10,581-51,904) 77 21,521 (11,845-34,103) 77 4,625 (2,600-12,125) 
Non-recurrence 136 47,812 (25,676-80,636) 136 21,129 (11,590-66,397) 135 22,108 (13,819-43,470) 135 5,653 (3,435-12,988) 
Baseline severity 
Severe 126 31,615 (22,991-58,849) 126 16,051 (9,798-35,973) 125 20,218 (11,332-31,681) 125 4,940 (2,682-12,885) 
Non-severe 180 49,031 (27,674-90,978) 180 21,313 (12,355-68,078) 175 22,617 (13,331-42,635) 175 5,424 (3,007-11,859) 
IgG: Immunoglobulin G; IgM: Immunoglobulin M; IQR: Interquartile range; n: number; tcdA: Clostridium difficile toxin A; tcdB: Clostridium difficile toxin B; 1: Coating = 
25.0 ug/ml; Detection = 1.0 ug/ml; Sample dilution = 1:40; 2. Coating = 25.0 ug/ml; Detection = 1.0 ug/ml; Sample dilution = 1:2; 
254 
 
Table 8.3 – Descriptive antibody response levels to binary toxin analytes versus multiple CDI outcomes 
 
IgG/cdtA1 IgG/cdtB-pre2 IgM/cdtA3 IgM/cdtB-pre4 
N Median, ng/ml (IQR) N Median, ng/ml (IQR) N Median, ng/ml (IQR) N Median, ng/ml (IQR) 
Case versus Control 
Case 289 668 (386-1,086) 293 1,693 (1,077-2,805) 289 401 (246-670) 293 552 (356-949) 
Control 132 592 (373-952) 134 1,755 (1,078-2,514) 132 407 (260-627) 134 553 (370-879) 
30-day mortality 
Death 25 668 (395-960) 25 2,288 (1,211-3,105) 25 343 (202-681) 25 509 (229-666) 
Non-death 261 668 (387-1,112) 265 1,670 (1,077-2,770) 261 408 (251-681) 265 566 (367-975) 
Duration of symptoms 
≥10 days 102 699 (343-1,123) 101 1,603 (804-2,439) 102 367 (219-578) 101 477 (316-790) 
≤9 days 150 668 (387-1,058) 156 1,717 (1,153-2,962) 150 442 (272-739) 156 693 (369-1,000) 
90-day recurrence 
Recurrence 77 600 (389-970) 77 1,778 (1,208-2,645) 77 368 (214-583) 77 542 (344-860) 
Non-recurrence 126 712 (395-1,180) 129 1,693 (1,131-2,895) 126 445 (272-701) 129 619 (381-975) 
Baseline severity 
Severe 116 624 (340-881) 119 1,603 (1,047-2,739) 116 384 (247-606) 119 516 (313-874) 
Non-severe 173 712 (387-1,171) 174 1,784 (1,099-2,931) 173 404 (243-702) 174 589 (364-992) 
cdtA: Clostridium difficile binary toxin A; cdtB-pre: Clostridium difficile binary toxin B precursor; IgG: Immunoglobulin G; IgM: Immunoglobulin M; IQR: Interquartile 
range; n: number; 1: Coating = 1.6 ug/ml; Detection = 0.1 ug/ml; Sample dilution = 1:500; 2. Coating = 4.0 ug/ml; Detection = 0.1 ug/ml; Sample dilution = 1:500; 3. 
Coating = 1.6 ug/ml; Detection = 0.8 ug/ml; Sample dilution = 1:50; 4. Coating = 4.0 ug/ml; Detection = 1.0 ug/ml; Sample dilution = 1:50;  
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Median serum concentrations of IgG against tcdA and tcdB were found to be 
significantly lower in patients suffering from severe CDI compared to those with 
mild disease (31,615 versus 49,031 ECL units (p<0.01) & 16,051 versus 21,313 
ECL units (p=0.04), respectively; Tables 8.2 & 8.4). Similarly, medium serum 
concentration of IgM against cdtB-pre was significantly lower in patients whose 
symptoms lasted ≥10 days compared to those patients with symptoms ≤9 days 
(503 versus 696 ECL units (p=0.01); Tables 8.3 & 8.5). In relation to disease 
recurrence, median serum concentration of IgM against tcdB was significantly 
lower in patients experiencing disease recurrence within 90 days compared to 
non-recurrent patients (4,625 versus 5,653 ECL units (p=0.04); Tables 8.2 & 
8.6). 
 
Table 8.4 - Percentile analysis of immunoglobulin G response to 
Clostridium difficile toxins A and B: severe versus non-severe cases 
IgG/tcdA 
Severe 
(n=126) 
Non-severe 
(n=180) 
Adjusted P-
valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
37 
 
39 
 
- 
 
- 
Medium-High 22 54 0.52 1.25 (0.63-2.48) 
Medium-Low 26 51 <0.01 2.80 (1.43-5.45) 
Low 41 36 0.01 2.33 (1.19-4.55) 
 
Global p-value < 0.01 
 
IgG/tcdB 
Severe 
(n=126) 
Non-severe 
(n=180) 
Adjusted P-
valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
40 
 
35 
 
- 
 
- 
Medium-High 24 52 0.53 1.24 (0.63-2.42) 
Medium-Low 28 49 0.13 1.67 (0.87-3.24) 
Low 34 44 0.01 2.48 (1.28-4.81) 
 
Global p-value = 0.04 
 
n: number; OR: odds ratio; CI: confidence interval; IgG: Immunoglobulin G; tcdA: toxin A; tcdB: 
toxin B; a P-value and ORs remain unadjusted as no assessed covariates were found to be 
significant 
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Table 8.5 - Percentile analysis of immunoglobulin M response to 
Clostridium difficile binary toxin B-precursor: ≥10 versus ≤9 days of 
symptoms 
IgM/cdtB-pre 
≥10 days 
(n=164) 
≤9 days 
(n=111) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
36 
 
30 
 
- 
 
- 
Medium-High 33 38 0.35 0.72 (0.37-1.42) 
Medium-Low 48 20 0.06 2.00 (0.98-4.08) 
Low 47 23 0.13 1.70 (0.85-3.41) 
 
Global p-value = 0.01 
 
n: number; OR: odds ratio; CI: confidence interval; IgM: Immunoglobulin M; cdtB-pre: binary toxin 
B-precursor; a P-values and ORs were unadjusted as no assessed covariates were found to be 
significant; 
 
Table 8.6 - Percentile analysis of immunoglobulin M response to 
Clostridium difficile toxin B: recurrence within 90 days versus non-
recurrence 
IgM/tcdB 
Recurrence 
(n=77) 
Non-recurrence 
(n=135) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
19 
 
36 
 
- 
 
- 
Medium-High 15 38 0.97 0.98 (0.42-2.31) 
Medium-Low 16 36 0.71 0.85 (0.36-1.98) 
Low 27 25 0.03 2.48 (1.09-5.61) 
 
Global p-value = 0.04 
 
n: number; OR: odds ratio; CI: confidence interval; IgM: Immunoglobulin M; tcdB: toxin B; a P-
values and ORs were all adjusted for age; 
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Although median serum concentrations of both IgG and IgM against all tested 
toxin epitopes were generally lower in those patients experiencing an 
unfavourable CDI outcome compared to those not, no further associations were 
identified (Tables 8.7-8.14). Furthermore, no significant differences in median 
levels were identified between CDI cases and non-infected AAD controls across 
any of the toxin epitopes tested (Tables 8.15 & 8.16). 
 
Table 8.7 - Percentile analysis of immune response to C. diff toxins A and 
B: severe versus non-severe cases 
IgM/tcdA 
Severe 
(n=125) 
Non-severe 
(n=175) 
Adjusted P-
value 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
34 
 
41 
 
- 
 
- 
Medium-High 26 49 0.32 1.40 (0.73-2.71) 
Medium-Low 32 43 0.24 1.48 (0.77-2.86) 
Low 33 42 0.18 1.56 (0.81-3.02) 
 
Global p-value = 0.55 
 
IgM/tcdB 
Severe 
(n=125) 
Non-severe 
(n=175) 
Adjusted P-
value 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
34 
 
41 
 
- 
 
- 
Medium-High 32 43 0.40 0.76 (0.39-1.46) 
Medium-Low 27 48 1.00 1.00 (0.52-1.91) 
Low 32 43 0.74 1.11 (0.59-2.12) 
 
Global p-value = 0.69 
 
CI: confidence interval; IgG: Immunoglobulin G; IgM: Immunoglobulin M; n: number; OR: odds 
ratio; tcdA: toxin A; tcdB: toxin B; 
P-value and ORs remain unadjusted as no assessed covariates were found to be significant 
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Table 8.8 - Percentile analysis of immune response to C. diff binary toxin 
analytes A and B-precursor: severe versus non-severe cases 
IgG/cdtA 
Severe 
(n=116) 
Non-severe 
(n=173) 
Adjusted P-
value 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
31 
 
40 
 
- 
 
- 
Medium-High 20 52 0.04 2.09 (1.05-4.17) 
Medium-Low 33 41 0.04 2.08 (1.04-4.17) 
Low 32 40 0.05 2.02 (1.00-4.05) 
 
Global p-value = 0.11  
 
IgG/cdtB-pre 
Severe 
(n=119) 
Non-severe 
(n=174) 
Adjusted P-
value 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
31 
 
42 
 
- 
 
- 
Medium-High 28 45 0.56 0.82 (0.42-1.61) 
Medium-Low 25 49 0.24 1.48 (0.77-2.86) 
Low 35 38 0.61 1.19 (0.61-2.30) 
 
Global p-value = 0.35 
 
IgM/cdtA 
Severe 
(n=116) 
Non-severe 
(n=173) 
Adjusted P-
value 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
28 
 
43 
 
- 
 
- 
Medium-High 25 48 0.21 1.54 (0.79-3.00) 
Medium-Low 32 40 0.31 1.42 (0.73-2.77) 
Low 31 42 0.52 1.25 (0.63-2.46) 
 
Global p-value = 0.62 
 
IgM/cdtB-pre 
Severe 
(n=119) 
Non-severe 
(n=174) 
Adjusted P-
value 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
32 
 
41 
 
- 
 
- 
Medium-High 26 47 0.54 1.23 (0.63-2.40) 
Medium-Low 30 44 0.39 1.33 (0.69-2.60) 
Low 31 42 0.31 1.41 (0.73-2.75) 
 
Global p-value = 0.76 
 
cdtA: binary toxin A; cdtB-pre: binary toxin B-precursor; CI: confidence interval; IgG: 
Immunoglobulin G; IgM: Immunoglobulin M; n: number; OR: odds ratio;  
P-value and OR remain unadjusted as no assessed covariates were found to be significant  
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Table 8.9 - Percentile analysis of immune response to C. diff toxins A and 
B: duration of symptoms ≥10 days versus ≤9 days 
IgG/tcdA 
≥10 days 
(n=174) 
≤9 days 
(n=114) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
38 
 
31 
 
- 
 
- 
Medium-High 42 32 0.84 1.07 (0.55-2.07) 
Medium-Low 47 27 0.31 1.42 (0.73-2.78) 
Low 47 24 0.18 1.60 (0.81-3.16) 
 
Global p-value = 0.47 
 
IgG/tcdB 
≥10 days 
(n=174) 
≤9 days 
(n=114) 
Adjusted 
P-value 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
41 
 
27 
 
- 
 
- 
Medium-High 45 30 0.97 0.99 (0.51-1.93) 
Medium-Low 46 31 0.95 0.98 (0.50-1.90) 
Low 42 26 0.86 1.06 (0.53-2.12) 
 
Global p-value = 1.00 
 
IgM/tcdA 
≥10 days 
(n=169) 
≤9 days 
(n=113) 
Adjusted 
P-value 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
39 
 
29 
 
- 
 
- 
Medium-High 45 30 0.75 1.12 (0.57-2.17) 
Medium-Low 41 27 0.73 1.13 (0.57-2.24) 
Low 44 27 0.58 1.21 (0.62-2.39) 
 
Global p-value = 0.96 
 
IgM/tcdB 
≥10 days 
(n=168) 
≤9 days 
(n=114) 
Adjusted 
P-value 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
41 
 
25 
 
- 
 
- 
Medium-High 42 30 0.65 0.85 (0.43-1.69) 
Medium-Low 40 32 0.43 0.76 (0.39-1.51) 
Low 45 27 0.96 1.02 (0.51-2.03) 
 
Global p-value = 0.81 
 
cdtA: binary toxin A; cdtB-pre: binary toxin B-precursor; CI: confidence interval; IgG: 
Immunoglobulin G; IgM: Immunoglobulin M; n: number; OR: odds ratio;  
P-values and ORs remain unadjusted as no assessed covariates were found to be significant 
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Table 8.10 - Percentile analysis of immune response to C. diff binary toxin 
analytes A and B-precursor: duration of symptoms ≥10 days versus ≤9 
days 
IgG/cdtA 
≥10 days 
(n=163) 
≤9 days 
(n=108) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
42 
 
26 
 
- 
 
- 
Medium-High 37 30 0.34 0.71 (0.36-1.43) 
Medium-Low 40 27 0.62 0.84 (0.41-1.69) 
Low 44 25 0.98 1.01 (0.50-2.04) 
 
Global p-value = 0.73 
 
IgG/cdtB-pre 
≥10 days 
(n=164) 
≤9 days 
(n=111) 
Adjusted 
P-valueb 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
31 
 
31 
 
- 
 
- 
Medium-High 44 27 0.08 1.95 (0.93-4.06) 
Medium-Low 45 27 0.05 2.08 (1.00-4.34) 
Low 44 26 0.10 1.86 (0.89-3.86) 
 
Global p-value = 0.19 
 
IgM/cdtA 
≥10 days 
(n=163) 
≤9 days 
(n=108) 
Adjusted 
P-valuec 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
37 
 
31 
 
- 
 
- 
Medium-High 42 27 0.45 1.30 (0.66-2.57) 
Medium-Low 40 30 0.75 1.12 (0.57-2.19) 
Low 44 20 0.09 1.84 (0.90-3.76) 
 
Global p-value = 0.37 
 
cdtA: binary toxin A; cdtB-pre: binary toxin B-precursor; CI: confidence interval; IgG: 
Immunoglobulin G; IgM: Immunoglobulin M; n: number; OR: odds ratio;  
P-values and ORs were adjusted for: a Age; b Presence of ribotype 027; c Unadjusted as no assessed 
covariates were found to be significant; 
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Table 8.11 - Percentile analysis of immune response to C. diff toxins A and 
B: recurrence within 90 days versus non-recurrence 
IgG/tcdA 
Recurrence 
(n=82) 
Non-recurrence 
(n=136) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
19 
 
36 
 
- 
 
- 
Medium-High 19 39 0.95 1.03 (0.46-2.31) 
Medium-Low 24 29 0.23 1.65 (0.74-3.71) 
Low 20 32 0.38 1.45 (0.64-3.31) 
 
Global p-value = 0.53 
 
IgG/tcdB 
Recurrence 
(n=82) 
Non-recurrence 
(n=136) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
19 
 
40 
 
- 
 
- 
Medium-High 23 33 0.16 1.78 (0.80-3.96) 
Medium-Low 18 37 0.59 1.25 (0.55-2.84) 
Low 22 26 0.06 2.21 (0.96-5.11) 
 
Global p-value = 0.24 
 
IgM/tcdA 
Recurrence 
(n=77) 
Non-recurrence 
(n=135) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
15 
 
44 
 
- 
 
- 
Medium-High 24 27 0.03 2.49 (1.08-5.74) 
Medium-Low 17 39 0.95 1.03 (0.44-2.39) 
Low 21 25 0.13 1.92 (0.82-4.51) 
 
Global p-value = 0.07 
 
CI: confidence interval; IgG: Immunoglobulin G; IgM: Immunoglobulin M; n: number; OR: odds 
ratio; tcdA: toxin A; tcdB: toxin B; 
P-values and ORs were adjusted for a age; 
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Table 8.12 - Percentile analysis of immune response to C. diff binary toxin 
A and B-precursor: recurrence within 90 days versus non-recurrence 
IgG/cdtA 
Recurrence 
(n=77) 
Non-recurrence 
(n=126) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
 16 
 
36 
 
- 
 
- 
Medium-High 17 34 0.88 0.94 (0.40-2.22) 
Medium-Low 26 29 0.22 1.68 (0.73-3.85) 
Low 18 27 0.44 1.41 (0.59-3.37) 
 
Global p-value = 0.45 
 
IgG/cdtB-pre 
Recurrence 
(n=77) 
Non-recurrence 
(n=129) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
18 
 
32 
 
- 
 
- 
Medium-High 22 33 0.63 1.22 (0.54-2.79) 
Medium-Low 23 33 0.61 1.24 (0.55-2.81) 
Low 14 31 0.76 0.87 (0.36-2.11) 
 
Global p-value = 0.82 
 
IgM/cdtA 
Recurrence 
(n=77) 
Non-recurrence 
(n=126) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
14 
 
36 
 
- 
 
- 
Medium-High 20 36 0.47 1.37 (0.58-3.24) 
Medium-Low 21 28 0.44 1.41 (0.59-3.38) 
Low 22 26 0.26 1.65 (0.69-3.94) 
 
Global p-value = 0.73 
 
IgM/cdtB-pre 
Recurrence 
(n=77) 
Non-recurrence 
(n=129) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
16 
 
35 
 
- 
 
- 
Medium-High 21 34 0.34 1.50 (0.65-3.48) 
Medium-Low 20 35 0.91 1.05 (0.45-2.43) 
Low 20 25 0.49 1.35 (0.57-3.21) 
 
Global p-value = 0.73 
 
cdtA: binary toxin A; cdtB-pre: binary toxin B-precursor; CI: confidence interval; IgG: 
Immunoglobulin G; IgM: Immunoglobulin M; n: number; OR: odds ratio;  
P-values and ORs were adjusted for a age; 
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Table 8.13 - Percentile analysis of immune response to C. diff toxins A and 
B: death within 30 days versus survival 
IgG/tcdA 
Death 
(n=26) 
Survival 
(n=277) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
7 
 
68 
 
- 
 
- 
Medium-High 5 72 0.79 0.84 (0.22-3.20) 
Medium-Low 8 69 0.69 1.29 (0.37-4.51) 
Low 6 68 0.81 1.17 (0.34-4.05) 
 
Global p-value = 0.93 
 
IgG/tcdB 
Death 
(n=26) 
Survival 
(n=277) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
8 
 
67 
 
- 
 
- 
Medium-High 6 71 0.62 0.71 (0.19-2.72) 
Medium-Low 9 69 0.53 1.45 (0.45-4.66) 
Low 3 70 0.60 0.67 (0.16-2.94) 
 
Global p-value = 0.65 
 
IgM/tcdA 
Death 
(n=26) 
Survival 
(n=271) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
3 
 
72 
 
- 
 
- 
Medium-High 8 66 0.16 2.84 (0.67-12.14) 
Medium-Low 7 68 0.94 1.07 (0.21-5.54) 
Low 8 65 0.17 2.73 (0.64-11.59) 
 
Global p-value = 0.28 
 
IgM/tcdB 
Death 
(n=26) 
Survival 
(n=271) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
5 
 
70 
 
- 
 
- 
Medium-High 6 69 0.43 1.77 (0.43-7.29) 
Medium-Low 8 67 0.34 2.02 (0.48-8.46) 
Low 7 65 0.16 2.72 (0.67-11.07) 
 
Global p-value = 0.58 
 
CI: confidence interval; IgG: Immunoglobulin G; IgM: Immunoglobulin M; n: number; OR: odds 
ratio; tcdA: toxin A; tcdB: toxin B; 
P-values and ORs were adjusted for a age, body mass index, score on the Charlson Comorbidity 
Index (exclusive of age) and disease severity at baseline  
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Table 8.14 - Percentile analysis of immune response to C. diff binary toxin 
A and B-precursor: death within 30 days versus non-death 
IgG/cdtA 
Death 
(n=25) 
Non-death 
(n=261) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
4 
 
67 
 
- 
 
- 
Medium-High 9 65 0.42 1.76 (0.45-6.95) 
Medium-Low 6 66 0.96 1.04 (0.24-4.52) 
Low 6 63 0.48 1.64 (0.42-6.50) 
 
Global p-value = 0.78 
 
IgG/cdtB-pre 
Death 
(n=25) 
Non-death 
(n=265) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
9 
 
63 
 
- 
 
- 
Medium-High 7 67 0.76 0.83 (0.25-2.76) 
Medium-Low 4 69 0.51 0.63 (0.16-2.46) 
Low 5 66 0.49 0.62 (0.16-2.39) 
 
Global p-value = 0.88 
 
IgM/cdtA 
Death 
(n=25) 
Non-death 
(n=261) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
6 
 
67 
 
- 
 
- 
Medium-High 5 66 0.76 1.25 (0.30-5.20) 
Medium-Low 6 67 0.91 1.08 (0.26-4.51) 
Low 8 61 0.51 1.59 (0.40-6.28) 
 
Global p-value = 0.90 
 
IgM/cdtB-pre 
Death 
(n=25) 
Non-death 
(n=265) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
4 
 
69 
 
- 
 
- 
Medium-High 6 67 0.32 2.17 (0.47-9.99) 
Medium-Low 7 66 0.22 2.53 (0.58-11.01) 
Low 8 63 0.35 2.01 (0.46-8.75) 
 
Global p-value = 0.66 
 
cdtA: binary toxin A; cdtB-pre: binary toxin B-precursor; CI: confidence interval; IgG: 
Immunoglobulin G; IgM: Immunoglobulin M; n: number; OR: odds ratio;  
P-values and ORs were adjusted for a age, body mass index, score on the Charlson Comorbidity 
Index (exclusive of age) and disease severity at baseline 
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Table 8.15 - Percentile analysis of immune response to C. diff toxins A and 
B: CDI cases versus non-colonised AAD controls 
IgG/tcdA 
CDI cases 
(n=306) 
AAD controls 
(n=142) 
Adjusted P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
78 
 
34 
 
- 
 
- 
Medium-High 78 34 0.89 1.04 (0.57-1.90) 
Medium-Low 76 36 0.60 0.85 (0.47-1.55) 
Low 74 38 0.50 0.82 (0.45-1.47) 
 
Global p-value = 0.82 
 
IgG/tcdB 
CDI cases 
(n=306) 
AAD controls 
(n=142) 
Adjusted P-valueb 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
83 
 
29 
 
- 
 
- 
Medium-High 70 42 0.05 0.55 (0.30-1.01) 
Medium-Low 74 38 0.22 0.68 (0.37-1.25) 
Low 79 33 0.63 0.86 (0.46-1.59) 
 
Global p-value = 0.23 
 
IgM/tcdA 
CDI cases 
(n=300) 
AAD controls 
(n=136) 
Adjusted P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
70 
 
39 
 
- 
 
- 
Medium-High 73 36 0.99 1.01 (0.55-1.83) 
Medium-Low 77 32 0.62 1.17 (0.64-2.14) 
Low 80 29 0.33 1.36 (0.73-2.53) 
 
Global p-value = 0.75 
 
IgM/tcdB 
CDI cases 
(n=300) 
AAD controls 
(n=137) 
Adjusted P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
82 
 
27 
 
- 
 
- 
Medium-High 69 41 0.12 0.62 (0.34-1.14) 
Medium-Low 77 32 0.68 0.88 (0.47-1.65) 
Low 72 37 0.31 0.73 (0.39-1.35) 
 
Global p-value = 0.43 
 
AAD: Antibiotic-associated diarrhea; CDI: Clostridium difficile infection; CI: confidence interval; 
IgG: Immunoglobulin G; IgM: Immunoglobulin M; n: number; OR: odds ratio; tcdA: toxin A; tcdB: 
toxin B;  
P-values and ORs were all adjusted for: a age, body mass index, time delay between testing positive 
& recruitment and presence of diabetes; b age, body mass index, time delay between testing positive 
& recruitment and presence of diabetes and immunosuppression; 
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Table 8.16 - Percentile analysis of immune response to C. diff binary toxin 
A and B-precursor: CDI cases versus non-colonised AAD controls 
IgG/cdtA 
CDI cases 
(n=289) 
AAD controls 
(n=132) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
80 
 
25 
 
- 
 
- 
Medium-High 71 35 0.10 0.58 (0.31-1.10) 
Medium-Low 67 38 0.04 0.51 (0.27-0.96) 
Low 71 34 0.20 0.66 (0.35-1.25) 
 
Global p-value = 0.19 
 
IgG/cdtB-pre 
CDI cases 
(n=293) 
AAD controls 
(n=134) 
Adjusted 
P-valueb 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
78 
 
29 
 
- 
 
- 
Medium-High 66 41 0.13 0.66 (0.34-1.15) 
Medium-Low 76 31 0.88 0.95 (0.51-1.78) 
Low 73 33 0.70 0.89 (0.47-1.65) 
 
Global p-value = 0.39 
 
IgM/cdtA 
CDI cases 
(n=289) 
AAD controls 
(n=132) 
Adjusted 
P-valuea 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
76 
 
29 
 
- 
 
- 
Medium-High 67 39 0.36 0.75 (0.40-1.39) 
Medium-Low 72 33 0.43 0.77 (0.41-1.47) 
Low 74 31 0.71 0.88 (0.46-1.67) 
 
Global p-value = 0.79 
 
IgM/cdtB-pre 
CDI cases 
(n=293) 
AAD controls 
(n=134) 
Adjusted 
P-valueb 
Adjusted OR 
(95% CI) 
 
High (Comparator) 
 
78 
 
29 
 
- 
 
- 
Medium-High 69 38 0.41 0.77 (0.42-1.42) 
Medium-Low 72 36 0.41 0.77 (0.42-1.43) 
Low 74 31 0.63 0.86 (0.45-1.62) 
 
Global p-value = 0.82 
 
AAD: Antibiotic-associated diarrhea; CDI: Clostridium difficile infection; cdtA: binary toxin A; cdtB-
pre: binary toxin B-precursor; CI: confidence interval; IgG: Immunoglobulin G; IgM: 
Immunoglobulin M; n: number; OR: odds ratio; 
P-values and ORs were all adjusted for: a age, body mass index and time delay between testing 
positive and subsequent recruitment; b age, body mass index, time delay between testing positive 
and subsequent recruitment and diabetes;  
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Interestingly, the presence/absence of a binary toxin-producing strain 
produced no significant effects on immune response (Table 8.17). Advanced 
age, using a previously defined cut-off of ≥65 years (Bauer et al., 2011; Kyne et 
al., 2001; Pepin et al., 2005), displayed a moderate effect on overall response 
levels, however the trend was not consistent for all measures (Table 8.17). 
After adjusting data for differences in coating, detection and sample dilution 
factors, observed signals were still significantly higher for IgG compared to IgM, 
and this was consistent across all tested toxin components. In general, antibody 
response to tcdA was higher than that of tcdB, and a high degree of correlation 
was observed between their antibody responses (Figure 8.1). For the tested 
binary toxin components, IgG response was comparable though measurements 
for IgM response was slightly higher against cdtA, and as with the tcdA and tcdB 
toxins there was a significant degree of concurrence between the antibody 
responses to both cdtA and cdtB-pre (Figure 8.1). Correlation of cdtA and cdtB 
with either tcdA or tcdB toxins was less pronounced and was not consistent 
across all combinations (Figure 8.1).  
 
Table 8.17 - Assessing the impact of increased age and presence of a 
binary toxin-producing strain on immune response to C. diff toxins 
 Age ≥65 yrs 
Binary 
toxin-producing strain 
 No (n=97) Yes (n=210) P-value No (n=159) Yes (n=122) P-value 
IgG/tcdA 44,571 42,305 0.60 38,890 44,607 0.95 
IgG/tcdB 16,900 20,280 0.29 19,286 17,718 0.66 
IgM/tcdA 26,844 18,830 <0.01 22,092 20,124 0.87 
IgM/tcdB 5,280 5,158 0.97 4,655 5,609 0.28 
IgG/cdtA 806 626 0.03 700 626 0.69 
IgG/cdtB-pre 1,626 1,778 0.39 1,658 1,778 0.44 
IgM/cdtA 548 343 <0.01 404 403 0.58 
IgM/cdtB-pre 746 504 <0.01 554 557 0.75 
cdtA: binary toxin A; cdtB-pre: binary toxin B-precursor; IgG: Immunoglobulin G; IgM: 
Immunoglobulin M; tcdA: toxin A; tcdB: toxin B; 
268 
 
 
 
IgG/tcdA 
       
        IgG/tcdA 
  
IgG/tcdB 
        
      IgG/tcdB 
R = 0.45   
IgM/tcdA 
     P < 0.01   
     IgM/tcdA 
R = 0.29 R = 0.18   
IgM/tcdB 
    P < 0.01 P < 0.01   
    IgM/tcdB 
R = 0.21 R = 0.52 R = 0.34   
IgG/cdtA 
   P < 0.01 P < 0.01 P < 0.01   
   IgG/cdtA 
R = 0.19 R = 0.01 R = 0.18 R = 0.02   
IgG/cdtB-pre 
  P < 0.01 P = 0.86 P < 0.01 P = 0.76   
  IgG/cdtB-pre 
R = 0.44 R = 0.24 R = 0.06 R = 0.14 R = 0.45   
IgM/cdtA 
 P < 0.01 P < 0.01 P = 0.34 P < 0.05 P < 0.01   
 IgM/cdtA 
R = 0.22 R = 0.09 R = 0.39 R = 0.07 R = 0.29 R = 0.23   IgM/cdtB-
pre P < 0.01 P = 0.15 P < 0.01 P = 0.24 P < 0.01 P < 0.01   
IgM/cdtB-pre 
R = 0.06 R = 0.05 R = 0.14 R = 0.08 R = 0.53 R = 0.73 R = 0.37   
P = 0.34 P = 0.43 P < 0.05 P = 0.17 P < 0.01 P < 0.01 P < 0.01   
 
Figure 8.1 – Overview of correlation across Clostridium difficile toxin epitopes 
cdtA: C. diff binary toxin A; cdtB-pre: C. diff binary toxin B precursor; IgG: Immunoglobulin G; IgM: Immunoglobulin M; tcdA: C. diff toxin A; tcdB: C. diff tox in B;  
Correlation calculated using Pearsons Correlation Coefficient (R); Colour coding: Darker green = Positive correlation within toxin group; Lighter green = Positive 
correlation across toxin groups: Pale blue = Weak correlation 
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8.3.3 Power calculations 
Across all toxin epitopes and disease outcomes assessed, power to detect a 
significant difference was calculated as ≥90% for 30/40 (75%) of the analyses 
(Table 8.18). Inadequate power (<80%) was observed in 7/40 (18%), the 
majority of which (4/7; 57%) arose from Case versus Control analyses. 
 
Table 8.18 - Assessment of power across outcome analyses 
Disease outcome 
Percentage power achieved 
(Number needed in each group to achieve 80% power) 
tcdA 
IgG 
tcdB 
IgG 
tcdA 
IgM 
tcdB 
IgM 
cdtA 
IgG 
cdtB-pre 
IgG 
cdtA 
IgM 
cdtB-pre 
IgM 
Case versus control 99 6a 99 8b 99 99 47c 5d 
30-day mortality 40e 22f 99 89 * 99 98 96 
Prolonged symptoms 99 99 99 99 92 99 99 99 
90-day recurrence 99 84 32g 99 99 93 99 99 
Disease severity 99 99 99 99 99 99 99 99 
cdtA: binary toxin A; cdtB-pre: binary toxin B-precursor; IgG: Immunoglobulin G; IgM: 
Immunoglobulin M; tcdA: toxin A; tcdB: toxin B; * No difference was observed between the two 
median values and therefore retrospective power could not be estimated;  
In order to achieve 80% power, the following number of patients would be needed in each group: a 
13,345; b 5,290; c 127; d 27,692; e 264; f 394; g 333; 
 
8.3.4 Time delay stratification 
Though the median time delay between testing positive and subsequent 
recruitment across our CDI patients was 3.0 days (Chapter 7: Section 7.3.1), a 
small number (n=18) were recruited ≥7 days post-testing positive for C. diff. 
These patients were found to have an increased IgG and IgM response to all C. 
diff toxin epitopes compared to those with a time delay <7 days (n=290), which 
reached significance (p<0.05) for IgG response against tcdB and both IgG and 
IgM responses against cdtB-pre; Figures 8.2 & 8.3). 
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Figure 8.2 – Immune response levels to C. diff tcdA and tcdB toxins after 
time delay stratification (* = P<0.05) 
 
 
 
 
Figure 8.3 – Immune response levels to C. diff binary toxin components 
after time delay stratification (* = P<0.05) 
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8.4 Discussion 
This study represents the first to have quantified the immune response to both 
the glucosylating toxins and binary toxin of C. diff, using a large, well-
characterised and stringently-phenotyped set of individuals. Immune response 
was quantified using a novel in-house ECL-based method (described in detail in 
Chapter 6), which attempted to provide more clarity where previously used 
ELISA-based methods were lacking. Furthermore, stringent analysis 
methodology was employed to assess multiple covariates across all CDI patients 
for each outcome analysis. 
Anti-toxin immune response in a non-colonised control group suffering from 
antibiotic-associated diarrhoea was found to be very similar to that of the CDI 
patients, which is in line with previous research (Jiang et al., 2007; Viscidi et al., 
1983; Warny et al., 1994) and indicates a significant level of prior exposure. It is 
therefore likely that the immune response being measured here relates 
predominantly to pre-existing immunity mounted over time rather than a sole 
result from the current infectious episode. Conversely, associations were 
identified between lower anti-tcdA and anti-tcdB IgG titres and severe disease 
(assessed at baseline), which is consistent with previous research 
demonstrating a protective role of high serum anti-toxin IgG in severe CDI in 
animals (Johnson, 2012; Steele et al., 2012). Minor associations were also 
identified between lower anti-tcdB & anti-cdtB-pre IgM titres and disease 
recurrence & prolonged disease, respectively. 
Although anti-toxin immune titres were generally lower in patients 
experiencing an unfavourable CDI outcome compared to those not, no further 
associations were identified across all investigated disease outcomes and toxin 
epitopes. Therefore, despite the minor associations highlighted above, this 
study failed to confirm previous claims for associations between anti-toxin 
immune response and either disease recurrence (Aronsson et al., 1985; Bauer 
et al., 2014; Kyne et al., 2001; Warny et al., 1994), prolonged symptoms (Warny 
et al., 1994), or mortality (Solomon et al., 2013). It is important to note that 
previous findings were identified using longitudinal sampling with samples 
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taken either at regimented post-diagnosis time points, or during allegedly acute 
(typically within 1-2 weeks post-diagnosis) and/or convalescent phases 
(anything thereafter). Consistent with our findings using only one baseline 
time-point, these previous studies also failed to identify any significant 
associations using baseline/acute samples only. The sole study to date to 
identify an association using baseline sampling did so by stratifying based upon 
IgG antibody sub-classes (Katchar et al., 2007). 
It can therefore be implied that a lack of longitudinal sampling has resulted in 
the failure to detect potential milestones in patients’ immune response 
trajectory resulting from their current infection. This concept has been 
strengthened based on examination of immune responses following 
stratification for the time delay, which occurred between positive diagnosis and 
patient recruitment/sampling, whereby those patients with a significantly 
longer time delay (≥7 days; n=18) displayed considerably higher IgG and IgM 
anti-toxin levels than patients with a time delay inferior to 7 days (Figures 8.2 & 
8.3). This suggests the existence of a boost in the immune response arising from 
current infection, thus lending further weight for the undertaking of 
longitudinal sampling. Notably, the elevation in the anti-toxin IgG & IgM 
responses was not observed following data analysis of the mannose-binding 
lectin (MBL) assay, described in Chapter 6. Therefore it is possible this rise may 
be restricted to the adaptive immune system rather than the innate immune 
system. 
This study also suffers from further limitations. The lack of an appropriate 
control group comprising asymptomatic carriers meant that it was not possible 
to investigate the role of the immune response in disease susceptibility due to 
the complexity of selectively recruiting these individuals. Secondly, for ethical 
reasons, patients that were medically very unwell could not be approached to 
join the study and as such it is possible that the immune response of these 
individuals would have differed from that found in our recruits. Thirdly, this 
study did not investigate the role of non-toxin antigens, antibody sub-classes, 
nor immunoglobulin A (IgA) response. Previous research has demonstrated 
that host response to non-toxin antigens may play a comparable role to the ones 
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induced by the toxins (Drudy et al., 2004; Péchiné et al., 2007) and that 
associations can be stratified based on specific antibody sub-classes (Katchar et 
al., 2007). Furthermore, despite initial flat findings for IgA, a recent study 
identified an association between disease susceptibility and lower pre-existing 
IgA titres against tcdB (Islam et al., 2014). Fourthly, the purified tcdA and tcdB 
aliquots were derived from reference strain vpi10463, and owing to probable 
functional differences specific to strain families (Lanis et al., 2010), it is possible 
that antibody levels measured using tcdB derived from vpi10463 may not 
reproduce accurate antibody measurements against the actual infecting strain. 
Unlike for tcdA and tcdB, there are currently no established methods to purify 
binary toxin from C. diff bacterial culture. Therefore recombinant binary toxin 
was used, which may or may not have the same biological properties as native 
binary toxins. Finally, despite employing the largest cohort size to date, the 
large degree of heterogeneity present within CDI-suffering patients means it is 
likely our study suffers from a lack of a power. 
The importance of anti-toxin antibodies in regulating disease susceptibility, 
severity and poor disease outcome is highlighted by the number of 
experimental CDI vaccines under development. The finding that lower anti-
toxin IgG titres result in severe disease advocates a prominent need for 
mounting a competent immune response to these toxins, in order to deter 
disease progression. Furthermore, it supports the use of active and passive 
immunotherapies for CDI management, whilst emphasising that neither toxin A 
nor toxin B can be downgraded in terms of importance. The finding that a lower 
IgM titre to the binary toxin precursor component B results in prolonged 
disease provides further evidence for the importance of binary toxin as an 
adjuvant virulence factor of C. diff, consistent with previous research 
demonstrating CDT-induced formation of microtubule-based protrusions that 
increase adherence of bacteria (Schwan et al., 2009). Pharmaceutical companies 
have been considering a potential need for its incorporation into novel 
therapeutic research. 
Future work should focus on further improvements of the quantification 
methodology with stratification for further immunoglobulin sub-classes, 
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combined with longitudinal sampling of larger, well-phenotyped patient 
cohorts to gain further understanding of the role of the adaptive immune 
system in mediating susceptibility and modulation of CDI. The use of 
hypothesis-free approaches for the identification of non-toxin immunogenic 
candidates is also warranted. 
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Chapter 9 
Final discussion  
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CDI is now regarded as the major cause of PMC, accounting for 15-39% of all 
cases of AAD (Dubberke and Wertheimer, 2009; McFarland, 2009; Viswanathan 
et al., 2010). Symptomatic patients exhibit a broad range of clinical 
manifestations, from mild, watery diarrhoea to life-threatening fulminant PMC 
that can lead to severe complications, including toxic megacolon, septic shock 
and death (Rupnik et al., 2009). The disease continues to be a major burden on 
healthcare facilities worldwide (Ghantoji et al., 2010; Wiegand et al., 2012).  A 
significant proportion of patients (5-50%) suffer from disease recurrence post-
treatment (Aslam et al., 2005), and the pooled attributable mortality has risen 
from 3.64% to 8.03% since the emergence of the last wave of epidemic strains 
between 2000-2009 (Dubberke et al., 2008; Karas et al., 2010; Kuijper et al., 
2006). More worryingly, patient recovery can be a very slow process for a 
significant proportion of patients, until the balance of their gut microbiota has 
been re-established.  Hospitals and healthcare systems have begun adopting 
specific policies and treatment regimens, and distinct standards exist for 
community identified cases (see Chapter 1 Section 1.8). 
Affected patients generally display a range of similar features, including 
advanced age, polypharmacy and comorbidities, as well as a number of 
overlapping symptoms that makes stratification of patients at the start of the 
disease process more complex. Certainly the determination of highly predictive 
disease parameters at an early stage would bring enormous benefits for the 
management of CDI and more cost-effective strategies for tackling recurrence 
and deterring transmission (Johnson, 2009; Louie et al., 2011). It would also 
increase confidence in implementing more aggressive treatment regimens for 
patients that are likely to develop clinical complications (Bauer et al., 2009; 
Cohen et al., 2010), as well as identify cases that may benefit from alternative 
therapies such as fibre supplementation, probiotics and faecal transplantation.  
Although a myriad of clinical variables have been implicated with poor CDI 
outcomes, the majority of previous studies on risk factors did not assess the 
robustness and performance of their models. Moreover, only a small number of 
CPRs have been developed to date (see Chapter 1 Section 1.9) and given the 
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heterogeneity that is evident across studies and the lack of external validation, 
it is not surprise that to date no CPR has gained widespread clinical acceptance.  
In order to identify independent risk predictors for CDI disease outcomes in our 
cohort, data for multiple clinical variables were derived and analysed (Chapter 
3) statistically to assess their performance. Using commonly adopted disease 
outcome measures (recurrence, severe-complicated disease and mortality) and 
a previously uninvestigated outcome (prolonged disease), we identified several 
significant predictors at univariate level, which overlapped with the current 
literature. However, statistical assessment of our models revealed that despite 
their acceptable predictive accuracy, the models were unstable and poorly 
validated in external cohorts. This was denoted by the large confidence 
intervals observed and fluctuations of independent predictors when cross-
validation approaches were employed. As a comparative exercise, I also used 
data from the cohort to assess existing CPRs for prediction of CDI disease 
outcomes. For the CPRs where equivalent information was extractable, it was 
not possible to replicate the findings, despite our sample size being comparable 
with the majority of studies (Bhangu et al., 2010; Butt et al., 2013; Drew and 
Boyle, 2009; Hensgens et al., 2014; Lungulescu et al., 2011). This further 
emphasises the poor external validity of CPRs, and further work, with much 
larger patient cohorts are needed.  
Despite several technological advances, the diagnosis of CDI is still challenging 
because of the broad spectrum of disease presentation. Historically, the 
diagnosis of nosocomial CDI cases has been made through an initial screening 
using C. diff toxin EIAs, which, despite their high PPV, tend to bias the 
identification towards overly symptomatic patients due to their limited 
sensitivity (see Chapter 1 Section 1.6.2). In particular, mild and incipient forms 
of the disease are less likely to be successfully diagnosed. In order to address 
the issue, modern guidelines are now endorsing the use of multi-step diagnostic 
algorithms, through the introduction of more sensitive first stage tests, such as 
the enzymatic detection of GDH and direct PCR from selected C. diff genomic 
targets (see Chapter 1 Section 1.6.6). Their increased sensitivity however also 
means that they cannot be used to definitively establish the diagnosis, since a 
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positive test does not necessarily imply CDI.  Thus, a more specific second test is 
necessary to rule out colonisation by C. diff or asymptomatic carriage. The 
scenario is further compounded by the fact that the vast majority of clinical 
specimens referred for CDI testing come from patients suffering from some sort 
of diarrhoea, which makes an accurate differentiation between true incipient 
cases from simple carriage/colonisation even more difficult. Clearly, the 
existence of selection bias due to the limitations of CDI diagnostic standards has 
had a downstream impact on the recruitment of patients for this, and for the 
majority of previous studies, thereby adding an extra layer of complexity for 
drawing definitive comparisons and replicating findings.  
Much larger sample sizes are clearly required to further elucidate the 
multifactorial basis of CDI.  Therefore, a meta-analysis of previous studies 
would be an extremely valid attempt but this has been severely limited due to 
the considerable heterogeneity observed across studies (Abou Chakra et al., 
2014), which stems from inconsistent outcome definitions, different follow-up 
periods, diagnostic testing methods employed and variables examined. A 
potential robust alternative would be to obtain original/raw data from previous 
studies to facilitate a larger and extensive Individual Patient Data (IPD) meta-
analysis.  This would reduce bias and improve the accuracy and quality of the 
previously reported associations.  In addition, this would allow some 
standardisation in definitions of the outcome measures used, and the follow-up 
periods.   However, this would be a major undertaking and relies on the original 
investigators providing the individual patient data and whether they are 
contactable. 
Biomarker evidence for the outcomes associated with CDI is certainly scarce, 
which is in part due to the lack of comprehensive studies and mechanistic 
understanding of the disease. There is therefore a need to identify robust 
biomarkers that can help in stratifying patients in terms of potential clinical 
outcome, allowing the clinician to define at the beginning the type and intensity 
of treatment to be utilised.  Pro-inflammatory cytokines constitute plausible 
candidates given that they can be released by toxin exposure (Hippenstiel et al., 
2000; Ishida et al., 2004). The SNP rs4073/-251T>A within the gene encoding 
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pro-inflammatory cytokine IL-8 is the only genetic association with CDI that has 
been reported to date, with the AA genotype being shown to increase the odds 
of developing CDI, as well as experiencing recurrent disease, by at least 3-fold 
(Garey et al., 2010; Jiang et al., 2006; Jiang et al., 2007). A replication of this 
finding was undertaken as part of this thesis (Chapter 4). Our data using a 
larger sample size than the original studies, but similar clinical outcome 
definitions, failed to show an association with the IL8 SNP.  A meta-analysis 
combining our data with the published data (Chapter 4), also failed to replicate 
the association.  It therefore seems unlikely that this polymorphism plays a 
major role in CDI risk and recurrence, and the genetic effect size (if any) is 
substantially smaller than previously anticipated.  
Since the increase in secretion of pro-inflammatory cytokines results in 
augmented intestinal inflammation, this study also sought to investigate the 
role of both faecal lactoferrin and calprotectin in CDI.  Tests for FC and FL are 
quite well established in that they are two of the most widely investigated faecal 
biomarkers in IBD.  Given the analogous conditions found in CDI, several 
authors have pursued this area with a number of positive association being 
reported for either marker individually (Archbald-Pannone et al., 2010; Boone 
et al., 2013; El Feghaly et al., 2013; LaSala et al., 2013; Shastri et al., 2008; 
Vaishnavi et al., 2000; Whitehead et al., 2014). Our work focused on 
simultaneous evaluation of both FL and FC, with the aim of assessing their 
clinical importance in patients already suffering from CDI (Chapter 5). Both FL 
and FC were good at differentiating between CDI cases and AAD controls in our 
cohort.  However, there was no association with disease outcomes, indicating 
that both faecal biomarkers have limited applicability for disease stratification. 
Although it is apparent that host intrinsic factors play a major role in both inter-
patient variability and susceptibility to CDI, it is pivotal that future studies 
adopt systematic approaches, larger cohort sizes and a well-defined array of 
phenotypes for the elucidation of mechanistic biomarkers to enable accurate 
prediction of unfavourable clinical outcomes so that more personalised 
interventional strategies can be developed and implemented.  Recently, CDI 
clinical complications have been linked to the cytokine IL-23 (Buonomo et al., 
280 
 
2013) and the peptide precursor to calcitonin PCT (Rao et al., 2013).  However 
both have yet to undergo independent replication.   
As outlined in Chapter 1 Section 1.3, both biochemical and molecular studies 
have shown that the major clinical signs and symptoms of CDI are largely 
explained by the detrimental actions of tcdA and tcdB (Babcock et al., 2006a; 
Kim et al., 1987; Lyerly et al., 1985; Lyras et al., 2009a). Neutralising them, 
either by natural or interventional resources, is therefore important for 
ameliorating symptoms. Indeed, there is growing evidence which shows that an 
adequate anti-toxin immunological response is important in reducing 
complications from the disease (Aronsson et al., 1985; Bauer et al., 2014; Drudy 
et al., 2004; Islam et al., 2014; Johnson et al., 1992; Katchar et al., 2007; Kyne et 
al., 2000a, 2001; Mulligan et al., 1993; Sanchez-Hurtado et al., 2008; Solomon et 
al., 2013; Warny et al., 1994). The recent emergence of so-called “hypervirulent” 
epidemic C. diff strains has accelerated the development of novel non-antibiotic 
based treatment regimes, and led to a stronger emphasis being placed on 
vaccine development and on immunoglobulin therapy against CDI. However, 
this area of research has been hampered by the lack of reliable methods to 
quantitate the pattern of specific immune responses to CDI, especially against 
tcdA and tcdB. This is consistent with ongoing discussions in the international 
community as to whether CDI specific biomarkers simply have yet to be 
discovered, or whether the current methodologies lack the necessary 
robustness for the validation of existing parameters due to their lack of fitness 
surrounding sensitivity, specificity, or reliability. Remarkably, no commercial 
assays are available for the quantitation of the anti-toxin immune response with 
previous research focusing on in-house methods based on traditional ELISA, 
which has several technical limitations. Therefore, one of the aims of the work 
pursued was to develop enhanced quantification assays, through the use of an 
ECL-based platform and a multi-step optimisation process, for measuring both 
IgG and IgM responses to tcdA and tcdB. In addition, novel quantitation assays 
for multiple CDT epitopes were also explored (Chapter 6). The assays 
developed were then taken forward for the evaluation of the IgG and IgM 
immune responses in our cohort of patients, which showed that lower anti-tcdA 
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and -tcdB IgG titres at baseline resulted in more severe disease (Chapter 8). 
This suggests that the the host needs to mount a competent immune response 
to these toxins in order to prevent disease progression. In addition, in situ 
detection of the C. diff binary toxin (cdtA/cdtB) has been attempted (Carman et 
al., 2011) but to the best of our knowledge this is the first study to focus on the 
antibody response to either cdtA, or cdtB. The binary toxin is an adjuvant 
virulence factor expressed by selected toxigenic strains.  Our finding that a 
lower IgM titre to the binary toxin precursor component B predicted a 
prolonged disease course further emphasises the need to better understand the 
biology of this protein, and hence its clinical importance.  Despite the novelty 
and potential benefits of the assays which were developed, it is important to 
emphasise that given the high homology between the toxin epitopes tested 
(especially tcdA and tcdB), it was not possible to rule out cross-reactivity 
between the assays, and how much of the measured response in each assay was 
indeed specific for each tested epitope and isotype. Indeed, since an individual 
antibody response to several antigens tends to correlate with the overall 
immune competence of the host, it is therefore not surprising that we have 
detected a degree of correlation in signal levels across our assays.  Given the 
flexibility offered by our development strategy, further customisation is also 
possible, for example, to investigate antibody sub-classes that may offer 
increased predictability. In this respect, it is interesting to note that one of the 
few associations reported between CDI and immune response using baseline 
samples was achieved through the evaluation of different IgG sub-classes 
(Katchar et al., 2007). Our inability to replicate associations that have been 
reported previously linking anti-toxin host response with disease recurrence, 
mortality and prolonged disease may be related to the limited predictive power 
of these markers, and the fact that we did not have samples at different time 
points during the course of the illness in the patients.  In order to further verify 
our assays and monitor longitudinal changes in the humoral immune response, 
a follow-on study is currently on-going, where patients have sample collections 
at baseline, 2 weeks and 6 weeks.  
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In order to identify other biomarkers, we went onto investigate MBL, a 
potentially interesting CDI biomarker that has been associated with 
susceptibility to several infectious diseases (Chapter 7). MBL is a key pattern 
recognition molecule of the complement system that binds to repetitive sugar 
arrays on several microbial surfaces, albeit not to C. diff (Townsend et al., 2001). 
Low MBL concentrations have been linked with increased susceptibility to 
infections in both animal models and humans (Møller-Kristensen et al., 2006; 
Shi et al., 2004). Equally important are the immunomodulatory properties of 
MBL, in which it acts in concert with major modulators of inflammation, such as 
toll‐like receptors and CRP, both of which have been implicated in CDI (Eyre et 
al., 2012b; Ryan et al., 2011). One of the difficulties in this work was the lack of 
clinical definition surrounding MBL deficiency, where previous studies 
evaluating had differed significantly in both the criteria employed for 
ascertaining genetic and serological deficiency, which resulted in heterogeneity 
across studies. Therefore, we chose to investigate both genotype and 
phenotype, as this approach can identify potential discordance between the 
two. By transferring an existing MBL assay from an ELISA standard onto a more 
robust ECL-based platform, we also sought to maximise serological assay 
performance while at the same time employing a well-established method for 
screening for functional MBL2 genetic polymorphisms (see Appendix 45). We 
were able to demonstrate a significant association between low levels of MBL 
and CDI recurrence, but not with MBL genetic variation (Chapter 7). Other 
studies have also identified associations with protein levels in other infections 
and immune conditions (Chapter 7, Table 7.1) but it has not been possible to 
infer definitive conclusions due to the aforementioned heterogeneity in 
standards across studies.  The mechanistic bases for this association is 
intriguing because MBL does not bind to the surface of C. diff (Townsend et al., 
2001) and thus MBL deficiency per se is unlikely to directly underpin CDI 
predisposition. However, MBL does appear to have other relevant functions that 
can modulate the disease, such as through immunomodulation of inflammation 
and clearance of apoptotic cells (Dommett et al., 2006). In addition, low MBL 
concentrations lead to increased secretion of pro-inflammatory cytokines 
(Garred et al., 2002; Jack et al., 2001b), which have been shown to be elevated 
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in response to CDI (Hirota et al., 2012; Vohra and Poxton, 2012). We have also 
confirmed an inverse correlation between MBL and CRP levels. Since elevated 
CRP concentrations have previously been associated with various CDI 
outcomes, including disease severity and recurrence (Eyre et al., 2012b; 
Khanafer et al., 2013), our findings further endorse a mechanistic relationship 
between MBL and acute conditions. 
It is well known that due to the upsurge of CDI cases in the last decade, 
stringent infection control measures have been introduced, such as revised 
antibiotic prescription policies, opening of isolation wards and improved 
hygiene and cleanliness.  While these measures have had a positive effect and 
must continue, clearly without a better comprehension of the disease 
pathogenesis, evolution and inter-individual variability (both at the host and 
bacterial levels), progress in this area will be hampered. One major factor 
limiting the majority of studies to date is the lack of study power. This has also 
been a major limitation for the work conducted in this thesis. A lack of adequate 
study power means we may have been unable to detect smaller effect sizes, 
something which is extremely important given the large degree of 
heterogeneity present within CDI-suffering patients and the seemingly multi-
factorial nature of the disease. Whilst we were able to demonstrate adequate 
statistical power using a post-hoc power analysis, this technique is seen as 
controversial and can result in uninformative and misleading values: post-hoc 
power in its simplest form is a one-to-one function of the p-value attained, and 
it has been demonstrated that all post-hoc power analyses suffer from the 
"power approach paradox”. The challenging nature of prospective CDI 
recruitment meant we were unable to meet our proposed recruitment targets, 
although these were likely an underestimation. Whilst we employ one of the 
largest prospectively recruited cohorts to date, study power for the clinical risk 
factor work conducted in Chapter 3 could have been achieved through the use 
of retrospective recruitment resulting in a larger patient cohort, although this 
would not have been a possibility for extending study power in the remaining 
experimental chapters pertaining to biomarker assessment. As well as lacking 
study power, our cohort may not be fully representative of the entire disease 
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spectrum, which may have further biased our data analysis. Our prospective 
recruitment method meant that we were unable to recruit the most severe of 
CDI patients, particular those in life threatening conditions, and we only used a 
single laboratory test (ELISA for CDT) for the primary identification of CDI 
cases. Although this is still a common procedure, modern algorithms currently 
make use of a more sensitive first step screening - based on either GDH, or a 
nucleic acid amplification test NAAT - to minimise the odds of reporting false 
negative results.  
A limited understanding of the disease across the research field has also 
produced several negative facets, especially in relation to the lack of 
standardised disease sub-phenotypes.  This has hampered validation of existing 
findings and prevented systematic comparisons across studies. There has also 
been little progress in determining the prognosis of CDI; reliable predictive 
tools that allow for the stratification of patients are needed in order to 
personalise the type and intensity of treatment. Some biomarkers have been 
successfully employed for the categorisation of other clinical conditions, but 
this seems a long way off for CDI.  It is extremely clear that the recruitment of 
extremely large patient cohorts using standardised phenotypes is essential for 
future studies to provide more definitive answers, something which will only be 
achieved through multi-centre international collaboration. 
In summary, the thesis has evaluated some of the clinical and biological features 
associated with CDI, which is a continuing public health problem affecting both 
primary and secondary care.  The genomic technological revolution has helped 
in understanding the disease from the point of view of the organism.  For 
example, some units are beginning to undertake sequence based typing of C. 
diff. However, genomics and other ‘omics’ technologies have not really impacted 
on the effect of infection on the host.  The thesis has evaluated some of these 
issues ranging from the heterogeneity in prediction rules to biological factors 
associated with the host immune response.  There is a need for further study in 
this area, and the underlying message is that these studies need to be conducted 
with greater attention to the sample size and phenotyping of the patients 
recruited to these cohorts, underpinned by mechanistic investigations.   
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1: Characteristics of CDI patients by recurrent versus non-recurrent disease 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) Recurrence (n=83) Non-recurrence (n=137) 
Demographics    
 Age at baseline: per decade 77.5 (66.4-84.7) 69.6 (56.0-77.9) <0.01 1.44 (1.19-1.76) 
 Gender: Female 45/83 (54) 80/137 (58) 0.54 0.84 (0.49-1.46) 
 Smoking pack years: per year increase 5.1 (0.0-35.0) 8.5 (0.0-33.0) 0.66 1.00 (0.99-1.01) 
 Body Mass Index 22.4 (19.4-27.4) 24.7 (21.0-28.3) 0.60 0.99 (0.95-1.03) 
Medication information    
 Number of co-medications at baseline 3.0 (2.0-5.0) 3.0 (2.0-4.0) 0.64 1.04 (0.89-1.20) 
 Taking fluoroquinolones prior to CDI 40/83 (48) 42/137 (31) 0.01 2.10 (1.20-3.70) 
 Taking PPIs prior to CDI 56/82 (68) 88/136 (65) 0.59 1.17 (0.66-2.10) 
 Concomitant antibiotics 44/83 (53) 67/137 (49) 0.56 1.18 (0.68-2.03) 
 Concomitant immunosuppressants 17/82 (21) 20/137 (15) 0.24 1.53 (0.75-3.12) 
 Clinical characteristics & underlying comorbidities    
 Number of stools at baseline 5.0 (3.0-6.0) 4.0 (3.0-6.0) 0.77 0.99 (0.90-1.08) 
 Fever (≥36.8°C) 5/78 (6) 9/133 (7) 0.92 0.94 (0.30-2.92) 
 Charlson Comorbidity Index score 1.0 (0.0-2.0) 1.0 (0.0-2.0) 0.84 0.98 (0.81-1.19) 
 Diabetes 16/82 (20) 24/137 (18) 0.71 1.14 (0.57-2.30) 
 Hypotension 9/79 (11) 16/135 (12) 0.92 0.96 (0.40-2.28) 
 Current malignancy 2/83 (2) 3/137 (2) 0.92 1.10 (0.18-6.74) 
 Respiratory comorbidities at baseline 52/82 (63) 71/137 (52) 0.10 1.61 (0.92-2.82) 
 GI comorbidities at baseline 47/83 (57) 87/136 (64) 0.28 0.74 (0.42-1.28) 
 Recent abdominal surgery (90 days) 3/77 (4) 23/133 (17) 0.01 0.19 (0.06-0.67) 
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1 (continued): Characteristics of CDI patients by recurrent versus non-recurrent disease 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) Recurrence (n=83) Non-recurrence (n=137) 
Laboratory results at baseline 
 Hb: per unit (mmol/L) decrease 10.9 (9.8-12.0) 10.8 (9.6-11.9) 0.69 0.97 (0.83-1.13) 
 WCC: per 109/L increase 13.1 (10.0-21.3) 10.6 (7.6-15.5) 0.05 1.02 (1.00-1.05) 
 Neutrophils: per 109/L increase 10.1 (7.5-16.9) 8.0 (5.4-12.6) 0.03 1.03 (1.00-1.06) 
 Platelets: per 109/L increase 293.0 (198.0-395.0) 300.0 (218.0-392.0) 0.77 1.00 (1.00-1.00) 
 C-reactive protein: per ten unit (mg/L) increase 76.0 (28.0-156.0) 65.5 (27.0-130.0) 0.29 1.02 (0.99-1.05) 
 Creatinine:  per unit (mmol/L) increase 95.5 (62.0-152.0) 71.5 (58.0-113.0) 0.04 1.00 (1.00-1.01) 
 eGFR: per ten unit (ml/min/1.73m2) decrease 58.5 (32.6-88.4) 76.2 (46.6-102.6) 0.02 1.08 (1.01-1.16) 
 Albumin: per unit (g/L) decrease 29.0 (25.0-34.0) 31.0 (26.0-35.0) 0.23 1.03 (0.98-1.08) 
 Sodium: per unit (mmol/L) increase 135.0 (132.0-138.0) 135.0 (133.0-137.0) 0.70 0.99 (0.93-1.05) 
 Potassium: per unit (mmol/L) increase 3.8 (3.4-4.2) 3.8 (3.4-4.2) 0.65 0.90 (0.57-1.43) 
 Urea: per unit (mmol/L) increase 7.6 (5.2-12.5) 5.3 (3.7-8.0) <0.01 1.08 (1.03-1.14) 
Microbiological information 
Presence of faecal leukocytes 45/80 (56) 67/135 (50) 0.35 1.30 (0.75-2.27) 
Toxin OD 1.6 (0.6-3.0) 2.6 (0.6-3.0) 0.22 0.86 (0.68-1.09) 
Presence of PCR ribotype 027 33/75 (44) 43/126 (34) 0.16 1.52 (0.84-2.73) 
Current admission information 
Length of hospitalisation prior to diagnosis, days 10.0 (1.0-30.0) 7.0 (1.0-19.0) 0.12 1.01 (1.00-1.02) 
Admitted via an emergency ward 59/83 (71) 83/136 (61) 0.13 1.57 (0.87-2.82) 
Admitted with diarrhoea 33/83 (40) 48/137 (35) 0.48 1.22 (0.70-2.15) 
Suffered from previous CDI 14/76 (18) 18/131 (14) 0.37 1.42 (0.66-3.04) 
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1 (continued): Characteristics of CDI patients by 90-day recurrence versus non-recurrence 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) Recurrence (n=83) Non-recurrence (n=137) 
 Current admission information (continued)    
 Recent CDI infection (90 days) 11/81 (14) 9/137 (7) 0.09 2.23 (0.88-5.65) 
 Recent ICU/HDU admission (90 days) 16/79 (20) 27/134 (20) 0.99 1.01 (0.50-2.01) 
 Nosocomial admission 52/82 (63) 89/136 (65) 0.76 0.92 (0.52-1.62) 
 Duration of symptoms prior to diagnosis, days 2.0 (0.0-7.0) 1.0 (0.0-4.0) 0.09 1.03 (1.00-1.06) 
CDI: Clostridium difficile infection; CI: Confidence interval; eGFR: Estimated glomerular filtration rate; GI: Gastrointestinal; Hb: Haemoglobin; HDU: High dependency 
unit; ICU: Intensive care unit; IQR: Interquartile range; N: Number; OD: Optical density; OR: Odds ratio; PPI: Proton pump inhibitor; WCC: White cell count;  
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2: Characteristics of CDI patients by severe-complicated versus mild disease 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) Severe-complicated (n=43) Mild disease (n=213) 
Demographics 
 Age at baseline: per decade 71.2 (58.1-78.7) 74.7 (61.2-80.9) 0.33 0.91 (0.76-1.10) 
 Gender: Female 30/43 (70) 121/213 (57) 0.12 1.75 (0.87-3.55) 
 Smoking pack years: per year increase 15.5 (0.0-30.0) 6.5 (0.0-35.0) 0.66 1.00 (0.98-1.01) 
 Body Mass Index 21.5 (18.1-28.5) 23.7 (20.5-27.6) 0.63 0.99 (0.94-1.04) 
Medication information 
 Number of co-medications at baseline 2.0 (0.0-4.0) 3.0 (2.0-4.0) <0.01 0.76 (0.63-0.91) 
 Taken fluoroquinolones prior to CDI 13/43 (30) 79/213 (37) 0.39 0.74 (0.36-1.49) 
 Taken PPIs prior to CDI 21/42 (50) 150/212 (71) 0.01 0.41 (0.21-0.81) 
 Concomitant antibiotics 22/43 (51) 107/213 (50) 0.91 1.04 (0.54-2.00) 
 Concomitant immunosuppressants 11/43 (26) 38/212 (18) 0.25 1.57 (0.73-3.40) 
 Clinical characteristics & underlying comorbidities 
 Number of stools at baseline 5.0 (3.0-7.0) 5.0 (3.0-6.0) 0.34 1.05 (0.95-1.17) 
 Fever (≥36.8°C) 5/41 (12) 11/202 (5) 0.12 2.41 (0.79-7.36) 
 Charlson Comorbidity Index score 1.0 (0.0-2.0) 1.0 (0.0-2.0) 0.51 0.93 (0.75-1.15) 
 Diabetes 8/43 (19) 36/212 (17) 0.80 1.12 (0.48-2.61) 
 Hypotension 9/38 (24) 21/208 (10) 0.02 2.76 (1.15-6.62) 
 Current malignancy 3/43 (7) 5/213 (2) 0.13 3.12 (0.72-13.58) 
 Respiratory comorbidities at baseline 29/43 (67) 115/212 (54) 0.11 1.75 (0.87-3.49) 
 GI comorbidities at baseline 33/43 (77) 122/212 (58) 0.02 2.43 (1.14-5.20) 
 Recent abdominal surgery (90 days) 7/42 (17) 24/210 (11) 0.35 1.55 (0.62-3.87) 
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2 (continued): Characteristics of CDI patients by severe-complicated versus mild disease 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) Severe-complicated (n=43) Mild disease (n=213) 
Laboratory results at baseline 
 Hb: per unit (mmol/L) decrease 9.9 (8.9-11.4) 10.9 (9.8-12.0) 0.03 1.26 (1.02-1.55) 
 WCC: per 109/L increase 15.2 (10.1-25.4) 11.0 (8.1-16.9) 0.16 1.01 (0.99-1.03) 
 Neutrophils: per 109/L increase 12.7 (8.0-21.6) 8.7 (5.6-13.1) 0.01 1.04 (1.01-1.07) 
 Platelets: per 109/L increase 275.0 (218.0-407.0) 296.0 (209.0-387.0) 0.38 1.00 (1.00-1.00) 
 C-reactive protein: per ten unit (mg/L) increase 108.5 (46.0-203.0) 66.0 (29.0-126.0) 0.01 1.05 (1.01-1.08) 
 Creatinine:  per unit (mmol/L) increase 85.5 (53.0-143.0) 80.5 (59.0-128.0) 0.59 1.00 (1.00-1.00) 
 eGFR: per ten unit (ml/min/1.73m2) decrease 59.1 (41.0-115.9) 69.1 (42.4-97.5) 0.27 0.96 (0.90-1.03) 
 Albumin: per unit (g/L) decrease 27.0 (23.5-30.0) 31.0 (26.0-35.5) <0.01 1.11 (1.05-1.19) 
 Sodium: per unit (mmol/L) increase 134.0 (133.0-137.0) 135.0 (132.0-137.0) 0.88 1.01 (0.93-1.09) 
 Potassium: per unit (mmol/L) increase 4.0 (3.6-4.4) 3.7 (3.4-4.1) 0.15 1.50 (0.87-2.59) 
 Urea: per unit (mmol/L) increase 8.2 (4.8-13.0) 6.0 (4.0-9.6) 0.02 1.06 (1.01-1.11) 
 Microbiological information 
 Presence of faecal leukocytes 18/43 (42) 117/213 (55) 0.12 0.59 (0.30-1.15) 
 Toxin OD 2.2 (1.0-3.0) 2.5 (0.6-3.0) 0.26 1.16 (0.90-1.51) 
 Presence of PCR ribotype 027 9/35 (26) 75/199 (38) 0.18 0.57 (0.25-1.29) 
 Current admission information 
 Length of hospitalisation prior to diagnosis, days 7.0 (2.0-19.0) 8.0 (1.0-20.0) 0.69 1.00 (0.99-1.02) 
 Admitted via an emergency ward 22/33 (67) 137/212 (65) 0.82 1.09 (0.50-2.38) 
 Admitted with diarrhoea 17/43 (40) 82/213 (39) 0.90 1.04 (0.53-2.04) 
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2 (continued): Characteristics of CDI patients by severe-complicated versus mild disease 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) Severe-complicated (n=43) Mild disease (n=213) 
 Current admission information (continued) 
 Suffered from previous CDI 9/39 (23) 32/207 (15) 0.25 1.64 (0.71-3.78) 
 Recent CDI infection (90 days) 6/39 (15) 20/211 (9) 0.27 1.74 (0.65-4.65) 
 Recent ICU/HDU admission (90 days) 8/33 (24) 36/213 (17) 0.31 1.57 (0.66-3.77) 
 Nosocomial admission 29/43 (67) 135/211 (64) 0.67 1.17 (0.58-2.34) 
 Duration of symptoms prior to diagnosis, days 1.0 (0.0-6.0) 2.0 (0.0-5.0) 0.89 1.00 (0.97-1.03) 
CDI: Clostridium difficile infection; CI: Confidence interval; eGFR: Estimated glomerular filtration rate; GI: Gastrointestinal; Hb: Haemoglobin; HDU: High dependency 
unit; ICU: Intensive care unit; IQR: Interquartile range; N: Number; OD: Optical density; OR: Odds ratio; PPI: Proton pump inhibitor; WCC: White cell count; 
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3: Characteristics of CDI patients by 30-day mortality versus survival 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) Mortality (n=26) Survival (n=279) 
Demographics 
 Age at baseline: per decade 79.4 (72.2-85.9) 74.4 (60.4-80.8) 0.02 1.49 (1.07-2.07) 
 Gender: Female 14/26 (54) 161/279 (58) 0.70 0.86 (0.38-1.92) 
 Smoking pack years: per year increase 22.3 (7.4-41.6) 7.5 (0.0-35.0) 0.18 1.01 (1.00-1.02) 
 Body Mass Index 20.6 (18.2-23.4) 23.9 (20.5-28.1) 0.01 0.88 (0.81-0.96) 
Medication information 
 Number of co-medications at baseline 2.0 (0.0-4.0) 3.0 (0.0-4.0) 0.32 0.90 (0.74-1.11) 
 Taking fluoroquinolones prior to CDI 11/26 (42) 95/279 (34) 0.40 1.42 (0.63-3.21) 
 Taking PPIs prior to CDI 18/26 (69) 188/277 (68) 0.89 1.07 (0.45-2.54) 
 Concomitant antibiotics 15/26 (58) 135/279 (48) 0.37 1.45 (0.65-3.28) 
 Concomitant immunosuppressants 2/26 (8) 50/278 (18) 0.20 0.38 (0.09-1.66) 
 Clinical characteristics & underlying comorbidities 
 Number of stools at baseline 4.0 (3.0-5.0) 5.0 (3.0-6.0) 0.51 0.95 (0.81-1.11) 
 Fever (≥36.8°C) 1/24 (4) 17/266 (6) 0.67 0.64 (0.08-5.00) 
 Charlson Comorbidity Index score 2.0 (0.0-4.0) 1.0 (0.0-2.0) 0.01 1.31 (1.07-1.61) 
 Diabetes 5/26 (19) 53/278 (19) 0.98 1.01 (0.36-2.80) 
 Hypotension 4/25 (16) 32/269 (12) 0.55 1.41 (0.46-4.37) 
 Current malignancy 2/26 (8) 6/279 (2) 0.11 3.79 (0.73-19.82) 
 Respiratory comorbidities at baseline 20/26 (77) 147/278 (53) 0.02 2.97 (1.16-7.62) 
 GI comorbidities at baseline 14/25 (56) 163/279 (58) 0.81 0.91 (0.40-2.07) 
 Recent abdominal surgery (90 days) 1/25 (4) 32/270 (12) 0.26 0.31 (0.04-2.37) 
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3 (continued): Characteristics of CDI patients by 30-day mortality versus survival 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) Mortality (n=26) Survival (n=279) 
Laboratory results at baseline 
 Hb: per unit (mmol/L) decrease 10.5 (9.9-11.9) 10.8 (9.6-11.9) 0.76 0.96 (0.76-1.22) 
 WCC: per 109/L increase 12.2 (10.0-15.6) 11.7 (8.1-17.7) 0.53 0.99 (0.94-1.03) 
 Neutrophils: per 109/L increase 10.0 (7.1-13.1) 9.0 (6.0-14.8) 0.81 0.99 (0.95-1.04) 
 Platelets: per 109/L increase 222.0 (184.0-342.0) 295.5 (213.0-395.0) 0.12 1.00 (0.99-1.00) 
 C-reactive protein: per ten unit (mg/L) increase 73.0 (45.0-131.0) 70.0 (29.0-140.0) 0.68 0.99 (0.94-1.04) 
 Creatinine:  per unit (mmol/L) increase 89.0 (59.0-107.0) 81.0 (59.0-138.0) 0.52 1.00 (0.99-1.00) 
 eGFR: per ten unit (ml/min/1.73m2) decrease 72.8 (44.6-114.4) 67.4 (41.4-99.9) 0.13 0.94 (0.88-1.02) 
 Albumin: per unit (g/L) decrease 30.0 (24.5-33.5) 30.0 (25.0-34.0) 0.79 1.01 (0.94-1.08) 
 Sodium: per unit (mmol/L) increase 134.0 (133.0-138.0) 135.0 (132.0-138.0) 0.81 1.01 (0.92-1.12) 
 Potassium: per unit (mmol/L) increase 3.7 (3.4-4.3) 3.8 (3.4-4.2) 0.82 0.92 (0.46-1.85) 
 Urea: per unit (mmol/L) increase 6.6 (5.0-11.6) 6.2 (4.0-10.5) 0.45 1.02 (0.97-1.08) 
 Microbiological information 
 Presence of faecal leukocytes 11/25 (44) 145/275 (53) 0.41 0.70 (0.31-1.61) 
 Toxin OD 3.0 (0.8-3.0) 2.4 (0.6-3.0) 0.64 1.07 (0.80-1.44) 
 Presence of PCR ribotype 027 8/24 (33) 81/256 (32) 0.87 1.08 (0.44-2.63) 
 Current admission information 
 Length of hospitalisation prior to diagnosis, days 11.0 (4.0-20.0) 8.0 (1.0-19.0) 0.38 0.99 (0.97-1.01) 
 Admitted via an emergency ward 17/21 (81) 150/235 (64) 0.12 2.41 (0.78-7.39) 
 Admitted with diarrhoea 8/26 (31) 105/279 (38) 0.49 0.74 (0.31-1.75) 
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3 (continued): Characteristics of CDI patients by 30-day mortality versus survival 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) Mortality (n=26) Survival (n=279) 
 Current admission information (continued) 
 Suffered from previous CDI 4/25 (16) 42/256 (16) 0.96 0.97 (0.32-2.97) 
 Recent CDI infection (90 days) 1/24 (4) 27/265 (10) 0.36 0.38 (0.05-2.95) 
 Recent ICU/HDU admission (90 days) 1/20 (5) 45/230 (20) 0.14 0.22 (0.03-1.66) 
 Nosocomial admission 20/26 (77) 181/277 (65) 0.24 1.77 (0.69-4.55) 
 Duration of symptoms prior to diagnosis, days 1.0 (0.0-6.0) 2.0 (0.0-5.0) 0.93 1.00 (0.96-1.04) 
CDI: Clostridium difficile infection; CI: Confidence interval; eGFR: Estimated glomerular filtration rate; GI: Gastrointestinal; Hb: Haemoglobin; HDU: High dependency 
unit; ICU: Intensive care unit; IQR: Interquartile range; N: Number; OD: Optical density; OR: Odds ratio; PPI: Proton pump inhibitor; WCC: White cell count; 
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4: Characteristics of CDI patients by symptoms ≥10 days versus <10 days 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) ≥10 days (n=109) <10 days (n=165) 
Demographics 
 Age at baseline: per decade 76.9 (62.8-83.5) 72.7 (60.0-79.0) 0.06 1.16 (0.99-1.35) 
 Gender: Female 62/109 (57) 96/165 (58) 0.83 0.95 (0.58-1.55) 
 Smoking pack years: per year increase 11.9 (0.0-32.4) 7.9 (0.0-35.0) 0.84 1.00 (0.99-1.01) 
 Body Mass Index 22.9 (19.8-27.5) 23.9 (20.6-28.3) 0.55 0.99 (0.95-1.03) 
Medication information 
 Number of co-medications at baseline 2.0 (0.0-4.0) 3.0 (0.0-4.0) 0.39 0.95 (0.84-1.07) 
 Taking fluoroquinolones prior to CDI 39/109 (36) 54/165 (33) 0.60 1.15 (0.69-1.91) 
 Taking PPIs prior to CDI 69/108 (64) 112/164 (68) 0.45 0.82 (0.49-1.37) 
 Concomitant antibiotics 50/109 (46) 84/165 (51) 0.41 0.82 (0.50-1.33) 
 Concomitant immunosuppressants 20/109 (18) 25/164 (15) 0.50 1.25 (0.66-2.38) 
 Clinical characteristics & underlying comorbidities 
 Number of stools at baseline 5.0 (3.0-7.0) 4.0 (3.0-6.0) 0.20 1.05 (0.97-1.14) 
 Fever (≥36.8°C) 10/106 (9) 6/159 (4) 0.07 2.66 (0.94-7.54) 
 Charlson Comorbidity Index score 1.0 (0.0-2.0) 1.0 (0.0-2.0) 0.21 0.90 (0.77-1.06) 
 Diabetes 20/108 (19) 32/165 (19) 0.86 0.94 (0.51-1.76) 
 Hypotension 14/103 (14) 17/161 (11) 0.46 1.33 (0.63-2.84) 
 Current malignancy 4/109 (4) 3/165 (2) 0.35 2.06 (0.45-9.38) 
 Respiratory comorbidities at baseline 59/108 (55) 85/165 (52) 0.61 1.13 (0.70-1.84) 
 GI comorbidities at baseline 70/108 (65) 90/165 (55) 0.09 1.54 (0.93-2.53) 
 Recent abdominal surgery (90 days) 11/105 (10) 20/161 (12) 0.63 0.83 (0.38-1.80) 
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4 (continued): Characteristics of CDI patients by symptoms ≥10 days versus <10 days 
  
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) ≥10 days (n=109) <10 days (n=165) 
Laboratory results at baseline 
 Hb: per unit (mmol/L) decrease 10.3 (9.3-11.8) 10.9 (9.8-12.0) 0.03 1.18 (1.02-1.36) 
 WCC: per 109/L increase 12.4 (9.2-19.8) 10.9 (7.9-15.5) 0.70 1.00 (0.99-1.02) 
 Neutrophils: per 109/L increase 10.3 (7.0-17.4) 8.6 (5.5-12.6) 0.05 1.03 (1.00-1.05) 
 Platelets: per 109/L increase 287.0 (213.0-354.0) 289.0 (208.5-394.0) 0.91 1.00 (1.00-1.00) 
 C-reactive protein: per ten unit (mg/L) increase 90.5 (39.0-164.0) 61.0 (29.0-106.0) 0.01 1.04 (1.01-1.07) 
 Creatinine:  per unit (mmol/L) increase 81.0 (59.0-141.0) 78.0 (58.0-129.0) 0.47 1.00 (1.00-1.00) 
 eGFR: per ten unit (ml/min/1.73m2) decrease 62.0 (40.8-99.4) 73.7 (43.9-102.1) 0.44 1.02 (0.97-1.07) 
 Albumin: per unit (g/L) decrease 29.0 (25.0-35.0) 31.0 (25.0-35.0) 0.06 1.04 (1.00-1.08) 
 Sodium: per unit (mmol/L) increase 135.0 (132.0-138.0) 136.0 (133.0-138.0) 0.42 0.98 (0.92-1.03) 
 Potassium: per unit (mmol/L) increase 3.7 (3.4-4.2) 3.8 (3.4-4.2) 0.80 0.95 (0.63-1.42) 
 Urea: per unit (mmol/L) increase 6.8 (4.3-10.5) 5.7 (3.9-9.4) 0.06 1.04 (1.00-1.08) 
 Microbiological information 
 Presence of faecal leukocytes 58/108 (54) 79/162 (49) 0.43 1.22 (0.75-1.99) 
 Toxin OD 2.4 (0.7-3.0) 2.5 (0.5-3.0) 0.57 0.95 (0.79-1.14) 
 Presence of PCR ribotype 027 34/95 (36) 43/155 (28) 0.18 1.45 (0.84-2.51) 
 Current admission information 
 Length of hospitalisation prior to diagnosis, days 8.5 (1.0-28.5) 7.0 (1.0-17.0) 0.06 1.01 (1.00-1.02) 
 Admitted via an emergency ward 56/87 (64) 86/135 (64) 0.92 1.03 (0.59-1.81) 
 Admitted with diarrhoea 42/109 (39) 63/165 (38) 0.95 1.01 (0.62-1.67) 
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4 (continued): Characteristics of CDI patients by symptoms ≥10 days versus <10 days 
 
N (%) or Median (IQR) 
P-value 
OR 
(95% CIs) ≥10 days (n=109) <10 days (n=165) 
 Current admission information (continued) 
 Suffered from previous CDI 19/97 (20) 22/155 (14) 0.26 1.47 (0.75-2.89) 
 Recent CDI infection (90 days) 12/102 (12) 11/156 (7) 0.20 1.76 (0.74-4.15) 
 Recent ICU/HDU admission (90 days) 15/84 (18) 23/133 (17) 0.92 1.04 (0.51-2.13) 
 Nosocomial admission 71/109 (65) 106/164 (65) 0.93 1.02 (0.62-1.70) 
 Duration of symptoms prior to diagnosis, days 2.0 (1.0-6.0) 1.0 (0.0-4.0) 0.01 1.04 (1.01-1.07) 
CDI: Clostridium difficile infection; CI: Confidence interval; eGFR: Estimated glomerular filtration rate; GI: Gastrointestinal; Hb: Haemoglobin; HDU: High dependency 
unit; ICU: Intensive care unit; IQR: Interquartile range; N: Number; OD: Optical density; OR: Odds ratio; PPI: Proton pump inhibitor; WCC: White cell count; 
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5: Random sampling model validation for 90-day recurrence 
Variable P-value OR (95% CIs) 
Initial model (Dataset 1; n=88) 
Age at baseline: per decade 0.20 1.22 (0.90-1.66) 
Taken fluoroquinolones prior to CDI 0.06 2.91 (0.97-8.67) 
Respiratory comorbidities at baseline 0.15 2.22 (0.75-6.60) 
Neutrophils: per 109/L increase 0.46 1.02 (0.97-1.07) 
eGFR:  per ten unit (ml/min/1.73m2) decrease 0.81 1.02 (0.87-1.19) 
Urea: per unit (mmol/L) increase 0.86 0.99 (0.90-1.09) 
Recent abdominal surgery (90 days) 0.95 0.94 (0.16-5.43) 
Presence of PCR ribotype 027 0.81 0.88 (0.32-2.45) 
Length of hospitalisation prior to diagnosis, days 0.47 1.01 (0.99-1.03) 
Admitted via an emergency ward 0.41 0.61 (0.19-1.95) 
Recent CDI infection (90 days) 0.71 1.45 (0.21-9.88) 
Duration of symptoms prior to diagnosis, days 0.26 1.04 (0.97-1.11) 
Reduced model (Dataset 1; n=99) 
Age at baseline: per decade 0.03 1.36 (1.03-1.78) 
Taken fluoroquinolones prior to CDI 0.03 2.86 (1.10-7.44) 
Recent abdominal surgery (90 days) 0.69 0.73 (0.15-3.52) 
Neutrophils: per 109/L increase 0.23 1.02 (0.99-1.06) 
Length of hospitalisation prior to diagnosis, days 0.43 1.01 (0.99-1.03) 
Duration of symptoms prior to diagnosis, days 0.34 1.03 (0.97-1.10) 
Reduced model (Dataset 2; n=91) 
Age at baseline: per decade <0.01 2.35 (1.47-3.76) 
Taken fluoroquinolones prior to CDI 0.22 1.94 (0.68-5.54) 
Neutrophils: per 109/L increase 0.87 0.99 (0.94-1.06) 
Length of hospitalisation prior to diagnosis, days 0.01 1.03 (1.01-1.05) 
Duration of symptoms prior to diagnosis, days 0.22 1.04 (0.98-1.10) 
CDI: Clostridium difficile infection; CI: Confidence interval; eGFR: Estimated glomerular filtration 
rate; OR: Odds ratio; PCR: Polymerase chain reaction; 
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6: Random sampling model validation for severe-complicated 
disease 
Variable P-value OR (95% CIs) 
Initial model (Dataset 1; n=67) 
GI comorbidities at baseline 0.08 14.72 (0.75-289.25) 
Hb: per unit (mmol/L) decrease 0.21 1.45 (0.81-2.61) 
Neutrophils: per 109/L increase 0.97 1.00 (0.88-1.13) 
Albumin: per unit (g/L) decrease 0.14 1.22 (0.94-1.58) 
C-reactive protein: per ten unit (mg/L) increase 0.97 1.00 (0.88-1.15) 
Urea: per unit (mmol/L) increase 0.11 1.13 (0.97-1.32) 
Potassium: per unit (mmol/L) increase 0.59 1.91 (0.18-19.91) 
Number of co-medications at baseline 0.14 0.53 (0.23-1.24) 
Taking PPIs prior to CDI 0.33 0.31 (0.03-3.25) 
Respiratory comorbidities at baseline 0.99 0.99 (0.07-14.53) 
Gender: Female 0.05 38.11 (1.06-1367.33) 
Presence of faecal leukocytes 0.58 0.59 (0.09-3.88) 
Presence of PCR ribotype 027 0.73 1.69 (0.09-31.17) 
Fever (≥38.6°C) 0.39 0.15 (0.00-11.30) 
Current malignancy 0.85 1.96 (0.00-2429.33) 
Hypotension 0.66 1.76 (0.14-22.51) 
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6 (continued): Random sampling model validation for severe-complicated 
disease 
Variable P-value OR (95% CIs) 
Reduced model (Dataset 1; n=83) 
GI comorbidities at baseline 0.08 4.98 (0.84-29.33) 
Hb: per unit (mmol/L) decrease 0.21 1.36 (0.84-2.20) 
Albumin: per unit (g/L) decrease 0.02 1.21 (1.02-.42) 
Urea: per unit (mmol/L) increase 0.40 1.04 (0.95-1.14) 
Potassium: per unit (mmol/L) increase 0.35 1.87 (0.51-6.87) 
Taking PPIs prior to CDI 0.27 0.45 (0.11-1.86) 
Gender: Female 0.03 7.40 (1.29-42.45) 
Fever (≥38.6°C) 0.84 1.30 (0.11-15.32) 
Current malignancy 0.65 2.11 (0.08-56.16) 
Hypotension 0.44 2.11 (0.32-13.83) 
Reduced model (Dataset 2; n=100)   
GI comorbidities at baseline 0.47 1.75 (0.38-8.01) 
Hb: per unit (mmol/L) decrease 0.19 1.33 (0.87-2.04) 
Albumin: per unit (g/L) decrease 0.21 1.08 (0.96-1.23) 
Urea: per unit (mmol/L) increase 0.10 1.14 (0.98-1.33) 
Potassium: per unit (mmol/L) increase 0.26 1.90 (0.63-5.72) 
Taking PPIs prior to CDI 0.04 0.18 (0.03-0.93) 
Gender: Female 0.40 2.08 (0.38-11.27) 
Fever (≥38.6°C) 0.02 25.81 (1.74-383.88) 
Hypotension 0.44 2.41 (0.26-22.77) 
CDI: Clostridium difficile infection; CI: Confidence interval; GI: Gastrointestinal; Hb: Haemoglobin; 
OR: Odds ratio; PCR: Polymerase chain reaction; PPI: Proton pump inhibitor; 
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7: Random sampling model validation for 30-day mortality 
Variable P-value OR (95% CIs) 
Initial model (Dataset 1; n=68) 
Age at baseline: per decade 0.99 1.01 (0.43-2.35) 
Body Mass Index 0.09 0.82 (0.66-1.03) 
Charlson Comorbidity Index score 0.03 2.77 (1.13-6.77) 
Smoking pack years: per year increase 0.29 1.02 (0.98-1.06) 
Platelets: per 109/L increase 0.63 0.98 (0.91-1.06) 
Respiratory comorbidities at baseline 0.50 0.32 (0.01-8.71) 
Admitted via an emergency ward 0.18 13.12 (0.30-582.62) 
Reduced model (Dataset 1; n=141) 
Age at baseline: per decade 0.20 1.42 (0.83-2.43) 
Body Mass Index 0.09 0.87 (0.73-1.02) 
Platelets: per 109/L increase 0.07 0.94 (0.87-1.01) 
Charlson Comorbidity Index score 0.14 1.40 (0.89-2.22) 
Reduced model (Dataset 2; n=145)   
Age at baseline: per decade 0.11 1.48 (0.92-2.39) 
Body Mass Index 0.03 0.86 (0.75-0.98) 
Platelets: per 109/L increase 0.52 0.98 (0.94-1.03) 
Charlson Comorbidity Index score 0.16 1.23 (0.92-1.65) 
CI: Confidence interval; OR: Odds ratio; 
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8: Random sampling model validation for prolonged disease 
Variable P-value OR (95% CIs) 
Initial model (Dataset 1; n=87) 
Age at baseline: per decade 0.68 1.07 (0.76-1.51) 
GI comorbidities at baseline 0.95 1.03 (0.37-2.93) 
Duration of symptoms prior to diagnosis, days 0.14 1.07 (0.98-1.16) 
Neutrophils: per 109/L increase 0.04 1.09 (1.00-1.18) 
Albumin: per unit (g/L) decrease 0.72 1.02 (0.93-1.11) 
Length of hospitalisation prior to diagnosis, days 0.73 1.00 (0.98-1.03) 
Hb: per unit (mmol/L) decrease 0.32 1.17 (0.86-1.59) 
Urea: per unit (mmol/L) increase 0.96 1.00 (0.91-1.11) 
Presence of PCR ribotype 027 0.71 1.25 (0.39-4.07) 
C-reactive protein: per ten unit (mg/L) increase 0.84 0.99 (0.92-1.07) 
Fever (≥38.6°C) 0.49 1.91 (0.30-12.19) 
Recent CDI infection (90 days) 0.88 1.13 (0.22-5.91) 
Number of stools at baseline 0.60 0.95 (0.79-1.15) 
Reduced model (Dataset 1; n=122) 
Age at baseline: per decade 0.32 1.15 (0.88-1.50) 
Duration of symptoms prior to diagnosis, days 0.19 1.05 (0.98-1.12) 
Presence of PCR ribotype 027 0.32 1.56 (0.65-3.70) 
Neutrophils: per 109/L increase 0.01 1.08 (1.02-1.14) 
Urea: per unit (mmol/L) increase 0.84 0.99 (0.92-1.07) 
Length of hospitalisation prior to diagnosis, days 0.31 1.01 (0.99-1.03) 
Hb: per unit (mmol/L) decrease 0.21 1.16 (0.92-1.46) 
Reduced model (Dataset 2; n=115)   
Age at baseline: per decade 0.40 1.13 (0.85-1.52) 
Duration of symptoms prior to diagnosis, days 0.03 1.05 (1.00-1.10) 
Presence of PCR ribotype 027 0.17 1.89 (0.76-4.71) 
Neutrophils: per 109/L increase 0.73 1.01 (0.97-1.04) 
Urea: per unit (mmol/L) increase 0.02 1.08 (1.01-1.15) 
Length of hospitalisation prior to diagnosis, days 0.06 1.02 (1.00-1.05) 
Hb: per unit (mmol/L) decrease 0.13 1.23 (0.94-1.61) 
CDI: Clostridium difficile infection; CI: Confidence interval; GI: Gastrointestinal; Hb: Haemoglobin; 
OR: Odds ratio; PCR: Polymerase chain reaction; 
 
305 
 
9: Imputed multivariate model for predicting disease 
recurrence (n=200) 
Variable P-value OR (95% CIs) 
Age at baseline: per decade <0.01 1.46 (1.19-1.80) 
Taken fluoroquinolones prior to CDI 0.02 2.10 (1.13-3.93) 
Recent abdominal surgery (90 days) 0.03 0.21 (0.05-0.82) 
Neutrophils: per 109/L increase 0.07 1.03 (1.00-1.06) 
Length of hospitalisation prior to diagnosis, days 0.03 1.01 (1.00-1.03) 
Duration of symptoms prior to diagnosis, days 0.15 1.03 (0.99-1.06) 
CDI: Clostridium difficile infection; CI: Confidence interval; OR: Odds ratio; 
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10: Imputed multivariate model for predicting severe-
complicated disease (n=183) 
Variable P-value OR (95% CIs) 
GI comorbidities at baseline 0.03 2.52 (1.08-5.87) 
Hb: per unit (mmol/L) decrease 0.20 1.18 (0.92-1.53) 
Albumin: per unit (g/L) decrease 0.03 1.09 (1.01-1.18) 
Urea: per unit (mmol/L) increase 0.06 1.06 (1.00-1.13) 
Potassium: per unit (mmol/L) increase 0.23 1.50 (0.78-2.89) 
Taking PPIs prior to CDI <0.01 0.17 (0.12-0.61) 
Gender: Female 0.04 2.47 (1.07-5.74) 
Fever (≥38.6°C) 0.10 3.16 (0.82-12.20) 
Current malignancy 0.17 3.24 (0.60-17.47) 
Hypotension 0.28 1.86 (0.60-5.77) 
CDI: Clostridium difficile infection; CI: Confidence interval; GI: Gastrointestinal; Hb: Haemoglobin; 
OR: Odds ratio; PPI: Proton pump inhibitor; 
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11: Imputed multivariate model for predicting mortality 
(n=286) 
Variable P-value OR (95% CIs) 
Age at baseline: per decade 0.03 1.45 (1.04-2.03) 
Body Mass Index <0.01 0.86 (0.78-0.95) 
Platelets: per 109/L increase 0.09 0.97 (0.93-1.01) 
Charlson Comorbidity Index score 0.02 1.32 (1.05-1.66) 
CI: Confidence interval; OR: Odds ratio; 
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12: Imputed multivariate model for predicting prolonged 
disease (n=237) 
Variable P-value OR (95% CIs) 
Age at baseline: per decade 0.30 1.09 (0.92-1.29) 
Duration of symptoms prior to diagnosis, days 0.01 1.05 (1.01-1.08) 
Presence of PCR ribotype 027 0.24 1.42 (0.79-2.57) 
Neutrophils: per 109/L increase 0.08 1.02 (1.00-1.05) 
Urea: per unit (mmol/L) increase 0.11 1.04 (0.99-1.08) 
Length of hospitalisation prior to diagnosis, days 0.08 1.01 (1.00-1.02) 
Hb: per unit (mmol/L) decrease 0.04 1.18 (1.01-1.39) 
CI: Confidence interval; Hb: Haemoglobin; OR: Odds ratio; PCR: Polymerase chain reaction; 
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13: Overview of systematic review process 
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14: Recurrence CPR assessment: D’Agostino et al. 2014 
Score 
Our study: 30-day 
(Overall prevalence = 30%) 
Our study: 90-day 
(Overall prevalence = 46%) 
D’Agostino: 30-day 
(Overall prevalence = 20%) 
Outcome 
prevalence (%) 
Prevalence based on 
cut-off (%) 
Outcome 
prevalence (%) 
Prevalence based on 
cut-off (%) 
Outcome 
prevalence (%) 
Prevalence based on 
cut-off (%) 
0 16/77 (21) 
65/227 (29) 
24/77 
100/227 (44) 
NP (NP) 
No cut-off suggested 
1 14/57 (25) 28/57 NP (NP) 
2 19/49 (39) 28/49 NP (NP) 
3 16/44 (36) 20/44 NP (NP) 
4 6/11 (55) 
7/12 (58) 
8/11 
9/12 (75) 
NP (NP) 
5 1/1 (100) 1/1 NP (NP) 
NP: Data not provided; * No cut-off was suggested by the authors therefore in order to produce descriptive stats for our cohort we decided upon a cut-off of ≥4; 
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15: Severe-complicated CPR assessment: Drew et al. 2009 
Score 
Our study 
(Overall prevalence = 18%) 
Drew et al* 
(Overall prevalence = 14%) 
Outcome prevalence (%) Prevalence based on cut-off (%) Outcome prevalence (%) Prevalence based on cut-off (%) 
0 1/21 (5) 
20/145 (14) 
NP (NP) 
NP (NP) 
1 3/50 (2) NP (NP) 
2 7/42 (17) NP (NP) 
3 9/32 (28) NP (NP) 
4 3/17 (18) 
15/46 (30) 
NP (NP) 
NP (NP) 
5 5/15 (33) NP (NP) 
6 1/4 (25) NP (NP) 
7 2/6 (33) NP (NP) 
8 1/2 (50) NP (NP) 
9 2/3 (67) NP (NP) 
NP: Data not provided; * Letter to the Editor; 
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16: Severe-complicated CPR assessment: Lungulescu et al. 2011 
Score 
Our study 
(Overall prevalence = 17%) 
Lungulescu et al 
(Overall prevalence = 21%) 
Outcome prevalence (%) Prevalence based on cut-off (%) Outcome prevalence (%) Prevalence based on cut-off (%) 
0 7/63 (11) 
20/136 (15) 
0/29 (0) 
6/89 (7) 
1 13/73 (18) 6/60 (10) 
2 8/43 (19) 
12/52 (23) 
18/53 (34) 
28/73 (38) 3 3/8 (38) 8/15 (53) 
4 1/1 (100) 2/5 (40) 
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17: Severe-complicated CPR assessment: Hensgens et al. 2014 
Score 
Our study 
(Overall prevalence = 12%) 
Hensgens et al: Derivation 
(Overall prevalence = 12%) 
Hensgens et al: Validation 
(Overall prevalence = 5%) 
Outcome 
prevalence (%) 
Prevalence based 
on cut-off (%) 
Outcome 
prevalence (%) 
Prevalence based 
on cut-off (%) 
Outcome 
prevalence (%) 
Prevalence based 
on cut-off (%) 
-3 0/1 (0) 
25/207 (12) 
0/15 (0) 
28/340 (8) 
NP (NP) 
4/125 (3) 
-2 2/14 (14) 0/40 (0) NP (NP) 
-1 1/2 (50) 0/7 (0) NP (NP) 
0 1/22 (5) 2/65 (3) NP (NP) 
1 6/71 (9) 6/92 (7) NP (NP) 
2 3/12 (25) 3/26 (11) NP (NP) 
3 12/85 (14) 17/95 (18) NP (NP) 
4 1/4 (25) 
4/27 (15) 
2/7 (34) 
21/55 (39) 
NP (NP) 
3/14 (21) 
5 3/21 (14) 11/35 (32) NP (NP) 
6 No patients 1/3 (33) NP (NP) 
7 0/2 (0) 4/6 (63) NP (NP) 
8 No patients 3/3 (100) NP (NP) 
NP: Data not provided; 
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18: Mortality CPR assessment: Bhangu et al. 2010 
Score 
Our study 
(Overall prevalence = 8%) 
Bhangu et al 
(Overall prevalence = 38%) 
Outcome prevalence (%) Prevalence based on cut-off (%) Outcome prevalence (%) Prevalence based on cut-off (%) 
0 7/92 (8) 
17/224 (8) 
3/22 (14) 
50/142 (35) 
1 6/85 (7) 16/64 (25) 
2 2/39 (5) 19/35 (54) 
3 2/8 (25) 12/21 (57) 
4 No patients 
No patients 
6/7 (86) 
8/9 (89) 
5 No patients 2/2 (100) 
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19: Mortality CPR assessment: Welfare et al. 2011 
Score 
Our study 
(Overall prevalence = 9%) 
Welfare et al 
(Overall prevalence = 30%) 
Outcome prevalence 
(%) 
Prevalence based on cut-off (%)* 
Outcome prevalence 
(%) 
Prevalence based on cut-off (%) 
0 2/40 (5) 
8/138 (6) 
19/254 (7) 
NP (NP) 
NP (<22) 
No binary cut-off 
suggested 
2 1/31 (3) NP (NP) 
3 5/67 (8) NP (NP) 
4 5/38 (13) 
17/166 (10) 
NP (NP) 
NP (32-
48) 
5 6/78 (8) NP (NP) 
6 6/49 (12) 
7/52 (13) 
NP (NP) 
7 0/1 (0) NP (NP) 
8 1/2 (50) 1/2 (50) NP (NP) NP (66) 
NP: Data not provided; *No binary cut-off was suggested by the authors therefore in order to produce descriptive stats for our cohort we decided upon a cut-off of ≥6;  
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20: Mortality CPR assessment: Butt et al. 2013 
Score 
Our study 
(Overall prevalence = 8%) 
Butt et al: Derivation 
(Overall prevalence = 21%) 
 Butt et al: Validation 
(Overall prevalence = 38%) 
Outcome 
prevalence (%) 
Prevalence based 
on cut-off (%)* 
Outcome 
prevalence (%) 
Prevalence based 
on cut-off (%) 
Outcome 
prevalence (%) 
Prevalence based 
on cut-off (%) 
0 6/93 (7) 
17/199 (9) 
13/125 (10) 
No cut-off 
suggested 
9/43 (21) 
No cut-off 
suggested 
1 11/106 (10) 20/86 (23) 23/62 (37) 
2 2/34 (6) 
2/40 (5) 
12/28 (43) 25/46 (54) 
3 0/6 (0) 5/5 (100) 2/3 (67) 
*No cut-off was suggested by the authors therefore in order to produce descriptive stats for our cohort we decided upon a cut-off of ≥2; 
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21: Summary of previous studies investigating serum immune response to Clostridium difficile toxins and 
non-toxin antigens 
Study Immunoglobulin Protein n Outcome Association 
Aronsson et al. 
(1985) 
IgA 
IgG 
IgM 
tcdA 
tcdB 
61 CDI cases Recurrence (FT) Anti-tcdB IgG 
Johnson et al. 
(1992) 
IgA 
IgG 
tcdA 
21 CDI cases 
9 Asymptomatic carriers 
10 Controls 
Disease susceptibility 
Anti-tcdA IgA 
Anti-tcdA IgG 
Asymptomatic carriage None 
Mulligan et al. 
(1993) 
IgA 
IgM 
Polyvalenta 
SCAs 
5 CDI cases 
21 Asymptomatic carriers 
26 Controls 
Disease susceptibility None 
Asymptomatic carriage 
Anti-SCA IgA 
Anti-SCA IgM 
Anti-SCA Polyvalent 
Warny et al. 
(1994) 
Serum IgA 
Serum IgG 
tcdA 
40 CDI cases 
280 Controls 
Disease susceptibility None 
60-day recurrence (FT) Anti-tcdA IgG 
Duration of symptoms Anti-tcdA IgG 
Kyne et al. 
(2000) 
IgA 
IgG 
IgM 
tcdA 
tcdB 
NTAs 
47 CDI cases 
37 Asymptomatic carriers 
187 Controls 
Colonisation None 
Asymptomatic carriage Anti-tcdA IgG 
Kyne et al. 
(2001) 
IgA 
IgG 
IgM 
tcdA 
tcdB 
NTAs 
63 CDI cases 60-day recurrence (FD) 
Anti-tcdA IgG 
Anti-tcdA IgM 
Drudy et al. 
(2004) 
IgA 
IgG 
IgM 
SLPs 
55 CDI cases 
34 Asymptomatic carriers 
57 Controls 
Disease susceptibility None 
Asymptomatic carriage None 
60-day recurrence (FT) Anti-SLP IgM 
Jiang et al. 
(2007) 
IgG tcdA 
24 CDI cases 
20 Controls 
Disease susceptibility Noneb 
Katchar et al. 
(2007) 
IgA 
IgG (total) 
IgG (subclasses 1-4) 
tcdA 
tcdB 
26 CDI casesc 60-day recurrence (FT) 
Anti-tcdA IgG2 
Anti-tcdA IgG3 
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21 (continued): Summary of previous studies investigating serum immune response to Clostridium difficile 
toxins and non-toxin antigens 
Study Immunoglobulin Protein n Outcome Association 
Sanchez-Hurtado 
et al. (2008) 
IgG 
IgM 
Crude toxind 
tcdA 
EDTA extractione 
SLPs 
LC 
21 CDI cases 
21 Asymptomatic controls 
26 Controls 
Disease susceptibility 
Anti-crude toxin IgG 
Anti-SLP IgG 
Asymptomatic carriage None 
Solomon et al. 
(2013) 
IgG 
IgM 
tcdA 
tcdB 
150 CDI cases 
30-day all-cause mortality Anti-tcdA IgG 
60-day recurrence (FS) None 
Bauer et al. 
(2014) 
IgA 
IgG 
tcdA 
tcdB 
Non-toxin CSAs 
120 CDI casesf 60-day recurrence (FT) 
Anti-tcdA IgA 
Anti-tcdA IgG 
Anti-tcdB IgG 
Islam et al. 
(2014) 
IgA 
IgG 
IgM 
tcdA 
tcdB 
20 CDI cases (Brighton) 
18 Controls 
Disease susceptibility 
Anti-tcdB Pooled antibody 
Anti-tcdB IgA 
20 CDI cases (Michigan) 
20 Controls 
None 
CSA: Cell surface antigen: EDTA: Ethylenediaminetetraacetic acid; FD: From discharge; FS: From symptom resolution; FT: From treatment completion; IgA: 
Immunoglobulin A; IgG: Immunoglobulin G; IgM: Immunoglobulin M; LC: Lipocarbohydrate; NTA: Non-toxin antigen; SCA: Somatic cell antigen; SLP: Surface layer 
protein; tcdA: Clostridium difficile toxin A; tcdB: Clostridium difficile toxin B;  
a IgA-, IgG- and IgM-specific; b Only identified a significant association when stratifying immune response based upon IL-8 rs4073 genotype; c 13 recurrent CDI cases 
versus 13 non-recurrent matched controls; d Dialysis culture supernatant containing toxins A and B together with other extracellular products, including surface-layer 
proteins; e Contained cell-surface proteins and carbohydrates; f Samples were taken during a prospective cohort study into the safety and efficacy of a whey protein 
concentrate to prevent recurrences after successful antibiotic treatment of CDI;   
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22: Comparison of standard- and high-bind plates for IgG 
response to tcdB 
Sample 
code 
Plate 
type 
Coating conc. 
(µg/ml) 
Fold Dilution 
Buffer 625 125 25 5 Neat 
A3X 
HB 
0.0 115 118 147 187 133 167 
2.5 122 119 142 153 105 167 
5.0 114 116 139 142 105 158 
10.0 115 118 140 142 96 142 
SB 
0.0 98 97 97 161 150 109 
2.5 91 94 94 127 120 99 
5.0 91 96 96 126 117 112 
10.0 99 100 100 147 139 119 
PHR 
HB 
0.0 105 115 115 207 162 772 
2.5 109 112 112 213 189 773 
5.0 101 112 112 211 184 862 
10.0 261 118 118 217 220 735 
SB 
0.0 90 98 98 279 316 195 
2.5 93 113 113 405 521 415 
5.0 91 114 114 374 532 509 
10.0 86 119 119 404 656 768 
HB: High bind; SB: Standard bind; 
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23: Comparison of standard- and high-bind plates for IgM 
response to tcdA 
Sample 
code 
Plate 
type 
Coating conc. 
(µg/ml) 
Fold Dilution 
Buffer 625 125 25 5 Neat 
A3X 
HB 
0.0 99 89 89 82 88 160 
2.5 111 89 89 81 84 152 
5.0 101 93 93 84 79 152 
10.0 103 86 88 84 80 146 
SB 
0.0 89 95 335 95 116 140 
2.5 89 94 89 91 108 140 
5.0 279 89 97 99 136 171 
10.0 77 90 93 107 137 270 
PHR 
HB 
0.0 87 89 87 83 80 118 
2.5 90 90 84 79 80 107 
5.0 90 88 86 81 82 103 
10.0 92 90 85 82 79 108 
SB 
0.0 101 102 103 113 107 109 
2.5 92 103 100 111 95 101 
5.0 106 96 98 100 93 104 
10.0 92 94 93 102 91 101 
HB: High bind; SB: Standard bind; 
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24: Comparison of standard- and high-bind plates for IgM 
response to tcdB 
Sample 
code 
Plate 
type 
Coating conc. 
(µg/ml) 
Fold Dilution 
Buffer 625 125 25 5 Neat 
A3X 
HB 
0.0 95 90 89 80 77 1296 
2.5 104 87 90 108 77 135 
5.0 87 85 87 77 77 132 
10.0 97 87 85 80 69 131 
SB 
0.0 93 96 94 98 107 114 
2.5 88 91 92 93 98 111 
5.0 88 91 95 94 95 129 
10.0 101 90 91 1164 101 109 
PHR 
HB 
0.0 87 86 83 79 83 110 
2.5 86 85 87 79 79 95 
5.0 84 85 81 76 77 92 
10.0 89 85 85 78 78 91 
SB 
0.0 91 91 96 104 90 95 
2.5 89 95 94 100 90 91 
5.0 92 92 97 104 91 95 
10.0 87 95 90 97 91 95 
HB: High bind; SB: Standard bind; 
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25: Block buffer comparison for IgG response to tcdA across 
varying coat concentrations 
Coat Block 
Coating conc. 
(µg/ml) 
Sample dilution 
Buffer SBR 
Neat 1:5 1:25 
PBS + 0.1% 
SDS 
Blocker 1 
0 107 135 140 97 1.1 
5 197 178 409 93 2.1 
25 202 226 772 86 2.3 
50 199 370 361 83 2.4 
PBST + 
5% FBS 
0 103 135 122 94 1.1 
5 486 795 640 275 1.8 
25 469 882 825 440 1.1 
50 645 440 815 251 2.6 
FBS: Foetal bovine serum; PBS: Phosphate buffer solution; PBST: 1x phosphate buffer solution + 
0.05% Tween20; SBR: Signal-to-background ratio; SDS: Sodium dodecyl sulfate; 
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26: Block buffer comparison for IgG response to tcdA across 
varying coat concentrations 
Coat Block 
Coating conc. 
(µg/ml) 
Sample dilution 
Buffer SBR 
Neat 1:5 1:25 
PBST-coat 
 
Blocker 1 
0 98 128 138 123 0.8 
5 91 106 118 112 0.8 
25 98 107 137 112 0.9 
50 118 104 170 105 1.1 
PBST + 
5% FBS 
0 84 97 97 109 0.8 
5 86 85 99 117 0.7 
25 81 82 104 102 0.8 
50 83 83 103 106 0.8 
FBS: Foetal bovine serum; PBS: Phosphate buffer solution; PBST: 1x phosphate buffer solution + 
0.05% Tween20; PBST-coat: 1x Phosphate buffer solution + 0.1% Tween20; SBR: Signal-to-
background ratio; 
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27: Block buffer comparison for IgM response to tcdA across 
varying coat concentrations 
Coat Block 
Coating conc. 
(µg/ml) 
Sample dilution 
Buffer SBR 
Neat 1:5 1:25 
PBS + 0.1% 
SDS 
Blocker 1 
0 91 103 104 88 1.0 
5 125 121 120 78 1.6 
25 171 171 153 77 2.2 
50 184 209 194 78 2.4 
PBST + 
5% FBS 
0 74 76 73 73 1.0 
5 169 96 97 74 2.3 
25 1431 111 100 71 20.2 
50 263 153 115 77 3.4 
FBS: Foetal bovine serum; PBS: Phosphate buffer solution; PBST: 1x phosphate buffer solution + 
0.05% Tween20; SBR: Signal-to-background ratio; SDS: Sodium dodecyl sulfate; 
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28: Block buffer comparison for IgM response to tcdA across 
varying coat concentrations 
Coat Block 
Coating conc. 
(µg/ml) 
Sample dilution 
Buffer SBR 
Neat 1:5 1:25 
PBST-coat 
 
Blocker 1 
0 122 119 122 109 1.1 
5 401 435 1894 106 3.8 
25 180 161 142 124 1.5 
50 119 123 128 113 1.1 
PBST + 
5% FBS 
0 84 80 88 95 0.9 
5 97 88 88 95 1.0 
25 405 363 502 239 1.7 
50 104 93 103 97 1.1 
FBS: Foetal bovine serum; PBS: Phosphate buffer solution; PBST: 1x phosphate buffer solution + 
0.05% Tween20; PBST-coat: 1x phosphate buffer solution + 0.1% Tween20; SBR: Signal-to-
background ratio; 
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29: ECL signal comparison for IgG response to tcdB across 
varying block buffers 
Antibody Analyte Sample Dilution 
Mean signal 
PBS (SBR) PBS + 0.1% SDS (SBR) 
IgG tcdB 
A3X 
Buffer 82 94 
Neat 641 (7.8) 579 (6.2) 
5 300 (3.7) 232 (2.5) 
25 130 (1.6) 153 (1.6) 
125 97 (1.2) 120 (1.3) 
PHR 
Buffer 89 94 
Neat 2,017 (22.7) 3,622 (38.5) 
5 1,202 (13.5) 1,463 (15.6) 
25 389 (4.4) 506 (5.4) 
124 133 (1.5) 195 (2.1) 
IgG: Immunoglobulin G; PBS: Phosphate buffer solution; SBR: Signal-to-background ratio; SDS: 
Sodium dodecyl sulfate; tcdB: Clostridium difficile toxin B; 
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30: ECL signal comparison for IgM response to tcdB across 
varying block buffers 
Antibody Analyte Sample Dilution 
Mean signal 
PBS (SBR) PBS + 0.1% SDS (SBR) 
IgM tcdB 
A3X 
Buffer 79 81 
Neat 89 (1.1) 82 (1.0) 
5 92 (1.2) 79 (1.0) 
PHR 
Buffer 86 82 
Neat 86 (1.0) 86 (1.0) 
5 82 (1.0) 83 (1.0) 
IgM: Immunoglobulin M; PBS: Phosphate buffer solution; SBR: Signal-to-background ratio; SDS: 
Sodium dodecyl sulfate; tcdA: Clostridium difficile toxin B; 
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31: Signal correlation across two different anti-IgG antibodies 
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32: Dilution linearity for IgG response to tcdB in a low response 
sample 
Sample Sample dilution Absolute signal (ECL units) Signal factored for dilution 
CDN 0538 
1:5 8,799 43,995 
1:10 5,161 51,610 
1:20 2,931 58,620 
1:40 1,454 58,160 
1:80 813 65,040 
1:160 466 74,560 
ECL: Electrochemiluminescence; 
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33: Dilution linearity for IgG assay with tcdB in a low response 
sample 
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34: Spiking results for IgG response to tcdA 
Toxin  
(pg/ml) 
Signal (1:40 dilution) 
Pooled high response (SBR) Pooled medium response (SBR) 
Buffer 133 133 
Unspiked 344,805 (2,593) 56,038 (421) 
12.5 195,207 (1,468) 26,338 (198) 
50 173,173 (1,302) 23,102 (174) 
200 162,583 (1,222) 23,500 (177) 
800 122,257 (919) 19,581 (147) 
1,600 115,547 (869) 21,633 (163) 
3,200 99,041 (745) 16,631 (125) 
SBR: Signal-to-background ratio; 
 
  
332 
 
35: Spiking results for IgG response to tcdB 
Toxin  
(pg/ml) 
Signal (1:2 dilution) 
Pooled high response (SBR) Pooled low response (SBR) 
Buffer 111 111 
Unspiked 443,284 (3,994) 52,181 (470) 
12.5 294,203 (2,650) 23,006 (207) 
50 259,571 (2,338) 21,030 (189) 
200 160,707 (1,448) 16,239 (146) 
800 78,944 (711) 12,899 (116) 
1,600 64,061 (577) 10,611 (96) 
3,200 57,896 (522) 8,495 (77) 
SBR: Signal-to-background ratio; 
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36: Dilution linearity plot for the IgG assay with cdtB-act using 
Blocker 1 
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37: Dilution linearity plot for the IgG assay with cdtB-pre using 
Blocker 1 
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38: Linearity for IgG response to cdtA with 1.6 µg/ml coat & 0.4 
µg/ml detection 
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39: Linearity for IgG response to cdtA with 3.2 µg/ml coat & 0.8 
µg/ml detection 
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40: Linearity for IgG response to cdtA with 3.2 µg/ml coat & 0.4 
µg/ml detection 
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41: Dilution linearity plot for IgM response to cdtA 
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42: Dilution linearity plot for IgM response to cdtB-act 
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43: Dilution linearity plot for IgM response to cdtA+cdtB-act 
 
 
  
0
50,000
100,000
150,000
200,000
250,000
300,000
5 10 50 100
D
il
u
ti
o
n
 C
o
rr
e
ct
e
d
 S
ig
n
a
l 
Dilution 
A1130
N545
N552
PHR
341 
 
44: Percentage of overall IgM response to all CDT analytes 
accounted for by background 
(A) Blocker 1; (B) Casein Blocker 
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45: Final assay protocols 
Toxin A & B 
1. Take standard bind plate and to each well add 25 μl of 25 µg/ml tcdA/B, 
diluted in 1x PBS. Tap plate to ensure even coverage. Seal and incubate 
overnight at 4°C 
2. Wash 3 x 150 μl with PBST 
3. Add 150 μl PBST + 1% BSA + 1% Milk powder (Blocker 1) and seal. 
Incubate for 1 h at room temperature with shaking 
4. Wash 3 x 150 μl with PBST 
5. Add 25 μl human serum, diluted 1:40/1:2 (IgG/IgM) in PBST + 1% BSA + 
1% Milk powder, and seal. Incubate for 2 h at room temperature with 
shaking 
6. Wash 3 x 150 μl with PBST 
7. Add 25 μl of polyclonal IgG/IgM antibody, diluted to 1 µg/ml in PBST + 
1% BSA + 1% Milk powder, and seal. Incubate for 1 h at room 
temperature with shaking 
8. Wash 3 x 150 μl with PBST 
9. Add 150 μl of MSD Read Buffer (diluted to 2x working mixture with 
distilled water) 
10. Read plate within 15 min 
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Binary toxin  
 All components (IgG & IgM) 
o Plate = Standard bind 
o Coating buffer = PBS 
o Blocking buffer = Casein 
 CDTb-act, CDTb-inact and CDTa+b-act (IgG/IgM) 
o Coating concentration = 0.1 µg/0.1 µg 
o Detection antibody concentration = 0.1 µg/ml/1.0 µg/ml 
o Sample dilution = 1:500/1:50 
 CDTa (IgG/IgM) 
o Coating concentration = 0.04 µg 
o Detection antibody concentration = 0.1 µg/ml/0.8 µg/ml 
o Sample dilution = 1:500/1:50 
 
 Take standard bind plate and coat with appropriate conc. of CDT 
component, diluted in PBS. Tap plate to ensure even coverage. Seal and 
incubate overnight at 4°C 
 Wash 3 x 150 μl with PBST 
 Add 25 μl casein and seal. Incubate for 1 h at room temperature with 
shaking 
 Add 25 μl human serum, diluted 1:500/1:50 (IgG/IgM) in casein, and 
seal. Incubate for 2 h at room temperature with shaking 
 Wash 3 x 150 μl with PBST 
 Add 25 μl of polyclonal IgG/IgM antibody, diluted to appropriate 
concentration in casein, and seal. Incubate for 1 h at room temperature 
with shaking 
 Wash 3 x 150 μl with PBST 
 Add 150 μl of MSD Read Buffer (diluted to 2x working mixture with 
distilled water) 
 Read plate within 15 min 
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46: Transferring MBL IVD ELISA kit onto MSD ECL platform 
The transition process occurs via three key steps: - 
1. Substituting the ELISA microtitre plate with one containing the carbon 
electrodes necessary for the redox reaction 
2. Labelling the detection antibody with the electrochemiluminescent tag 
3. Using MSD read buffer containing TPA 
This method development workflow is slightly differently from the C. diff toxin 
assays as it involves translating an existing IVD ELISA kit (Sanquin) onto the 
MSD platform, as opposed to developing a novel assay as with the C. diff toxins. 
The issue I had here was taking the kit protocol that uses microtitre plates, 
specific wash buffers and dilution buffers etc. and using them as part of the MSD 
assay workflow. 
 
Sulfo-tagging of unconjugated MBL1 antibody 
The Sanquin kit utilises anti-HRP antibody. This would not work well on the 
MSD platform therefore I requested an unconjugated antibody from them. I 
then sulfo-tagged this unconjugated form, as with my IgG and IgM antibodies for 
the C. diff toxin assays. Using ZEBA desalting columns, I took 2.0 mg/ml of anti-
MBL1 stock and diluted the resultant sulfo-tagged antibody 1:4 to obtain a 
working anti-MBL1 antibody solution of 0.5 mg/ml. 
 
Optimisation 1: Determination of detection antibody concentration plus need 
for further work on all other conditions 
For my first optimisation, I tried to keep everything as similar as possible, 
whilst making some slight tweaks that would allow it to be run via MSD. One 
notable change included attempting to reduce the amount of standard needed 
for each standard curve by having a lower top standard than their kit 
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recommended. This was done in the hope of reducing the financial burden of 
typing such a marker; using IVD ELISA kits for a large sample set can be very 
expensive. If I was able to use less standard then I could increase the number of 
samples being processed per kit. Further to this, standard bind MSD plates and 
two separate detection antibody concentrations (1.0 μg/ml and 2.0 μg/ml) 
were used. Recommended volumes were retained for all steps other than 
washing: this was reduced from 300 to 150 μl. The comparison protocol 
between Sanquin (black) and MSD (red) was as follows: - 
 
 COATING: Dilute mannan stock 100-fold in 0.1 M bicarb/carb buffer (pH 
9.6) and add 100 μl to each well 
 COATING: Dilute mannan stock 100-fold in 0.1 M bicarb/carb buffer (pH 
9.6) and add 100 μl to each well 
 Incubate with lid on at room temp. overnight 
 Incubate with seal on at 4°C overnight 
 Stds = 350, 140, 56, 22.4 and 9 ng/μl (diluted using kit dilution buffer) 
 Stds = 200, 100, 40, 16, 6.4 and 2.6 ng/μl (diluted using kit dilution buffer) 
 Samples = 1:20 dilution (diluted using kit dilution buffer) 
 Samples = 1:20 dilution (diluted using kit dilution buffer) 
 STEP 1 = Wash x3 using 300 μl wash buffer 
 STEP 1 = Wash x3 using 150 μl wash buffer 
 STEP 2 = Add 100 μl of std curve, control and samples. Gently agitate and 
then incubate at room temp for 1 h 
 STEP 2 = Add 100 μl of std curve, control and samples. Incubate at room 
temp for 1 h with shaking 
 STEP 3 = Wash x3 using 300 μl 
 STEP 3 = Wash x3 using 150 μl 
 STEP 4 = Add 100 μl anti-human MBL-HRP antibody diluted 1:100 and 
incubate for 1 h 
 STEP 4 = Add 100 μl sulfotagged MBL antibody diluted to working conc of 2 
μg/ml or 1 μg/ml and incubate at room temp with shaking for 1 h 
346 
 
 STEP 5 = Wash x3 using 300 μl 
 STEP 5 = Wash x3 using 150 μl 
 STEP 6 = Incubate with 3,3′,5,5′-Tetramethylbenzidine (TMB)-containing 
substrate for 30 min in dark 
 STEP 6 = Add 150 μl MSD read buffer (2x) and read plate 
 STEP 7 = Add stop solution 
 STEP 8 = Read plate at 450 nm 
 
Initial analysis of the standard curves showed that the minimum detection level 
was not as low as that of the kit itself (Figures 46.1 & 46.2). It was evident that a 
blocking step may be beneficial, as with my other MSD assays.  No significant 
difference was observed between calculated concentrations across the two 
detection antibody concentrations used (Table 46.1), nor minimum detection 
levels (Figures 46.1 & 46.2) and therefore only the 1.0 μg/ml concentration was 
taken forward for further optimisation. 
 
Figure 46.1 - MBL1 standard curve using a detection antibody 
concentration of 1.0 μg/ml 
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Figure 46.2 - MBL1 standard curve using a detection antibody 
concentration of 2.0 μg/ml 
 
 
 
 
Table 46.1 – Comparison of calculated concentrations observed across two 
different anti-MBL1 antibody concentrations 
Sample 
Calculated concentration 
using 1.0 μg/ml D 
Calculated concentration 
using 2.0 μg/ml D 
CV 
STD1 (200 ng/ml) 199.60 199.40 0.07 
STD2 (100 ng/ml) 100.78 101.08 0.21 
STD3 (40 ng/ml) 39.22 38.81 0.75 
STD4 (16 ng/ml) 16.40 17.20 3.36 
STD5 (6.4 ng/ml) 7.17 7.25 0.80 
STD6 (2.56 ng/ml) 2.41 2.98 15.03 
STD7 (0 ng/ml) 1.31 2.25 37.55 
Kit control 1,160.42 1,220.07 3.54 
Healthy control 1 652.36 741.66 9.06 
Healthy control 2 1,778.05 1,772.25 0.23 
Healthy control 3 5,153.50 4,918.73 3.30 
Healthy control 4 1,691.45 1,690.33 0.05 
CV: Coefficient of variation; D: Detection antibody; STD: Standard; 
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Optimisation 2: Determination of remaining optimal assay conditions  
With most blocking buffers containg carbohydrates, lectin assays can therefore 
be difficult to optimise as they are known carbohydrate-binders. I therefore 
used Carbo-Free Blocking Solution (Vector Labs, Peterborough, UK). I also 
changed the washing step to utilise the standard PBST from my other MSD 
assays, as opposed to the recommended kit wash buffer, and tested high-bind 
plates alongside the standard plates. Furthermore, dilution linearity was 
investigated through inclusion of multiple sample dilutions ranging from 1:2.5 
to 1:40. Zero coat control wells were also included. 
The results demonstrated desirable dilution linearity on the high-bind plate 
between the 1:10 and 1:40 dilutions (Figure 46.3). Therefore, the IVD kit-
recommended 1:20 dilution was deemed the best option. Samples did not dilute 
linearly on the standard bind plate (Figure 46.4) and this was excluded from 
further optimisation. Standard curve parameters (% CV, recovery & sensitivity) 
were also desirable using the high bind plate (Table 46.2), as was LLOD (0.5 
ng/ml; Figure 46.5). Zero coat controls were low highlighting the utility of the 
carbo-free blocking buffer (data not shown). All samples tested at the 1 in 20 
dilution were in the middle range of the curve, in terms of signal and 
concentration. However, as these are all healthy controls, the next step would 
be to revert to the kit recommended standard curve with a slightly higher top 
standard, including an extra standard point at the bottom of the curve, in order 
to ensure any clinical samples with potentially high titres will also be detected 
appropriately. 
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Figure 46.3 – Sample dilution linearity plot for MBL1 assay using high-
bind plate 
 
  
Figure 46.4 – Sample dilution linearity plot for MBL1 assay using standard 
bind plate 
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Table 46.2 - Standard curve statistics for MBL1 assay using high-bind plate 
Sample 
Concentration 
(ng/ml) 
Mean signal 
Signal
CV 
Mean % 
recovery 
Mean calculated 
concentration 
Calculated 
concentration: CV 
STD1 200 763 5.7 102.3 204.6 17.8 
STD2 100 586 5.1 96.4 96.4 13.3 
STD3 40 421 3.5 105.0 42.0 8.4 
STD4 16 278 4.8 98.8 15.8 11.4 
STD5 6.4 190 1.1 96.9 6.2 2.9 
STD6 2.56 139 1.0 101.6 2.6 3.1 
STD7 0 65 2.2 NaN 0.0 141.2 
CV: Coefficient of variation; NaN: Not a number; STD: Standard; 
 
Figure 46.5 – MBL1 standard curve using high-bind plate and a detection 
antibody concentration of 1.0 μg/ml 
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Optimisation 3: Testing utility of recombinant MBL protein as an alternative 
standard curve 
Alongside the heightened standard curve, the utility of recombinant MBL 
protein as a standard curve was also investigated. If successful, this would allow 
the curve to go higher than the kit recommended top standard, potentially 
allowing use of a lower sample dilution, which could improve the compressed 
sample range arising from the low signals described above. For storage 
purposes, 1% BSA was added to the recombinant MBL protein prior to use. To 
ensure the addition of BSA did not interfere with the assay, the recombinant 
protein prior to adding the 1% BSA was also tested. 
The recombinant MBL protein standard curves with/without 1% BSA both 
failed and were therefore excluded from further work. Despite the LLOD being 
higher than previous optimisations (11.3 ng/ml; Figure 46.6), this is likely due 
to the high variation observed at Standard Point 7. With regards to CV and 
percentage recovery (LLOQ), the curve is accurate to the lowest standard (3.6 
ng/ml; Table 46.3).  All but two of the samples tested were above this level and 
the majority of observed CVs were <10% (Table 46.4). 
Despite the low signal level, the assay is robust.  A major problem when 
working in this signal range is that assay consistency can be affected when 
reagent batches are changed, particularly antibodies. The reagents for the assay 
in question are from a validated kit, therefore should be stable. Optimal assay 
conditions had now been identified. 
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Figure 46.6 – Standard curve for MBL1 using optimally identified assay 
conditions 
 
 
Table 46.3 - Standard curve statistics for MBL1 assay using optimally 
identified assay conditions 
Sample 
Concentration 
(ng/ml) 
Mean 
signal 
Signal 
CV 
Mean calculated 
concentration (ng/ml) 
Calculated 
concentration: CV 
Mean % 
recovery 
STD1 350 574 2.8 366.5 8.0 104.7 
STD2 140 345 1.6 131.8 2.6 94.1 
STD3 56 196 3.6 58.7 4.9 104.8 
STD4 22.4 103 1.4 23.0 2.3 102.7 
STD5 9 64 5.6 7.8 18.7 86.7 
STD6 3.6 55 0.0 4.1 0.0 113.9 
STD7 0 48 7.4 0.9 141.4 NaN 
CV: Coefficient of variation; NaN: Not a number; STD: Standard; 
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Table 46.4 – Overview of sample values above or below LLOQ 
Sample Dilution Mean signal Signal CV 
Mean calculated 
concentration 
(ng/ml) 
Calculated 
concentration 
CV 
Calculated 
concentration/ 
Dilution 
Control 20 276 2.8 1,882.6 4.0 94.1 
N536 20 225 6.9 1,418.8 9.5 70.9 
N537 20 106 4.0 481.3 6.6 24.1 
N539 20 218 15.6 1,362.5 21.3 68.1 
N540 20 109 1.3 503.6 2.1 25.2 
N541 20 285 2.5 1,976.7 3.6 98.8 
N543 20 49 0.0 23.1 0.0 1.2 
N545 20 147 0.5 784.4 0.7 39.2 
N546 20 146 3.4 776.9 4.8 38.8 
N547 20 64 NaN 160.0 NaN 8.0 
N549 20 66 NaN 176.3 NaN 8.8 
N550 20 195 NaN 1,165.4 NaN 58.3 
N552 20 67 NaN 184.4 NaN 9.2 
N553 20 53 NaN 64.2 NaN 3.2 
N555 20 54 NaN 73.6 NaN 3.7 
N556 20 168 NaN 949.9 NaN 47.5 
N610 20 256 NaN 1,696.0 NaN 84.8 
CV: Coefficient of variation; NaN: Not a number; 
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Final assay protocol 
The kit control will be used across plates to determine the necessary correction 
factors, which will then applied to the appropriate plates. The optimised 
protocol is as follows: - 
 
 COATING: Dilute mannan stock 100-fold in 0.1 M bicarb/carb buffer (pH 
9.6) and add 100 μl to each well of high-bind plate 
 Incubate with seal on at 4°C overnight 
 Wash x3 using 150 μl PBST 
 Add 100 μl carbo-free blocking buffer. Incubate at room temp for 1 h with 
shaking 
 Wash x3 using 150 μl PBST 
 Add 100 μl of standard curve, kit control and samples. Incubate at room 
temp for 1 h with shaking 
o Standards = 350, 140, 56, 22.4, 9 and 3.6 ng/µl (diluted using 
carbo-free blocking buffer) 
o Samples = 1:20 dilution (diluted using carbo-free blocking 
buffer) 
 Wash x3 using 150 μl PBST 
 Add 100 μl sulfotagged MBL antibody at 1 μg/ml (diluted using carbo-free 
blocking buffer) and incubate at room temp with shaking for 1 h 
 Wash x3 using 150 μl PBST 
 Add 150 μl MSD read buffer (diluted to 2x using distilled water) 
 Read plate 
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47: Example pyrosequencing outputs for rs10554674 
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48: Example pyrosequencing outputs for rs1800451 
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49: Example pyrosequencing outputs for rs1800450 
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50: Example pyrosequencing outputs for rs5030737 
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51: Example pyrosequencing outputs for no calls/poor quality runs 
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